2025-06-18 19:16:07,778 - process_medbrowse_questions - INFO - Loading dataset AIM-Harvard/MedBrowseComp, split: MedBrowseComp_50
2025-06-18 19:16:08,725 - process_medbrowse_questions - INFO - Successfully loaded 50 questions from the dataset
2025-06-18 19:16:08,725 - process_medbrowse_questions - INFO - Processing questions 0 to 49 (50 total)
2025-06-18 19:16:08,725 - process_medbrowse_questions - INFO - üîÑ Starting question 1/50
2025-06-18 19:16:08,725 - process_medbrowse_questions - INFO - Processing question 1: "For clinical trial NCT00974311. Among the more effective regimen ingredients, find which ingredient...
2025-06-18 19:16:08,725 - process_medbrowse_questions - INFO - Running workflow (attempt 1) with params: max_plan_iterations=1, max_step_num=3
2025-06-18 19:16:08,725 - src.workflow - INFO - Starting async workflow with user input: "For clinical trial NCT00974311. Among the more effective regimen ingredients, find which ingredient starts with the letter 'E'.\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name."
2025-06-18 19:16:08,728 - src.graph.nodes - INFO - Coordinator talking.
2025-06-18 19:16:08,728 - src.graph.nodes - INFO - Starting new research session - clearing previous sources
2025-06-18 19:16:19,476 - httpx - INFO - HTTP Request: POST https://2791-3-16-2-146.ngrok-free.app/v1/chat/completions "HTTP/1.1 200 OK"
2025-06-18 19:16:19,487 - src.graph.nodes - INFO - background investigation node is running.
2025-06-18 19:16:25,422 - src.graph.nodes - INFO - Planner generating full plan
2025-06-18 19:16:32,483 - httpx - INFO - HTTP Request: POST https://2791-3-16-2-146.ngrok-free.app/v1/chat/completions "HTTP/1.1 200 OK"
2025-06-18 19:16:32,507 - process_medbrowse_questions - ERROR - Workflow execution failed: Failed to parse Plan from completion {}. Got: 4 validation errors for Plan
locale
  Field required [type=missing, input_value={}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
has_enough_context
  Field required [type=missing, input_value={}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
thought
  Field required [type=missing, input_value={}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
title
  Field required [type=missing, input_value={}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
For troubleshooting, visit: https://python.langchain.com/docs/troubleshooting/errors/OUTPUT_PARSING_FAILURE 
2025-06-18 19:16:32,507 - process_medbrowse_questions - WARNING - Parser error (attempt 1/5) for question 1: Failed to parse Plan from completion {}. Got: 4 validation errors for Plan
locale
  Field required [type=missing, input_value={}, input_type=dict]
    For further information visit https://errors.pyda...
2025-06-18 19:16:32,507 - process_medbrowse_questions - INFO - Will retry in 2s... (2/5)
2025-06-18 19:16:34,508 - process_medbrowse_questions - INFO - Retry attempt 2/5 for question 1
2025-06-18 19:16:34,509 - process_medbrowse_questions - INFO - Running workflow (attempt 2) with params: max_plan_iterations=1, max_step_num=3
2025-06-18 19:16:34,509 - src.workflow - INFO - Starting async workflow with user input: "For clinical trial NCT00974311. Among the more effective regimen ingredients, find which ingredient starts with the letter 'E'.\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name."
2025-06-18 19:16:34,514 - src.graph.nodes - INFO - Coordinator talking.
2025-06-18 19:16:34,514 - src.graph.nodes - INFO - Starting new research session - clearing previous sources
2025-06-18 19:16:38,606 - httpx - INFO - HTTP Request: POST https://2791-3-16-2-146.ngrok-free.app/v1/chat/completions "HTTP/1.1 200 OK"
2025-06-18 19:16:38,615 - src.graph.nodes - INFO - background investigation node is running.
2025-06-18 19:16:40,561 - src.graph.nodes - INFO - Planner generating full plan
2025-06-18 19:17:04,388 - httpx - INFO - HTTP Request: POST https://2791-3-16-2-146.ngrok-free.app/v1/chat/completions "HTTP/1.1 200 OK"
2025-06-18 19:17:04,390 - process_medbrowse_questions - ERROR - Workflow execution failed: Failed to parse Plan from completion {"reasoning": "The task is to extract and present all relevant information from the given text and images, ensuring clarity and completeness. The user provided a mix of complex text with citations and medical information, along with several images. The response must first detail the text-based content accurately and concisely, followed by a structured description of each image.\n\nFirst, I examined the complex text and identified it primarily discusses medication, focusing on enzalutamide (Xtandi) and its application in castration-resistant prostate cancer (CRPC) treatment. The text includes medical citations and references to various clinical studies, safety information, and pharmacological aspects. The structure follows a typical medical journal format, with specific headings like Overview, Mechanism of Action, Uses, Adverse Effects, Drug Interactions, Dosing, and Conclusion. The references are cited using numerical markers, which are important for academic and clinical integrity.\n\nNext, I analyzed the provided images to ensure they are correctly described and integrated into the summary. Each image includes a distinct theme: a medication label, a diagram explaining information sources, a list of inactive ingredients, food ingredient classes with definitions, and an alphabetical list of added sugar names. Describing these images accurately is crucial for the complete understanding of the material presented.\n\nI organized the response into text-based content and separate image summaries, making sure each description is clear and adheres to the given structure. The final check ensured all provided information is correctly captured and presented in an accessible manner without adding new information."}. Got: 4 validation errors for Plan
locale
  Field required [type=missing, input_value={'reasoning': 'The task i...dding new information.'}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
has_enough_context
  Field required [type=missing, input_value={'reasoning': 'The task i...dding new information.'}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
thought
  Field required [type=missing, input_value={'reasoning': 'The task i...dding new information.'}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
title
  Field required [type=missing, input_value={'reasoning': 'The task i...dding new information.'}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
For troubleshooting, visit: https://python.langchain.com/docs/troubleshooting/errors/OUTPUT_PARSING_FAILURE 
2025-06-18 19:17:04,390 - process_medbrowse_questions - WARNING - Parser error (attempt 2/5) for question 1: Failed to parse Plan from completion {"reasoning": "The task is to extract and present all relevant information from the given text and images, ensuring clarity and completeness. The user provided a m...
2025-06-18 19:17:04,390 - process_medbrowse_questions - INFO - Will retry in 3s... (3/5)
2025-06-18 19:17:07,391 - process_medbrowse_questions - INFO - Retry attempt 3/5 for question 1
2025-06-18 19:17:07,391 - process_medbrowse_questions - INFO - Running workflow (attempt 3) with params: max_plan_iterations=1, max_step_num=3
2025-06-18 19:17:07,391 - src.workflow - INFO - Starting async workflow with user input: "For clinical trial NCT00974311. Among the more effective regimen ingredients, find which ingredient starts with the letter 'E'.\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name."
2025-06-18 19:17:07,393 - src.graph.nodes - INFO - Coordinator talking.
2025-06-18 19:17:07,393 - src.graph.nodes - INFO - Starting new research session - clearing previous sources
2025-06-18 19:17:11,671 - httpx - INFO - HTTP Request: POST https://2791-3-16-2-146.ngrok-free.app/v1/chat/completions "HTTP/1.1 200 OK"
2025-06-18 19:17:11,688 - src.graph.nodes - INFO - background investigation node is running.
2025-06-18 19:17:14,277 - src.graph.nodes - INFO - Planner generating full plan
2025-06-18 19:17:21,121 - httpx - INFO - HTTP Request: POST https://2791-3-16-2-146.ngrok-free.app/v1/chat/completions "HTTP/1.1 200 OK"
2025-06-18 19:17:21,122 - process_medbrowse_questions - ERROR - Workflow execution failed: Failed to parse Plan from completion {}. Got: 4 validation errors for Plan
locale
  Field required [type=missing, input_value={}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
has_enough_context
  Field required [type=missing, input_value={}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
thought
  Field required [type=missing, input_value={}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
title
  Field required [type=missing, input_value={}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
For troubleshooting, visit: https://python.langchain.com/docs/troubleshooting/errors/OUTPUT_PARSING_FAILURE 
2025-06-18 19:17:21,123 - process_medbrowse_questions - WARNING - Parser error (attempt 3/5) for question 1: Failed to parse Plan from completion {}. Got: 4 validation errors for Plan
locale
  Field required [type=missing, input_value={}, input_type=dict]
    For further information visit https://errors.pyda...
2025-06-18 19:17:21,123 - process_medbrowse_questions - INFO - Will retry in 5s... (4/5)
2025-06-18 19:17:26,124 - process_medbrowse_questions - INFO - Retry attempt 4/5 for question 1
2025-06-18 19:17:26,124 - process_medbrowse_questions - INFO - Running workflow (attempt 4) with params: max_plan_iterations=1, max_step_num=3
2025-06-18 19:17:26,124 - src.workflow - INFO - Starting async workflow with user input: "For clinical trial NCT00974311. Among the more effective regimen ingredients, find which ingredient starts with the letter 'E'.\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name."
2025-06-18 19:17:26,126 - src.graph.nodes - INFO - Coordinator talking.
2025-06-18 19:17:26,126 - src.graph.nodes - INFO - Starting new research session - clearing previous sources
2025-06-18 19:17:31,029 - httpx - INFO - HTTP Request: POST https://2791-3-16-2-146.ngrok-free.app/v1/chat/completions "HTTP/1.1 200 OK"
2025-06-18 19:17:31,031 - src.graph.nodes - INFO - background investigation node is running.
2025-06-18 19:17:32,770 - src.graph.nodes - INFO - Planner generating full plan
2025-06-18 19:17:58,850 - httpx - INFO - HTTP Request: POST https://2791-3-16-2-146.ngrok-free.app/v1/chat/completions "HTTP/1.1 200 OK"
2025-06-18 19:17:58,860 - process_medbrowse_questions - ERROR - Workflow execution failed: Failed to parse Plan from completion {"type": "document", "content": "### Overview of Anti-Cancer Treatments in Advanced Prostate Cancer\n\nThe article reviews the current landscape of treatments for advanced and metastatic prostate cancer. Key therapies include\n\n1. **Chemotherapy**: Drugs like docetaxel (Taxotere) and cabazitaxel are first-line and later-line treatment options, particularly for patients who progress after hormone therapy.\n\n2. **Hormonal Therapy**: Androgen Deprivation Therapy (ADT) and newer agents such as abiraterone (Zytiga) and enzalutamide (Xtandi) work by targeting the androgen receptor pathway to inhibit tumor growth.\n\n3. **Immunotherapy**: Sipuleucel-T (Provenge) is an FDA-approved treatment that enhances the immune system to attack cancer cells.\n\n4. **Radiation and Radioisotopes**: Radium-223 (Xofigo) is used to treat prostate cancer that has spread to bone, providing palliative relief and improving survival in certain cases.\n\n5. **Targeted Therapies**: PARP inhibitors and other novel agents are being explored in trials for patients with specific genetic mutations such as BRCA1 or BRCA2.\n\n6. **Clinical Trials**: Ongoing research is evaluating novel combinations of existing therapies and new drugs in phase II/III trials for improved outcomes in the patient population.\n\n#### Challenges and Future Perspectives\n\nDespite advances, resistance and toxicity remain significant challenges. The article emphasizes the importance of personalizing treatment based on biomarkers such as tumor mutational status, patient comorbidities, and quality of life considerations.\n\n---"}. Got: 4 validation errors for Plan
locale
  Field required [type=missing, input_value={'type': 'document', 'con...considerations.\n\n---'}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
has_enough_context
  Field required [type=missing, input_value={'type': 'document', 'con...considerations.\n\n---'}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
thought
  Field required [type=missing, input_value={'type': 'document', 'con...considerations.\n\n---'}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
title
  Field required [type=missing, input_value={'type': 'document', 'con...considerations.\n\n---'}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
For troubleshooting, visit: https://python.langchain.com/docs/troubleshooting/errors/OUTPUT_PARSING_FAILURE 
2025-06-18 19:17:58,860 - process_medbrowse_questions - WARNING - Parser error (attempt 4/5) for question 1: Failed to parse Plan from completion {"type": "document", "content": "### Overview of Anti-Cancer Treatments in Advanced Prostate Cancer\n\nThe article reviews the current landscape of treatments for ...
2025-06-18 19:17:58,860 - process_medbrowse_questions - INFO - Will retry in 9s... (5/5)
2025-06-18 19:18:07,861 - process_medbrowse_questions - INFO - Retry attempt 5/5 for question 1
2025-06-18 19:18:07,861 - process_medbrowse_questions - INFO - Running workflow (attempt 5) with params: max_plan_iterations=1, max_step_num=3
2025-06-18 19:18:07,861 - src.workflow - INFO - Starting async workflow with user input: "For clinical trial NCT00974311. Among the more effective regimen ingredients, find which ingredient starts with the letter 'E'.\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name."
2025-06-18 19:18:07,863 - src.graph.nodes - INFO - Coordinator talking.
2025-06-18 19:18:07,863 - src.graph.nodes - INFO - Starting new research session - clearing previous sources
2025-06-18 19:18:12,170 - httpx - INFO - HTTP Request: POST https://2791-3-16-2-146.ngrok-free.app/v1/chat/completions "HTTP/1.1 200 OK"
2025-06-18 19:18:12,177 - src.graph.nodes - INFO - background investigation node is running.
2025-06-18 19:18:13,634 - src.graph.nodes - INFO - Planner generating full plan
2025-06-18 19:18:21,016 - httpx - INFO - HTTP Request: POST https://2791-3-16-2-146.ngrok-free.app/v1/chat/completions "HTTP/1.1 200 OK"
2025-06-18 19:18:21,019 - process_medbrowse_questions - ERROR - Workflow execution failed: Failed to parse Plan from completion {"error": "Invalid API key."}. Got: 4 validation errors for Plan
locale
  Field required [type=missing, input_value={'error': 'Invalid API key.'}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
has_enough_context
  Field required [type=missing, input_value={'error': 'Invalid API key.'}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
thought
  Field required [type=missing, input_value={'error': 'Invalid API key.'}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
title
  Field required [type=missing, input_value={'error': 'Invalid API key.'}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
For troubleshooting, visit: https://python.langchain.com/docs/troubleshooting/errors/OUTPUT_PARSING_FAILURE 
2025-06-18 19:18:21,020 - process_medbrowse_questions - ERROR - All 5 retry attempts failed with parsing errors for question 1
2025-06-18 19:18:21,020 - process_medbrowse_questions - WARNING - Primary processing failed for question 1: Failed to parse Plan from completion {"error": "Invalid API key."}. Got: 4 validation errors for Plan
locale
  Field required [type=missing, input_value={'error': 'Invalid API key.'}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
has_enough_context
  Field required [type=missing, input_value={'error': 'Invalid API key.'}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
thought
  Field required [type=missing, input_value={'error': 'Invalid API key.'}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
title
  Field required [type=missing, input_value={'error': 'Invalid API key.'}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
For troubleshooting, visit: https://python.langchain.com/docs/troubleshooting/errors/OUTPUT_PARSING_FAILURE 
2025-06-18 19:18:21,020 - process_medbrowse_questions - INFO - Attempting fallback processing for question 1
2025-06-18 19:18:21,020 - process_medbrowse_questions - INFO - Using fallback workflow with simplified parameters
2025-06-18 19:18:21,020 - process_medbrowse_questions - INFO - Fallback using: {'max_plan_iterations': 1, 'max_step_num': 2, 'enable_background_investigation': False}
2025-06-18 19:18:21,026 - src.workflow - INFO - Starting async workflow with user input: "For clinical trial NCT00974311. Among the more effective regimen ingredients, find which ingredient starts with the letter 'E'.\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name."
2025-06-18 19:18:21,029 - src.graph.nodes - INFO - Coordinator talking.
2025-06-18 19:18:21,029 - src.graph.nodes - INFO - Starting new research session - clearing previous sources
2025-06-18 19:18:21,029 - src.tools.tavily_extractor - DEBUG - Cleared 3 temp sources
2025-06-18 19:18:25,162 - httpx - INFO - HTTP Request: POST https://2791-3-16-2-146.ngrok-free.app/v1/chat/completions "HTTP/1.1 200 OK"
2025-06-18 19:18:25,167 - src.graph.nodes - DEBUG - Current state messages: [HumanMessage(content='"For clinical trial NCT00974311. Among the more effective regimen ingredients, find which ingredient starts with the letter \'E\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name."', additional_kwargs={}, response_metadata={}, id='1a24d82e-ae30-4740-b2cc-7fdf75a35c13')]
2025-06-18 19:18:25,171 - src.graph.nodes - INFO - Planner generating full plan
2025-06-18 19:18:41,084 - httpx - INFO - HTTP Request: POST https://2791-3-16-2-146.ngrok-free.app/v1/chat/completions "HTTP/1.1 200 OK"
2025-06-18 19:18:41,091 - process_medbrowse_questions - ERROR - Fallback workflow execution failed: Failed to parse Plan from completion {"has_enough_context": false, "thought": "The current information provides the clinical trial ID 'NCT00974311' and asks to identify which ingredient among the more effective regimen starts with the letter 'E'. However, the current context doesn't include the ingredients used in the trial or their effectiveness. There is insufficient context to directly answer this question without further gathering of clinical trial data on NCT00974311 to obtain information on regimen ingredients and their effectiveness.", "title": "NCT00974311 Clinical Trial Ingredients Research", "steps": [{"need_web_search": true, "title": "Obtain Clinical Trial Details for NCT00974311", "description": "Access the clinical trial record for NCT00974311 to collect information on regimen ingredients and their effectiveness. Include ingredients, dosages, and treatment effectiveness data from the trial documentation and study results."}, {"need_web_search": true, "title": "Identify Ingredients Effective and Starting with 'E'", "description": "From the gathered clinical trial data, examine the ingredients that are identified as more effective in the regimen. Identify and compile the details of the ingredient(s) that start with the letter 'E',' including their specific characteristics."}]}. Got: 3 validation errors for Plan
locale
  Field required [type=missing, input_value={'has_enough_context': Fa...fic characteristics."}]}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
steps.0.step_type
  Field required [type=missing, input_value={'need_web_search': True,...ion and study results.'}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
steps.1.step_type
  Field required [type=missing, input_value={'need_web_search': True,...cific characteristics."}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
For troubleshooting, visit: https://python.langchain.com/docs/troubleshooting/errors/OUTPUT_PARSING_FAILURE 
2025-06-18 19:18:41,091 - process_medbrowse_questions - ERROR - Both primary and fallback processing failed for question 1
2025-06-18 19:18:41,091 - process_medbrowse_questions - INFO - ‚ùå Question 1 completed - Status: error, Method: failed, Time: 152.37s
2025-06-18 19:18:41,091 - process_medbrowse_questions - INFO - ‚ùå Error: Failed to parse Plan from completion {"error": "Invalid API key."}. Got: 4 validation errors for Pla
2025-06-18 19:18:41,122 - process_medbrowse_questions - INFO - üîÑ Starting question 2/50
2025-06-18 19:18:41,122 - process_medbrowse_questions - INFO - Processing question 2: "For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient...
2025-06-18 19:18:41,122 - process_medbrowse_questions - INFO - Running workflow (attempt 1) with params: max_plan_iterations=1, max_step_num=3
2025-06-18 19:18:41,122 - src.workflow - INFO - Starting async workflow with user input: "For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter 'C'.\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name."
2025-06-18 19:18:41,132 - src.graph.nodes - INFO - Coordinator talking.
2025-06-18 19:18:41,132 - src.graph.nodes - INFO - Starting new research session - clearing previous sources
2025-06-18 19:18:41,133 - src.tools.tavily_extractor - DEBUG - Cleared 0 temp sources
2025-06-18 19:18:45,242 - httpx - INFO - HTTP Request: POST https://2791-3-16-2-146.ngrok-free.app/v1/chat/completions "HTTP/1.1 200 OK"
2025-06-18 19:18:45,245 - src.graph.nodes - DEBUG - Current state messages: [HumanMessage(content='"For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter \'C\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name."', additional_kwargs={}, response_metadata={}, id='6307574e-e4a9-4fcd-b94f-37fd9a2acbbc')]
2025-06-18 19:18:45,247 - src.graph.nodes - INFO - background investigation node is running.
2025-06-18 19:18:45,249 - src.tools.decorators - DEBUG - Tool TavilySearchResultsWithImages._run called with parameters: "For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter 'C'.\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name."
2025-06-18 19:18:55,315 - src.tools.tavily_extractor - DEBUG - Stored Tavily source: AIM-Harvard/MedBrowseComp ¬∑ Datasets at Hugging Face
2025-06-18 19:18:55,316 - src.tools.tavily_extractor - DEBUG - Stored Tavily source: Alectinib and Crizotinib in Anaplastic Lymphoma Kinase-positive Non ...
2025-06-18 19:18:55,316 - src.tools.tavily_extractor - DEBUG - Stored Tavily source: Alectinib vs crizotinib in Asian patients with treatment-na√Øve ... - Roche
2025-06-18 19:18:55,317 - src.tools.decorators - DEBUG - Tool TavilySearchResultsWithImages returned: ([{'type': 'page', 'title': 'AIM-Harvard/MedBrowseComp ¬∑ Datasets at Hugging Face', 'url': 'https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp', 'content': '| CRIZOTINIB | "For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter \'C\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient | [...] | PF PRISM CV | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name | [...] | May 12, 2027 | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |', 'score': 0.92684203, 'raw_content': 'AIM-Harvard/MedBrowseComp ¬∑ Datasets at Hugging Face\n\n===============\n\n[![Image 1: Hugging Face\'s logo](https://huggingface.co/front/assets/huggingface_logo-noborder.svg)Hugging Face](https://huggingface.co/)\n\n*   [Models](https://huggingface.co/models)\n*   [Datasets](https://huggingface.co/datasets)\n*   [Spaces](https://huggingface.co/spaces)\n*    Community  \n*   [Docs](https://huggingface.co/docs)\n*   [Enterprise](https://huggingface.co/enterprise)\n*   [Pricing](https://huggingface.co/pricing)\n*    \n*   \n* * *\n\n*   [Log In](https://huggingface.co/login)\n*   [Sign Up](https://huggingface.co/join)\n\n[Datasets:](https://huggingface.co/datasets)\n\n* * *\n\n[![Image 2](https://cdn-avatars.huggingface.co/v1/production/uploads/63600b93d9e4214b9a67807c/ZRnXCRmf600I8gTKJH-V0.png)](https://huggingface.co/AIM-Harvard)\n\n[AIM-Harvard](https://huggingface.co/AIM-Harvard)\n\n/\n\n[MedBrowseComp](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp)\n\nlike 1\n\nFollow\n\n![Image 3](https://cdn-avatars.huggingface.co/v1/production/uploads/63600b93d9e4214b9a67807c/ZRnXCRmf600I8gTKJH-V0.png)AIM-Harvard 23\n===================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================\n\nTasks: [Question Answering](https://huggingface.co/datasets?task_categories=task_categories%3Aquestion-answering)[Text Retrieval](https://huggingface.co/datasets?task_categories=task_categories%3Atext-retrieval)\n\nModalities: [Text](https://huggingface.co/datasets?modality=modality%3Atext)\n\nFormats: [csv](https://huggingface.co/datasets?format=format%3Acsv)\n\nLanguages: [English](https://huggingface.co/datasets?language=language%3Aen)\n\nSize: [1K - 10K](https://huggingface.co/datasets?size_categories=size_categories%3A1K%3Cn%3C10K)\n\nArXiv: \n\narxiv:2505.14963\n\nTags: [medical](https://huggingface.co/datasets?other=medical)[healthcare](https://huggingface.co/datasets?other=healthcare)[browsing](https://huggingface.co/datasets?other=browsing)[comparison](https://huggingface.co/datasets?other=comparison)\n\nLibraries: [Datasets](https://huggingface.co/datasets?library=library%3Adatasets)[pandas](https://huggingface.co/datasets?library=library%3Apandas)\n\nCroissant\n\n+ 1\n\nLicense: \n\napache-2.0\n\n[Dataset card](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp)[Data Studio](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/viewer/)[Files Files and versions](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/tree/main)[Community 1](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/discussions)\n\nDataset Viewer\n\n[Auto-converted to Parquet](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/tree/refs%2Fconvert%2Fparquet/default)API Embed Data Studio\n\nSubset (1)\n\ndefault¬∑1.14k rows\n\n \n\nSplit (3)\n\nMedBrowseComp_50¬∑50 rows\n\n \n\nSQL \n\n Console \n\n| gold string lengths 5 24 | prompt string lengths 227 657 | task_name string classes 5 values |\n| --- | --- | --- |\n| ENZALUTAMIDE | "For clinical trial NCT00974311. Among the more effective regimen ingredients, find which ingredient starts with the letter \'E\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| CRIZOTINIB | "For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter \'C\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| LENALIDOMIDE | "For clinical trial NCT01938001. Among the more effective regimen ingredients, find which ingredient starts with the letter \'L\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| AZACITIDINE | "For clinical trial NCT00071799. Among the more effective regimen ingredients, find which ingredient starts with the letter \'A\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| IRINOTECAN HYDROCHLORIDE | "For clinical trial NCT00720512. Among the more effective regimen ingredients, find which ingredient starts with the letter \'I\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| VENETOCLAX | "For clinical trial NCT02755597. Among the more effective regimen ingredients, find which ingredient starts with the letter \'V\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| DEXAMETHASONE | "For clinical trial NCT00833833. Among the more effective regimen ingredients, find which ingredient starts with the letter \'D\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| IBRUTINIB | "For clinical trial NCT01973387. Among the more effective regimen ingredients, find which ingredient starts with the letter \'I\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| LENALIDOMIDE | "For clinical trial NCT00843882. Among the more effective regimen ingredients, find which ingredient starts with the letter \'L\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| SIROLIMUS | "For clinical trial NCT01231412. Among the more effective regimen ingredients, find which ingredient starts with the letter \'S\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| ASTELLAS | "First, for clinical trial NCT00974311, among the more effective regimen ingredients, identify which ingredient starts with the letter \'E\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| PF PRISM CV | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| BRISTOL MYERS SQUIBB | "First, for clinical trial NCT01938001, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| BRISTOL | "First, for clinical trial NCT00071799, among the more effective regimen ingredients, identify which ingredient starts with the letter \'A\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| IPSEN | "First, for clinical trial NCT00720512, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| ABBVIE | "First, for clinical trial NCT02755597, among the more effective regimen ingredients, identify which ingredient starts with the letter \'V\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| DEXCEL | "First, for clinical trial NCT00833833, among the more effective regimen ingredients, identify which ingredient starts with the letter \'D\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| PHARMACYCLICS LLC | "First, for clinical trial NCT01973387, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| BRISTOL MYERS SQUIBB | "First, for clinical trial NCT00843882, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| AADI SUB | "First, for clinical trial NCT01231412, among the more effective regimen ingredients, identify which ingredient starts with the letter \'S\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| Aug 13, 2027 | "First, for clinical trial NCT00974311, among the more effective regimen ingredients, identify which ingredient starts with the letter \'E\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| May 12, 2027 | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Apr 27, 2027 | "First, for clinical trial NCT01938001, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| May 14, 2029 | "First, for clinical trial NCT00071799, among the more effective regimen ingredients, identify which ingredient starts with the letter \'A\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Jan 6, 2027 | "First, for clinical trial NCT00720512, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Jan 29, 2032 | "First, for clinical trial NCT02755597, among the more effective regimen ingredients, identify which ingredient starts with the letter \'V\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Dec 18, 2037 | "First, for clinical trial NCT00833833, among the more effective regimen ingredients, identify which ingredient starts with the letter \'D\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Dec 3, 2031 | "First, for clinical trial NCT01973387, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Apr 27, 2027 | "First, for clinical trial NCT00843882, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Mar 5, 2036 | "First, for clinical trial NCT01231412, among the more effective regimen ingredients, identify which ingredient starts with the letter \'S\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Nov 17, 2026 | "For clinical trial NCT00974311, among the more effective regimen ingredients, identify which ingredient starts with the letter \'E\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Jul 14, 2025 | "For clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| May 28, 2026 | "For clinical trial NCT01938001, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Sep 1, 2027 | "For clinical trial NCT00071799, among the more effective regimen ingredients, identify which ingredient starts with the letter \'A\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Feb 13, 2031 | "For clinical trial NCT00720512, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| May 15, 2026 | "For clinical trial NCT02755597, among the more effective regimen ingredients, identify which ingredient starts with the letter \'V\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Oct 3, 2026 | "For clinical trial NCT00833833, among the more effective regimen ingredients, identify which ingredient starts with the letter \'D\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Aug 24, 2029 | "For clinical trial NCT01973387, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| May 28, 2026 | "For clinical trial NCT00843882, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Nov 22, 2028 | "For clinical trial NCT01231412, among the more effective regimen ingredients, identify which ingredient starts with the letter \'S\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| 15.98999977 | "For clinical trial NCT00974311, review the more effective regimen ingredients and identify which ingredient starts with the letter \'E\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 34.47000122 | "For clinical trial NCT02838420, review the less effective regimen ingredients and identify which ingredient starts with the letter \'C\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 46.72999954 | "For clinical trial NCT01938001, review the more effective regimen ingredients and identify which ingredient starts with the letter \'L\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 62.20000076 | "For clinical trial NCT00071799, review the more effective regimen ingredients and identify which ingredient starts with the letter \'A\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 15.14000034 | "For clinical trial NCT00720512, review the more effective regimen ingredients and identify which ingredient starts with the letter \'I\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 58.59000015 | "For clinical trial NCT02755597, review the more effective regimen ingredients and identify which ingredient starts with the letter \'V\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| NOT LISTED | "For clinical trial NCT00833833, review the more effective regimen ingredients and identify which ingredient starts with the letter \'D\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| NOT LISTED | "For clinical trial NCT01973387, review the more effective regimen ingredients and identify which ingredient starts with the letter \'I\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 46.72999954 | "For clinical trial NCT00843882, review the more effective regimen ingredients and identify which ingredient starts with the letter \'L\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 39.84000015 | "For clinical trial NCT01231412, review the more effective regimen ingredients and identify which ingredient starts with the letter \'S\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n\n*   [Datasets](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#datasets "Datasets")\n\n*   [Usage](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#usage "Usage")\n\n*   [GitHub Repository](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#github-repository "GitHub Repository")\n\n*   [Citation](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#citation "Citation")\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#medbrowsecomp-dataset) MedBrowseComp Dataset\n=========================================================================================================\n\nThis repository contains datasets for medical information-seeking-oriented deep research and computer use tasks.\n\n[![Image 4: Overall](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/resolve/main/medcomp.png)](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/blob/main/medcomp.png)\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#datasets) Datasets\n-------------------------------------------------------------------------------\n\nThe repository contains three harmonized datasets:\n\n1.   **MedBrowseComp_50**: A collection of 50 medical entries for browsing and comparison.\n2.   **MedBrowseComp_605**: A comprehensive collection of 605 medical entries.\n3.   **MedBrowseComp_CUA**: A curated collection of medical data for comparison and analysis.\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#usage) Usage\n-------------------------------------------------------------------------\n\nThese datasets can be used for various medical text processing tasks, information retrieval, and comparative analysis.\n\nExample usage with the Hugging Face datasets library:\n\n```python\nfrom datasets import load_dataset\n\n# Load the dataset\ndataset = load_dataset("AIM-Harvard/MedBrowseComp")\n\n# Access specific splits\nmed50_data = dataset["MedBrowseComp_50"]\nmed605_data = dataset["MedBrowseComp_605"]\ncua_data = dataset["MedBrowseComp_CUA"]\n```\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#github-repository) GitHub Repository\n-------------------------------------------------------------------------------------------------\n\nFor more information and related tools, visit: [https://github.com/MedBrowseComp](https://github.com/MedBrowseComp)\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#citation) Citation\n-------------------------------------------------------------------------------\n\nIf you use this dataset in your research, please cite: [https://arxiv.org/abs/2505.14963](https://arxiv.org/abs/2505.14963)\n\n```\n@misc{chen2025medbrowsecompbenchmarkingmedicaldeep,\n      title={MedBrowseComp: Benchmarking Medical Deep Research and Computer Use}, \n      author={Shan Chen and Pedro Moreira and Yuxin Xiao and Sam Schmidgall and Jeremy Warner and Hugo Aerts and Thomas Hartvigsen and Jack Gallifant and Danielle S. Bitterman},\n      year={2025},\n      eprint={2505.14963},\n      archivePrefix={arXiv},\n      primaryClass={cs.CL},\n      url={https://arxiv.org/abs/2505.14963}, \n}\n```\n\nDownloads last month 179\n\n Use this dataset \n\nSize of downloaded dataset files: 448 kB[Size of the auto-converted Parquet files: 58 kB](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/tree/refs%2Fconvert%2Fparquet/)Number of rows: 1,139\n\nCollection including AIM-Harvard/MedBrowseComp\n----------------------------------------------\n\n[#### MedBrowseComp Collection MedBrowseComp: Benchmarking Medical Deep Research and Computer Use‚Ä¢ 3 items‚Ä¢ Updated 10 days ago](https://huggingface.co/collections/AIM-Harvard/medbrowsecomp-6822637df90521b5d8b8b23f)\n\n System theme \n\nCompany\n\n[TOS](https://huggingface.co/terms-of-service)[Privacy](https://huggingface.co/privacy)[About](https://huggingface.co/huggingface)[Jobs](https://apply.workable.com/huggingface/)[](https://huggingface.co/)\n\nWebsite\n\n[Models](https://huggingface.co/models)[Datasets](https://huggingface.co/datasets)[Spaces](https://huggingface.co/spaces)[Pricing](https://huggingface.co/pricing)[Docs](https://huggingface.co/docs)\n'}, {'type': 'page', 'title': 'Alectinib and Crizotinib in Anaplastic Lymphoma Kinase-positive Non ...', 'url': 'https://ichgcp.net/clinical-trials-registry/NCT02838420', 'content': 'USA (FDA)\n       UK (MHRA)\n       AUSTRALIA (NHMRC)\n       JAPAN (PMDA)\n       EU (EMA)\n\n   CRO List\n   Clinical Trials\n\n       US Clinical Trials Registry\n       EU Clinical Trials Registry\n       Pharmaceutical Companies\n       Clinical Research Labs\n       Service Companies\n       Clinical Research Events\n       Publications\n       Researchers\n\n   Jobs\n   Publications\n   News\n\n   \n   \n\n   ICH GCP\n   US Clinical Trials Registry\n   Clinical Trial NCT02838420', 'score': 0.54724693, 'raw_content': 'Published Time: 2022-12-12T02:32:10+00:00\n\nAlectinib and Crizotinib in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer - Clinical Trials Registry - ICH GCP\n\n===============\n\n[![Image 1: ICHGCP](https://ichgcp.net/img/ichgcp_logo.png)](https://ichgcp.net/)\n\n*   Regulations\n\n    *   [GLOBAL¬ª](https://ichgcp.net/clinical-trials-registry/NCT02838420#)\n\n        *   [ICH GCP (De)](https://ichgcp.net/de)\n        *   [ICH GCP (En)](https://ichgcp.net/)\n        *   [ICH GCP (Es)](https://ichgcp.net/es)\n        *   [ICH GCP (Fr)](https://ichgcp.net/fr)\n        *   [ICH GCP (It)](https://ichgcp.net/it)\n        *   [ICH GCP (Pt)](https://ichgcp.net/pt)\n        *   [ICH GCP (Ru)](https://ichgcp.net/ru)\n\n    *   [USA (FDA)](https://ichgcp.net/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects)\n    *   [UK (MHRA)](https://ichgcp.net/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol)\n    *   [AUSTRALIA (NHMRC)](https://ichgcp.net/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia)\n    *   [JAPAN (PMDA)](https://ichgcp.net/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan)\n    *   [EU (EMA)](https://ichgcp.net/ich-e-group-of-guidelines)\n\n*   [CRO List](https://ichgcp.net/cro-list)\n*   Clinical Trials\n\n    *   [US Clinical Trials Registry](https://ichgcp.net/clinical-trials-registry)\n    *   [EU Clinical Trials Registry](https://ichgcp.net/eu-clinical-trials-registry)\n    *   [Pharmaceutical Companies](https://ichgcp.net/pharma-list)\n    *   [Clinical Research Labs](https://ichgcp.net/labs)\n    *   [Service Companies](https://ichgcp.net/service-companies)\n    *   [Clinical Research Events](https://ichgcp.net/events)\n    *   [Publications](https://ichgcp.net/clinical-trials-registry/publications)\n    *   [Researchers](https://ichgcp.net/clinical-trials-registry/researchers)\n\n*   [Jobs](https://ichgcp.net/jobs)\n*   [Publications](https://ichgcp.net/publications)\n*   [News](https://ichgcp.net/news)\n\n*   [](https://telegram.me/share/url?url=https://ichgcp.net/clinical-trials-registry/NCT02838420&text= "Share on telegram")\n*   [](https://twitter.com/intent/tweet?url=https://ichgcp.net/clinical-trials-registry/NCT02838420 "Share on Twitter")\n\n*   [ICH GCP](https://ichgcp.net/)\n*   [US Clinical Trials Registry](https://ichgcp.net/clinical-trials-registry)\n*   Clinical Trial NCT02838420\n\nA Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)\n=========================================================================================================================================================================================================================================================================\n\nMarch 24, 2025 updated by: [Hoffmann-La Roche](https://ichgcp.net/clinical-trials-registry/research/list?spons=Hoffmann-La%20Roche "List all studies sponsored by Hoffmann-La Roche")\n\nRandomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Asian Patients With Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer\n--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\nThis randomized, multicenter, Phase III, open-label study will evaluate the efficacy and safety of alectinib versus crizotinib and to evaluate the pharmacokinetics of alectinib in asian participants with treatment-naive ALK-positive advanced NSCLC. Participants will be randomized 2:1 into one of the two treatment groups to receive either alectinib (600 milligrams [mg] twice daily [BID]) or crizotinib (250 mg BID) orally, respectively.\n\nStudy Overview\n--------------\n\n#### Status\n\nActive, not recruiting\n\n#### Conditions\n\n*   [Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%20Lymphoma%20Kinase-positive%20Non-small%20Cell%20Lung%20Cancer "List all studies focused on condition Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer")\n\n#### Intervention / Treatment\n\n*   [Drug: Alectinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Alectinib "List all studies with intervention Alectinib")\n*   [Drug: Crizotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Crizotinib "List all studies with intervention Crizotinib")\n\n#### Study Type\n\n Interventional \n\n#### Enrollment (Actual)\n\n 187 \n\n#### Phase\n\n*   Phase 3\n\nContacts and Locations\n----------------------\n\nThis section provides the contact details for those conducting the study, and information on where this study is being conducted.\n\n### Study Locations\n\n*   [China](https://ichgcp.net/clinical-trials-registry/research/list?locn=China "List all studies conducted in China") \n    *           *   Beijing, China, 100142 \n            *   Beijing Cancer Hospital\n\n        *   Beijing, China, 101149 \n            *   Beijing Chest Hospital\n\n        *   Changchun, China, 130021 \n            *   The First Hospital of Jilin University\n\n        *   Changchun, China, 132013 \n            *   Jilin cancer hospital\n\n        *   Chengdu, China, 610041 \n            *   West China Hospital, Sichuan University\n\n        *   Guangzhou, China, 510060 \n            *   Sun Yet-sen University Cancer Center\n\n        *   Guangzhou, China, 510080 \n            *   Guangdong General Hospital\n\n        *   Guangzhou, China, 510120 \n            *   The First Affiliated Hospital of Guangzhou Medical University\n\n        *   Hangzhou, China, 310003 \n            *   The First Affiliated Hospital of College of Medicine, Zhejiang University\n\n        *   Hangzhou, China, 310022 \n            *   Zhejiang Cancer Hospital\n\n        *   Harbin, China, 150081 \n            *   Harbin Medical University Cancer Hospital\n\n        *   Nanjing, China, 210009 \n            *   Jiangsu Cancer Hospital\n\n        *   Shanghai, China, 200030 \n            *   Shanghai Chest Hospital\n\n        *   Shanghai, China, 200032 \n            *   Fudan University Shanghai Cancer Center\n\n        *   Shanghai, China, 200433 \n            *   Shanghai Pulmonary Hospital\n\n*   [Korea, Republic of](https://ichgcp.net/clinical-trials-registry/research/list?locn=Korea%2C%20Republic%20of "List all studies conducted in Korea, Republic of") \n    *           *   Seoul, Korea, Republic of, 05505 \n            *   Asan Medical Center\n\n        *   Seoul, Korea, Republic of, 06351 \n            *   Samsung Medical Center\n\n        *   Seoul, Korea, Republic of, 03181 \n            *   Kangbuk Samsung Hospital\n\n*   [Thailand](https://ichgcp.net/clinical-trials-registry/research/list?locn=Thailand "List all studies conducted in Thailand") \n    *           *   Bangkok, Thailand, 10400 \n            *   Rajavithi Hospital\n\n        *   Bangkok, Thailand, 10400 \n            *   Ramathibodi Hospital\n\n        *   Songkhla, Thailand, 90110 \n            *   Songklanagarind hospital\n\nParticipation Criteria\n----------------------\n\nResearchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person\'s general health condition or prior treatments.\n\n### Eligibility Criteria\n\n#### Ages Eligible for Study\n\n 18 years and older (Adult, Older Adult) \n\n#### Accepts Healthy Volunteers\n\n No \n\n#### Description\n\nInclusion Criteria:\n\n*   Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive as assessed by the Ventana immunohistochemistry (IHC) test. Sufficient tumor tissue available to perform ALK IHC is required. Ventana IHC testing will be performed at the designated central laboratory\n*   Life expectancy of at least 12 weeks\n*   Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2\n*   No history of receiving systemic treatment for advanced, recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC\n*   Adequate hematologic function: Platelet count greater than equal to (>=) 100√ó10^9 per liter (/L); absolute neutrophil count (ANC) >=1500 cells per microliter (cells/mcL); hemoglobin>=9.0 grams per deciliter (g/dL)\n*   Adequate renal function: an estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease (MDRD) formula of >=45 milliliters per minute per 1.73 square meter\n*   Participants must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before receiving the first dose of study treatment\n*   Measurable disease (by Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v1.1]) before administration of study treatment\n*   Previous brain or leptomeningeal metastases are allowed if the participant is asymptomatic (e.g., diagnosed incidentally at study baseline). Asymptomatic central nervous system (CNS) lesions may be treated at the discretion of the investigator as per local clinical practice. If participant has neurological symptoms or signs because of CNS metastasis, the participant must complete whole-brain radiation or gamma knife irradiation treatment. In all cases, radiation treatment must be completed >=14 days before enrollment and disease must be clinically stable\n*   For all females of childbearing potential, a negative serum pregnancy test result must be obtained within 3 days prior to starting study treatment\n*   For women who are not postmenopausal (>=12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus), agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Examples of contraceptive methods with a failure rate of <1% per year include tubal ligation, male sterilization, hormonal implants, established, proper use of combined oral or injected hormonal contraceptives, and certain intrauterine devices. Alternatively, two methods (e.g., two barrier methods such as a condom and a cervical cap) may be combined to achieve a failure rate of <1% per year. Barrier methods must always be supplemented with the use of a spermicide\n*   For men, agreement to remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception\n\nExclusion Criteria:\n\n*   A malignancy within the previous 3 years (other than curatively treated basal cell carcinoma of the skin, early gastrointestinal (GI) cancer by endoscopic resection, in situ carcinoma of the cervix, or any cured cancer that is considered to have no impact in progression-free survival (PFS) or overall survival (OS) for the current NSCLC)\n*   Any GI disorder that may affect absorption of oral medications, such as malabsorption syndrome or status post-major bowel resection\n*   Liver disease characterized by:\n*   Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than (>) 3√ó the upper limit of normal (ULN; >=5√óULN for participants with concurrent liver metastases) confirmed on two consecutive measurements; or\n*   Impaired excretory function (e.g., hyperbilirubinemia), synthetic function, or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices; or\n*   Acute viral or active autoimmune, alcoholic, or other types of hepatitis\n*   National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 Grade 3 or higher toxicities because of any previous therapy (e.g., radiotherapy) (excluding alopecia), which have not shown improvement and are strictly considered to interfere with current study medication\n*   History of organ transplant\n*   Co-administration of anti-cancer therapies other than those administered in this study\n*   Baseline QTc >470 ms or symptomatic bradycardia\n*   Administration of strong/potent cytochrome P4503A inhibitors or inducers within 14 days prior to the receiving the first dose of study treatment and during treatment with alectinib or crizotinib\n*   Administration of agents with potential QT interval prolonging effects within 14 days prior to receiving the first dose of study drug\n*   History of hypersensitivity to any of the additives in the alectinib or crizotinib drug formulation\n*   Pregnant or lactating\n*   Known human immunodeficiency virus (HIV-positivity or acquired immunodeficiency syndrome (AIDS)-related illness\n*   Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or the absorption of oral medications or that would, in the opinion of the Principal Investigator, pose an unacceptable risk to the participant in this study\n*   Any psychological, familial, sociological, or geographical condition that potentially hampers compliance with the study protocol requirements or follow-up procedures; those conditions should be discussed with the participant before study entry\n\nStudy Plan\n----------\n\nThis section provides details of the study plan, including how the study is designed and what the study is measuring.\n\n### How is the study designed?\n\n#### Design Details\n\n*   **Primary Purpose**: Treatment\n*   **Allocation**: Randomized\n*   **Interventional Model**: Parallel Assignment\n*   **Masking**: None (Open Label)\n\n#### Number of Arms\n\n2\n\n#### Arms and Interventions\n\n| ##### Participant Group / Arm | ##### Intervention / Treatment |\n| --- | --- |\n| Experimental: Alectinib Participants will receive alectinib capsules orally at a dose of 600 mg BID with food until disease progression, unacceptable toxicity withdrawal of consent, or death. | [Drug: Alectinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Alectinib "List all studies with intervention Alectinib") Alectinib capsules will be administered orally at a dose of 600 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death. Other Names: * RO5424802 |\n| Active Comparator: Crizotinib Participants will receive crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity withdrawal of consent, or death. | [Drug: Crizotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Crizotinib "List all studies with intervention Crizotinib") Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death. |\n\n### What is the study measuring?\n\n#### Primary Outcome Measures\n\n| ##### Outcome Measure | ##### Measure Description | ##### Time Frame |\n| --- | --- | --- |\n| Progression-Free Survival (PFS) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 Time Frame: From the date of randomization to the date of the first documented disease progression or death, whichever occurred first (up to overall period of approximately 40 months) | PFS was defined as the time (in months) from randomization to the first documentation of disease progression, as determined by the investigators, or to death from any cause, whichever occurred first. | From the date of randomization to the date of the first documented disease progression or death, whichever occurred first (up to overall period of approximately 40 months) |\n\n#### Secondary Outcome Measures\n\n| ##### Outcome Measure | ##### Measure Description | ##### Time Frame |\n| --- | --- | --- |\n| PFS as Determined by Independent Review Committee (IRC) Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) | PFS was defined as the time (in months) from randomization to the first documentation of disease progression, as determined by an independent review committee, or to death from any cause, whichever occurred first. | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Percentage of Participants With Objective Response of Complete Response (CR) or Partial Response (PR) as Determined by Investigator Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Time to Progression of Disease in the CNS as Determined by IRC Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Time to Progression of Disease in the CNS as Determined by IRC Using Response Assessment in Neuro-Oncology (RANO) Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Duration of Response (DOR) Assessed by Investigator Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Overall Survival Time Time Frame: Baseline, until death (up to overall period of approximately 40 months) |  | Baseline, until death (up to overall period of approximately 40 months) |\n| Percentage of Participants With Non-serious Adverse Events and Serious Adverse Events Time Frame: Up to overall period of approximately 40 months | An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. | Up to overall period of approximately 40 months |\n| Time to Deterioration Assessed Using EORTC Quality of Life Questionnaire-Core (QLQ-C30) Score Time Frame: Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Time to Deterioration Assessed Using EORTC Quality of Life Questionnaire-Lung Cancer Module (QLQ-LC13) Score Time Frame: Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Area Under the Plasma Concentration-time Curve (AUC) of Alectinib and Its Metabolite Time Frame: Baseline and Week 4 predose (within 2 hours before administration of study drug) | AUC was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time. | Baseline and Week 4 predose (within 2 hours before administration of study drug) |\n| Maximum Plasma Concentration Observed (Cmax) of Alectinib and Its Metabolite Time Frame: Baseline and Week 4 predose (within 2 hours before administration of study drug) | Cmax was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time. | Baseline and Week 4 predose (within 2 hours before administration of study drug) |\n| Time to Cmax (Tmax) of Alectinib and Its Metabolite Time Frame: Baseline and Week 4 predose (within 2 hours before administration of study drug) | Tmax was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time. | Baseline and Week 4 predose (within 2 hours before administration of study drug) |\n\nCollaborators and Investigators\n-------------------------------\n\nThis is where you will find people and organizations involved with this study.\n\n#### Sponsor\n\n[Hoffmann-La Roche](https://ichgcp.net/clinical-trials-registry/research/list?spons=Hoffmann-La%20Roche "List all studies sponsored by Hoffmann-La Roche")\n\n#### Investigators\n\n*    Study Director: Clinical Trials, Hoffmann-La Roche \n\nPublications and helpful links\n------------------------------\n\nThe person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.\n\n#### General Publications\n\n*   [Zhou C, Kim SW, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang JJ, Cheng Y, Lee SH, Bu L, Xu T, Yang L, Wang C, Liu T, Morcos PN, Lu Y, Zhang L. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med. 2019 May;7(5):437-446. doi: 10.1016/S2213-2600(19)30053-0. Epub 2019 Apr 10.](https://pubmed.ncbi.nlm.nih.gov/30981696)\n\nStudy record dates\n------------------\n\nThese dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.\n\n### Study Major Dates\n\n#### Study Start (Actual)\n\n August 3, 2016 \n\n#### Primary Completion (Actual)\n\n May 31, 2018 \n\n#### Study Completion (Estimated)\n\n December 31, 2025 \n\n### Study Registration Dates\n\n#### First Submitted\n\nJuly 18, 2016\n\n#### First Submitted That Met QC Criteria\n\nJuly 18, 2016\n\n#### First Posted (Estimated)\n\nJuly 20, 2016\n\n### Study Record Updates\n\n#### Last Update Posted (Actual)\n\nMarch 25, 2025\n\n#### Last Update Submitted That Met QC Criteria\n\nMarch 24, 2025\n\n#### Last Verified\n\nMarch 1, 2025\n\nMore Information\n----------------\n\n### Terms related to this study\n\n#### Additional Relevant MeSH Terms\n\n*   [Neoplasms by Site](https://ichgcp.net/clinical-trials-registry/research/list?cond=Neoplasms%20by%20Site "List all studies by MeSH term: Neoplasms by Site")\n*   [Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Neoplasms "List all studies by MeSH term: Neoplasms")\n*   [Immune System Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Immune%20System%20Diseases "List all studies by MeSH term: Immune System Diseases")\n*   [Respiratory Tract Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Diseases "List all studies by MeSH term: Respiratory Tract Diseases")\n*   [Neoplasms by Histologic Type](https://ichgcp.net/clinical-trials-registry/research/list?cond=Neoplasms%20by%20Histologic%20Type "List all studies by MeSH term: Neoplasms by Histologic Type")\n*   [Lung Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%20Diseases "List all studies by MeSH term: Lung Diseases")\n*   [Respiratory Tract Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Neoplasms "List all studies by MeSH term: Respiratory Tract Neoplasms")\n*   [Thoracic Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Thoracic%20Neoplasms "List all studies by MeSH term: Thoracic Neoplasms")\n*   [Lymphatic Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphatic%20Diseases "List all studies by MeSH term: Lymphatic Diseases")\n*   [Lymphoproliferative Disorders](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoproliferative%20Disorders "List all studies by MeSH term: Lymphoproliferative Disorders")\n*   [Immunoproliferative Disorders](https://ichgcp.net/clinical-trials-registry/research/list?cond=Immunoproliferative%20Disorders "List all studies by MeSH term: Immunoproliferative Disorders")\n*   [Carcinoma, Bronchogenic](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%2C%20Bronchogenic "List all studies by MeSH term: Carcinoma, Bronchogenic")\n*   [Bronchial Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Bronchial%20Neoplasms "List all studies by MeSH term: Bronchial Neoplasms")\n*   [Lung Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%20Neoplasms "List all studies by MeSH term: Lung Neoplasms")\n*   [Lymphoma](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma "List all studies by MeSH term: Lymphoma")\n*   [Carcinoma, Non-Small-Cell Lung](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%2C%20Non-Small-Cell%20Lung "List all studies by MeSH term: Carcinoma, Non-Small-Cell Lung")\n*   [Tyrosine Kinase Inhibitors](https://ichgcp.net/clinical-trials-registry/research/list?intr=Tyrosine%20Kinase%20Inhibitors "List all studies by MeSH term: Tyrosine Kinase Inhibitors")\n*   [Antineoplastic Agents](https://ichgcp.net/clinical-trials-registry/research/list?intr=Antineoplastic%20Agents "List all studies by MeSH term: Antineoplastic Agents")\n*   [Molecular Mechanisms of Pharmacological Action](https://ichgcp.net/clinical-trials-registry/research/list?intr=Molecular%20Mechanisms%20of%20Pharmacological%20Action "List all studies by MeSH term: Molecular Mechanisms of Pharmacological Action")\n*   [Enzyme Inhibitors](https://ichgcp.net/clinical-trials-registry/research/list?intr=Enzyme%20Inhibitors "List all studies by MeSH term: Enzyme Inhibitors")\n*   [Protein Kinase Inhibitors](https://ichgcp.net/clinical-trials-registry/research/list?intr=Protein%20Kinase%20Inhibitors "List all studies by MeSH term: Protein Kinase Inhibitors")\n*   [Crizotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Crizotinib "List all studies by MeSH term: Crizotinib")\n*   [Alectinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Alectinib "List all studies by MeSH term: Alectinib")\n\n#### Other Study ID Numbers\n\n*    YO29449 \n\n### Drug and device information, study documents\n\n#### Studies a U.S. FDA-regulated drug product\n\n Yes \n\n#### Studies a U.S. FDA-regulated device product\n\n No \n\nThis information was retrieved directly from the website [clinicaltrials.gov](https://clinicaltrials.gov/) without any changes. If you have any requests to change, remove or update your study details, please contact [register@clinicaltrials.gov](mailto:register@clinicaltrials.gov). As soon as a change is implemented on [clinicaltrials.gov](https://clinicaltrials.gov/), this will be updated automatically on our website as well.\n\nClinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer\n---------------------------------------------------------------------------------\n\n*    Pfizer   Completed  [A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001)](https://ichgcp.net/clinical-trials-registry/NCT00585195)  Systemic Anaplastic Large-Cell Lymphoma | Non-Small Cell Lung Cancer ALK-positive | Non-Small Cell Lung Cancer c-Met Dependent | Non-Small Cell Lung Cancer ROS Marker Positive | Advanced Malignancies Except Leukemia   United States, Korea, Republic of, Australia, Japan    \n*    Novartis Pharmaceuticals   Available  [Managed Access Programs for LDK378, Ceritinib](https://ichgcp.net/clinical-trials-registry/NCT05100134)  Non-small Cell Lung Cancer (NSCLC) | Anaplastic Lymphoma Kinase (ALK)- Positive Tumors    \n*    Novartis Pharmaceuticals   Completed  [Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer](https://ichgcp.net/clinical-trials-registry/NCT01772797)  Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase (ALK)   Australia, Spain, Singapore, Italy, United States    \n*    Nuvalent Inc.   Recruiting  [Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC (ALKAZAR)](https://ichgcp.net/clinical-trials-registry/NCT06765109)  Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase-positive   United States    \n*    Intergroupe Francophone de Cancerologie Thoracique   Completed  [Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements (CLINALK)](https://ichgcp.net/clinical-trials-registry/NCT02727335)  Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase Gene Mutation   France    \n*    Takeda   Completed  [A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors](https://ichgcp.net/clinical-trials-registry/NCT03546894)  Carcinoma Non-small-cell Lung | Anaplastic Lymphoma Kinase-positive   United States    \n*    Astellas Pharma Inc   Completed  [Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)](https://ichgcp.net/clinical-trials-registry/NCT01284192)  Solid Tumor | B-Cell Lymphoma | Advanced Malignancies | Positive for Anaplastic Lymphoma Kinase | Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS   United States    \n*    University Medical Center Groningen  Radboud University Medical Center; Maastricht University Medical Center; Erasmus... and other collaborators    Recruiting  [Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels (ADAPT ALEC)](https://ichgcp.net/clinical-trials-registry/NCT05525338)  Carcinoma, Non-Small-Cell Lung | Lung Cancer | Drug Monitoring | Anaplastic Lymphoma Kinase Gene Mutation | Anaplastic Lymphoma Kinase Gene Translocation   Netherlands, France    \n*    Takeda   Withdrawn  [Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors](https://ichgcp.net/clinical-trials-registry/NCT04260009)  Solid Tumors | Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma | Inflammatory Myofibroblastic Tumors    \n*    Massachusetts General Hospital  LUNGevity Foundation; Addario Lung Cancer Medical Institute    Recruiting  [Immune and Genomic Markers in ALK+ NSCLC](https://ichgcp.net/clinical-trials-registry/NCT04881916)  Non-Small Cell Lung Cancer | Anaplastic Lymphoma Kinase Gene Translocation   United States    \n\nClinical Trials on Alectinib\n----------------------------\n\n*    Aarhus University Hospital  Roche Pharma AG    Enrolling by invitation  [Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients (MonAlec)](https://ichgcp.net/clinical-trials-registry/NCT04708639)  Lung Cancer | ALK Gene Mutation | Resistance, Disease | Mutation   Denmark    \n*    Hoffmann-La Roche   Completed  [A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (ATALK)](https://ichgcp.net/clinical-trials-registry/NCT03155009)  Carcinoma, Non-Small-Cell Lung   France    \n*    Hoffmann-La Roche   Completed  [Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea](https://ichgcp.net/clinical-trials-registry/NCT03271554)  Non-Small Cell Lung Cancer   Korea, Republic of    \n*    Dana-Farber Cancer Institute  Genentech, Inc.    Terminated  [A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer](https://ichgcp.net/clinical-trials-registry/NCT03131206)  ALK-positive Non-small Cell Lung Cancer (NSCLC) | RET-positive Non-small Cell Lung Cancer (NSCLC) | RET-positive Thyroid Cancer   United States    \n*    Hoffmann-La Roche   Completed  [Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib](https://ichgcp.net/clinical-trials-registry/NCT02621047)  Hepatic Impairment   Czechia, Slovakia    \n*    Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...  UnitedHealthcare    Not yet recruiting  [Pharmacogenomics IND EXEMPT SNP Clinical Study - Alectinib and Single Nucleotide Polymorphisms (Drugs-SNPs)](https://ichgcp.net/clinical-trials-registry/NCT05987956)  Non-small Cell Lung Cancer   United States    \n*    Hoffmann-La Roche   Terminated  [A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors (ALpha-T)](https://ichgcp.net/clinical-trials-registry/NCT04644315)  Digestive System Diseases | Gastrointestinal Diseases | Melanoma | Sarcoma | Neoplasms | Respiratory Tract Diseases | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasms | Head and Neck Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms and other conditions   United States    \n*    China Medical University Hospital   Active, not recruiting  [Alectinib in Combination with Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided with Serum RNase1 and Tumor Expression of PD-L1](https://ichgcp.net/clinical-trials-registry/NCT06354387)  Hepatocellular Carcinoma   Taiwan    \n*    Genentech, Inc.   No longer available  [Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy](https://ichgcp.net/clinical-trials-registry/NCT02271139)  Non-Small Cell Lung Cancer   United States    \n*    Hoffmann-La Roche   Completed  [A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)](https://ichgcp.net/clinical-trials-registry/NCT01871805)  Non-Small Cell Lung Cancer   United States, Canada    \n\nSearch Similar Trials\n---------------------\n\n*   [Clinical Trials on Lymphoma in Singapore](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=Singapore)\n*   [Clinical Trials on Lymphosarcoma in Australia](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=Australia)\n*   [Clinical Trials on Carcinoma, Non-Small-Cell Lung in Singapore](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BNon-Small-Cell%2BLung&locn=Singapore)\n*   [Clinical Trials on Lymphoma in New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=New%2BZealand)\n*   [Clinical Trials on Carcinoma, Non-Small-Cell Lung in United States](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BNon-Small-Cell%2BLung&locn=United%2BStates)\n*   [Clinical Trials on Lung Neoplasms in Ireland](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%2BNeoplasms&locn=Ireland)\n*   [Clinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%2BLymphoma%2BKinase-positive%2BNon-small%2BCell%2BLung%2BCancer&locn=South%2BAfrica)\n*   [Clinical Trials on Lymphosarcoma in India](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=India)\n*   [Clinical Trials on Lymphoma in United States](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=United%2BStates)\n*   [Clinical Trials on Lymphoma in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=South%2BAfrica)\n*   [Clinical Trials on Lymphoma in Hong Kong](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=Hong%2BKong)\n*   [Clinical Trials on Lymphosarcoma in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=South%2BAfrica)\n*   [Clinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer in Ireland](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%2BLymphoma%2BKinase-positive%2BNon-small%2BCell%2BLung%2BCancer&locn=Ireland)\n*   [Clinical Trials on Lung Neoplasms in New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%2BNeoplasms&locn=New%2BZealand)\n*   [Clinical Trials on Lung Neoplasms in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%2BNeoplasms&locn=South%2BAfrica)\n*   [Clinical Trials on Lymphoma in India](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=India)\n*   [Clinical Trials on Lymphosarcoma in Singapore](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=Singapore)\n*   [Clinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer in New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%2BLymphoma%2BKinase-positive%2BNon-small%2BCell%2BLung%2BCancer&locn=New%2BZealand)\n*   [Clinical Trials on Lymphosarcoma in United States](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=United%2BStates)\n*   [Clinical Trials on Carcinoma, Non-Small-Cell Lung in United Kingdom](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BNon-Small-Cell%2BLung&locn=United%2BKingdom)\n*   [Search All Trials](https://ichgcp.net/clinical-trials-registry/research/list)\n\nSponsors and Collaborators\n--------------------------\n\n*   [Eisai Korea Inc.](https://ichgcp.net/clinical-trials-registry/research/list?spons=Eisai%2BKorea%2BInc.)\n*   [Leukaemia & Blood Cancer New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?spons=Leukaemia%2B%2526%2BBlood%2BCancer%2BNew%2BZealand)\n*   [Udaan](https://ichgcp.net/clinical-trials-registry/research/list?spons=Udaan)\n*   [Makarenko Irina Romanovna](https://ichgcp.net/clinical-trials-registry/research/list?spons=Makarenko%2BIrina%2BRomanovna)\n*   [Adriane Aver Vanin](https://ichgcp.net/clinical-trials-registry/research/list?spons=Adriane%2BAver%2BVanin)\n*   [University of Memphis](https://ichgcp.net/clinical-trials-registry/research/list?spons=University%2Bof%2BMemphis)\n*   [Sleep Research Society Foundation](https://ichgcp.net/clinical-trials-registry/research/list?spons=Sleep%2BResearch%2BSociety%2BFoundation)\n*   [Immuron Ltd.](https://ichgcp.net/clinical-trials-registry/research/list?spons=Immuron%2BLtd.)\n*   [Arthro-Anda Tianjin Biologic Technology Co., Ltd.](https://ichgcp.net/clinical-trials-registry/research/list?spons=Arthro-Anda%2BTianjin%2BBiologic%2BTechnology%2BCo.%252C%2BLtd.)\n*   [CoheroHealth](https://ichgcp.net/clinical-trials-registry/research/list?spons=CoheroHealth)\n*   [Center for Military Mental Health, Berlin, Germany](https://ichgcp.net/clinical-trials-registry/research/list?spons=Center%2Bfor%2BMilitary%2BMental%2BHealth%252C%2BBerlin%252C%2BGermany)\n*   [Kevin Flanigan](https://ichgcp.net/clinical-trials-registry/research/list?spons=Kevin%2BFlanigan)\n*   [Periannan Kuppusamy](https://ichgcp.net/clinical-trials-registry/research/list?spons=Periannan%2BKuppusamy)\n*   [Chiang Mai University Hospital, THAILAND](https://ichgcp.net/clinical-trials-registry/research/list?spons=Chiang%2BMai%2BUniversity%2BHospital%252C%2BTHAILAND)\n*   [Centre for Emergency Health Sciences](https://ichgcp.net/clinical-trials-registry/research/list?spons=Centre%2Bfor%2BEmergency%2BHealth%2BSciences)\n*   [Therapex Co., Ltd](https://ichgcp.net/clinical-trials-registry/research/list?spons=Therapex%2BCo.%252C%2BLtd)\n*   [MIT William Asbjornsen Albert Memorial Fellowship](https://ichgcp.net/clinical-trials-registry/research/list?spons=MIT%2BWilliam%2BAsbjornsen%2BAlbert%2BMemorial%2BFellowship)\n*   [Fabiana Aceto](https://ichgcp.net/clinical-trials-registry/research/list?spons=Fabiana%2BAceto)\n*   [North American Spine Society](https://ichgcp.net/clinical-trials-registry/research/list?spons=North%2BAmerican%2BSpine%2BSociety)\n*   [SGS proderm GmbH](https://ichgcp.net/clinical-trials-registry/research/list?spons=SGS%2Bproderm%2BGmbH)\n*   [View Full List](https://ichgcp.net/clinical-trials-registry/research/browse/spns_alpha_all)\n\nMedical Conditions\n------------------\n\n*   [Infrarenal Abdominal Aortic Aneurysms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Infrarenal%2BAbdominal%2BAortic%2BAneurysms)\n*   [Myeloproliferative Disease, Not Classified](https://ichgcp.net/clinical-trials-registry/research/list?cond=Myeloproliferative%2BDisease%252C%2BNot%2BClassified)\n*   [Lifestyle-related Condition](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lifestyle-related%2BCondition)\n*   [Compliance](https://ichgcp.net/clinical-trials-registry/research/list?cond=Compliance)\n*   [Patients With Opioid Induced Constipation](https://ichgcp.net/clinical-trials-registry/research/list?cond=Patients%2BWith%2BOpioid%2BInduced%2BConstipation)\n*   [Femoral Vascular Anastomosis](https://ichgcp.net/clinical-trials-registry/research/list?cond=Femoral%2BVascular%2BAnastomosis)\n*   [Observation Safety](https://ichgcp.net/clinical-trials-registry/research/list?cond=Observation%2BSafety)\n*   [Improvement of Functionality](https://ichgcp.net/clinical-trials-registry/research/list?cond=Improvement%2Bof%2BFunctionality)\n*   [CD4 Deficiency](https://ichgcp.net/clinical-trials-registry/research/list?cond=CD4%2BDeficiency)\n*   [Malassezia Infection](https://ichgcp.net/clinical-trials-registry/research/list?cond=Malassezia%2BInfection)\n*   [Anti-cancer Cell Immunotherapy](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anti-cancer%2BCell%2BImmunotherapy)\n*   [Health Knowledge Attitudes and Practice](https://ichgcp.net/clinical-trials-registry/research/list?cond=Health%2BKnowledge%2BAttitudes%2Band%2BPractice)\n*   [School Adjustment](https://ichgcp.net/clinical-trials-registry/research/list?cond=School%2BAdjustment)\n*   [Difficult Mask Ventilation](https://ichgcp.net/clinical-trials-registry/research/list?cond=Difficult%2BMask%2BVentilation)\n*   [Intrapartum Mortality](https://ichgcp.net/clinical-trials-registry/research/list?cond=Intrapartum%2BMortality)\n*   [Diabetes Mellitus II](https://ichgcp.net/clinical-trials-registry/research/list?cond=Diabetes%2BMellitus%2BII)\n*   [Painless Myocardial Ischemia](https://ichgcp.net/clinical-trials-registry/research/list?cond=Painless%2BMyocardial%2BIschemia)\n*   [Corona Virus Disease 19 (COVID-19)](https://ichgcp.net/clinical-trials-registry/research/list?cond=Corona%2BVirus%2BDisease%2B19%2B%2528COVID-19%2529)\n*   [Pressure Injury Stage 2](https://ichgcp.net/clinical-trials-registry/research/list?cond=Pressure%2BInjury%2BStage%2B2)\n*   [Escape; Rhythm](https://ichgcp.net/clinical-trials-registry/research/list?cond=Escape%253B%2BRhythm)\n*   [View Full List](https://ichgcp.net/clinical-trials-registry/research/browse/cond_alpha_all)\n\nDrug Interventions\n------------------\n\n*   [Methylprednisolone](https://ichgcp.net/clinical-trials-registry/research/list?intr=Methylprednisolone)\n*   [Anetumab Ravtansine](https://ichgcp.net/clinical-trials-registry/research/list?intr=Anetumab%2BRavtansine)\n*   [ESES treated with clobazam](https://ichgcp.net/clinical-trials-registry/research/list?intr=ESES%2Btreated%2Bwith%2Bclobazam)\n*   [Droperidol Injectable Solution](https://ichgcp.net/clinical-trials-registry/research/list?intr=Droperidol%2BInjectable%2BSolution)\n*   [ATx201](https://ichgcp.net/clinical-trials-registry/research/list?intr=ATx201)\n*   [Cyclophosphamide](https://ichgcp.net/clinical-trials-registry/research/list?intr=Cyclophosphamide)\n*   [Pioglitazone](https://ichgcp.net/clinical-trials-registry/research/list?intr=Pioglitazone)\n*   [Botulinum Toxin A](https://ichgcp.net/clinical-trials-registry/research/list?intr=Botulinum%2BToxin%2BA)\n*   [Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Gefitinib%2B250mg%2Bpo%2Bqd%2Bor%2BTarceva%2B150mg%2Bpo%2Bqd%2Bor%2BIcotinib%2B125mg%2Bpo%2Btid%2BOther%2BName%253A%2BGefitinib%252FTarceva%252FIcotinib)\n*   [Ramosetron](https://ichgcp.net/clinical-trials-registry/research/list?intr=Ramosetron)\n*   [KN046](https://ichgcp.net/clinical-trials-registry/research/list?intr=KN046)\n*   [Doxorubicin](https://ichgcp.net/clinical-trials-registry/research/list?intr=Doxorubicin)\n*   [Corticosteroids (CS)](https://ichgcp.net/clinical-trials-registry/research/list?intr=Corticosteroids%2B%2528CS%2529)\n*   [Dimenhydrinate](https://ichgcp.net/clinical-trials-registry/research/list?intr=Dimenhydrinate)\n*   [Ropivacaine 150 mg](https://ichgcp.net/clinical-trials-registry/research/list?intr=Ropivacaine%2B150%2Bmg)\n*   [Iso-Fludelone](https://ichgcp.net/clinical-trials-registry/research/list?intr=Iso-Fludelone)\n*   [Clonidine](https://ichgcp.net/clinical-trials-registry/research/list?intr=Clonidine)\n*   [Lidocaine topical](https://ichgcp.net/clinical-trials-registry/research/list?intr=Lidocaine%2Btopical)\n*   [Nusinersen](https://ichgcp.net/clinical-trials-registry/research/list?intr=Nusinersen)\n*   [Cyclophosphamide and fludarabine](https://ichgcp.net/clinical-trials-registry/research/list?intr=Cyclophosphamide%2Band%2Bfludarabine)\n*   [View Full List](https://ichgcp.net/clinical-trials-registry/research/browse/intr_alpha_all)\n\n### CROs by country\n\n*   [Contract Research Organizations in Azerbaijan](https://ichgcp.net/cro-list/country/azerbaijan)\n*   [Contract Research Organizations in Bulgaria](https://ichgcp.net/cro-list/country/bulgaria)\n*   [Contract Research Organizations in Burundi](https://ichgcp.net/cro-list/country/burundi)\n*   [Contract Research Organizations in Dominican Republic](https://ichgcp.net/cro-list/country/dominican_republic)\n*   [Contract Research Organizations in Kosovo](https://ichgcp.net/cro-list/country/kosovo)\n*   [Contract Research Organizations in Mexico](https://ichgcp.net/cro-list/country/mexico)\n*   [Contract Research Organizations in Moldova](https://ichgcp.net/cro-list/country/moldova)\n*   [Contract Research Organizations in Poland](https://ichgcp.net/cro-list/country/poland)\n*   [Contract Research Organizations in Slovakia](https://ichgcp.net/cro-list/country/slovakia)\n*   [Contract Research Organizations in Sri Lanka](https://ichgcp.net/cro-list/country/sri_lanka)\n*   [Contract Research Organizations in Ukraine](https://ichgcp.net/cro-list/country/ukraine)\n*   [Contract Research Organizations in United Arab Emirates](https://ichgcp.net/cro-list/country/united_arab_emirates)\n*   [Contract Research Organizations in Uzbekistan](https://ichgcp.net/cro-list/country/uzbekistan)\n*   [CRO list by country](https://ichgcp.net/cro-list)\n\n### CROs in Ghana\n\n*   [54gene‚Äôs Clinical Programs Group (CPG)](https://ichgcp.net/cro-list/country/ghana/company/54gene_s_clinical_programs_group_cpg)\n*   [SGS](https://ichgcp.net/cro-list/country/ghana/company/sgs)\n*   [ACROSS Global](https://ichgcp.net/cro-list/country/ghana/company/across_global)\n*   [All CROs in Ghana](https://ichgcp.net/cro-list/country/ghana)\n\n### Conditions\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/cond_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/cond_cat)\n\n### Rare Diseases\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/ord_alpha_all)\n\n### Drug Interventions\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/intr_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/intr_cat)\n\n### Dietary Supplements\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/diet_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/diet_cat)\n\n### Sponsor/Collaborators\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/spns_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/spns_cat)\n\n### Locations\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/locn_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/locn_cat)\n\nRegulations\n\n*   [GLOBAL (ICH GCP)](https://ichgcp.net/)\n*   [USA (FDA)](https://ichgcp.net/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects)\n*   [UK (MHRA)](https://ichgcp.net/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol)\n*   [AUSTRALIA (NHMRC)](https://ichgcp.net/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia)\n*   [JAPAN (PMDA)](https://ichgcp.net/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan)\n*   [EU (EMA)](https://ichgcp.net/guideline-for-the-notification-of-serious-breaches-of-regulation-eu-no-536-2014)\n\nResources\n\n*   [CRO List](https://ichgcp.net/cro-list)\n*   [Pharmaceutical Companies](https://ichgcp.net/pharma-list)\n*   [Clinical Research Labs](https://ichgcp.net/labs)\n*   [Service Companies](https://ichgcp.net/service-companies)\n*   [Jobs](https://ichgcp.net/cra-jobs)\n*   [US Clinical Trials Registry](https://ichgcp.net/clinical-trials-registry)\n*   [EU Clinical Trials Registry](https://ichgcp.net/eu-clinical-trials-registry)\n\nArticles\n\n*   [Publications](https://ichgcp.net/publications)\n*   [News](https://ichgcp.net/news)\n*   [About us / Our mission](https://ichgcp.net/about-us-our-mission)\n\nSearch trials\n\nExample: Heart Attack\n\n¬© ICH GCP. All Rights Reserved.\n\n*   [Sitemap](https://ichgcp.net/sitemap)\n*   [Contact us](https://ichgcp.net/contact-us)\n*   [RSS feed](https://ichgcp.net/feed)\n*   [Privacy Policy](https://ichgcp.net/privacy)\n*   [Disclaimer](https://ichgcp.net/disclaimer)\n\n English \n\n[Dansk](https://ichgcp.net/da/clinical-trials-registry/NCT02838420)[Deutsch](https://ichgcp.net/de/clinical-trials-registry/NCT02838420)[English](https://ichgcp.net/clinical-trials-registry/NCT02838420)[Espa√±ol](https://ichgcp.net/es/clinical-trials-registry/NCT02838420)[Fran√ßais](https://ichgcp.net/fr/clinical-trials-registry/NCT02838420)[Italiano](https://ichgcp.net/it/clinical-trials-registry/NCT02838420)[Magyar](https://ichgcp.net/hu/clinical-trials-registry/NCT02838420)[Nederlands](https://ichgcp.net/nl/clinical-trials-registry/NCT02838420)[Norsk](https://ichgcp.net/no/clinical-trials-registry/NCT02838420)[Polski](https://ichgcp.net/pl/clinical-trials-registry/NCT02838420)[Portugu√™s](https://ichgcp.net/pt/clinical-trials-registry/NCT02838420)[Suomi](https://ichgcp.net/fi/clinical-trials-registry/NCT02838420)[Svenska](https://ichgcp.net/sv/clinical-trials-registry/NCT02838420)[ƒåe≈°tina](https://ichgcp.net/cs/clinical-trials-registry/NCT02838420)[–†—É—Å—Å–∫–∏–π](https://ichgcp.net/ru/clinical-trials-registry/NCT02838420)[Êó•Êú¨Ë™û](https://ichgcp.net/ja/clinical-trials-registry/NCT02838420)[ÁÆÄ‰Ωì‰∏≠Êñá](https://ichgcp.net/zh/clinical-trials-registry/NCT02838420)[ÌïúÍµ≠Ïñ¥](https://ichgcp.net/ko/clinical-trials-registry/NCT02838420)\n\nGOOD CLINICAL PRACTICE NETWORK\n\nSubscribe to receive notifications of new clinical trials you are interested in.\n\nSubscribe\n\n‚úï\n\nGOOD CLINICAL PRACTICE NETWORK\n\nSubscribe to receive notifications of new clinical trials you are interested in.\n\nSubscribe for upcoming trials that contain the following conditions: \n\n- [x] Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer \n\n[Choose more conditions](https://ichgcp.net/mailing-list/conditions)\n\nSubscribe for upcoming trials that contain the following interventions: \n\n- [x] Alectinib \n\n- [x] Crizotinib \n\n[Choose more interventions](https://ichgcp.net/mailing-list/interventions)\n\nSubscribe for upcoming trials sponsored by: \n\n- [x] Hoffmann-La Roche \n\n[Choose more organizations](https://ichgcp.net/mailing-list/organizations)\n\nSubscribe\n\nSubscribe\n\nSubscribe\n'}, {'type': 'page', 'title': 'Alectinib vs crizotinib in Asian patients with treatment-na√Øve ... - Roche', 'url': 'https://medically.roche.com/global/en/medical-material/ESMO-Asia-2022-presentation-zhou-alectinib-vs-crizotinib-in-asian-patients-with-treatment-naive-advanced-pdf.html', 'content': 'Data cut -off 16 May 2022. ClinicalTrials.gov: NCT02838420. CNS, central nervous system; DOR, duration of response;  ECOG PS, Eastern Cooperative Oncology Group performance status; IHC, immunohistochemistry; INV, investigator \n\nIRC, independent review committee; NSCLC, non -small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, p rogression -free survival \n\n2:1 \n\nN=187 \n\nR\n\nAlectinib \n\n600mg  twice daily \n\nCrizotinib \n\n250mg twice daily \n\nTreat until disease', 'score': 0.5393963, 'raw_content': "Alectinib vs crizotinib in Asian patients \n\n## with treatment -na√Øve advanced  ALK +\n\n## non -small cell lung cancer: 5 -year \n\n## update from the Phase 3 ALESIA study \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nFaculty of Medicine  Ramathibodi  Hospital, Mahidol University, \n\nBangkok, Thailand \n\nZhou C, 1 Lu Y, 2 Kim S -W, 3 Baisamut  (Reungwetwattana) T, 4 Zhou J, 5 Zhang Y, 6 He J, 7 Yang J -J, 8 Cheng Y, 9 Lee S -H, 10  Chang J, 11 \n\nFang J, 12  Liu Z, 13  Bu L, 14  Qian L, 14  Xu T, 14  Archer V, 15  Hilton M, 16  Zhou M, 14  Zhang L 17 \n\n1Shanghai Pulmonary Hospital, Tongji University, Shanghai, China;  2West China Hospital, Sichuan University, Chengdu, China;  3Asan Medical \n\nCenter , University of Ulsan College of Medicine, Seoul, South Korea;  4Faculty of Medicine  Ramathibodi  Hospital, Mahidol University, Bangkok, \n\nThailand;  5The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China;  6Zhejiang Cancer Hospital, Hangzhou, China; \n\n7The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;  8Guangdong Lung Cancer Institute, Guangdong General Hospital, \n\nGuangzhou, China;  9Jilin Cancer Hospital, Changchun, China;  10 Sungkyunkwan University School of Medicine, Seoul, South Korea;  11 Cancer \n\nHospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China;  12 Beijing Cancer \n\nHospital, Beijing, China;  13 Beijing Chest Hospital, Capital Medical University, Beijing, China;  14 Roche Pharma Development, Shanghai, China; \n\n15 Roche Products Ltd, Welwyn Garden City, UK;  16 F. Hoffmann -La Roche Ltd, Basel, Switzerland;  17 Sun  Yat -sen  University Cancer  Center ,\n\nState Key Laboratory of Oncology in South China, Collaborative Innovation  Center  for Cancer Medicine, Guangzhou, China Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## DECLARATION OF INTERESTS \n\nThanyanan  Baisamut  (Reungwetwattana) \n\n‚Ä¢ Received honorarium from AstraZeneca, Pfizer, MSD, Roche, BMS, Amgen, J&J, Novartis,  Yuhan  and  Zuellig \n\n‚Ä¢ Participated as Principal Investigator on clinical trials for AstraZeneca, MSD, Roche, Novartis and  Yuhan   \n\n> Thanyanan Baisamut (Reungwetwattana)\n\nContent of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## ALESIA: alectinib vs crizotinib in treatment -na√Øve Asian patients \n\n## with advanced  ALK+  NSCLC \n\n‚Ä¢ Stratification factors:  ECOG PS (0/1 vs 2) \n\nand CNS metastases at baseline (yes vs no) \n\n‚Ä¢ Primary endpoint:  PFS by INV \n\n‚Ä¢ Secondary endpoints:  Time to CNS \n\nprogression by IRC, ORR by INV, \n\nDOR by INV, OS and safety \n\n‚Ä¢ Median duration of survival follow -up: \n\n61 months  alectinib vs  51 months  crizotinib \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nPatients were enrolled from China, Thailand and South Korea. *Asymptomatic CNS metastases allowed. \n\nData cut -off 16 May 2022. ClinicalTrials.gov: NCT02838420. CNS, central nervous system; DOR, duration of response;  ECOG PS, Eastern Cooperative Oncology Group performance status; IHC, immunohistochemistry; INV, investigator \n\nIRC, independent review committee; NSCLC, non -small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, p rogression -free survival \n\n2:1 \n\nN=187 \n\nR\n\nAlectinib \n\n600mg  twice daily \n\nCrizotinib \n\n250mg twice daily \n\nTreat until disease \n\nprogression, toxicity, \n\nwithdrawal or death \n\nNo crossover permitted \n\nStage IIIB/IV  ALK + NSCLC* \n\n‚Ä¢ Asian patients \n\n‚Ä¢ Treatment na√Øve \n\n‚Ä¢ ECOG PS 0 ‚Äì2\n\n‚Ä¢ Central  ALK  testing (Ventana IHC) \n\nBaseline demographics \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nAge, years  Median (range)  51.0 (21‚àí78)  49.0 (28‚àí83) \n\nGender, %  Male / Female  51.2 / 48.8  54.8 / 45.2 \n\nECOG PS, %  0‚Äì1 / 2  96.8 / 3.2  98.4 / 1.6 \n\nSmoking status, %  Active smoker / Non -smoker / \n\nPast smoker  3.2 / 67.2 / 29.6  4.8 / 72.6 / 22.6 \n\nCNS metastases by IRC, %  Yes  35.2  37.1 \n\nCNS metastases by INV, %  Yes  33.6  32.3 \n\nPrior brain radiation, %  Yes  6.4  8.1 Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Updated analyses from ALESIA demonstrate durable PFS benefit for \n\n## alectinib versus crizotinib, irrespective of CNS involvement at baseline \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nData cut -off 16 May 2022. CI, confidence interval; CNS, central nervous system; HR, hazard ratio; ITT, intent -to -treat;  mets , metastases;  PFS, progression -free survival \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nMedian  PFS, months \n\n(95% CI) \n\n41.6 \n\n(33.1 ‚Äì58.9) \n\n11.1 \n\n(9.1 ‚Äì18.4) \n\nHR  (95% CI)  0.33  (0.23 ‚Äì0.49) \n\n0\n\n> PFS (%)\n\n6 36  66 60 54 48 42 30 24 18 12 \n\nTime (months) \n\n100 \n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\nCrizotinib (n=62) \n\nAlectinib (n=125) \n\nWith  CNS  mets  at baseline  Without  CNS  mets  at baseline \n\nAlectinib \n\nn=44 \n\nCrizotinib \n\nn=23 \n\nAlectinib \n\nn=81 \n\nCrizotinib \n\nn=39 \n\nMedian  PFS, months \n\n(95% CI) \n\n42.3 \n\n(27.8 ‚Äì60.7) \n\n9.2 \n\n(5.5 ‚Äì12.2) \n\n41.6 \n\n(29.5 ‚Äì64.9) \n\n12.7 \n\n(9.2 ‚Äì27.6) \n\nHR  (95% CI)  0.17  (0.09 ‚Äì0.33)  0.45  (0.29 ‚Äì0.71) \n\nCrizotinib (n=39) \n\nWithout  CNS  mets  at baseline \n\nAlectinib (n=81) \n\nUpdated PFS: ITT population \n\nTime (months) \n\n100 \n\n0\n\n> PFS (%)\n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\n36  66 54 18 6 60 42 30 24 12  48 \n\nCrizotinib (n=23) \n\nWith  CNS  mets  at baseline \n\nAlectinib (n=44) \n\nPFS according to CNS status at baseline Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## A clinically meaningful improvement in 5 -year OS rate was observed \n\n## for alectinib compared with crizotinib \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nData cut -off 16 May 2022. CI, confidence interval; CNS, central nervous system; HR, hazard ratio; ITT, intent -to -treat;  mets , metastases; NE, not evaluable; OS, overall survival; pts, patients \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nPts with event, n (%)  41 (32.8)  26 (41.9) \n\nMedian  OS, months \n\n(95% CI) \n\nNE \n\n(NE ‚ÄìNE) \n\nNE \n\n(45.5 ‚ÄìNE) \n\nHR  (95% CI)  0.60  (0.37 ‚Äì0.99) \n\n5-year OS rate , % \n\n(95% CI) \n\n66.4 \n\n(57.9 ‚Äì74.9) \n\n56.0 \n\n(43.0 ‚Äì69.1) \n\nPts remaining at risk, n  69  25 \n\n0\n\n> OS (%)\n\n6 36  66 60 54 48 42 30 24 18 12 \n\nTime (months) \n\n100 \n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\nCrizotinib (n=62) \n\nAlectinib (n=125) \n\nWith  CNS  mets  at baseline  Without  CNS  mets  at baseline \n\nAlectinib \n\nn=44 \n\nCrizotinib \n\nn=23 \n\nAlectinib \n\nn=81 \n\nCrizotinib \n\nn=39 \n\nPts with event, n (%)  16 (36.4)  12 (52.2)  25 (30.9)  14 (35.9) \n\nMedian  OS, months \n\n(95% CI) \n\nNE \n\n(51.4 ‚ÄìNE) \n\n46.2 \n\n(12.2 ‚ÄìNE) \n\nNE \n\n(NE ‚ÄìNE) \n\nNE \n\n(59.8 ‚ÄìNE) \n\nHR  (95% CI)  0.40  (0.19 ‚Äì0.85)  0.81  (0.42 ‚Äì1.55) \n\n5-year OS rate, % \n\n(95% CI) \n\n63.6 \n\n(48.9 ‚Äì78.3) \n\n39.3 \n\n(17.4 ‚Äì61.2) \n\n67.8 \n\n(57.4 ‚Äì78.2) \n\n64.9 \n\n(49.3 ‚Äì80.4) \n\nPts remaining at risk, n  25  6 44  19 \n\nCrizotinib (n=39) \n\nWithout  CNS  mets  at baseline \n\nAlectinib (n=81) \n\nUpdated OS: ITT population \n\nTime (months) \n\n100 \n\n0\n\n> OS (%)\n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\n36  66 54 18 6 60 42 30 24 12  48 \n\nCrizotinib (n=23) \n\nWith  CNS  mets  at baseline \n\nAlectinib (n=44) \n\nOS according to CNS status at baseline Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Treatment with alectinib delayed the time to CNS progression* \n\nThanyanan  Baisamut  (Reungwetwattana) \n\n*Derived from investigators' assessment. CNS PD = CNS Target Lesion PD per RECIST version 1.1, appearance of new CNS lesion(s ),  and/or unequivocal PD of Non -Target CNS lesion(s) \n\nData cut -off 16 May 2022. CI, confidence interval;  CIR, cumulative incidence rate;  CNS, central nervous system; HR, hazard ratio;  PD, progressive disease \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nCNS progression without prior systemic progression \n\nPatients with events, n (%)  18 (14.4)  22 (35.5) \n\nCause -specific HR  (95% CI)  0.16  (0.08 ‚Äì0.32) \n\nEstimated cumulative incidence, % (95% CI) \n\nAt 36 months  11.6 (6.7 ‚Äì18.1)  34.0 (22.1 ‚Äì46.2) \n\nAt 60 months  14.2 (8.6 ‚Äì21.1)  37.4 (25.0 ‚Äì49.7) \n\n40 \n\n0\n\n> Cumulative incidence (%)\n\n30 \n\n20 \n\n10 \n\n0 6 36  60 54 48 42 30 24 18 12 \n\nTime (months) \n\nCrizotinib (n=62) \n\nAlectinib (n=125) \n\nCIR: \n\n11.6% (95% CI 6.7 ‚Äì18.1) \n\nCIR: \n\n14.2% (95% CI 8.6 ‚Äì21.1) \n\nCIR: \n\n34.0% (95% CI 22.1 ‚Äì46.2) \n\nCIR: \n\n37.4% (95% CI 25.0 ‚Äì49.7) Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Post -progression therapy \n\nThanyanan  Baisamut  (Reungwetwattana)  \n\n> Data cut -off 16 May 2022. PD, progressive disease; VEGF, vascular endothelial growth factor\n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nPatients with PD , n  68  48 \n\nAnti -cancer therapy after PD , n (%)  42 (61.8)  38 (79.2) \n\nALK inhibitor , n (%)  25 (36.8)  28 (58.3) \n\nAlectinib  5 (7.4)  14 (29.2) \n\nLorlatinib  8 (11.8)  6 (12.5) \n\nBrigatinib  6 (8.8)  7 (14.6) \n\nCrizotinib  7 (10.3)  2 (4.2) \n\nCeritinib  3 (4.4)  4 (8.3) \n\nEnsartinib  2 (2.9)  1 (2.1) \n\nInvestigational drug  1 (1.5)  0\n\nChemotherapy , n (%)  24 (35.3)  15 (31.3) \n\nAnti -VEGF therapies , n ( %Ôºâ 9 (13.2)  3 (6.3) \n\nImmunotherapy , n (%)  3 (4.4)  2 (4.2) \n\nOther therapies , n (%)  6 (8.8)  7 (14.6) \n\nMore crizotinib patients (79.2% vs 61.8% alectinib) received at least one anti -cancer therapy post -progression \n\nApproximately 30% of patients in the crizotinib arm received alectinib after their disease progressed Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## The safety profile of alectinib remained favourable with longer \n\n## follow -up; no new safety signals were observed \n\nThanyanan  Baisamut  (Reungwetwattana) \n\n> *Three additional fatal events occurred during the longer follow -up: one was due to COVID -19 pneumonia, and the other two were r eported as ‚Äòdeath‚Äô and not related to alectinib treatment\n> Data cut -off 16 May 2022. AE, adverse event; ALT, alanine aminotransferase; ECG, electrocardiogram\n\nEvent, n  (%) \n\nAlectinib \n\n(n=125) \n\nCrizotinib \n\n(n=62) \n\nPatients with ‚â•1 \n\nAll grade AEs  125 (100)  62 (100) \n\nSerious AEs  35 (28.0)  18 (29.0) \n\nGrade ‚â•3 AEs  60 (48.0)  34 (54.8) \n\nFatal AEs  5 (4.0)*  3 (4.8) \n\nAEs leading to treatment discontinuation  14 (11.2)  9 (14.5) \n\nAEs leading to dose reduction  33 (26.4)  17 (27.4) \n\nAEs leading to dose interruption  33 (26.4)  19 (30.6) \n\nGrade ‚â•3 AEs with ‚â•3% difference \n\nin frequency between treatment arms, n  (%) \n\nAlectinib \n\n(n=125) \n\nCrizotinib \n\n(n=62) \n\nWeight increased  11 (8.8)  1 (1.6) \n\nBlood creatine phosphokinase increased  8 (6.4)  2 (3.2) \n\nALT increased  3 (2.4)  4 (6.5) \n\nNausea  1 (0.8)  3 (4.8) \n\nNeutrophil count decreased  0 9 (14.5) \n\nECG QT prolonged  0 3 (4.8) \n\nWhite blood cell count decreased  0 3 (4.8) \n\nDecreased appetite  0 3 (4.8) \n\nHyponatraemia  0 3 (4.8) \n\nInterstitial lung disease  0 3 (4.8) \n\nVomiting  0 3 (4.8) \n\nBradycardia  0 2 (3.2) \n\nHepatic function abnormal  0 2 (3.2) \n\nMedian treatment duration was more than three -times greater for alectinib (42.3 months) \n\ncompared to crizotinib (12.6 months) Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Conclusions:  5-year update from the Phase 3 ALESIA study   \n\n> Thanyanan Baisamut (Reungwetwattana )\n\nWith  at least 5 years  of follow -up, 1L alectinib  600mg twice daily  continues \n\nto demonstrate clinical benefit to Asian patients with advanced  ALK+  NSCLC, \n\nconsistent with  that observed in the  global ALEX study \n\nTreatment with alectinib also delayed the time to CNS progression \n\nThis clinical benefit, coupled with a tolerable and manageable safety profile, \n\nconfirms alectinib as standard -of -care treatment \n\nfor patients with advanced  ALK+  NSCLC Acknowledgements \n\nWe thank the participating patients and their families, study investigators, and research nurses \n\nThe ALESIA study was funded by F. Hoffmann -La Roche Ltd \n\nMedical writing support for the development of this presentation, under the direction \n\nof the authors, was provided by Fiona Duthie, PhD, of Ashfield MedComms, \n\nan Inizio company, and was funded by F. Hoffmann -La Roche Ltd\n"}, {'type': 'image', 'image_url': 'https://www.umc.edu/Research/Centers-and-Institutes/External-Designation-Centers/Mississippi-Poison-Control-Center/images/Medication-Label-1-A-E.jpg', 'image_description': 'The document outlines the drug facts of a medication, including its active ingredient, purposes such as pain relief and fever reduction, specific uses, warnings about allergic reactions and stomach bleeding, and instructions for use.'}, {'type': 'image', 'image_url': 'https://images.ctfassets.net/gi8mrztylj0k/7uYtc358SoGmfbZJwSffV4/4a6b40b9f5e3f8e7fea16ea0a96f143a/pasted_image_0__10_.png', 'image_description': 'The contents list various classes of food ingredients along with their definitions and requirements for labeling, including edible oils, fats, fish, meat, cheese, spices, and gums.'}, {'type': 'image', 'image_url': 'https://images.ctfassets.net/gi8mrztylj0k/2SwoBWSwLlal4WhyRZp7mK/424ea61f0461de8a7b51935a15fc5019/pasted_image_0__11_.png', 'image_description': 'A table listing various food and ingredient classes along with their respective class titles.'}, {'type': 'image', 'image_url': 'https://i.etsystatic.com/16874044/r/il/a74daa/3750620251/il_fullxfull.3750620251_8kd8.jpg', 'image_description': 'A list of ingredients includes Cocoa Mass, Cocoa Butter, and Milk, among others.'}, {'type': 'image', 'image_url': 'https://7esl.com/wp-content/uploads/2021/03/Foods-starting-with-r-scaled.jpg', 'image_description': 'A poster of foods that start with the letter R.'}], {'query': '"For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter \'C\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name."', 'follow_up_questions': None, 'answer': None, 'images': [{'url': 'https://www.umc.edu/Research/Centers-and-Institutes/External-Designation-Centers/Mississippi-Poison-Control-Center/images/Medication-Label-1-A-E.jpg', 'description': 'The document outlines the drug facts of a medication, including its active ingredient, purposes such as pain relief and fever reduction, specific uses, warnings about allergic reactions and stomach bleeding, and instructions for use.'}, {'url': 'https://images.ctfassets.net/gi8mrztylj0k/7uYtc358SoGmfbZJwSffV4/4a6b40b9f5e3f8e7fea16ea0a96f143a/pasted_image_0__10_.png', 'description': 'The contents list various classes of food ingredients along with their definitions and requirements for labeling, including edible oils, fats, fish, meat, cheese, spices, and gums.'}, {'url': 'https://images.ctfassets.net/gi8mrztylj0k/2SwoBWSwLlal4WhyRZp7mK/424ea61f0461de8a7b51935a15fc5019/pasted_image_0__11_.png', 'description': 'A table listing various food and ingredient classes along with their respective class titles.'}, {'url': 'https://i.etsystatic.com/16874044/r/il/a74daa/3750620251/il_fullxfull.3750620251_8kd8.jpg', 'description': 'A list of ingredients includes Cocoa Mass, Cocoa Butter, and Milk, among others.'}, {'url': 'https://7esl.com/wp-content/uploads/2021/03/Foods-starting-with-r-scaled.jpg', 'description': 'A poster of foods that start with the letter R.'}], 'results': [{'url': 'https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp', 'title': 'AIM-Harvard/MedBrowseComp ¬∑ Datasets at Hugging Face', 'content': '| CRIZOTINIB | "For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter \'C\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient | [...] | PF PRISM CV | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name | [...] | May 12, 2027 | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |', 'score': 0.92684203, 'raw_content': 'AIM-Harvard/MedBrowseComp ¬∑ Datasets at Hugging Face\n\n===============\n\n[![Image 1: Hugging Face\'s logo](https://huggingface.co/front/assets/huggingface_logo-noborder.svg)Hugging Face](https://huggingface.co/)\n\n*   [Models](https://huggingface.co/models)\n*   [Datasets](https://huggingface.co/datasets)\n*   [Spaces](https://huggingface.co/spaces)\n*    Community  \n*   [Docs](https://huggingface.co/docs)\n*   [Enterprise](https://huggingface.co/enterprise)\n*   [Pricing](https://huggingface.co/pricing)\n*    \n*   \n* * *\n\n*   [Log In](https://huggingface.co/login)\n*   [Sign Up](https://huggingface.co/join)\n\n[Datasets:](https://huggingface.co/datasets)\n\n* * *\n\n[![Image 2](https://cdn-avatars.huggingface.co/v1/production/uploads/63600b93d9e4214b9a67807c/ZRnXCRmf600I8gTKJH-V0.png)](https://huggingface.co/AIM-Harvard)\n\n[AIM-Harvard](https://huggingface.co/AIM-Harvard)\n\n/\n\n[MedBrowseComp](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp)\n\nlike 1\n\nFollow\n\n![Image 3](https://cdn-avatars.huggingface.co/v1/production/uploads/63600b93d9e4214b9a67807c/ZRnXCRmf600I8gTKJH-V0.png)AIM-Harvard 23\n===================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================\n\nTasks: [Question Answering](https://huggingface.co/datasets?task_categories=task_categories%3Aquestion-answering)[Text Retrieval](https://huggingface.co/datasets?task_categories=task_categories%3Atext-retrieval)\n\nModalities: [Text](https://huggingface.co/datasets?modality=modality%3Atext)\n\nFormats: [csv](https://huggingface.co/datasets?format=format%3Acsv)\n\nLanguages: [English](https://huggingface.co/datasets?language=language%3Aen)\n\nSize: [1K - 10K](https://huggingface.co/datasets?size_categories=size_categories%3A1K%3Cn%3C10K)\n\nArXiv: \n\narxiv:2505.14963\n\nTags: [medical](https://huggingface.co/datasets?other=medical)[healthcare](https://huggingface.co/datasets?other=healthcare)[browsing](https://huggingface.co/datasets?other=browsing)[comparison](https://huggingface.co/datasets?other=comparison)\n\nLibraries: [Datasets](https://huggingface.co/datasets?library=library%3Adatasets)[pandas](https://huggingface.co/datasets?library=library%3Apandas)\n\nCroissant\n\n+ 1\n\nLicense: \n\napache-2.0\n\n[Dataset card](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp)[Data Studio](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/viewer/)[Files Files and versions](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/tree/main)[Community 1](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/discussions)\n\nDataset Viewer\n\n[Auto-converted to Parquet](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/tree/refs%2Fconvert%2Fparquet/default)API Embed Data Studio\n\nSubset (1)\n\ndefault¬∑1.14k rows\n\n \n\nSplit (3)\n\nMedBrowseComp_50¬∑50 rows\n\n \n\nSQL \n\n Console \n\n| gold string lengths 5 24 | prompt string lengths 227 657 | task_name string classes 5 values |\n| --- | --- | --- |\n| ENZALUTAMIDE | "For clinical trial NCT00974311. Among the more effective regimen ingredients, find which ingredient starts with the letter \'E\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| CRIZOTINIB | "For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter \'C\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| LENALIDOMIDE | "For clinical trial NCT01938001. Among the more effective regimen ingredients, find which ingredient starts with the letter \'L\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| AZACITIDINE | "For clinical trial NCT00071799. Among the more effective regimen ingredients, find which ingredient starts with the letter \'A\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| IRINOTECAN HYDROCHLORIDE | "For clinical trial NCT00720512. Among the more effective regimen ingredients, find which ingredient starts with the letter \'I\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| VENETOCLAX | "For clinical trial NCT02755597. Among the more effective regimen ingredients, find which ingredient starts with the letter \'V\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| DEXAMETHASONE | "For clinical trial NCT00833833. Among the more effective regimen ingredients, find which ingredient starts with the letter \'D\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| IBRUTINIB | "For clinical trial NCT01973387. Among the more effective regimen ingredients, find which ingredient starts with the letter \'I\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| LENALIDOMIDE | "For clinical trial NCT00843882. Among the more effective regimen ingredients, find which ingredient starts with the letter \'L\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| SIROLIMUS | "For clinical trial NCT01231412. Among the more effective regimen ingredients, find which ingredient starts with the letter \'S\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| ASTELLAS | "First, for clinical trial NCT00974311, among the more effective regimen ingredients, identify which ingredient starts with the letter \'E\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| PF PRISM CV | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| BRISTOL MYERS SQUIBB | "First, for clinical trial NCT01938001, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| BRISTOL | "First, for clinical trial NCT00071799, among the more effective regimen ingredients, identify which ingredient starts with the letter \'A\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| IPSEN | "First, for clinical trial NCT00720512, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| ABBVIE | "First, for clinical trial NCT02755597, among the more effective regimen ingredients, identify which ingredient starts with the letter \'V\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| DEXCEL | "First, for clinical trial NCT00833833, among the more effective regimen ingredients, identify which ingredient starts with the letter \'D\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| PHARMACYCLICS LLC | "First, for clinical trial NCT01973387, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| BRISTOL MYERS SQUIBB | "First, for clinical trial NCT00843882, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| AADI SUB | "First, for clinical trial NCT01231412, among the more effective regimen ingredients, identify which ingredient starts with the letter \'S\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| Aug 13, 2027 | "First, for clinical trial NCT00974311, among the more effective regimen ingredients, identify which ingredient starts with the letter \'E\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| May 12, 2027 | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Apr 27, 2027 | "First, for clinical trial NCT01938001, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| May 14, 2029 | "First, for clinical trial NCT00071799, among the more effective regimen ingredients, identify which ingredient starts with the letter \'A\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Jan 6, 2027 | "First, for clinical trial NCT00720512, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Jan 29, 2032 | "First, for clinical trial NCT02755597, among the more effective regimen ingredients, identify which ingredient starts with the letter \'V\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Dec 18, 2037 | "First, for clinical trial NCT00833833, among the more effective regimen ingredients, identify which ingredient starts with the letter \'D\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Dec 3, 2031 | "First, for clinical trial NCT01973387, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Apr 27, 2027 | "First, for clinical trial NCT00843882, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Mar 5, 2036 | "First, for clinical trial NCT01231412, among the more effective regimen ingredients, identify which ingredient starts with the letter \'S\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Nov 17, 2026 | "For clinical trial NCT00974311, among the more effective regimen ingredients, identify which ingredient starts with the letter \'E\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Jul 14, 2025 | "For clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| May 28, 2026 | "For clinical trial NCT01938001, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Sep 1, 2027 | "For clinical trial NCT00071799, among the more effective regimen ingredients, identify which ingredient starts with the letter \'A\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Feb 13, 2031 | "For clinical trial NCT00720512, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| May 15, 2026 | "For clinical trial NCT02755597, among the more effective regimen ingredients, identify which ingredient starts with the letter \'V\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Oct 3, 2026 | "For clinical trial NCT00833833, among the more effective regimen ingredients, identify which ingredient starts with the letter \'D\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Aug 24, 2029 | "For clinical trial NCT01973387, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| May 28, 2026 | "For clinical trial NCT00843882, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Nov 22, 2028 | "For clinical trial NCT01231412, among the more effective regimen ingredients, identify which ingredient starts with the letter \'S\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| 15.98999977 | "For clinical trial NCT00974311, review the more effective regimen ingredients and identify which ingredient starts with the letter \'E\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 34.47000122 | "For clinical trial NCT02838420, review the less effective regimen ingredients and identify which ingredient starts with the letter \'C\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 46.72999954 | "For clinical trial NCT01938001, review the more effective regimen ingredients and identify which ingredient starts with the letter \'L\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 62.20000076 | "For clinical trial NCT00071799, review the more effective regimen ingredients and identify which ingredient starts with the letter \'A\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 15.14000034 | "For clinical trial NCT00720512, review the more effective regimen ingredients and identify which ingredient starts with the letter \'I\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 58.59000015 | "For clinical trial NCT02755597, review the more effective regimen ingredients and identify which ingredient starts with the letter \'V\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| NOT LISTED | "For clinical trial NCT00833833, review the more effective regimen ingredients and identify which ingredient starts with the letter \'D\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| NOT LISTED | "For clinical trial NCT01973387, review the more effective regimen ingredients and identify which ingredient starts with the letter \'I\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 46.72999954 | "For clinical trial NCT00843882, review the more effective regimen ingredients and identify which ingredient starts with the letter \'L\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 39.84000015 | "For clinical trial NCT01231412, review the more effective regimen ingredients and identify which ingredient starts with the letter \'S\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n\n*   [Datasets](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#datasets "Datasets")\n\n*   [Usage](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#usage "Usage")\n\n*   [GitHub Repository](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#github-repository "GitHub Repository")\n\n*   [Citation](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#citation "Citation")\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#medbrowsecomp-dataset) MedBrowseComp Dataset\n=========================================================================================================\n\nThis repository contains datasets for medical information-seeking-oriented deep research and computer use tasks.\n\n[![Image 4: Overall](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/resolve/main/medcomp.png)](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/blob/main/medcomp.png)\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#datasets) Datasets\n-------------------------------------------------------------------------------\n\nThe repository contains three harmonized datasets:\n\n1.   **MedBrowseComp_50**: A collection of 50 medical entries for browsing and comparison.\n2.   **MedBrowseComp_605**: A comprehensive collection of 605 medical entries.\n3.   **MedBrowseComp_CUA**: A curated collection of medical data for comparison and analysis.\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#usage) Usage\n-------------------------------------------------------------------------\n\nThese datasets can be used for various medical text processing tasks, information retrieval, and comparative analysis.\n\nExample usage with the Hugging Face datasets library:\n\n```python\nfrom datasets import load_dataset\n\n# Load the dataset\ndataset = load_dataset("AIM-Harvard/MedBrowseComp")\n\n# Access specific splits\nmed50_data = dataset["MedBrowseComp_50"]\nmed605_data = dataset["MedBrowseComp_605"]\ncua_data = dataset["MedBrowseComp_CUA"]\n```\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#github-repository) GitHub Repository\n-------------------------------------------------------------------------------------------------\n\nFor more information and related tools, visit: [https://github.com/MedBrowseComp](https://github.com/MedBrowseComp)\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#citation) Citation\n-------------------------------------------------------------------------------\n\nIf you use this dataset in your research, please cite: [https://arxiv.org/abs/2505.14963](https://arxiv.org/abs/2505.14963)\n\n```\n@misc{chen2025medbrowsecompbenchmarkingmedicaldeep,\n      title={MedBrowseComp: Benchmarking Medical Deep Research and Computer Use}, \n      author={Shan Chen and Pedro Moreira and Yuxin Xiao and Sam Schmidgall and Jeremy Warner and Hugo Aerts and Thomas Hartvigsen and Jack Gallifant and Danielle S. Bitterman},\n      year={2025},\n      eprint={2505.14963},\n      archivePrefix={arXiv},\n      primaryClass={cs.CL},\n      url={https://arxiv.org/abs/2505.14963}, \n}\n```\n\nDownloads last month 179\n\n Use this dataset \n\nSize of downloaded dataset files: 448 kB[Size of the auto-converted Parquet files: 58 kB](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/tree/refs%2Fconvert%2Fparquet/)Number of rows: 1,139\n\nCollection including AIM-Harvard/MedBrowseComp\n----------------------------------------------\n\n[#### MedBrowseComp Collection MedBrowseComp: Benchmarking Medical Deep Research and Computer Use‚Ä¢ 3 items‚Ä¢ Updated 10 days ago](https://huggingface.co/collections/AIM-Harvard/medbrowsecomp-6822637df90521b5d8b8b23f)\n\n System theme \n\nCompany\n\n[TOS](https://huggingface.co/terms-of-service)[Privacy](https://huggingface.co/privacy)[About](https://huggingface.co/huggingface)[Jobs](https://apply.workable.com/huggingface/)[](https://huggingface.co/)\n\nWebsite\n\n[Models](https://huggingface.co/models)[Datasets](https://huggingface.co/datasets)[Spaces](https://huggingface.co/spaces)[Pricing](https://huggingface.co/pricing)[Docs](https://huggingface.co/docs)\n'}, {'title': 'Alectinib and Crizotinib in Anaplastic Lymphoma Kinase-positive Non ...', 'url': 'https://ichgcp.net/clinical-trials-registry/NCT02838420', 'content': 'USA (FDA)\n       UK (MHRA)\n       AUSTRALIA (NHMRC)\n       JAPAN (PMDA)\n       EU (EMA)\n\n   CRO List\n   Clinical Trials\n\n       US Clinical Trials Registry\n       EU Clinical Trials Registry\n       Pharmaceutical Companies\n       Clinical Research Labs\n       Service Companies\n       Clinical Research Events\n       Publications\n       Researchers\n\n   Jobs\n   Publications\n   News\n\n   \n   \n\n   ICH GCP\n   US Clinical Trials Registry\n   Clinical Trial NCT02838420', 'score': 0.54724693, 'raw_content': 'Published Time: 2022-12-12T02:32:10+00:00\n\nAlectinib and Crizotinib in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer - Clinical Trials Registry - ICH GCP\n\n===============\n\n[![Image 1: ICHGCP](https://ichgcp.net/img/ichgcp_logo.png)](https://ichgcp.net/)\n\n*   Regulations\n\n    *   [GLOBAL¬ª](https://ichgcp.net/clinical-trials-registry/NCT02838420#)\n\n        *   [ICH GCP (De)](https://ichgcp.net/de)\n        *   [ICH GCP (En)](https://ichgcp.net/)\n        *   [ICH GCP (Es)](https://ichgcp.net/es)\n        *   [ICH GCP (Fr)](https://ichgcp.net/fr)\n        *   [ICH GCP (It)](https://ichgcp.net/it)\n        *   [ICH GCP (Pt)](https://ichgcp.net/pt)\n        *   [ICH GCP (Ru)](https://ichgcp.net/ru)\n\n    *   [USA (FDA)](https://ichgcp.net/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects)\n    *   [UK (MHRA)](https://ichgcp.net/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol)\n    *   [AUSTRALIA (NHMRC)](https://ichgcp.net/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia)\n    *   [JAPAN (PMDA)](https://ichgcp.net/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan)\n    *   [EU (EMA)](https://ichgcp.net/ich-e-group-of-guidelines)\n\n*   [CRO List](https://ichgcp.net/cro-list)\n*   Clinical Trials\n\n    *   [US Clinical Trials Registry](https://ichgcp.net/clinical-trials-registry)\n    *   [EU Clinical Trials Registry](https://ichgcp.net/eu-clinical-trials-registry)\n    *   [Pharmaceutical Companies](https://ichgcp.net/pharma-list)\n    *   [Clinical Research Labs](https://ichgcp.net/labs)\n    *   [Service Companies](https://ichgcp.net/service-companies)\n    *   [Clinical Research Events](https://ichgcp.net/events)\n    *   [Publications](https://ichgcp.net/clinical-trials-registry/publications)\n    *   [Researchers](https://ichgcp.net/clinical-trials-registry/researchers)\n\n*   [Jobs](https://ichgcp.net/jobs)\n*   [Publications](https://ichgcp.net/publications)\n*   [News](https://ichgcp.net/news)\n\n*   [](https://telegram.me/share/url?url=https://ichgcp.net/clinical-trials-registry/NCT02838420&text= "Share on telegram")\n*   [](https://twitter.com/intent/tweet?url=https://ichgcp.net/clinical-trials-registry/NCT02838420 "Share on Twitter")\n\n*   [ICH GCP](https://ichgcp.net/)\n*   [US Clinical Trials Registry](https://ichgcp.net/clinical-trials-registry)\n*   Clinical Trial NCT02838420\n\nA Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)\n=========================================================================================================================================================================================================================================================================\n\nMarch 24, 2025 updated by: [Hoffmann-La Roche](https://ichgcp.net/clinical-trials-registry/research/list?spons=Hoffmann-La%20Roche "List all studies sponsored by Hoffmann-La Roche")\n\nRandomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Asian Patients With Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer\n--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\nThis randomized, multicenter, Phase III, open-label study will evaluate the efficacy and safety of alectinib versus crizotinib and to evaluate the pharmacokinetics of alectinib in asian participants with treatment-naive ALK-positive advanced NSCLC. Participants will be randomized 2:1 into one of the two treatment groups to receive either alectinib (600 milligrams [mg] twice daily [BID]) or crizotinib (250 mg BID) orally, respectively.\n\nStudy Overview\n--------------\n\n#### Status\n\nActive, not recruiting\n\n#### Conditions\n\n*   [Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%20Lymphoma%20Kinase-positive%20Non-small%20Cell%20Lung%20Cancer "List all studies focused on condition Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer")\n\n#### Intervention / Treatment\n\n*   [Drug: Alectinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Alectinib "List all studies with intervention Alectinib")\n*   [Drug: Crizotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Crizotinib "List all studies with intervention Crizotinib")\n\n#### Study Type\n\n Interventional \n\n#### Enrollment (Actual)\n\n 187 \n\n#### Phase\n\n*   Phase 3\n\nContacts and Locations\n----------------------\n\nThis section provides the contact details for those conducting the study, and information on where this study is being conducted.\n\n### Study Locations\n\n*   [China](https://ichgcp.net/clinical-trials-registry/research/list?locn=China "List all studies conducted in China") \n    *           *   Beijing, China, 100142 \n            *   Beijing Cancer Hospital\n\n        *   Beijing, China, 101149 \n            *   Beijing Chest Hospital\n\n        *   Changchun, China, 130021 \n            *   The First Hospital of Jilin University\n\n        *   Changchun, China, 132013 \n            *   Jilin cancer hospital\n\n        *   Chengdu, China, 610041 \n            *   West China Hospital, Sichuan University\n\n        *   Guangzhou, China, 510060 \n            *   Sun Yet-sen University Cancer Center\n\n        *   Guangzhou, China, 510080 \n            *   Guangdong General Hospital\n\n        *   Guangzhou, China, 510120 \n            *   The First Affiliated Hospital of Guangzhou Medical University\n\n        *   Hangzhou, China, 310003 \n            *   The First Affiliated Hospital of College of Medicine, Zhejiang University\n\n        *   Hangzhou, China, 310022 \n            *   Zhejiang Cancer Hospital\n\n        *   Harbin, China, 150081 \n            *   Harbin Medical University Cancer Hospital\n\n        *   Nanjing, China, 210009 \n            *   Jiangsu Cancer Hospital\n\n        *   Shanghai, China, 200030 \n            *   Shanghai Chest Hospital\n\n        *   Shanghai, China, 200032 \n            *   Fudan University Shanghai Cancer Center\n\n        *   Shanghai, China, 200433 \n            *   Shanghai Pulmonary Hospital\n\n*   [Korea, Republic of](https://ichgcp.net/clinical-trials-registry/research/list?locn=Korea%2C%20Republic%20of "List all studies conducted in Korea, Republic of") \n    *           *   Seoul, Korea, Republic of, 05505 \n            *   Asan Medical Center\n\n        *   Seoul, Korea, Republic of, 06351 \n            *   Samsung Medical Center\n\n        *   Seoul, Korea, Republic of, 03181 \n            *   Kangbuk Samsung Hospital\n\n*   [Thailand](https://ichgcp.net/clinical-trials-registry/research/list?locn=Thailand "List all studies conducted in Thailand") \n    *           *   Bangkok, Thailand, 10400 \n            *   Rajavithi Hospital\n\n        *   Bangkok, Thailand, 10400 \n            *   Ramathibodi Hospital\n\n        *   Songkhla, Thailand, 90110 \n            *   Songklanagarind hospital\n\nParticipation Criteria\n----------------------\n\nResearchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person\'s general health condition or prior treatments.\n\n### Eligibility Criteria\n\n#### Ages Eligible for Study\n\n 18 years and older (Adult, Older Adult) \n\n#### Accepts Healthy Volunteers\n\n No \n\n#### Description\n\nInclusion Criteria:\n\n*   Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive as assessed by the Ventana immunohistochemistry (IHC) test. Sufficient tumor tissue available to perform ALK IHC is required. Ventana IHC testing will be performed at the designated central laboratory\n*   Life expectancy of at least 12 weeks\n*   Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2\n*   No history of receiving systemic treatment for advanced, recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC\n*   Adequate hematologic function: Platelet count greater than equal to (>=) 100√ó10^9 per liter (/L); absolute neutrophil count (ANC) >=1500 cells per microliter (cells/mcL); hemoglobin>=9.0 grams per deciliter (g/dL)\n*   Adequate renal function: an estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease (MDRD) formula of >=45 milliliters per minute per 1.73 square meter\n*   Participants must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before receiving the first dose of study treatment\n*   Measurable disease (by Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v1.1]) before administration of study treatment\n*   Previous brain or leptomeningeal metastases are allowed if the participant is asymptomatic (e.g., diagnosed incidentally at study baseline). Asymptomatic central nervous system (CNS) lesions may be treated at the discretion of the investigator as per local clinical practice. If participant has neurological symptoms or signs because of CNS metastasis, the participant must complete whole-brain radiation or gamma knife irradiation treatment. In all cases, radiation treatment must be completed >=14 days before enrollment and disease must be clinically stable\n*   For all females of childbearing potential, a negative serum pregnancy test result must be obtained within 3 days prior to starting study treatment\n*   For women who are not postmenopausal (>=12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus), agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Examples of contraceptive methods with a failure rate of <1% per year include tubal ligation, male sterilization, hormonal implants, established, proper use of combined oral or injected hormonal contraceptives, and certain intrauterine devices. Alternatively, two methods (e.g., two barrier methods such as a condom and a cervical cap) may be combined to achieve a failure rate of <1% per year. Barrier methods must always be supplemented with the use of a spermicide\n*   For men, agreement to remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception\n\nExclusion Criteria:\n\n*   A malignancy within the previous 3 years (other than curatively treated basal cell carcinoma of the skin, early gastrointestinal (GI) cancer by endoscopic resection, in situ carcinoma of the cervix, or any cured cancer that is considered to have no impact in progression-free survival (PFS) or overall survival (OS) for the current NSCLC)\n*   Any GI disorder that may affect absorption of oral medications, such as malabsorption syndrome or status post-major bowel resection\n*   Liver disease characterized by:\n*   Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than (>) 3√ó the upper limit of normal (ULN; >=5√óULN for participants with concurrent liver metastases) confirmed on two consecutive measurements; or\n*   Impaired excretory function (e.g., hyperbilirubinemia), synthetic function, or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices; or\n*   Acute viral or active autoimmune, alcoholic, or other types of hepatitis\n*   National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 Grade 3 or higher toxicities because of any previous therapy (e.g., radiotherapy) (excluding alopecia), which have not shown improvement and are strictly considered to interfere with current study medication\n*   History of organ transplant\n*   Co-administration of anti-cancer therapies other than those administered in this study\n*   Baseline QTc >470 ms or symptomatic bradycardia\n*   Administration of strong/potent cytochrome P4503A inhibitors or inducers within 14 days prior to the receiving the first dose of study treatment and during treatment with alectinib or crizotinib\n*   Administration of agents with potential QT interval prolonging effects within 14 days prior to receiving the first dose of study drug\n*   History of hypersensitivity to any of the additives in the alectinib or crizotinib drug formulation\n*   Pregnant or lactating\n*   Known human immunodeficiency virus (HIV-positivity or acquired immunodeficiency syndrome (AIDS)-related illness\n*   Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or the absorption of oral medications or that would, in the opinion of the Principal Investigator, pose an unacceptable risk to the participant in this study\n*   Any psychological, familial, sociological, or geographical condition that potentially hampers compliance with the study protocol requirements or follow-up procedures; those conditions should be discussed with the participant before study entry\n\nStudy Plan\n----------\n\nThis section provides details of the study plan, including how the study is designed and what the study is measuring.\n\n### How is the study designed?\n\n#### Design Details\n\n*   **Primary Purpose**: Treatment\n*   **Allocation**: Randomized\n*   **Interventional Model**: Parallel Assignment\n*   **Masking**: None (Open Label)\n\n#### Number of Arms\n\n2\n\n#### Arms and Interventions\n\n| ##### Participant Group / Arm | ##### Intervention / Treatment |\n| --- | --- |\n| Experimental: Alectinib Participants will receive alectinib capsules orally at a dose of 600 mg BID with food until disease progression, unacceptable toxicity withdrawal of consent, or death. | [Drug: Alectinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Alectinib "List all studies with intervention Alectinib") Alectinib capsules will be administered orally at a dose of 600 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death. Other Names: * RO5424802 |\n| Active Comparator: Crizotinib Participants will receive crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity withdrawal of consent, or death. | [Drug: Crizotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Crizotinib "List all studies with intervention Crizotinib") Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death. |\n\n### What is the study measuring?\n\n#### Primary Outcome Measures\n\n| ##### Outcome Measure | ##### Measure Description | ##### Time Frame |\n| --- | --- | --- |\n| Progression-Free Survival (PFS) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 Time Frame: From the date of randomization to the date of the first documented disease progression or death, whichever occurred first (up to overall period of approximately 40 months) | PFS was defined as the time (in months) from randomization to the first documentation of disease progression, as determined by the investigators, or to death from any cause, whichever occurred first. | From the date of randomization to the date of the first documented disease progression or death, whichever occurred first (up to overall period of approximately 40 months) |\n\n#### Secondary Outcome Measures\n\n| ##### Outcome Measure | ##### Measure Description | ##### Time Frame |\n| --- | --- | --- |\n| PFS as Determined by Independent Review Committee (IRC) Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) | PFS was defined as the time (in months) from randomization to the first documentation of disease progression, as determined by an independent review committee, or to death from any cause, whichever occurred first. | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Percentage of Participants With Objective Response of Complete Response (CR) or Partial Response (PR) as Determined by Investigator Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Time to Progression of Disease in the CNS as Determined by IRC Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Time to Progression of Disease in the CNS as Determined by IRC Using Response Assessment in Neuro-Oncology (RANO) Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Duration of Response (DOR) Assessed by Investigator Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Overall Survival Time Time Frame: Baseline, until death (up to overall period of approximately 40 months) |  | Baseline, until death (up to overall period of approximately 40 months) |\n| Percentage of Participants With Non-serious Adverse Events and Serious Adverse Events Time Frame: Up to overall period of approximately 40 months | An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. | Up to overall period of approximately 40 months |\n| Time to Deterioration Assessed Using EORTC Quality of Life Questionnaire-Core (QLQ-C30) Score Time Frame: Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Time to Deterioration Assessed Using EORTC Quality of Life Questionnaire-Lung Cancer Module (QLQ-LC13) Score Time Frame: Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Area Under the Plasma Concentration-time Curve (AUC) of Alectinib and Its Metabolite Time Frame: Baseline and Week 4 predose (within 2 hours before administration of study drug) | AUC was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time. | Baseline and Week 4 predose (within 2 hours before administration of study drug) |\n| Maximum Plasma Concentration Observed (Cmax) of Alectinib and Its Metabolite Time Frame: Baseline and Week 4 predose (within 2 hours before administration of study drug) | Cmax was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time. | Baseline and Week 4 predose (within 2 hours before administration of study drug) |\n| Time to Cmax (Tmax) of Alectinib and Its Metabolite Time Frame: Baseline and Week 4 predose (within 2 hours before administration of study drug) | Tmax was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time. | Baseline and Week 4 predose (within 2 hours before administration of study drug) |\n\nCollaborators and Investigators\n-------------------------------\n\nThis is where you will find people and organizations involved with this study.\n\n#### Sponsor\n\n[Hoffmann-La Roche](https://ichgcp.net/clinical-trials-registry/research/list?spons=Hoffmann-La%20Roche "List all studies sponsored by Hoffmann-La Roche")\n\n#### Investigators\n\n*    Study Director: Clinical Trials, Hoffmann-La Roche \n\nPublications and helpful links\n------------------------------\n\nThe person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.\n\n#### General Publications\n\n*   [Zhou C, Kim SW, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang JJ, Cheng Y, Lee SH, Bu L, Xu T, Yang L, Wang C, Liu T, Morcos PN, Lu Y, Zhang L. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med. 2019 May;7(5):437-446. doi: 10.1016/S2213-2600(19)30053-0. Epub 2019 Apr 10.](https://pubmed.ncbi.nlm.nih.gov/30981696)\n\nStudy record dates\n------------------\n\nThese dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.\n\n### Study Major Dates\n\n#### Study Start (Actual)\n\n August 3, 2016 \n\n#### Primary Completion (Actual)\n\n May 31, 2018 \n\n#### Study Completion (Estimated)\n\n December 31, 2025 \n\n### Study Registration Dates\n\n#### First Submitted\n\nJuly 18, 2016\n\n#### First Submitted That Met QC Criteria\n\nJuly 18, 2016\n\n#### First Posted (Estimated)\n\nJuly 20, 2016\n\n### Study Record Updates\n\n#### Last Update Posted (Actual)\n\nMarch 25, 2025\n\n#### Last Update Submitted That Met QC Criteria\n\nMarch 24, 2025\n\n#### Last Verified\n\nMarch 1, 2025\n\nMore Information\n----------------\n\n### Terms related to this study\n\n#### Additional Relevant MeSH Terms\n\n*   [Neoplasms by Site](https://ichgcp.net/clinical-trials-registry/research/list?cond=Neoplasms%20by%20Site "List all studies by MeSH term: Neoplasms by Site")\n*   [Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Neoplasms "List all studies by MeSH term: Neoplasms")\n*   [Immune System Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Immune%20System%20Diseases "List all studies by MeSH term: Immune System Diseases")\n*   [Respiratory Tract Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Diseases "List all studies by MeSH term: Respiratory Tract Diseases")\n*   [Neoplasms by Histologic Type](https://ichgcp.net/clinical-trials-registry/research/list?cond=Neoplasms%20by%20Histologic%20Type "List all studies by MeSH term: Neoplasms by Histologic Type")\n*   [Lung Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%20Diseases "List all studies by MeSH term: Lung Diseases")\n*   [Respiratory Tract Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Neoplasms "List all studies by MeSH term: Respiratory Tract Neoplasms")\n*   [Thoracic Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Thoracic%20Neoplasms "List all studies by MeSH term: Thoracic Neoplasms")\n*   [Lymphatic Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphatic%20Diseases "List all studies by MeSH term: Lymphatic Diseases")\n*   [Lymphoproliferative Disorders](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoproliferative%20Disorders "List all studies by MeSH term: Lymphoproliferative Disorders")\n*   [Immunoproliferative Disorders](https://ichgcp.net/clinical-trials-registry/research/list?cond=Immunoproliferative%20Disorders "List all studies by MeSH term: Immunoproliferative Disorders")\n*   [Carcinoma, Bronchogenic](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%2C%20Bronchogenic "List all studies by MeSH term: Carcinoma, Bronchogenic")\n*   [Bronchial Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Bronchial%20Neoplasms "List all studies by MeSH term: Bronchial Neoplasms")\n*   [Lung Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%20Neoplasms "List all studies by MeSH term: Lung Neoplasms")\n*   [Lymphoma](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma "List all studies by MeSH term: Lymphoma")\n*   [Carcinoma, Non-Small-Cell Lung](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%2C%20Non-Small-Cell%20Lung "List all studies by MeSH term: Carcinoma, Non-Small-Cell Lung")\n*   [Tyrosine Kinase Inhibitors](https://ichgcp.net/clinical-trials-registry/research/list?intr=Tyrosine%20Kinase%20Inhibitors "List all studies by MeSH term: Tyrosine Kinase Inhibitors")\n*   [Antineoplastic Agents](https://ichgcp.net/clinical-trials-registry/research/list?intr=Antineoplastic%20Agents "List all studies by MeSH term: Antineoplastic Agents")\n*   [Molecular Mechanisms of Pharmacological Action](https://ichgcp.net/clinical-trials-registry/research/list?intr=Molecular%20Mechanisms%20of%20Pharmacological%20Action "List all studies by MeSH term: Molecular Mechanisms of Pharmacological Action")\n*   [Enzyme Inhibitors](https://ichgcp.net/clinical-trials-registry/research/list?intr=Enzyme%20Inhibitors "List all studies by MeSH term: Enzyme Inhibitors")\n*   [Protein Kinase Inhibitors](https://ichgcp.net/clinical-trials-registry/research/list?intr=Protein%20Kinase%20Inhibitors "List all studies by MeSH term: Protein Kinase Inhibitors")\n*   [Crizotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Crizotinib "List all studies by MeSH term: Crizotinib")\n*   [Alectinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Alectinib "List all studies by MeSH term: Alectinib")\n\n#### Other Study ID Numbers\n\n*    YO29449 \n\n### Drug and device information, study documents\n\n#### Studies a U.S. FDA-regulated drug product\n\n Yes \n\n#### Studies a U.S. FDA-regulated device product\n\n No \n\nThis information was retrieved directly from the website [clinicaltrials.gov](https://clinicaltrials.gov/) without any changes. If you have any requests to change, remove or update your study details, please contact [register@clinicaltrials.gov](mailto:register@clinicaltrials.gov). As soon as a change is implemented on [clinicaltrials.gov](https://clinicaltrials.gov/), this will be updated automatically on our website as well.\n\nClinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer\n---------------------------------------------------------------------------------\n\n*    Pfizer   Completed  [A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001)](https://ichgcp.net/clinical-trials-registry/NCT00585195)  Systemic Anaplastic Large-Cell Lymphoma | Non-Small Cell Lung Cancer ALK-positive | Non-Small Cell Lung Cancer c-Met Dependent | Non-Small Cell Lung Cancer ROS Marker Positive | Advanced Malignancies Except Leukemia   United States, Korea, Republic of, Australia, Japan    \n*    Novartis Pharmaceuticals   Available  [Managed Access Programs for LDK378, Ceritinib](https://ichgcp.net/clinical-trials-registry/NCT05100134)  Non-small Cell Lung Cancer (NSCLC) | Anaplastic Lymphoma Kinase (ALK)- Positive Tumors    \n*    Novartis Pharmaceuticals   Completed  [Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer](https://ichgcp.net/clinical-trials-registry/NCT01772797)  Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase (ALK)   Australia, Spain, Singapore, Italy, United States    \n*    Nuvalent Inc.   Recruiting  [Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC (ALKAZAR)](https://ichgcp.net/clinical-trials-registry/NCT06765109)  Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase-positive   United States    \n*    Intergroupe Francophone de Cancerologie Thoracique   Completed  [Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements (CLINALK)](https://ichgcp.net/clinical-trials-registry/NCT02727335)  Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase Gene Mutation   France    \n*    Takeda   Completed  [A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors](https://ichgcp.net/clinical-trials-registry/NCT03546894)  Carcinoma Non-small-cell Lung | Anaplastic Lymphoma Kinase-positive   United States    \n*    Astellas Pharma Inc   Completed  [Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)](https://ichgcp.net/clinical-trials-registry/NCT01284192)  Solid Tumor | B-Cell Lymphoma | Advanced Malignancies | Positive for Anaplastic Lymphoma Kinase | Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS   United States    \n*    University Medical Center Groningen  Radboud University Medical Center; Maastricht University Medical Center; Erasmus... and other collaborators    Recruiting  [Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels (ADAPT ALEC)](https://ichgcp.net/clinical-trials-registry/NCT05525338)  Carcinoma, Non-Small-Cell Lung | Lung Cancer | Drug Monitoring | Anaplastic Lymphoma Kinase Gene Mutation | Anaplastic Lymphoma Kinase Gene Translocation   Netherlands, France    \n*    Takeda   Withdrawn  [Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors](https://ichgcp.net/clinical-trials-registry/NCT04260009)  Solid Tumors | Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma | Inflammatory Myofibroblastic Tumors    \n*    Massachusetts General Hospital  LUNGevity Foundation; Addario Lung Cancer Medical Institute    Recruiting  [Immune and Genomic Markers in ALK+ NSCLC](https://ichgcp.net/clinical-trials-registry/NCT04881916)  Non-Small Cell Lung Cancer | Anaplastic Lymphoma Kinase Gene Translocation   United States    \n\nClinical Trials on Alectinib\n----------------------------\n\n*    Aarhus University Hospital  Roche Pharma AG    Enrolling by invitation  [Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients (MonAlec)](https://ichgcp.net/clinical-trials-registry/NCT04708639)  Lung Cancer | ALK Gene Mutation | Resistance, Disease | Mutation   Denmark    \n*    Hoffmann-La Roche   Completed  [A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (ATALK)](https://ichgcp.net/clinical-trials-registry/NCT03155009)  Carcinoma, Non-Small-Cell Lung   France    \n*    Hoffmann-La Roche   Completed  [Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea](https://ichgcp.net/clinical-trials-registry/NCT03271554)  Non-Small Cell Lung Cancer   Korea, Republic of    \n*    Dana-Farber Cancer Institute  Genentech, Inc.    Terminated  [A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer](https://ichgcp.net/clinical-trials-registry/NCT03131206)  ALK-positive Non-small Cell Lung Cancer (NSCLC) | RET-positive Non-small Cell Lung Cancer (NSCLC) | RET-positive Thyroid Cancer   United States    \n*    Hoffmann-La Roche   Completed  [Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib](https://ichgcp.net/clinical-trials-registry/NCT02621047)  Hepatic Impairment   Czechia, Slovakia    \n*    Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...  UnitedHealthcare    Not yet recruiting  [Pharmacogenomics IND EXEMPT SNP Clinical Study - Alectinib and Single Nucleotide Polymorphisms (Drugs-SNPs)](https://ichgcp.net/clinical-trials-registry/NCT05987956)  Non-small Cell Lung Cancer   United States    \n*    Hoffmann-La Roche   Terminated  [A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors (ALpha-T)](https://ichgcp.net/clinical-trials-registry/NCT04644315)  Digestive System Diseases | Gastrointestinal Diseases | Melanoma | Sarcoma | Neoplasms | Respiratory Tract Diseases | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasms | Head and Neck Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms and other conditions   United States    \n*    China Medical University Hospital   Active, not recruiting  [Alectinib in Combination with Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided with Serum RNase1 and Tumor Expression of PD-L1](https://ichgcp.net/clinical-trials-registry/NCT06354387)  Hepatocellular Carcinoma   Taiwan    \n*    Genentech, Inc.   No longer available  [Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy](https://ichgcp.net/clinical-trials-registry/NCT02271139)  Non-Small Cell Lung Cancer   United States    \n*    Hoffmann-La Roche   Completed  [A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)](https://ichgcp.net/clinical-trials-registry/NCT01871805)  Non-Small Cell Lung Cancer   United States, Canada    \n\nSearch Similar Trials\n---------------------\n\n*   [Clinical Trials on Lymphoma in Singapore](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=Singapore)\n*   [Clinical Trials on Lymphosarcoma in Australia](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=Australia)\n*   [Clinical Trials on Carcinoma, Non-Small-Cell Lung in Singapore](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BNon-Small-Cell%2BLung&locn=Singapore)\n*   [Clinical Trials on Lymphoma in New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=New%2BZealand)\n*   [Clinical Trials on Carcinoma, Non-Small-Cell Lung in United States](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BNon-Small-Cell%2BLung&locn=United%2BStates)\n*   [Clinical Trials on Lung Neoplasms in Ireland](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%2BNeoplasms&locn=Ireland)\n*   [Clinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%2BLymphoma%2BKinase-positive%2BNon-small%2BCell%2BLung%2BCancer&locn=South%2BAfrica)\n*   [Clinical Trials on Lymphosarcoma in India](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=India)\n*   [Clinical Trials on Lymphoma in United States](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=United%2BStates)\n*   [Clinical Trials on Lymphoma in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=South%2BAfrica)\n*   [Clinical Trials on Lymphoma in Hong Kong](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=Hong%2BKong)\n*   [Clinical Trials on Lymphosarcoma in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=South%2BAfrica)\n*   [Clinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer in Ireland](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%2BLymphoma%2BKinase-positive%2BNon-small%2BCell%2BLung%2BCancer&locn=Ireland)\n*   [Clinical Trials on Lung Neoplasms in New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%2BNeoplasms&locn=New%2BZealand)\n*   [Clinical Trials on Lung Neoplasms in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%2BNeoplasms&locn=South%2BAfrica)\n*   [Clinical Trials on Lymphoma in India](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=India)\n*   [Clinical Trials on Lymphosarcoma in Singapore](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=Singapore)\n*   [Clinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer in New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%2BLymphoma%2BKinase-positive%2BNon-small%2BCell%2BLung%2BCancer&locn=New%2BZealand)\n*   [Clinical Trials on Lymphosarcoma in United States](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=United%2BStates)\n*   [Clinical Trials on Carcinoma, Non-Small-Cell Lung in United Kingdom](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BNon-Small-Cell%2BLung&locn=United%2BKingdom)\n*   [Search All Trials](https://ichgcp.net/clinical-trials-registry/research/list)\n\nSponsors and Collaborators\n--------------------------\n\n*   [Eisai Korea Inc.](https://ichgcp.net/clinical-trials-registry/research/list?spons=Eisai%2BKorea%2BInc.)\n*   [Leukaemia & Blood Cancer New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?spons=Leukaemia%2B%2526%2BBlood%2BCancer%2BNew%2BZealand)\n*   [Udaan](https://ichgcp.net/clinical-trials-registry/research/list?spons=Udaan)\n*   [Makarenko Irina Romanovna](https://ichgcp.net/clinical-trials-registry/research/list?spons=Makarenko%2BIrina%2BRomanovna)\n*   [Adriane Aver Vanin](https://ichgcp.net/clinical-trials-registry/research/list?spons=Adriane%2BAver%2BVanin)\n*   [University of Memphis](https://ichgcp.net/clinical-trials-registry/research/list?spons=University%2Bof%2BMemphis)\n*   [Sleep Research Society Foundation](https://ichgcp.net/clinical-trials-registry/research/list?spons=Sleep%2BResearch%2BSociety%2BFoundation)\n*   [Immuron Ltd.](https://ichgcp.net/clinical-trials-registry/research/list?spons=Immuron%2BLtd.)\n*   [Arthro-Anda Tianjin Biologic Technology Co., Ltd.](https://ichgcp.net/clinical-trials-registry/research/list?spons=Arthro-Anda%2BTianjin%2BBiologic%2BTechnology%2BCo.%252C%2BLtd.)\n*   [CoheroHealth](https://ichgcp.net/clinical-trials-registry/research/list?spons=CoheroHealth)\n*   [Center for Military Mental Health, Berlin, Germany](https://ichgcp.net/clinical-trials-registry/research/list?spons=Center%2Bfor%2BMilitary%2BMental%2BHealth%252C%2BBerlin%252C%2BGermany)\n*   [Kevin Flanigan](https://ichgcp.net/clinical-trials-registry/research/list?spons=Kevin%2BFlanigan)\n*   [Periannan Kuppusamy](https://ichgcp.net/clinical-trials-registry/research/list?spons=Periannan%2BKuppusamy)\n*   [Chiang Mai University Hospital, THAILAND](https://ichgcp.net/clinical-trials-registry/research/list?spons=Chiang%2BMai%2BUniversity%2BHospital%252C%2BTHAILAND)\n*   [Centre for Emergency Health Sciences](https://ichgcp.net/clinical-trials-registry/research/list?spons=Centre%2Bfor%2BEmergency%2BHealth%2BSciences)\n*   [Therapex Co., Ltd](https://ichgcp.net/clinical-trials-registry/research/list?spons=Therapex%2BCo.%252C%2BLtd)\n*   [MIT William Asbjornsen Albert Memorial Fellowship](https://ichgcp.net/clinical-trials-registry/research/list?spons=MIT%2BWilliam%2BAsbjornsen%2BAlbert%2BMemorial%2BFellowship)\n*   [Fabiana Aceto](https://ichgcp.net/clinical-trials-registry/research/list?spons=Fabiana%2BAceto)\n*   [North American Spine Society](https://ichgcp.net/clinical-trials-registry/research/list?spons=North%2BAmerican%2BSpine%2BSociety)\n*   [SGS proderm GmbH](https://ichgcp.net/clinical-trials-registry/research/list?spons=SGS%2Bproderm%2BGmbH)\n*   [View Full List](https://ichgcp.net/clinical-trials-registry/research/browse/spns_alpha_all)\n\nMedical Conditions\n------------------\n\n*   [Infrarenal Abdominal Aortic Aneurysms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Infrarenal%2BAbdominal%2BAortic%2BAneurysms)\n*   [Myeloproliferative Disease, Not Classified](https://ichgcp.net/clinical-trials-registry/research/list?cond=Myeloproliferative%2BDisease%252C%2BNot%2BClassified)\n*   [Lifestyle-related Condition](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lifestyle-related%2BCondition)\n*   [Compliance](https://ichgcp.net/clinical-trials-registry/research/list?cond=Compliance)\n*   [Patients With Opioid Induced Constipation](https://ichgcp.net/clinical-trials-registry/research/list?cond=Patients%2BWith%2BOpioid%2BInduced%2BConstipation)\n*   [Femoral Vascular Anastomosis](https://ichgcp.net/clinical-trials-registry/research/list?cond=Femoral%2BVascular%2BAnastomosis)\n*   [Observation Safety](https://ichgcp.net/clinical-trials-registry/research/list?cond=Observation%2BSafety)\n*   [Improvement of Functionality](https://ichgcp.net/clinical-trials-registry/research/list?cond=Improvement%2Bof%2BFunctionality)\n*   [CD4 Deficiency](https://ichgcp.net/clinical-trials-registry/research/list?cond=CD4%2BDeficiency)\n*   [Malassezia Infection](https://ichgcp.net/clinical-trials-registry/research/list?cond=Malassezia%2BInfection)\n*   [Anti-cancer Cell Immunotherapy](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anti-cancer%2BCell%2BImmunotherapy)\n*   [Health Knowledge Attitudes and Practice](https://ichgcp.net/clinical-trials-registry/research/list?cond=Health%2BKnowledge%2BAttitudes%2Band%2BPractice)\n*   [School Adjustment](https://ichgcp.net/clinical-trials-registry/research/list?cond=School%2BAdjustment)\n*   [Difficult Mask Ventilation](https://ichgcp.net/clinical-trials-registry/research/list?cond=Difficult%2BMask%2BVentilation)\n*   [Intrapartum Mortality](https://ichgcp.net/clinical-trials-registry/research/list?cond=Intrapartum%2BMortality)\n*   [Diabetes Mellitus II](https://ichgcp.net/clinical-trials-registry/research/list?cond=Diabetes%2BMellitus%2BII)\n*   [Painless Myocardial Ischemia](https://ichgcp.net/clinical-trials-registry/research/list?cond=Painless%2BMyocardial%2BIschemia)\n*   [Corona Virus Disease 19 (COVID-19)](https://ichgcp.net/clinical-trials-registry/research/list?cond=Corona%2BVirus%2BDisease%2B19%2B%2528COVID-19%2529)\n*   [Pressure Injury Stage 2](https://ichgcp.net/clinical-trials-registry/research/list?cond=Pressure%2BInjury%2BStage%2B2)\n*   [Escape; Rhythm](https://ichgcp.net/clinical-trials-registry/research/list?cond=Escape%253B%2BRhythm)\n*   [View Full List](https://ichgcp.net/clinical-trials-registry/research/browse/cond_alpha_all)\n\nDrug Interventions\n------------------\n\n*   [Methylprednisolone](https://ichgcp.net/clinical-trials-registry/research/list?intr=Methylprednisolone)\n*   [Anetumab Ravtansine](https://ichgcp.net/clinical-trials-registry/research/list?intr=Anetumab%2BRavtansine)\n*   [ESES treated with clobazam](https://ichgcp.net/clinical-trials-registry/research/list?intr=ESES%2Btreated%2Bwith%2Bclobazam)\n*   [Droperidol Injectable Solution](https://ichgcp.net/clinical-trials-registry/research/list?intr=Droperidol%2BInjectable%2BSolution)\n*   [ATx201](https://ichgcp.net/clinical-trials-registry/research/list?intr=ATx201)\n*   [Cyclophosphamide](https://ichgcp.net/clinical-trials-registry/research/list?intr=Cyclophosphamide)\n*   [Pioglitazone](https://ichgcp.net/clinical-trials-registry/research/list?intr=Pioglitazone)\n*   [Botulinum Toxin A](https://ichgcp.net/clinical-trials-registry/research/list?intr=Botulinum%2BToxin%2BA)\n*   [Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Gefitinib%2B250mg%2Bpo%2Bqd%2Bor%2BTarceva%2B150mg%2Bpo%2Bqd%2Bor%2BIcotinib%2B125mg%2Bpo%2Btid%2BOther%2BName%253A%2BGefitinib%252FTarceva%252FIcotinib)\n*   [Ramosetron](https://ichgcp.net/clinical-trials-registry/research/list?intr=Ramosetron)\n*   [KN046](https://ichgcp.net/clinical-trials-registry/research/list?intr=KN046)\n*   [Doxorubicin](https://ichgcp.net/clinical-trials-registry/research/list?intr=Doxorubicin)\n*   [Corticosteroids (CS)](https://ichgcp.net/clinical-trials-registry/research/list?intr=Corticosteroids%2B%2528CS%2529)\n*   [Dimenhydrinate](https://ichgcp.net/clinical-trials-registry/research/list?intr=Dimenhydrinate)\n*   [Ropivacaine 150 mg](https://ichgcp.net/clinical-trials-registry/research/list?intr=Ropivacaine%2B150%2Bmg)\n*   [Iso-Fludelone](https://ichgcp.net/clinical-trials-registry/research/list?intr=Iso-Fludelone)\n*   [Clonidine](https://ichgcp.net/clinical-trials-registry/research/list?intr=Clonidine)\n*   [Lidocaine topical](https://ichgcp.net/clinical-trials-registry/research/list?intr=Lidocaine%2Btopical)\n*   [Nusinersen](https://ichgcp.net/clinical-trials-registry/research/list?intr=Nusinersen)\n*   [Cyclophosphamide and fludarabine](https://ichgcp.net/clinical-trials-registry/research/list?intr=Cyclophosphamide%2Band%2Bfludarabine)\n*   [View Full List](https://ichgcp.net/clinical-trials-registry/research/browse/intr_alpha_all)\n\n### CROs by country\n\n*   [Contract Research Organizations in Azerbaijan](https://ichgcp.net/cro-list/country/azerbaijan)\n*   [Contract Research Organizations in Bulgaria](https://ichgcp.net/cro-list/country/bulgaria)\n*   [Contract Research Organizations in Burundi](https://ichgcp.net/cro-list/country/burundi)\n*   [Contract Research Organizations in Dominican Republic](https://ichgcp.net/cro-list/country/dominican_republic)\n*   [Contract Research Organizations in Kosovo](https://ichgcp.net/cro-list/country/kosovo)\n*   [Contract Research Organizations in Mexico](https://ichgcp.net/cro-list/country/mexico)\n*   [Contract Research Organizations in Moldova](https://ichgcp.net/cro-list/country/moldova)\n*   [Contract Research Organizations in Poland](https://ichgcp.net/cro-list/country/poland)\n*   [Contract Research Organizations in Slovakia](https://ichgcp.net/cro-list/country/slovakia)\n*   [Contract Research Organizations in Sri Lanka](https://ichgcp.net/cro-list/country/sri_lanka)\n*   [Contract Research Organizations in Ukraine](https://ichgcp.net/cro-list/country/ukraine)\n*   [Contract Research Organizations in United Arab Emirates](https://ichgcp.net/cro-list/country/united_arab_emirates)\n*   [Contract Research Organizations in Uzbekistan](https://ichgcp.net/cro-list/country/uzbekistan)\n*   [CRO list by country](https://ichgcp.net/cro-list)\n\n### CROs in Ghana\n\n*   [54gene‚Äôs Clinical Programs Group (CPG)](https://ichgcp.net/cro-list/country/ghana/company/54gene_s_clinical_programs_group_cpg)\n*   [SGS](https://ichgcp.net/cro-list/country/ghana/company/sgs)\n*   [ACROSS Global](https://ichgcp.net/cro-list/country/ghana/company/across_global)\n*   [All CROs in Ghana](https://ichgcp.net/cro-list/country/ghana)\n\n### Conditions\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/cond_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/cond_cat)\n\n### Rare Diseases\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/ord_alpha_all)\n\n### Drug Interventions\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/intr_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/intr_cat)\n\n### Dietary Supplements\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/diet_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/diet_cat)\n\n### Sponsor/Collaborators\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/spns_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/spns_cat)\n\n### Locations\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/locn_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/locn_cat)\n\nRegulations\n\n*   [GLOBAL (ICH GCP)](https://ichgcp.net/)\n*   [USA (FDA)](https://ichgcp.net/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects)\n*   [UK (MHRA)](https://ichgcp.net/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol)\n*   [AUSTRALIA (NHMRC)](https://ichgcp.net/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia)\n*   [JAPAN (PMDA)](https://ichgcp.net/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan)\n*   [EU (EMA)](https://ichgcp.net/guideline-for-the-notification-of-serious-breaches-of-regulation-eu-no-536-2014)\n\nResources\n\n*   [CRO List](https://ichgcp.net/cro-list)\n*   [Pharmaceutical Companies](https://ichgcp.net/pharma-list)\n*   [Clinical Research Labs](https://ichgcp.net/labs)\n*   [Service Companies](https://ichgcp.net/service-companies)\n*   [Jobs](https://ichgcp.net/cra-jobs)\n*   [US Clinical Trials Registry](https://ichgcp.net/clinical-trials-registry)\n*   [EU Clinical Trials Registry](https://ichgcp.net/eu-clinical-trials-registry)\n\nArticles\n\n*   [Publications](https://ichgcp.net/publications)\n*   [News](https://ichgcp.net/news)\n*   [About us / Our mission](https://ichgcp.net/about-us-our-mission)\n\nSearch trials\n\nExample: Heart Attack\n\n¬© ICH GCP. All Rights Reserved.\n\n*   [Sitemap](https://ichgcp.net/sitemap)\n*   [Contact us](https://ichgcp.net/contact-us)\n*   [RSS feed](https://ichgcp.net/feed)\n*   [Privacy Policy](https://ichgcp.net/privacy)\n*   [Disclaimer](https://ichgcp.net/disclaimer)\n\n English \n\n[Dansk](https://ichgcp.net/da/clinical-trials-registry/NCT02838420)[Deutsch](https://ichgcp.net/de/clinical-trials-registry/NCT02838420)[English](https://ichgcp.net/clinical-trials-registry/NCT02838420)[Espa√±ol](https://ichgcp.net/es/clinical-trials-registry/NCT02838420)[Fran√ßais](https://ichgcp.net/fr/clinical-trials-registry/NCT02838420)[Italiano](https://ichgcp.net/it/clinical-trials-registry/NCT02838420)[Magyar](https://ichgcp.net/hu/clinical-trials-registry/NCT02838420)[Nederlands](https://ichgcp.net/nl/clinical-trials-registry/NCT02838420)[Norsk](https://ichgcp.net/no/clinical-trials-registry/NCT02838420)[Polski](https://ichgcp.net/pl/clinical-trials-registry/NCT02838420)[Portugu√™s](https://ichgcp.net/pt/clinical-trials-registry/NCT02838420)[Suomi](https://ichgcp.net/fi/clinical-trials-registry/NCT02838420)[Svenska](https://ichgcp.net/sv/clinical-trials-registry/NCT02838420)[ƒåe≈°tina](https://ichgcp.net/cs/clinical-trials-registry/NCT02838420)[–†—É—Å—Å–∫–∏–π](https://ichgcp.net/ru/clinical-trials-registry/NCT02838420)[Êó•Êú¨Ë™û](https://ichgcp.net/ja/clinical-trials-registry/NCT02838420)[ÁÆÄ‰Ωì‰∏≠Êñá](https://ichgcp.net/zh/clinical-trials-registry/NCT02838420)[ÌïúÍµ≠Ïñ¥](https://ichgcp.net/ko/clinical-trials-registry/NCT02838420)\n\nGOOD CLINICAL PRACTICE NETWORK\n\nSubscribe to receive notifications of new clinical trials you are interested in.\n\nSubscribe\n\n‚úï\n\nGOOD CLINICAL PRACTICE NETWORK\n\nSubscribe to receive notifications of new clinical trials you are interested in.\n\nSubscribe for upcoming trials that contain the following conditions: \n\n- [x] Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer \n\n[Choose more conditions](https://ichgcp.net/mailing-list/conditions)\n\nSubscribe for upcoming trials that contain the following interventions: \n\n- [x] Alectinib \n\n- [x] Crizotinib \n\n[Choose more interventions](https://ichgcp.net/mailing-list/interventions)\n\nSubscribe for upcoming trials sponsored by: \n\n- [x] Hoffmann-La Roche \n\n[Choose more organizations](https://ichgcp.net/mailing-list/organizations)\n\nSubscribe\n\nSubscribe\n\nSubscribe\n'}, {'title': 'Alectinib vs crizotinib in Asian patients with treatment-na√Øve ... - Roche', 'url': 'https://medically.roche.com/global/en/medical-material/ESMO-Asia-2022-presentation-zhou-alectinib-vs-crizotinib-in-asian-patients-with-treatment-naive-advanced-pdf.html', 'content': 'Data cut -off 16 May 2022. ClinicalTrials.gov: NCT02838420. CNS, central nervous system; DOR, duration of response;  ECOG PS, Eastern Cooperative Oncology Group performance status; IHC, immunohistochemistry; INV, investigator \n\nIRC, independent review committee; NSCLC, non -small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, p rogression -free survival \n\n2:1 \n\nN=187 \n\nR\n\nAlectinib \n\n600mg  twice daily \n\nCrizotinib \n\n250mg twice daily \n\nTreat until disease', 'score': 0.5393963, 'raw_content': "Alectinib vs crizotinib in Asian patients \n\n## with treatment -na√Øve advanced  ALK +\n\n## non -small cell lung cancer: 5 -year \n\n## update from the Phase 3 ALESIA study \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nFaculty of Medicine  Ramathibodi  Hospital, Mahidol University, \n\nBangkok, Thailand \n\nZhou C, 1 Lu Y, 2 Kim S -W, 3 Baisamut  (Reungwetwattana) T, 4 Zhou J, 5 Zhang Y, 6 He J, 7 Yang J -J, 8 Cheng Y, 9 Lee S -H, 10  Chang J, 11 \n\nFang J, 12  Liu Z, 13  Bu L, 14  Qian L, 14  Xu T, 14  Archer V, 15  Hilton M, 16  Zhou M, 14  Zhang L 17 \n\n1Shanghai Pulmonary Hospital, Tongji University, Shanghai, China;  2West China Hospital, Sichuan University, Chengdu, China;  3Asan Medical \n\nCenter , University of Ulsan College of Medicine, Seoul, South Korea;  4Faculty of Medicine  Ramathibodi  Hospital, Mahidol University, Bangkok, \n\nThailand;  5The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China;  6Zhejiang Cancer Hospital, Hangzhou, China; \n\n7The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;  8Guangdong Lung Cancer Institute, Guangdong General Hospital, \n\nGuangzhou, China;  9Jilin Cancer Hospital, Changchun, China;  10 Sungkyunkwan University School of Medicine, Seoul, South Korea;  11 Cancer \n\nHospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China;  12 Beijing Cancer \n\nHospital, Beijing, China;  13 Beijing Chest Hospital, Capital Medical University, Beijing, China;  14 Roche Pharma Development, Shanghai, China; \n\n15 Roche Products Ltd, Welwyn Garden City, UK;  16 F. Hoffmann -La Roche Ltd, Basel, Switzerland;  17 Sun  Yat -sen  University Cancer  Center ,\n\nState Key Laboratory of Oncology in South China, Collaborative Innovation  Center  for Cancer Medicine, Guangzhou, China Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## DECLARATION OF INTERESTS \n\nThanyanan  Baisamut  (Reungwetwattana) \n\n‚Ä¢ Received honorarium from AstraZeneca, Pfizer, MSD, Roche, BMS, Amgen, J&J, Novartis,  Yuhan  and  Zuellig \n\n‚Ä¢ Participated as Principal Investigator on clinical trials for AstraZeneca, MSD, Roche, Novartis and  Yuhan   \n\n> Thanyanan Baisamut (Reungwetwattana)\n\nContent of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## ALESIA: alectinib vs crizotinib in treatment -na√Øve Asian patients \n\n## with advanced  ALK+  NSCLC \n\n‚Ä¢ Stratification factors:  ECOG PS (0/1 vs 2) \n\nand CNS metastases at baseline (yes vs no) \n\n‚Ä¢ Primary endpoint:  PFS by INV \n\n‚Ä¢ Secondary endpoints:  Time to CNS \n\nprogression by IRC, ORR by INV, \n\nDOR by INV, OS and safety \n\n‚Ä¢ Median duration of survival follow -up: \n\n61 months  alectinib vs  51 months  crizotinib \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nPatients were enrolled from China, Thailand and South Korea. *Asymptomatic CNS metastases allowed. \n\nData cut -off 16 May 2022. ClinicalTrials.gov: NCT02838420. CNS, central nervous system; DOR, duration of response;  ECOG PS, Eastern Cooperative Oncology Group performance status; IHC, immunohistochemistry; INV, investigator \n\nIRC, independent review committee; NSCLC, non -small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, p rogression -free survival \n\n2:1 \n\nN=187 \n\nR\n\nAlectinib \n\n600mg  twice daily \n\nCrizotinib \n\n250mg twice daily \n\nTreat until disease \n\nprogression, toxicity, \n\nwithdrawal or death \n\nNo crossover permitted \n\nStage IIIB/IV  ALK + NSCLC* \n\n‚Ä¢ Asian patients \n\n‚Ä¢ Treatment na√Øve \n\n‚Ä¢ ECOG PS 0 ‚Äì2\n\n‚Ä¢ Central  ALK  testing (Ventana IHC) \n\nBaseline demographics \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nAge, years  Median (range)  51.0 (21‚àí78)  49.0 (28‚àí83) \n\nGender, %  Male / Female  51.2 / 48.8  54.8 / 45.2 \n\nECOG PS, %  0‚Äì1 / 2  96.8 / 3.2  98.4 / 1.6 \n\nSmoking status, %  Active smoker / Non -smoker / \n\nPast smoker  3.2 / 67.2 / 29.6  4.8 / 72.6 / 22.6 \n\nCNS metastases by IRC, %  Yes  35.2  37.1 \n\nCNS metastases by INV, %  Yes  33.6  32.3 \n\nPrior brain radiation, %  Yes  6.4  8.1 Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Updated analyses from ALESIA demonstrate durable PFS benefit for \n\n## alectinib versus crizotinib, irrespective of CNS involvement at baseline \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nData cut -off 16 May 2022. CI, confidence interval; CNS, central nervous system; HR, hazard ratio; ITT, intent -to -treat;  mets , metastases;  PFS, progression -free survival \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nMedian  PFS, months \n\n(95% CI) \n\n41.6 \n\n(33.1 ‚Äì58.9) \n\n11.1 \n\n(9.1 ‚Äì18.4) \n\nHR  (95% CI)  0.33  (0.23 ‚Äì0.49) \n\n0\n\n> PFS (%)\n\n6 36  66 60 54 48 42 30 24 18 12 \n\nTime (months) \n\n100 \n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\nCrizotinib (n=62) \n\nAlectinib (n=125) \n\nWith  CNS  mets  at baseline  Without  CNS  mets  at baseline \n\nAlectinib \n\nn=44 \n\nCrizotinib \n\nn=23 \n\nAlectinib \n\nn=81 \n\nCrizotinib \n\nn=39 \n\nMedian  PFS, months \n\n(95% CI) \n\n42.3 \n\n(27.8 ‚Äì60.7) \n\n9.2 \n\n(5.5 ‚Äì12.2) \n\n41.6 \n\n(29.5 ‚Äì64.9) \n\n12.7 \n\n(9.2 ‚Äì27.6) \n\nHR  (95% CI)  0.17  (0.09 ‚Äì0.33)  0.45  (0.29 ‚Äì0.71) \n\nCrizotinib (n=39) \n\nWithout  CNS  mets  at baseline \n\nAlectinib (n=81) \n\nUpdated PFS: ITT population \n\nTime (months) \n\n100 \n\n0\n\n> PFS (%)\n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\n36  66 54 18 6 60 42 30 24 12  48 \n\nCrizotinib (n=23) \n\nWith  CNS  mets  at baseline \n\nAlectinib (n=44) \n\nPFS according to CNS status at baseline Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## A clinically meaningful improvement in 5 -year OS rate was observed \n\n## for alectinib compared with crizotinib \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nData cut -off 16 May 2022. CI, confidence interval; CNS, central nervous system; HR, hazard ratio; ITT, intent -to -treat;  mets , metastases; NE, not evaluable; OS, overall survival; pts, patients \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nPts with event, n (%)  41 (32.8)  26 (41.9) \n\nMedian  OS, months \n\n(95% CI) \n\nNE \n\n(NE ‚ÄìNE) \n\nNE \n\n(45.5 ‚ÄìNE) \n\nHR  (95% CI)  0.60  (0.37 ‚Äì0.99) \n\n5-year OS rate , % \n\n(95% CI) \n\n66.4 \n\n(57.9 ‚Äì74.9) \n\n56.0 \n\n(43.0 ‚Äì69.1) \n\nPts remaining at risk, n  69  25 \n\n0\n\n> OS (%)\n\n6 36  66 60 54 48 42 30 24 18 12 \n\nTime (months) \n\n100 \n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\nCrizotinib (n=62) \n\nAlectinib (n=125) \n\nWith  CNS  mets  at baseline  Without  CNS  mets  at baseline \n\nAlectinib \n\nn=44 \n\nCrizotinib \n\nn=23 \n\nAlectinib \n\nn=81 \n\nCrizotinib \n\nn=39 \n\nPts with event, n (%)  16 (36.4)  12 (52.2)  25 (30.9)  14 (35.9) \n\nMedian  OS, months \n\n(95% CI) \n\nNE \n\n(51.4 ‚ÄìNE) \n\n46.2 \n\n(12.2 ‚ÄìNE) \n\nNE \n\n(NE ‚ÄìNE) \n\nNE \n\n(59.8 ‚ÄìNE) \n\nHR  (95% CI)  0.40  (0.19 ‚Äì0.85)  0.81  (0.42 ‚Äì1.55) \n\n5-year OS rate, % \n\n(95% CI) \n\n63.6 \n\n(48.9 ‚Äì78.3) \n\n39.3 \n\n(17.4 ‚Äì61.2) \n\n67.8 \n\n(57.4 ‚Äì78.2) \n\n64.9 \n\n(49.3 ‚Äì80.4) \n\nPts remaining at risk, n  25  6 44  19 \n\nCrizotinib (n=39) \n\nWithout  CNS  mets  at baseline \n\nAlectinib (n=81) \n\nUpdated OS: ITT population \n\nTime (months) \n\n100 \n\n0\n\n> OS (%)\n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\n36  66 54 18 6 60 42 30 24 12  48 \n\nCrizotinib (n=23) \n\nWith  CNS  mets  at baseline \n\nAlectinib (n=44) \n\nOS according to CNS status at baseline Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Treatment with alectinib delayed the time to CNS progression* \n\nThanyanan  Baisamut  (Reungwetwattana) \n\n*Derived from investigators' assessment. CNS PD = CNS Target Lesion PD per RECIST version 1.1, appearance of new CNS lesion(s ),  and/or unequivocal PD of Non -Target CNS lesion(s) \n\nData cut -off 16 May 2022. CI, confidence interval;  CIR, cumulative incidence rate;  CNS, central nervous system; HR, hazard ratio;  PD, progressive disease \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nCNS progression without prior systemic progression \n\nPatients with events, n (%)  18 (14.4)  22 (35.5) \n\nCause -specific HR  (95% CI)  0.16  (0.08 ‚Äì0.32) \n\nEstimated cumulative incidence, % (95% CI) \n\nAt 36 months  11.6 (6.7 ‚Äì18.1)  34.0 (22.1 ‚Äì46.2) \n\nAt 60 months  14.2 (8.6 ‚Äì21.1)  37.4 (25.0 ‚Äì49.7) \n\n40 \n\n0\n\n> Cumulative incidence (%)\n\n30 \n\n20 \n\n10 \n\n0 6 36  60 54 48 42 30 24 18 12 \n\nTime (months) \n\nCrizotinib (n=62) \n\nAlectinib (n=125) \n\nCIR: \n\n11.6% (95% CI 6.7 ‚Äì18.1) \n\nCIR: \n\n14.2% (95% CI 8.6 ‚Äì21.1) \n\nCIR: \n\n34.0% (95% CI 22.1 ‚Äì46.2) \n\nCIR: \n\n37.4% (95% CI 25.0 ‚Äì49.7) Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Post -progression therapy \n\nThanyanan  Baisamut  (Reungwetwattana)  \n\n> Data cut -off 16 May 2022. PD, progressive disease; VEGF, vascular endothelial growth factor\n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nPatients with PD , n  68  48 \n\nAnti -cancer therapy after PD , n (%)  42 (61.8)  38 (79.2) \n\nALK inhibitor , n (%)  25 (36.8)  28 (58.3) \n\nAlectinib  5 (7.4)  14 (29.2) \n\nLorlatinib  8 (11.8)  6 (12.5) \n\nBrigatinib  6 (8.8)  7 (14.6) \n\nCrizotinib  7 (10.3)  2 (4.2) \n\nCeritinib  3 (4.4)  4 (8.3) \n\nEnsartinib  2 (2.9)  1 (2.1) \n\nInvestigational drug  1 (1.5)  0\n\nChemotherapy , n (%)  24 (35.3)  15 (31.3) \n\nAnti -VEGF therapies , n ( %Ôºâ 9 (13.2)  3 (6.3) \n\nImmunotherapy , n (%)  3 (4.4)  2 (4.2) \n\nOther therapies , n (%)  6 (8.8)  7 (14.6) \n\nMore crizotinib patients (79.2% vs 61.8% alectinib) received at least one anti -cancer therapy post -progression \n\nApproximately 30% of patients in the crizotinib arm received alectinib after their disease progressed Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## The safety profile of alectinib remained favourable with longer \n\n## follow -up; no new safety signals were observed \n\nThanyanan  Baisamut  (Reungwetwattana) \n\n> *Three additional fatal events occurred during the longer follow -up: one was due to COVID -19 pneumonia, and the other two were r eported as ‚Äòdeath‚Äô and not related to alectinib treatment\n> Data cut -off 16 May 2022. AE, adverse event; ALT, alanine aminotransferase; ECG, electrocardiogram\n\nEvent, n  (%) \n\nAlectinib \n\n(n=125) \n\nCrizotinib \n\n(n=62) \n\nPatients with ‚â•1 \n\nAll grade AEs  125 (100)  62 (100) \n\nSerious AEs  35 (28.0)  18 (29.0) \n\nGrade ‚â•3 AEs  60 (48.0)  34 (54.8) \n\nFatal AEs  5 (4.0)*  3 (4.8) \n\nAEs leading to treatment discontinuation  14 (11.2)  9 (14.5) \n\nAEs leading to dose reduction  33 (26.4)  17 (27.4) \n\nAEs leading to dose interruption  33 (26.4)  19 (30.6) \n\nGrade ‚â•3 AEs with ‚â•3% difference \n\nin frequency between treatment arms, n  (%) \n\nAlectinib \n\n(n=125) \n\nCrizotinib \n\n(n=62) \n\nWeight increased  11 (8.8)  1 (1.6) \n\nBlood creatine phosphokinase increased  8 (6.4)  2 (3.2) \n\nALT increased  3 (2.4)  4 (6.5) \n\nNausea  1 (0.8)  3 (4.8) \n\nNeutrophil count decreased  0 9 (14.5) \n\nECG QT prolonged  0 3 (4.8) \n\nWhite blood cell count decreased  0 3 (4.8) \n\nDecreased appetite  0 3 (4.8) \n\nHyponatraemia  0 3 (4.8) \n\nInterstitial lung disease  0 3 (4.8) \n\nVomiting  0 3 (4.8) \n\nBradycardia  0 2 (3.2) \n\nHepatic function abnormal  0 2 (3.2) \n\nMedian treatment duration was more than three -times greater for alectinib (42.3 months) \n\ncompared to crizotinib (12.6 months) Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Conclusions:  5-year update from the Phase 3 ALESIA study   \n\n> Thanyanan Baisamut (Reungwetwattana )\n\nWith  at least 5 years  of follow -up, 1L alectinib  600mg twice daily  continues \n\nto demonstrate clinical benefit to Asian patients with advanced  ALK+  NSCLC, \n\nconsistent with  that observed in the  global ALEX study \n\nTreatment with alectinib also delayed the time to CNS progression \n\nThis clinical benefit, coupled with a tolerable and manageable safety profile, \n\nconfirms alectinib as standard -of -care treatment \n\nfor patients with advanced  ALK+  NSCLC Acknowledgements \n\nWe thank the participating patients and their families, study investigators, and research nurses \n\nThe ALESIA study was funded by F. Hoffmann -La Roche Ltd \n\nMedical writing support for the development of this presentation, under the direction \n\nof the authors, was provided by Fiona Duthie, PhD, of Ashfield MedComms, \n\nan Inizio company, and was funded by F. Hoffmann -La Roche Ltd\n"}], 'response_time': 9.73})
2025-06-18 19:18:55,322 - src.graph.nodes - INFO - Planner generating full plan
2025-06-18 19:19:02,255 - httpx - INFO - HTTP Request: POST https://2791-3-16-2-146.ngrok-free.app/v1/chat/completions "HTTP/1.1 200 OK"
2025-06-18 19:19:02,266 - process_medbrowse_questions - ERROR - Workflow execution failed: Failed to parse Plan from completion {}. Got: 4 validation errors for Plan
locale
  Field required [type=missing, input_value={}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
has_enough_context
  Field required [type=missing, input_value={}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
thought
  Field required [type=missing, input_value={}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
title
  Field required [type=missing, input_value={}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
For troubleshooting, visit: https://python.langchain.com/docs/troubleshooting/errors/OUTPUT_PARSING_FAILURE 
2025-06-18 19:19:02,267 - process_medbrowse_questions - WARNING - Parser error (attempt 1/5) for question 2: Failed to parse Plan from completion {}. Got: 4 validation errors for Plan
locale
  Field required [type=missing, input_value={}, input_type=dict]
    For further information visit https://errors.pyda...
2025-06-18 19:19:02,267 - process_medbrowse_questions - INFO - Will retry in 2s... (2/5)
2025-06-18 19:19:04,269 - process_medbrowse_questions - INFO - Retry attempt 2/5 for question 2
2025-06-18 19:19:04,270 - process_medbrowse_questions - INFO - Running workflow (attempt 2) with params: max_plan_iterations=1, max_step_num=3
2025-06-18 19:19:04,270 - src.workflow - INFO - Starting async workflow with user input: "For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter 'C'.\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name."
2025-06-18 19:19:04,277 - src.graph.nodes - INFO - Coordinator talking.
2025-06-18 19:19:04,278 - src.graph.nodes - INFO - Starting new research session - clearing previous sources
2025-06-18 19:19:04,278 - src.tools.tavily_extractor - DEBUG - Cleared 3 temp sources
2025-06-18 19:19:08,696 - httpx - INFO - HTTP Request: POST https://2791-3-16-2-146.ngrok-free.app/v1/chat/completions "HTTP/1.1 200 OK"
2025-06-18 19:19:08,700 - src.graph.nodes - DEBUG - Current state messages: [HumanMessage(content='"For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter \'C\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name."', additional_kwargs={}, response_metadata={}, id='d44146db-7e6a-4808-a65f-2465a4f62446')]
2025-06-18 19:19:08,704 - src.graph.nodes - INFO - background investigation node is running.
2025-06-18 19:19:08,705 - src.tools.decorators - DEBUG - Tool TavilySearchResultsWithImages._run called with parameters: "For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter 'C'.\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name."
2025-06-18 19:19:09,926 - src.tools.tavily_extractor - DEBUG - Stored Tavily source: AIM-Harvard/MedBrowseComp ¬∑ Datasets at Hugging Face
2025-06-18 19:19:09,926 - src.tools.tavily_extractor - DEBUG - Stored Tavily source: Alectinib and Crizotinib in Anaplastic Lymphoma Kinase-positive Non ...
2025-06-18 19:19:09,926 - src.tools.tavily_extractor - DEBUG - Stored Tavily source: Alectinib vs crizotinib in Asian patients with treatment-na√Øve ... - Roche
2025-06-18 19:19:09,935 - src.tools.decorators - DEBUG - Tool TavilySearchResultsWithImages returned: ([{'type': 'page', 'title': 'AIM-Harvard/MedBrowseComp ¬∑ Datasets at Hugging Face', 'url': 'https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp', 'content': '| CRIZOTINIB | "For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter \'C\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient | [...] | PF PRISM CV | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name | [...] | May 12, 2027 | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |', 'score': 0.92684203, 'raw_content': 'AIM-Harvard/MedBrowseComp ¬∑ Datasets at Hugging Face\n\n===============\n\n[![Image 1: Hugging Face\'s logo](https://huggingface.co/front/assets/huggingface_logo-noborder.svg)Hugging Face](https://huggingface.co/)\n\n*   [Models](https://huggingface.co/models)\n*   [Datasets](https://huggingface.co/datasets)\n*   [Spaces](https://huggingface.co/spaces)\n*    Community  \n*   [Docs](https://huggingface.co/docs)\n*   [Enterprise](https://huggingface.co/enterprise)\n*   [Pricing](https://huggingface.co/pricing)\n*    \n*   \n* * *\n\n*   [Log In](https://huggingface.co/login)\n*   [Sign Up](https://huggingface.co/join)\n\n[Datasets:](https://huggingface.co/datasets)\n\n* * *\n\n[![Image 2](https://cdn-avatars.huggingface.co/v1/production/uploads/63600b93d9e4214b9a67807c/ZRnXCRmf600I8gTKJH-V0.png)](https://huggingface.co/AIM-Harvard)\n\n[AIM-Harvard](https://huggingface.co/AIM-Harvard)\n\n/\n\n[MedBrowseComp](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp)\n\nlike 1\n\nFollow\n\n![Image 3](https://cdn-avatars.huggingface.co/v1/production/uploads/63600b93d9e4214b9a67807c/ZRnXCRmf600I8gTKJH-V0.png)AIM-Harvard 23\n===================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================\n\nTasks: [Question Answering](https://huggingface.co/datasets?task_categories=task_categories%3Aquestion-answering)[Text Retrieval](https://huggingface.co/datasets?task_categories=task_categories%3Atext-retrieval)\n\nModalities: [Text](https://huggingface.co/datasets?modality=modality%3Atext)\n\nFormats: [csv](https://huggingface.co/datasets?format=format%3Acsv)\n\nLanguages: [English](https://huggingface.co/datasets?language=language%3Aen)\n\nSize: [1K - 10K](https://huggingface.co/datasets?size_categories=size_categories%3A1K%3Cn%3C10K)\n\nArXiv: \n\narxiv:2505.14963\n\nTags: [medical](https://huggingface.co/datasets?other=medical)[healthcare](https://huggingface.co/datasets?other=healthcare)[browsing](https://huggingface.co/datasets?other=browsing)[comparison](https://huggingface.co/datasets?other=comparison)\n\nLibraries: [Datasets](https://huggingface.co/datasets?library=library%3Adatasets)[pandas](https://huggingface.co/datasets?library=library%3Apandas)\n\nCroissant\n\n+ 1\n\nLicense: \n\napache-2.0\n\n[Dataset card](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp)[Data Studio](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/viewer/)[Files Files and versions](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/tree/main)[Community 1](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/discussions)\n\nDataset Viewer\n\n[Auto-converted to Parquet](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/tree/refs%2Fconvert%2Fparquet/default)API Embed Data Studio\n\nSubset (1)\n\ndefault¬∑1.14k rows\n\n \n\nSplit (3)\n\nMedBrowseComp_50¬∑50 rows\n\n \n\nSQL \n\n Console \n\n| gold string lengths 5 24 | prompt string lengths 227 657 | task_name string classes 5 values |\n| --- | --- | --- |\n| ENZALUTAMIDE | "For clinical trial NCT00974311. Among the more effective regimen ingredients, find which ingredient starts with the letter \'E\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| CRIZOTINIB | "For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter \'C\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| LENALIDOMIDE | "For clinical trial NCT01938001. Among the more effective regimen ingredients, find which ingredient starts with the letter \'L\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| AZACITIDINE | "For clinical trial NCT00071799. Among the more effective regimen ingredients, find which ingredient starts with the letter \'A\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| IRINOTECAN HYDROCHLORIDE | "For clinical trial NCT00720512. Among the more effective regimen ingredients, find which ingredient starts with the letter \'I\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| VENETOCLAX | "For clinical trial NCT02755597. Among the more effective regimen ingredients, find which ingredient starts with the letter \'V\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| DEXAMETHASONE | "For clinical trial NCT00833833. Among the more effective regimen ingredients, find which ingredient starts with the letter \'D\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| IBRUTINIB | "For clinical trial NCT01973387. Among the more effective regimen ingredients, find which ingredient starts with the letter \'I\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| LENALIDOMIDE | "For clinical trial NCT00843882. Among the more effective regimen ingredients, find which ingredient starts with the letter \'L\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| SIROLIMUS | "For clinical trial NCT01231412. Among the more effective regimen ingredients, find which ingredient starts with the letter \'S\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| ASTELLAS | "First, for clinical trial NCT00974311, among the more effective regimen ingredients, identify which ingredient starts with the letter \'E\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| PF PRISM CV | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| BRISTOL MYERS SQUIBB | "First, for clinical trial NCT01938001, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| BRISTOL | "First, for clinical trial NCT00071799, among the more effective regimen ingredients, identify which ingredient starts with the letter \'A\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| IPSEN | "First, for clinical trial NCT00720512, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| ABBVIE | "First, for clinical trial NCT02755597, among the more effective regimen ingredients, identify which ingredient starts with the letter \'V\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| DEXCEL | "First, for clinical trial NCT00833833, among the more effective regimen ingredients, identify which ingredient starts with the letter \'D\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| PHARMACYCLICS LLC | "First, for clinical trial NCT01973387, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| BRISTOL MYERS SQUIBB | "First, for clinical trial NCT00843882, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| AADI SUB | "First, for clinical trial NCT01231412, among the more effective regimen ingredients, identify which ingredient starts with the letter \'S\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| Aug 13, 2027 | "First, for clinical trial NCT00974311, among the more effective regimen ingredients, identify which ingredient starts with the letter \'E\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| May 12, 2027 | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Apr 27, 2027 | "First, for clinical trial NCT01938001, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| May 14, 2029 | "First, for clinical trial NCT00071799, among the more effective regimen ingredients, identify which ingredient starts with the letter \'A\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Jan 6, 2027 | "First, for clinical trial NCT00720512, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Jan 29, 2032 | "First, for clinical trial NCT02755597, among the more effective regimen ingredients, identify which ingredient starts with the letter \'V\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Dec 18, 2037 | "First, for clinical trial NCT00833833, among the more effective regimen ingredients, identify which ingredient starts with the letter \'D\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Dec 3, 2031 | "First, for clinical trial NCT01973387, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Apr 27, 2027 | "First, for clinical trial NCT00843882, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Mar 5, 2036 | "First, for clinical trial NCT01231412, among the more effective regimen ingredients, identify which ingredient starts with the letter \'S\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Nov 17, 2026 | "For clinical trial NCT00974311, among the more effective regimen ingredients, identify which ingredient starts with the letter \'E\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Jul 14, 2025 | "For clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| May 28, 2026 | "For clinical trial NCT01938001, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Sep 1, 2027 | "For clinical trial NCT00071799, among the more effective regimen ingredients, identify which ingredient starts with the letter \'A\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Feb 13, 2031 | "For clinical trial NCT00720512, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| May 15, 2026 | "For clinical trial NCT02755597, among the more effective regimen ingredients, identify which ingredient starts with the letter \'V\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Oct 3, 2026 | "For clinical trial NCT00833833, among the more effective regimen ingredients, identify which ingredient starts with the letter \'D\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Aug 24, 2029 | "For clinical trial NCT01973387, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| May 28, 2026 | "For clinical trial NCT00843882, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Nov 22, 2028 | "For clinical trial NCT01231412, among the more effective regimen ingredients, identify which ingredient starts with the letter \'S\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| 15.98999977 | "For clinical trial NCT00974311, review the more effective regimen ingredients and identify which ingredient starts with the letter \'E\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 34.47000122 | "For clinical trial NCT02838420, review the less effective regimen ingredients and identify which ingredient starts with the letter \'C\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 46.72999954 | "For clinical trial NCT01938001, review the more effective regimen ingredients and identify which ingredient starts with the letter \'L\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 62.20000076 | "For clinical trial NCT00071799, review the more effective regimen ingredients and identify which ingredient starts with the letter \'A\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 15.14000034 | "For clinical trial NCT00720512, review the more effective regimen ingredients and identify which ingredient starts with the letter \'I\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 58.59000015 | "For clinical trial NCT02755597, review the more effective regimen ingredients and identify which ingredient starts with the letter \'V\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| NOT LISTED | "For clinical trial NCT00833833, review the more effective regimen ingredients and identify which ingredient starts with the letter \'D\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| NOT LISTED | "For clinical trial NCT01973387, review the more effective regimen ingredients and identify which ingredient starts with the letter \'I\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 46.72999954 | "For clinical trial NCT00843882, review the more effective regimen ingredients and identify which ingredient starts with the letter \'L\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 39.84000015 | "For clinical trial NCT01231412, review the more effective regimen ingredients and identify which ingredient starts with the letter \'S\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n\n*   [Datasets](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#datasets "Datasets")\n\n*   [Usage](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#usage "Usage")\n\n*   [GitHub Repository](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#github-repository "GitHub Repository")\n\n*   [Citation](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#citation "Citation")\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#medbrowsecomp-dataset) MedBrowseComp Dataset\n=========================================================================================================\n\nThis repository contains datasets for medical information-seeking-oriented deep research and computer use tasks.\n\n[![Image 4: Overall](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/resolve/main/medcomp.png)](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/blob/main/medcomp.png)\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#datasets) Datasets\n-------------------------------------------------------------------------------\n\nThe repository contains three harmonized datasets:\n\n1.   **MedBrowseComp_50**: A collection of 50 medical entries for browsing and comparison.\n2.   **MedBrowseComp_605**: A comprehensive collection of 605 medical entries.\n3.   **MedBrowseComp_CUA**: A curated collection of medical data for comparison and analysis.\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#usage) Usage\n-------------------------------------------------------------------------\n\nThese datasets can be used for various medical text processing tasks, information retrieval, and comparative analysis.\n\nExample usage with the Hugging Face datasets library:\n\n```python\nfrom datasets import load_dataset\n\n# Load the dataset\ndataset = load_dataset("AIM-Harvard/MedBrowseComp")\n\n# Access specific splits\nmed50_data = dataset["MedBrowseComp_50"]\nmed605_data = dataset["MedBrowseComp_605"]\ncua_data = dataset["MedBrowseComp_CUA"]\n```\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#github-repository) GitHub Repository\n-------------------------------------------------------------------------------------------------\n\nFor more information and related tools, visit: [https://github.com/MedBrowseComp](https://github.com/MedBrowseComp)\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#citation) Citation\n-------------------------------------------------------------------------------\n\nIf you use this dataset in your research, please cite: [https://arxiv.org/abs/2505.14963](https://arxiv.org/abs/2505.14963)\n\n```\n@misc{chen2025medbrowsecompbenchmarkingmedicaldeep,\n      title={MedBrowseComp: Benchmarking Medical Deep Research and Computer Use}, \n      author={Shan Chen and Pedro Moreira and Yuxin Xiao and Sam Schmidgall and Jeremy Warner and Hugo Aerts and Thomas Hartvigsen and Jack Gallifant and Danielle S. Bitterman},\n      year={2025},\n      eprint={2505.14963},\n      archivePrefix={arXiv},\n      primaryClass={cs.CL},\n      url={https://arxiv.org/abs/2505.14963}, \n}\n```\n\nDownloads last month 179\n\n Use this dataset \n\nSize of downloaded dataset files: 448 kB[Size of the auto-converted Parquet files: 58 kB](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/tree/refs%2Fconvert%2Fparquet/)Number of rows: 1,139\n\nCollection including AIM-Harvard/MedBrowseComp\n----------------------------------------------\n\n[#### MedBrowseComp Collection MedBrowseComp: Benchmarking Medical Deep Research and Computer Use‚Ä¢ 3 items‚Ä¢ Updated 10 days ago](https://huggingface.co/collections/AIM-Harvard/medbrowsecomp-6822637df90521b5d8b8b23f)\n\n System theme \n\nCompany\n\n[TOS](https://huggingface.co/terms-of-service)[Privacy](https://huggingface.co/privacy)[About](https://huggingface.co/huggingface)[Jobs](https://apply.workable.com/huggingface/)[](https://huggingface.co/)\n\nWebsite\n\n[Models](https://huggingface.co/models)[Datasets](https://huggingface.co/datasets)[Spaces](https://huggingface.co/spaces)[Pricing](https://huggingface.co/pricing)[Docs](https://huggingface.co/docs)\n'}, {'type': 'page', 'title': 'Alectinib and Crizotinib in Anaplastic Lymphoma Kinase-positive Non ...', 'url': 'https://ichgcp.net/clinical-trials-registry/NCT02838420', 'content': 'USA (FDA)\n       UK (MHRA)\n       AUSTRALIA (NHMRC)\n       JAPAN (PMDA)\n       EU (EMA)\n\n   CRO List\n   Clinical Trials\n\n       US Clinical Trials Registry\n       EU Clinical Trials Registry\n       Pharmaceutical Companies\n       Clinical Research Labs\n       Service Companies\n       Clinical Research Events\n       Publications\n       Researchers\n\n   Jobs\n   Publications\n   News\n\n   \n   \n\n   ICH GCP\n   US Clinical Trials Registry\n   Clinical Trial NCT02838420', 'score': 0.54724693, 'raw_content': 'Published Time: 2022-12-12T02:32:10+00:00\n\nAlectinib and Crizotinib in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer - Clinical Trials Registry - ICH GCP\n\n===============\n\n[![Image 1: ICHGCP](https://ichgcp.net/img/ichgcp_logo.png)](https://ichgcp.net/)\n\n*   Regulations\n\n    *   [GLOBAL¬ª](https://ichgcp.net/clinical-trials-registry/NCT02838420#)\n\n        *   [ICH GCP (De)](https://ichgcp.net/de)\n        *   [ICH GCP (En)](https://ichgcp.net/)\n        *   [ICH GCP (Es)](https://ichgcp.net/es)\n        *   [ICH GCP (Fr)](https://ichgcp.net/fr)\n        *   [ICH GCP (It)](https://ichgcp.net/it)\n        *   [ICH GCP (Pt)](https://ichgcp.net/pt)\n        *   [ICH GCP (Ru)](https://ichgcp.net/ru)\n\n    *   [USA (FDA)](https://ichgcp.net/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects)\n    *   [UK (MHRA)](https://ichgcp.net/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol)\n    *   [AUSTRALIA (NHMRC)](https://ichgcp.net/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia)\n    *   [JAPAN (PMDA)](https://ichgcp.net/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan)\n    *   [EU (EMA)](https://ichgcp.net/ich-e-group-of-guidelines)\n\n*   [CRO List](https://ichgcp.net/cro-list)\n*   Clinical Trials\n\n    *   [US Clinical Trials Registry](https://ichgcp.net/clinical-trials-registry)\n    *   [EU Clinical Trials Registry](https://ichgcp.net/eu-clinical-trials-registry)\n    *   [Pharmaceutical Companies](https://ichgcp.net/pharma-list)\n    *   [Clinical Research Labs](https://ichgcp.net/labs)\n    *   [Service Companies](https://ichgcp.net/service-companies)\n    *   [Clinical Research Events](https://ichgcp.net/events)\n    *   [Publications](https://ichgcp.net/clinical-trials-registry/publications)\n    *   [Researchers](https://ichgcp.net/clinical-trials-registry/researchers)\n\n*   [Jobs](https://ichgcp.net/jobs)\n*   [Publications](https://ichgcp.net/publications)\n*   [News](https://ichgcp.net/news)\n\n*   [](https://telegram.me/share/url?url=https://ichgcp.net/clinical-trials-registry/NCT02838420&text= "Share on telegram")\n*   [](https://twitter.com/intent/tweet?url=https://ichgcp.net/clinical-trials-registry/NCT02838420 "Share on Twitter")\n\n*   [ICH GCP](https://ichgcp.net/)\n*   [US Clinical Trials Registry](https://ichgcp.net/clinical-trials-registry)\n*   Clinical Trial NCT02838420\n\nA Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)\n=========================================================================================================================================================================================================================================================================\n\nMarch 24, 2025 updated by: [Hoffmann-La Roche](https://ichgcp.net/clinical-trials-registry/research/list?spons=Hoffmann-La%20Roche "List all studies sponsored by Hoffmann-La Roche")\n\nRandomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Asian Patients With Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer\n--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\nThis randomized, multicenter, Phase III, open-label study will evaluate the efficacy and safety of alectinib versus crizotinib and to evaluate the pharmacokinetics of alectinib in asian participants with treatment-naive ALK-positive advanced NSCLC. Participants will be randomized 2:1 into one of the two treatment groups to receive either alectinib (600 milligrams [mg] twice daily [BID]) or crizotinib (250 mg BID) orally, respectively.\n\nStudy Overview\n--------------\n\n#### Status\n\nActive, not recruiting\n\n#### Conditions\n\n*   [Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%20Lymphoma%20Kinase-positive%20Non-small%20Cell%20Lung%20Cancer "List all studies focused on condition Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer")\n\n#### Intervention / Treatment\n\n*   [Drug: Alectinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Alectinib "List all studies with intervention Alectinib")\n*   [Drug: Crizotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Crizotinib "List all studies with intervention Crizotinib")\n\n#### Study Type\n\n Interventional \n\n#### Enrollment (Actual)\n\n 187 \n\n#### Phase\n\n*   Phase 3\n\nContacts and Locations\n----------------------\n\nThis section provides the contact details for those conducting the study, and information on where this study is being conducted.\n\n### Study Locations\n\n*   [China](https://ichgcp.net/clinical-trials-registry/research/list?locn=China "List all studies conducted in China") \n    *           *   Beijing, China, 100142 \n            *   Beijing Cancer Hospital\n\n        *   Beijing, China, 101149 \n            *   Beijing Chest Hospital\n\n        *   Changchun, China, 130021 \n            *   The First Hospital of Jilin University\n\n        *   Changchun, China, 132013 \n            *   Jilin cancer hospital\n\n        *   Chengdu, China, 610041 \n            *   West China Hospital, Sichuan University\n\n        *   Guangzhou, China, 510060 \n            *   Sun Yet-sen University Cancer Center\n\n        *   Guangzhou, China, 510080 \n            *   Guangdong General Hospital\n\n        *   Guangzhou, China, 510120 \n            *   The First Affiliated Hospital of Guangzhou Medical University\n\n        *   Hangzhou, China, 310003 \n            *   The First Affiliated Hospital of College of Medicine, Zhejiang University\n\n        *   Hangzhou, China, 310022 \n            *   Zhejiang Cancer Hospital\n\n        *   Harbin, China, 150081 \n            *   Harbin Medical University Cancer Hospital\n\n        *   Nanjing, China, 210009 \n            *   Jiangsu Cancer Hospital\n\n        *   Shanghai, China, 200030 \n            *   Shanghai Chest Hospital\n\n        *   Shanghai, China, 200032 \n            *   Fudan University Shanghai Cancer Center\n\n        *   Shanghai, China, 200433 \n            *   Shanghai Pulmonary Hospital\n\n*   [Korea, Republic of](https://ichgcp.net/clinical-trials-registry/research/list?locn=Korea%2C%20Republic%20of "List all studies conducted in Korea, Republic of") \n    *           *   Seoul, Korea, Republic of, 05505 \n            *   Asan Medical Center\n\n        *   Seoul, Korea, Republic of, 06351 \n            *   Samsung Medical Center\n\n        *   Seoul, Korea, Republic of, 03181 \n            *   Kangbuk Samsung Hospital\n\n*   [Thailand](https://ichgcp.net/clinical-trials-registry/research/list?locn=Thailand "List all studies conducted in Thailand") \n    *           *   Bangkok, Thailand, 10400 \n            *   Rajavithi Hospital\n\n        *   Bangkok, Thailand, 10400 \n            *   Ramathibodi Hospital\n\n        *   Songkhla, Thailand, 90110 \n            *   Songklanagarind hospital\n\nParticipation Criteria\n----------------------\n\nResearchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person\'s general health condition or prior treatments.\n\n### Eligibility Criteria\n\n#### Ages Eligible for Study\n\n 18 years and older (Adult, Older Adult) \n\n#### Accepts Healthy Volunteers\n\n No \n\n#### Description\n\nInclusion Criteria:\n\n*   Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive as assessed by the Ventana immunohistochemistry (IHC) test. Sufficient tumor tissue available to perform ALK IHC is required. Ventana IHC testing will be performed at the designated central laboratory\n*   Life expectancy of at least 12 weeks\n*   Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2\n*   No history of receiving systemic treatment for advanced, recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC\n*   Adequate hematologic function: Platelet count greater than equal to (>=) 100√ó10^9 per liter (/L); absolute neutrophil count (ANC) >=1500 cells per microliter (cells/mcL); hemoglobin>=9.0 grams per deciliter (g/dL)\n*   Adequate renal function: an estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease (MDRD) formula of >=45 milliliters per minute per 1.73 square meter\n*   Participants must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before receiving the first dose of study treatment\n*   Measurable disease (by Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v1.1]) before administration of study treatment\n*   Previous brain or leptomeningeal metastases are allowed if the participant is asymptomatic (e.g., diagnosed incidentally at study baseline). Asymptomatic central nervous system (CNS) lesions may be treated at the discretion of the investigator as per local clinical practice. If participant has neurological symptoms or signs because of CNS metastasis, the participant must complete whole-brain radiation or gamma knife irradiation treatment. In all cases, radiation treatment must be completed >=14 days before enrollment and disease must be clinically stable\n*   For all females of childbearing potential, a negative serum pregnancy test result must be obtained within 3 days prior to starting study treatment\n*   For women who are not postmenopausal (>=12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus), agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Examples of contraceptive methods with a failure rate of <1% per year include tubal ligation, male sterilization, hormonal implants, established, proper use of combined oral or injected hormonal contraceptives, and certain intrauterine devices. Alternatively, two methods (e.g., two barrier methods such as a condom and a cervical cap) may be combined to achieve a failure rate of <1% per year. Barrier methods must always be supplemented with the use of a spermicide\n*   For men, agreement to remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception\n\nExclusion Criteria:\n\n*   A malignancy within the previous 3 years (other than curatively treated basal cell carcinoma of the skin, early gastrointestinal (GI) cancer by endoscopic resection, in situ carcinoma of the cervix, or any cured cancer that is considered to have no impact in progression-free survival (PFS) or overall survival (OS) for the current NSCLC)\n*   Any GI disorder that may affect absorption of oral medications, such as malabsorption syndrome or status post-major bowel resection\n*   Liver disease characterized by:\n*   Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than (>) 3√ó the upper limit of normal (ULN; >=5√óULN for participants with concurrent liver metastases) confirmed on two consecutive measurements; or\n*   Impaired excretory function (e.g., hyperbilirubinemia), synthetic function, or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices; or\n*   Acute viral or active autoimmune, alcoholic, or other types of hepatitis\n*   National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 Grade 3 or higher toxicities because of any previous therapy (e.g., radiotherapy) (excluding alopecia), which have not shown improvement and are strictly considered to interfere with current study medication\n*   History of organ transplant\n*   Co-administration of anti-cancer therapies other than those administered in this study\n*   Baseline QTc >470 ms or symptomatic bradycardia\n*   Administration of strong/potent cytochrome P4503A inhibitors or inducers within 14 days prior to the receiving the first dose of study treatment and during treatment with alectinib or crizotinib\n*   Administration of agents with potential QT interval prolonging effects within 14 days prior to receiving the first dose of study drug\n*   History of hypersensitivity to any of the additives in the alectinib or crizotinib drug formulation\n*   Pregnant or lactating\n*   Known human immunodeficiency virus (HIV-positivity or acquired immunodeficiency syndrome (AIDS)-related illness\n*   Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or the absorption of oral medications or that would, in the opinion of the Principal Investigator, pose an unacceptable risk to the participant in this study\n*   Any psychological, familial, sociological, or geographical condition that potentially hampers compliance with the study protocol requirements or follow-up procedures; those conditions should be discussed with the participant before study entry\n\nStudy Plan\n----------\n\nThis section provides details of the study plan, including how the study is designed and what the study is measuring.\n\n### How is the study designed?\n\n#### Design Details\n\n*   **Primary Purpose**: Treatment\n*   **Allocation**: Randomized\n*   **Interventional Model**: Parallel Assignment\n*   **Masking**: None (Open Label)\n\n#### Number of Arms\n\n2\n\n#### Arms and Interventions\n\n| ##### Participant Group / Arm | ##### Intervention / Treatment |\n| --- | --- |\n| Experimental: Alectinib Participants will receive alectinib capsules orally at a dose of 600 mg BID with food until disease progression, unacceptable toxicity withdrawal of consent, or death. | [Drug: Alectinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Alectinib "List all studies with intervention Alectinib") Alectinib capsules will be administered orally at a dose of 600 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death. Other Names: * RO5424802 |\n| Active Comparator: Crizotinib Participants will receive crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity withdrawal of consent, or death. | [Drug: Crizotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Crizotinib "List all studies with intervention Crizotinib") Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death. |\n\n### What is the study measuring?\n\n#### Primary Outcome Measures\n\n| ##### Outcome Measure | ##### Measure Description | ##### Time Frame |\n| --- | --- | --- |\n| Progression-Free Survival (PFS) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 Time Frame: From the date of randomization to the date of the first documented disease progression or death, whichever occurred first (up to overall period of approximately 40 months) | PFS was defined as the time (in months) from randomization to the first documentation of disease progression, as determined by the investigators, or to death from any cause, whichever occurred first. | From the date of randomization to the date of the first documented disease progression or death, whichever occurred first (up to overall period of approximately 40 months) |\n\n#### Secondary Outcome Measures\n\n| ##### Outcome Measure | ##### Measure Description | ##### Time Frame |\n| --- | --- | --- |\n| PFS as Determined by Independent Review Committee (IRC) Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) | PFS was defined as the time (in months) from randomization to the first documentation of disease progression, as determined by an independent review committee, or to death from any cause, whichever occurred first. | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Percentage of Participants With Objective Response of Complete Response (CR) or Partial Response (PR) as Determined by Investigator Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Time to Progression of Disease in the CNS as Determined by IRC Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Time to Progression of Disease in the CNS as Determined by IRC Using Response Assessment in Neuro-Oncology (RANO) Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Duration of Response (DOR) Assessed by Investigator Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Overall Survival Time Time Frame: Baseline, until death (up to overall period of approximately 40 months) |  | Baseline, until death (up to overall period of approximately 40 months) |\n| Percentage of Participants With Non-serious Adverse Events and Serious Adverse Events Time Frame: Up to overall period of approximately 40 months | An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. | Up to overall period of approximately 40 months |\n| Time to Deterioration Assessed Using EORTC Quality of Life Questionnaire-Core (QLQ-C30) Score Time Frame: Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Time to Deterioration Assessed Using EORTC Quality of Life Questionnaire-Lung Cancer Module (QLQ-LC13) Score Time Frame: Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Area Under the Plasma Concentration-time Curve (AUC) of Alectinib and Its Metabolite Time Frame: Baseline and Week 4 predose (within 2 hours before administration of study drug) | AUC was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time. | Baseline and Week 4 predose (within 2 hours before administration of study drug) |\n| Maximum Plasma Concentration Observed (Cmax) of Alectinib and Its Metabolite Time Frame: Baseline and Week 4 predose (within 2 hours before administration of study drug) | Cmax was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time. | Baseline and Week 4 predose (within 2 hours before administration of study drug) |\n| Time to Cmax (Tmax) of Alectinib and Its Metabolite Time Frame: Baseline and Week 4 predose (within 2 hours before administration of study drug) | Tmax was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time. | Baseline and Week 4 predose (within 2 hours before administration of study drug) |\n\nCollaborators and Investigators\n-------------------------------\n\nThis is where you will find people and organizations involved with this study.\n\n#### Sponsor\n\n[Hoffmann-La Roche](https://ichgcp.net/clinical-trials-registry/research/list?spons=Hoffmann-La%20Roche "List all studies sponsored by Hoffmann-La Roche")\n\n#### Investigators\n\n*    Study Director: Clinical Trials, Hoffmann-La Roche \n\nPublications and helpful links\n------------------------------\n\nThe person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.\n\n#### General Publications\n\n*   [Zhou C, Kim SW, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang JJ, Cheng Y, Lee SH, Bu L, Xu T, Yang L, Wang C, Liu T, Morcos PN, Lu Y, Zhang L. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med. 2019 May;7(5):437-446. doi: 10.1016/S2213-2600(19)30053-0. Epub 2019 Apr 10.](https://pubmed.ncbi.nlm.nih.gov/30981696)\n\nStudy record dates\n------------------\n\nThese dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.\n\n### Study Major Dates\n\n#### Study Start (Actual)\n\n August 3, 2016 \n\n#### Primary Completion (Actual)\n\n May 31, 2018 \n\n#### Study Completion (Estimated)\n\n December 31, 2025 \n\n### Study Registration Dates\n\n#### First Submitted\n\nJuly 18, 2016\n\n#### First Submitted That Met QC Criteria\n\nJuly 18, 2016\n\n#### First Posted (Estimated)\n\nJuly 20, 2016\n\n### Study Record Updates\n\n#### Last Update Posted (Actual)\n\nMarch 25, 2025\n\n#### Last Update Submitted That Met QC Criteria\n\nMarch 24, 2025\n\n#### Last Verified\n\nMarch 1, 2025\n\nMore Information\n----------------\n\n### Terms related to this study\n\n#### Additional Relevant MeSH Terms\n\n*   [Neoplasms by Site](https://ichgcp.net/clinical-trials-registry/research/list?cond=Neoplasms%20by%20Site "List all studies by MeSH term: Neoplasms by Site")\n*   [Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Neoplasms "List all studies by MeSH term: Neoplasms")\n*   [Immune System Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Immune%20System%20Diseases "List all studies by MeSH term: Immune System Diseases")\n*   [Respiratory Tract Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Diseases "List all studies by MeSH term: Respiratory Tract Diseases")\n*   [Neoplasms by Histologic Type](https://ichgcp.net/clinical-trials-registry/research/list?cond=Neoplasms%20by%20Histologic%20Type "List all studies by MeSH term: Neoplasms by Histologic Type")\n*   [Lung Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%20Diseases "List all studies by MeSH term: Lung Diseases")\n*   [Respiratory Tract Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Neoplasms "List all studies by MeSH term: Respiratory Tract Neoplasms")\n*   [Thoracic Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Thoracic%20Neoplasms "List all studies by MeSH term: Thoracic Neoplasms")\n*   [Lymphatic Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphatic%20Diseases "List all studies by MeSH term: Lymphatic Diseases")\n*   [Lymphoproliferative Disorders](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoproliferative%20Disorders "List all studies by MeSH term: Lymphoproliferative Disorders")\n*   [Immunoproliferative Disorders](https://ichgcp.net/clinical-trials-registry/research/list?cond=Immunoproliferative%20Disorders "List all studies by MeSH term: Immunoproliferative Disorders")\n*   [Carcinoma, Bronchogenic](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%2C%20Bronchogenic "List all studies by MeSH term: Carcinoma, Bronchogenic")\n*   [Bronchial Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Bronchial%20Neoplasms "List all studies by MeSH term: Bronchial Neoplasms")\n*   [Lung Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%20Neoplasms "List all studies by MeSH term: Lung Neoplasms")\n*   [Lymphoma](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma "List all studies by MeSH term: Lymphoma")\n*   [Carcinoma, Non-Small-Cell Lung](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%2C%20Non-Small-Cell%20Lung "List all studies by MeSH term: Carcinoma, Non-Small-Cell Lung")\n*   [Tyrosine Kinase Inhibitors](https://ichgcp.net/clinical-trials-registry/research/list?intr=Tyrosine%20Kinase%20Inhibitors "List all studies by MeSH term: Tyrosine Kinase Inhibitors")\n*   [Antineoplastic Agents](https://ichgcp.net/clinical-trials-registry/research/list?intr=Antineoplastic%20Agents "List all studies by MeSH term: Antineoplastic Agents")\n*   [Molecular Mechanisms of Pharmacological Action](https://ichgcp.net/clinical-trials-registry/research/list?intr=Molecular%20Mechanisms%20of%20Pharmacological%20Action "List all studies by MeSH term: Molecular Mechanisms of Pharmacological Action")\n*   [Enzyme Inhibitors](https://ichgcp.net/clinical-trials-registry/research/list?intr=Enzyme%20Inhibitors "List all studies by MeSH term: Enzyme Inhibitors")\n*   [Protein Kinase Inhibitors](https://ichgcp.net/clinical-trials-registry/research/list?intr=Protein%20Kinase%20Inhibitors "List all studies by MeSH term: Protein Kinase Inhibitors")\n*   [Crizotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Crizotinib "List all studies by MeSH term: Crizotinib")\n*   [Alectinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Alectinib "List all studies by MeSH term: Alectinib")\n\n#### Other Study ID Numbers\n\n*    YO29449 \n\n### Drug and device information, study documents\n\n#### Studies a U.S. FDA-regulated drug product\n\n Yes \n\n#### Studies a U.S. FDA-regulated device product\n\n No \n\nThis information was retrieved directly from the website [clinicaltrials.gov](https://clinicaltrials.gov/) without any changes. If you have any requests to change, remove or update your study details, please contact [register@clinicaltrials.gov](mailto:register@clinicaltrials.gov). As soon as a change is implemented on [clinicaltrials.gov](https://clinicaltrials.gov/), this will be updated automatically on our website as well.\n\nClinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer\n---------------------------------------------------------------------------------\n\n*    Pfizer   Completed  [A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001)](https://ichgcp.net/clinical-trials-registry/NCT00585195)  Systemic Anaplastic Large-Cell Lymphoma | Non-Small Cell Lung Cancer ALK-positive | Non-Small Cell Lung Cancer c-Met Dependent | Non-Small Cell Lung Cancer ROS Marker Positive | Advanced Malignancies Except Leukemia   United States, Korea, Republic of, Australia, Japan    \n*    Novartis Pharmaceuticals   Available  [Managed Access Programs for LDK378, Ceritinib](https://ichgcp.net/clinical-trials-registry/NCT05100134)  Non-small Cell Lung Cancer (NSCLC) | Anaplastic Lymphoma Kinase (ALK)- Positive Tumors    \n*    Novartis Pharmaceuticals   Completed  [Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer](https://ichgcp.net/clinical-trials-registry/NCT01772797)  Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase (ALK)   Australia, Spain, Singapore, Italy, United States    \n*    Nuvalent Inc.   Recruiting  [Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC (ALKAZAR)](https://ichgcp.net/clinical-trials-registry/NCT06765109)  Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase-positive   United States    \n*    Intergroupe Francophone de Cancerologie Thoracique   Completed  [Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements (CLINALK)](https://ichgcp.net/clinical-trials-registry/NCT02727335)  Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase Gene Mutation   France    \n*    Takeda   Completed  [A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors](https://ichgcp.net/clinical-trials-registry/NCT03546894)  Carcinoma Non-small-cell Lung | Anaplastic Lymphoma Kinase-positive   United States    \n*    Astellas Pharma Inc   Completed  [Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)](https://ichgcp.net/clinical-trials-registry/NCT01284192)  Solid Tumor | B-Cell Lymphoma | Advanced Malignancies | Positive for Anaplastic Lymphoma Kinase | Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS   United States    \n*    University Medical Center Groningen  Radboud University Medical Center; Maastricht University Medical Center; Erasmus... and other collaborators    Recruiting  [Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels (ADAPT ALEC)](https://ichgcp.net/clinical-trials-registry/NCT05525338)  Carcinoma, Non-Small-Cell Lung | Lung Cancer | Drug Monitoring | Anaplastic Lymphoma Kinase Gene Mutation | Anaplastic Lymphoma Kinase Gene Translocation   Netherlands, France    \n*    Takeda   Withdrawn  [Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors](https://ichgcp.net/clinical-trials-registry/NCT04260009)  Solid Tumors | Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma | Inflammatory Myofibroblastic Tumors    \n*    Massachusetts General Hospital  LUNGevity Foundation; Addario Lung Cancer Medical Institute    Recruiting  [Immune and Genomic Markers in ALK+ NSCLC](https://ichgcp.net/clinical-trials-registry/NCT04881916)  Non-Small Cell Lung Cancer | Anaplastic Lymphoma Kinase Gene Translocation   United States    \n\nClinical Trials on Alectinib\n----------------------------\n\n*    Aarhus University Hospital  Roche Pharma AG    Enrolling by invitation  [Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients (MonAlec)](https://ichgcp.net/clinical-trials-registry/NCT04708639)  Lung Cancer | ALK Gene Mutation | Resistance, Disease | Mutation   Denmark    \n*    Hoffmann-La Roche   Completed  [A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (ATALK)](https://ichgcp.net/clinical-trials-registry/NCT03155009)  Carcinoma, Non-Small-Cell Lung   France    \n*    Hoffmann-La Roche   Completed  [Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea](https://ichgcp.net/clinical-trials-registry/NCT03271554)  Non-Small Cell Lung Cancer   Korea, Republic of    \n*    Dana-Farber Cancer Institute  Genentech, Inc.    Terminated  [A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer](https://ichgcp.net/clinical-trials-registry/NCT03131206)  ALK-positive Non-small Cell Lung Cancer (NSCLC) | RET-positive Non-small Cell Lung Cancer (NSCLC) | RET-positive Thyroid Cancer   United States    \n*    Hoffmann-La Roche   Completed  [Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib](https://ichgcp.net/clinical-trials-registry/NCT02621047)  Hepatic Impairment   Czechia, Slovakia    \n*    Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...  UnitedHealthcare    Not yet recruiting  [Pharmacogenomics IND EXEMPT SNP Clinical Study - Alectinib and Single Nucleotide Polymorphisms (Drugs-SNPs)](https://ichgcp.net/clinical-trials-registry/NCT05987956)  Non-small Cell Lung Cancer   United States    \n*    Hoffmann-La Roche   Terminated  [A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors (ALpha-T)](https://ichgcp.net/clinical-trials-registry/NCT04644315)  Digestive System Diseases | Gastrointestinal Diseases | Melanoma | Sarcoma | Neoplasms | Respiratory Tract Diseases | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasms | Head and Neck Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms and other conditions   United States    \n*    China Medical University Hospital   Active, not recruiting  [Alectinib in Combination with Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided with Serum RNase1 and Tumor Expression of PD-L1](https://ichgcp.net/clinical-trials-registry/NCT06354387)  Hepatocellular Carcinoma   Taiwan    \n*    Genentech, Inc.   No longer available  [Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy](https://ichgcp.net/clinical-trials-registry/NCT02271139)  Non-Small Cell Lung Cancer   United States    \n*    Hoffmann-La Roche   Completed  [A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)](https://ichgcp.net/clinical-trials-registry/NCT01871805)  Non-Small Cell Lung Cancer   United States, Canada    \n\nSearch Similar Trials\n---------------------\n\n*   [Clinical Trials on Lymphoma in Singapore](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=Singapore)\n*   [Clinical Trials on Lymphosarcoma in Australia](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=Australia)\n*   [Clinical Trials on Carcinoma, Non-Small-Cell Lung in Singapore](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BNon-Small-Cell%2BLung&locn=Singapore)\n*   [Clinical Trials on Lymphoma in New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=New%2BZealand)\n*   [Clinical Trials on Carcinoma, Non-Small-Cell Lung in United States](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BNon-Small-Cell%2BLung&locn=United%2BStates)\n*   [Clinical Trials on Lung Neoplasms in Ireland](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%2BNeoplasms&locn=Ireland)\n*   [Clinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%2BLymphoma%2BKinase-positive%2BNon-small%2BCell%2BLung%2BCancer&locn=South%2BAfrica)\n*   [Clinical Trials on Lymphosarcoma in India](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=India)\n*   [Clinical Trials on Lymphoma in United States](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=United%2BStates)\n*   [Clinical Trials on Lymphoma in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=South%2BAfrica)\n*   [Clinical Trials on Lymphoma in Hong Kong](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=Hong%2BKong)\n*   [Clinical Trials on Lymphosarcoma in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=South%2BAfrica)\n*   [Clinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer in Ireland](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%2BLymphoma%2BKinase-positive%2BNon-small%2BCell%2BLung%2BCancer&locn=Ireland)\n*   [Clinical Trials on Lung Neoplasms in New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%2BNeoplasms&locn=New%2BZealand)\n*   [Clinical Trials on Lung Neoplasms in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%2BNeoplasms&locn=South%2BAfrica)\n*   [Clinical Trials on Lymphoma in India](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=India)\n*   [Clinical Trials on Lymphosarcoma in Singapore](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=Singapore)\n*   [Clinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer in New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%2BLymphoma%2BKinase-positive%2BNon-small%2BCell%2BLung%2BCancer&locn=New%2BZealand)\n*   [Clinical Trials on Lymphosarcoma in United States](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=United%2BStates)\n*   [Clinical Trials on Carcinoma, Non-Small-Cell Lung in United Kingdom](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BNon-Small-Cell%2BLung&locn=United%2BKingdom)\n*   [Search All Trials](https://ichgcp.net/clinical-trials-registry/research/list)\n\nSponsors and Collaborators\n--------------------------\n\n*   [Eisai Korea Inc.](https://ichgcp.net/clinical-trials-registry/research/list?spons=Eisai%2BKorea%2BInc.)\n*   [Leukaemia & Blood Cancer New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?spons=Leukaemia%2B%2526%2BBlood%2BCancer%2BNew%2BZealand)\n*   [Udaan](https://ichgcp.net/clinical-trials-registry/research/list?spons=Udaan)\n*   [Makarenko Irina Romanovna](https://ichgcp.net/clinical-trials-registry/research/list?spons=Makarenko%2BIrina%2BRomanovna)\n*   [Adriane Aver Vanin](https://ichgcp.net/clinical-trials-registry/research/list?spons=Adriane%2BAver%2BVanin)\n*   [University of Memphis](https://ichgcp.net/clinical-trials-registry/research/list?spons=University%2Bof%2BMemphis)\n*   [Sleep Research Society Foundation](https://ichgcp.net/clinical-trials-registry/research/list?spons=Sleep%2BResearch%2BSociety%2BFoundation)\n*   [Immuron Ltd.](https://ichgcp.net/clinical-trials-registry/research/list?spons=Immuron%2BLtd.)\n*   [Arthro-Anda Tianjin Biologic Technology Co., Ltd.](https://ichgcp.net/clinical-trials-registry/research/list?spons=Arthro-Anda%2BTianjin%2BBiologic%2BTechnology%2BCo.%252C%2BLtd.)\n*   [CoheroHealth](https://ichgcp.net/clinical-trials-registry/research/list?spons=CoheroHealth)\n*   [Center for Military Mental Health, Berlin, Germany](https://ichgcp.net/clinical-trials-registry/research/list?spons=Center%2Bfor%2BMilitary%2BMental%2BHealth%252C%2BBerlin%252C%2BGermany)\n*   [Kevin Flanigan](https://ichgcp.net/clinical-trials-registry/research/list?spons=Kevin%2BFlanigan)\n*   [Periannan Kuppusamy](https://ichgcp.net/clinical-trials-registry/research/list?spons=Periannan%2BKuppusamy)\n*   [Chiang Mai University Hospital, THAILAND](https://ichgcp.net/clinical-trials-registry/research/list?spons=Chiang%2BMai%2BUniversity%2BHospital%252C%2BTHAILAND)\n*   [Centre for Emergency Health Sciences](https://ichgcp.net/clinical-trials-registry/research/list?spons=Centre%2Bfor%2BEmergency%2BHealth%2BSciences)\n*   [Therapex Co., Ltd](https://ichgcp.net/clinical-trials-registry/research/list?spons=Therapex%2BCo.%252C%2BLtd)\n*   [MIT William Asbjornsen Albert Memorial Fellowship](https://ichgcp.net/clinical-trials-registry/research/list?spons=MIT%2BWilliam%2BAsbjornsen%2BAlbert%2BMemorial%2BFellowship)\n*   [Fabiana Aceto](https://ichgcp.net/clinical-trials-registry/research/list?spons=Fabiana%2BAceto)\n*   [North American Spine Society](https://ichgcp.net/clinical-trials-registry/research/list?spons=North%2BAmerican%2BSpine%2BSociety)\n*   [SGS proderm GmbH](https://ichgcp.net/clinical-trials-registry/research/list?spons=SGS%2Bproderm%2BGmbH)\n*   [View Full List](https://ichgcp.net/clinical-trials-registry/research/browse/spns_alpha_all)\n\nMedical Conditions\n------------------\n\n*   [Infrarenal Abdominal Aortic Aneurysms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Infrarenal%2BAbdominal%2BAortic%2BAneurysms)\n*   [Myeloproliferative Disease, Not Classified](https://ichgcp.net/clinical-trials-registry/research/list?cond=Myeloproliferative%2BDisease%252C%2BNot%2BClassified)\n*   [Lifestyle-related Condition](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lifestyle-related%2BCondition)\n*   [Compliance](https://ichgcp.net/clinical-trials-registry/research/list?cond=Compliance)\n*   [Patients With Opioid Induced Constipation](https://ichgcp.net/clinical-trials-registry/research/list?cond=Patients%2BWith%2BOpioid%2BInduced%2BConstipation)\n*   [Femoral Vascular Anastomosis](https://ichgcp.net/clinical-trials-registry/research/list?cond=Femoral%2BVascular%2BAnastomosis)\n*   [Observation Safety](https://ichgcp.net/clinical-trials-registry/research/list?cond=Observation%2BSafety)\n*   [Improvement of Functionality](https://ichgcp.net/clinical-trials-registry/research/list?cond=Improvement%2Bof%2BFunctionality)\n*   [CD4 Deficiency](https://ichgcp.net/clinical-trials-registry/research/list?cond=CD4%2BDeficiency)\n*   [Malassezia Infection](https://ichgcp.net/clinical-trials-registry/research/list?cond=Malassezia%2BInfection)\n*   [Anti-cancer Cell Immunotherapy](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anti-cancer%2BCell%2BImmunotherapy)\n*   [Health Knowledge Attitudes and Practice](https://ichgcp.net/clinical-trials-registry/research/list?cond=Health%2BKnowledge%2BAttitudes%2Band%2BPractice)\n*   [School Adjustment](https://ichgcp.net/clinical-trials-registry/research/list?cond=School%2BAdjustment)\n*   [Difficult Mask Ventilation](https://ichgcp.net/clinical-trials-registry/research/list?cond=Difficult%2BMask%2BVentilation)\n*   [Intrapartum Mortality](https://ichgcp.net/clinical-trials-registry/research/list?cond=Intrapartum%2BMortality)\n*   [Diabetes Mellitus II](https://ichgcp.net/clinical-trials-registry/research/list?cond=Diabetes%2BMellitus%2BII)\n*   [Painless Myocardial Ischemia](https://ichgcp.net/clinical-trials-registry/research/list?cond=Painless%2BMyocardial%2BIschemia)\n*   [Corona Virus Disease 19 (COVID-19)](https://ichgcp.net/clinical-trials-registry/research/list?cond=Corona%2BVirus%2BDisease%2B19%2B%2528COVID-19%2529)\n*   [Pressure Injury Stage 2](https://ichgcp.net/clinical-trials-registry/research/list?cond=Pressure%2BInjury%2BStage%2B2)\n*   [Escape; Rhythm](https://ichgcp.net/clinical-trials-registry/research/list?cond=Escape%253B%2BRhythm)\n*   [View Full List](https://ichgcp.net/clinical-trials-registry/research/browse/cond_alpha_all)\n\nDrug Interventions\n------------------\n\n*   [Methylprednisolone](https://ichgcp.net/clinical-trials-registry/research/list?intr=Methylprednisolone)\n*   [Anetumab Ravtansine](https://ichgcp.net/clinical-trials-registry/research/list?intr=Anetumab%2BRavtansine)\n*   [ESES treated with clobazam](https://ichgcp.net/clinical-trials-registry/research/list?intr=ESES%2Btreated%2Bwith%2Bclobazam)\n*   [Droperidol Injectable Solution](https://ichgcp.net/clinical-trials-registry/research/list?intr=Droperidol%2BInjectable%2BSolution)\n*   [ATx201](https://ichgcp.net/clinical-trials-registry/research/list?intr=ATx201)\n*   [Cyclophosphamide](https://ichgcp.net/clinical-trials-registry/research/list?intr=Cyclophosphamide)\n*   [Pioglitazone](https://ichgcp.net/clinical-trials-registry/research/list?intr=Pioglitazone)\n*   [Botulinum Toxin A](https://ichgcp.net/clinical-trials-registry/research/list?intr=Botulinum%2BToxin%2BA)\n*   [Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Gefitinib%2B250mg%2Bpo%2Bqd%2Bor%2BTarceva%2B150mg%2Bpo%2Bqd%2Bor%2BIcotinib%2B125mg%2Bpo%2Btid%2BOther%2BName%253A%2BGefitinib%252FTarceva%252FIcotinib)\n*   [Ramosetron](https://ichgcp.net/clinical-trials-registry/research/list?intr=Ramosetron)\n*   [KN046](https://ichgcp.net/clinical-trials-registry/research/list?intr=KN046)\n*   [Doxorubicin](https://ichgcp.net/clinical-trials-registry/research/list?intr=Doxorubicin)\n*   [Corticosteroids (CS)](https://ichgcp.net/clinical-trials-registry/research/list?intr=Corticosteroids%2B%2528CS%2529)\n*   [Dimenhydrinate](https://ichgcp.net/clinical-trials-registry/research/list?intr=Dimenhydrinate)\n*   [Ropivacaine 150 mg](https://ichgcp.net/clinical-trials-registry/research/list?intr=Ropivacaine%2B150%2Bmg)\n*   [Iso-Fludelone](https://ichgcp.net/clinical-trials-registry/research/list?intr=Iso-Fludelone)\n*   [Clonidine](https://ichgcp.net/clinical-trials-registry/research/list?intr=Clonidine)\n*   [Lidocaine topical](https://ichgcp.net/clinical-trials-registry/research/list?intr=Lidocaine%2Btopical)\n*   [Nusinersen](https://ichgcp.net/clinical-trials-registry/research/list?intr=Nusinersen)\n*   [Cyclophosphamide and fludarabine](https://ichgcp.net/clinical-trials-registry/research/list?intr=Cyclophosphamide%2Band%2Bfludarabine)\n*   [View Full List](https://ichgcp.net/clinical-trials-registry/research/browse/intr_alpha_all)\n\n### CROs by country\n\n*   [Contract Research Organizations in Azerbaijan](https://ichgcp.net/cro-list/country/azerbaijan)\n*   [Contract Research Organizations in Bulgaria](https://ichgcp.net/cro-list/country/bulgaria)\n*   [Contract Research Organizations in Burundi](https://ichgcp.net/cro-list/country/burundi)\n*   [Contract Research Organizations in Dominican Republic](https://ichgcp.net/cro-list/country/dominican_republic)\n*   [Contract Research Organizations in Kosovo](https://ichgcp.net/cro-list/country/kosovo)\n*   [Contract Research Organizations in Mexico](https://ichgcp.net/cro-list/country/mexico)\n*   [Contract Research Organizations in Moldova](https://ichgcp.net/cro-list/country/moldova)\n*   [Contract Research Organizations in Poland](https://ichgcp.net/cro-list/country/poland)\n*   [Contract Research Organizations in Slovakia](https://ichgcp.net/cro-list/country/slovakia)\n*   [Contract Research Organizations in Sri Lanka](https://ichgcp.net/cro-list/country/sri_lanka)\n*   [Contract Research Organizations in Ukraine](https://ichgcp.net/cro-list/country/ukraine)\n*   [Contract Research Organizations in United Arab Emirates](https://ichgcp.net/cro-list/country/united_arab_emirates)\n*   [Contract Research Organizations in Uzbekistan](https://ichgcp.net/cro-list/country/uzbekistan)\n*   [CRO list by country](https://ichgcp.net/cro-list)\n\n### CROs in Ghana\n\n*   [54gene‚Äôs Clinical Programs Group (CPG)](https://ichgcp.net/cro-list/country/ghana/company/54gene_s_clinical_programs_group_cpg)\n*   [SGS](https://ichgcp.net/cro-list/country/ghana/company/sgs)\n*   [ACROSS Global](https://ichgcp.net/cro-list/country/ghana/company/across_global)\n*   [All CROs in Ghana](https://ichgcp.net/cro-list/country/ghana)\n\n### Conditions\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/cond_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/cond_cat)\n\n### Rare Diseases\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/ord_alpha_all)\n\n### Drug Interventions\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/intr_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/intr_cat)\n\n### Dietary Supplements\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/diet_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/diet_cat)\n\n### Sponsor/Collaborators\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/spns_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/spns_cat)\n\n### Locations\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/locn_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/locn_cat)\n\nRegulations\n\n*   [GLOBAL (ICH GCP)](https://ichgcp.net/)\n*   [USA (FDA)](https://ichgcp.net/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects)\n*   [UK (MHRA)](https://ichgcp.net/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol)\n*   [AUSTRALIA (NHMRC)](https://ichgcp.net/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia)\n*   [JAPAN (PMDA)](https://ichgcp.net/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan)\n*   [EU (EMA)](https://ichgcp.net/guideline-for-the-notification-of-serious-breaches-of-regulation-eu-no-536-2014)\n\nResources\n\n*   [CRO List](https://ichgcp.net/cro-list)\n*   [Pharmaceutical Companies](https://ichgcp.net/pharma-list)\n*   [Clinical Research Labs](https://ichgcp.net/labs)\n*   [Service Companies](https://ichgcp.net/service-companies)\n*   [Jobs](https://ichgcp.net/cra-jobs)\n*   [US Clinical Trials Registry](https://ichgcp.net/clinical-trials-registry)\n*   [EU Clinical Trials Registry](https://ichgcp.net/eu-clinical-trials-registry)\n\nArticles\n\n*   [Publications](https://ichgcp.net/publications)\n*   [News](https://ichgcp.net/news)\n*   [About us / Our mission](https://ichgcp.net/about-us-our-mission)\n\nSearch trials\n\nExample: Heart Attack\n\n¬© ICH GCP. All Rights Reserved.\n\n*   [Sitemap](https://ichgcp.net/sitemap)\n*   [Contact us](https://ichgcp.net/contact-us)\n*   [RSS feed](https://ichgcp.net/feed)\n*   [Privacy Policy](https://ichgcp.net/privacy)\n*   [Disclaimer](https://ichgcp.net/disclaimer)\n\n English \n\n[Dansk](https://ichgcp.net/da/clinical-trials-registry/NCT02838420)[Deutsch](https://ichgcp.net/de/clinical-trials-registry/NCT02838420)[English](https://ichgcp.net/clinical-trials-registry/NCT02838420)[Espa√±ol](https://ichgcp.net/es/clinical-trials-registry/NCT02838420)[Fran√ßais](https://ichgcp.net/fr/clinical-trials-registry/NCT02838420)[Italiano](https://ichgcp.net/it/clinical-trials-registry/NCT02838420)[Magyar](https://ichgcp.net/hu/clinical-trials-registry/NCT02838420)[Nederlands](https://ichgcp.net/nl/clinical-trials-registry/NCT02838420)[Norsk](https://ichgcp.net/no/clinical-trials-registry/NCT02838420)[Polski](https://ichgcp.net/pl/clinical-trials-registry/NCT02838420)[Portugu√™s](https://ichgcp.net/pt/clinical-trials-registry/NCT02838420)[Suomi](https://ichgcp.net/fi/clinical-trials-registry/NCT02838420)[Svenska](https://ichgcp.net/sv/clinical-trials-registry/NCT02838420)[ƒåe≈°tina](https://ichgcp.net/cs/clinical-trials-registry/NCT02838420)[–†—É—Å—Å–∫–∏–π](https://ichgcp.net/ru/clinical-trials-registry/NCT02838420)[Êó•Êú¨Ë™û](https://ichgcp.net/ja/clinical-trials-registry/NCT02838420)[ÁÆÄ‰Ωì‰∏≠Êñá](https://ichgcp.net/zh/clinical-trials-registry/NCT02838420)[ÌïúÍµ≠Ïñ¥](https://ichgcp.net/ko/clinical-trials-registry/NCT02838420)\n\nGOOD CLINICAL PRACTICE NETWORK\n\nSubscribe to receive notifications of new clinical trials you are interested in.\n\nSubscribe\n\n‚úï\n\nGOOD CLINICAL PRACTICE NETWORK\n\nSubscribe to receive notifications of new clinical trials you are interested in.\n\nSubscribe for upcoming trials that contain the following conditions: \n\n- [x] Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer \n\n[Choose more conditions](https://ichgcp.net/mailing-list/conditions)\n\nSubscribe for upcoming trials that contain the following interventions: \n\n- [x] Alectinib \n\n- [x] Crizotinib \n\n[Choose more interventions](https://ichgcp.net/mailing-list/interventions)\n\nSubscribe for upcoming trials sponsored by: \n\n- [x] Hoffmann-La Roche \n\n[Choose more organizations](https://ichgcp.net/mailing-list/organizations)\n\nSubscribe\n\nSubscribe\n\nSubscribe\n'}, {'type': 'page', 'title': 'Alectinib vs crizotinib in Asian patients with treatment-na√Øve ... - Roche', 'url': 'https://medically.roche.com/global/en/medical-material/ESMO-Asia-2022-presentation-zhou-alectinib-vs-crizotinib-in-asian-patients-with-treatment-naive-advanced-pdf.html', 'content': 'Data cut -off 16 May 2022. ClinicalTrials.gov: NCT02838420. CNS, central nervous system; DOR, duration of response;  ECOG PS, Eastern Cooperative Oncology Group performance status; IHC, immunohistochemistry; INV, investigator \n\nIRC, independent review committee; NSCLC, non -small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, p rogression -free survival \n\n2:1 \n\nN=187 \n\nR\n\nAlectinib \n\n600mg  twice daily \n\nCrizotinib \n\n250mg twice daily \n\nTreat until disease', 'score': 0.5393963, 'raw_content': "Alectinib vs crizotinib in Asian patients \n\n## with treatment -na√Øve advanced  ALK +\n\n## non -small cell lung cancer: 5 -year \n\n## update from the Phase 3 ALESIA study \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nFaculty of Medicine  Ramathibodi  Hospital, Mahidol University, \n\nBangkok, Thailand \n\nZhou C, 1 Lu Y, 2 Kim S -W, 3 Baisamut  (Reungwetwattana) T, 4 Zhou J, 5 Zhang Y, 6 He J, 7 Yang J -J, 8 Cheng Y, 9 Lee S -H, 10  Chang J, 11 \n\nFang J, 12  Liu Z, 13  Bu L, 14  Qian L, 14  Xu T, 14  Archer V, 15  Hilton M, 16  Zhou M, 14  Zhang L 17 \n\n1Shanghai Pulmonary Hospital, Tongji University, Shanghai, China;  2West China Hospital, Sichuan University, Chengdu, China;  3Asan Medical \n\nCenter , University of Ulsan College of Medicine, Seoul, South Korea;  4Faculty of Medicine  Ramathibodi  Hospital, Mahidol University, Bangkok, \n\nThailand;  5The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China;  6Zhejiang Cancer Hospital, Hangzhou, China; \n\n7The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;  8Guangdong Lung Cancer Institute, Guangdong General Hospital, \n\nGuangzhou, China;  9Jilin Cancer Hospital, Changchun, China;  10 Sungkyunkwan University School of Medicine, Seoul, South Korea;  11 Cancer \n\nHospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China;  12 Beijing Cancer \n\nHospital, Beijing, China;  13 Beijing Chest Hospital, Capital Medical University, Beijing, China;  14 Roche Pharma Development, Shanghai, China; \n\n15 Roche Products Ltd, Welwyn Garden City, UK;  16 F. Hoffmann -La Roche Ltd, Basel, Switzerland;  17 Sun  Yat -sen  University Cancer  Center ,\n\nState Key Laboratory of Oncology in South China, Collaborative Innovation  Center  for Cancer Medicine, Guangzhou, China Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## DECLARATION OF INTERESTS \n\nThanyanan  Baisamut  (Reungwetwattana) \n\n‚Ä¢ Received honorarium from AstraZeneca, Pfizer, MSD, Roche, BMS, Amgen, J&J, Novartis,  Yuhan  and  Zuellig \n\n‚Ä¢ Participated as Principal Investigator on clinical trials for AstraZeneca, MSD, Roche, Novartis and  Yuhan   \n\n> Thanyanan Baisamut (Reungwetwattana)\n\nContent of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## ALESIA: alectinib vs crizotinib in treatment -na√Øve Asian patients \n\n## with advanced  ALK+  NSCLC \n\n‚Ä¢ Stratification factors:  ECOG PS (0/1 vs 2) \n\nand CNS metastases at baseline (yes vs no) \n\n‚Ä¢ Primary endpoint:  PFS by INV \n\n‚Ä¢ Secondary endpoints:  Time to CNS \n\nprogression by IRC, ORR by INV, \n\nDOR by INV, OS and safety \n\n‚Ä¢ Median duration of survival follow -up: \n\n61 months  alectinib vs  51 months  crizotinib \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nPatients were enrolled from China, Thailand and South Korea. *Asymptomatic CNS metastases allowed. \n\nData cut -off 16 May 2022. ClinicalTrials.gov: NCT02838420. CNS, central nervous system; DOR, duration of response;  ECOG PS, Eastern Cooperative Oncology Group performance status; IHC, immunohistochemistry; INV, investigator \n\nIRC, independent review committee; NSCLC, non -small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, p rogression -free survival \n\n2:1 \n\nN=187 \n\nR\n\nAlectinib \n\n600mg  twice daily \n\nCrizotinib \n\n250mg twice daily \n\nTreat until disease \n\nprogression, toxicity, \n\nwithdrawal or death \n\nNo crossover permitted \n\nStage IIIB/IV  ALK + NSCLC* \n\n‚Ä¢ Asian patients \n\n‚Ä¢ Treatment na√Øve \n\n‚Ä¢ ECOG PS 0 ‚Äì2\n\n‚Ä¢ Central  ALK  testing (Ventana IHC) \n\nBaseline demographics \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nAge, years  Median (range)  51.0 (21‚àí78)  49.0 (28‚àí83) \n\nGender, %  Male / Female  51.2 / 48.8  54.8 / 45.2 \n\nECOG PS, %  0‚Äì1 / 2  96.8 / 3.2  98.4 / 1.6 \n\nSmoking status, %  Active smoker / Non -smoker / \n\nPast smoker  3.2 / 67.2 / 29.6  4.8 / 72.6 / 22.6 \n\nCNS metastases by IRC, %  Yes  35.2  37.1 \n\nCNS metastases by INV, %  Yes  33.6  32.3 \n\nPrior brain radiation, %  Yes  6.4  8.1 Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Updated analyses from ALESIA demonstrate durable PFS benefit for \n\n## alectinib versus crizotinib, irrespective of CNS involvement at baseline \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nData cut -off 16 May 2022. CI, confidence interval; CNS, central nervous system; HR, hazard ratio; ITT, intent -to -treat;  mets , metastases;  PFS, progression -free survival \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nMedian  PFS, months \n\n(95% CI) \n\n41.6 \n\n(33.1 ‚Äì58.9) \n\n11.1 \n\n(9.1 ‚Äì18.4) \n\nHR  (95% CI)  0.33  (0.23 ‚Äì0.49) \n\n0\n\n> PFS (%)\n\n6 36  66 60 54 48 42 30 24 18 12 \n\nTime (months) \n\n100 \n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\nCrizotinib (n=62) \n\nAlectinib (n=125) \n\nWith  CNS  mets  at baseline  Without  CNS  mets  at baseline \n\nAlectinib \n\nn=44 \n\nCrizotinib \n\nn=23 \n\nAlectinib \n\nn=81 \n\nCrizotinib \n\nn=39 \n\nMedian  PFS, months \n\n(95% CI) \n\n42.3 \n\n(27.8 ‚Äì60.7) \n\n9.2 \n\n(5.5 ‚Äì12.2) \n\n41.6 \n\n(29.5 ‚Äì64.9) \n\n12.7 \n\n(9.2 ‚Äì27.6) \n\nHR  (95% CI)  0.17  (0.09 ‚Äì0.33)  0.45  (0.29 ‚Äì0.71) \n\nCrizotinib (n=39) \n\nWithout  CNS  mets  at baseline \n\nAlectinib (n=81) \n\nUpdated PFS: ITT population \n\nTime (months) \n\n100 \n\n0\n\n> PFS (%)\n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\n36  66 54 18 6 60 42 30 24 12  48 \n\nCrizotinib (n=23) \n\nWith  CNS  mets  at baseline \n\nAlectinib (n=44) \n\nPFS according to CNS status at baseline Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## A clinically meaningful improvement in 5 -year OS rate was observed \n\n## for alectinib compared with crizotinib \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nData cut -off 16 May 2022. CI, confidence interval; CNS, central nervous system; HR, hazard ratio; ITT, intent -to -treat;  mets , metastases; NE, not evaluable; OS, overall survival; pts, patients \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nPts with event, n (%)  41 (32.8)  26 (41.9) \n\nMedian  OS, months \n\n(95% CI) \n\nNE \n\n(NE ‚ÄìNE) \n\nNE \n\n(45.5 ‚ÄìNE) \n\nHR  (95% CI)  0.60  (0.37 ‚Äì0.99) \n\n5-year OS rate , % \n\n(95% CI) \n\n66.4 \n\n(57.9 ‚Äì74.9) \n\n56.0 \n\n(43.0 ‚Äì69.1) \n\nPts remaining at risk, n  69  25 \n\n0\n\n> OS (%)\n\n6 36  66 60 54 48 42 30 24 18 12 \n\nTime (months) \n\n100 \n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\nCrizotinib (n=62) \n\nAlectinib (n=125) \n\nWith  CNS  mets  at baseline  Without  CNS  mets  at baseline \n\nAlectinib \n\nn=44 \n\nCrizotinib \n\nn=23 \n\nAlectinib \n\nn=81 \n\nCrizotinib \n\nn=39 \n\nPts with event, n (%)  16 (36.4)  12 (52.2)  25 (30.9)  14 (35.9) \n\nMedian  OS, months \n\n(95% CI) \n\nNE \n\n(51.4 ‚ÄìNE) \n\n46.2 \n\n(12.2 ‚ÄìNE) \n\nNE \n\n(NE ‚ÄìNE) \n\nNE \n\n(59.8 ‚ÄìNE) \n\nHR  (95% CI)  0.40  (0.19 ‚Äì0.85)  0.81  (0.42 ‚Äì1.55) \n\n5-year OS rate, % \n\n(95% CI) \n\n63.6 \n\n(48.9 ‚Äì78.3) \n\n39.3 \n\n(17.4 ‚Äì61.2) \n\n67.8 \n\n(57.4 ‚Äì78.2) \n\n64.9 \n\n(49.3 ‚Äì80.4) \n\nPts remaining at risk, n  25  6 44  19 \n\nCrizotinib (n=39) \n\nWithout  CNS  mets  at baseline \n\nAlectinib (n=81) \n\nUpdated OS: ITT population \n\nTime (months) \n\n100 \n\n0\n\n> OS (%)\n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\n36  66 54 18 6 60 42 30 24 12  48 \n\nCrizotinib (n=23) \n\nWith  CNS  mets  at baseline \n\nAlectinib (n=44) \n\nOS according to CNS status at baseline Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Treatment with alectinib delayed the time to CNS progression* \n\nThanyanan  Baisamut  (Reungwetwattana) \n\n*Derived from investigators' assessment. CNS PD = CNS Target Lesion PD per RECIST version 1.1, appearance of new CNS lesion(s ),  and/or unequivocal PD of Non -Target CNS lesion(s) \n\nData cut -off 16 May 2022. CI, confidence interval;  CIR, cumulative incidence rate;  CNS, central nervous system; HR, hazard ratio;  PD, progressive disease \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nCNS progression without prior systemic progression \n\nPatients with events, n (%)  18 (14.4)  22 (35.5) \n\nCause -specific HR  (95% CI)  0.16  (0.08 ‚Äì0.32) \n\nEstimated cumulative incidence, % (95% CI) \n\nAt 36 months  11.6 (6.7 ‚Äì18.1)  34.0 (22.1 ‚Äì46.2) \n\nAt 60 months  14.2 (8.6 ‚Äì21.1)  37.4 (25.0 ‚Äì49.7) \n\n40 \n\n0\n\n> Cumulative incidence (%)\n\n30 \n\n20 \n\n10 \n\n0 6 36  60 54 48 42 30 24 18 12 \n\nTime (months) \n\nCrizotinib (n=62) \n\nAlectinib (n=125) \n\nCIR: \n\n11.6% (95% CI 6.7 ‚Äì18.1) \n\nCIR: \n\n14.2% (95% CI 8.6 ‚Äì21.1) \n\nCIR: \n\n34.0% (95% CI 22.1 ‚Äì46.2) \n\nCIR: \n\n37.4% (95% CI 25.0 ‚Äì49.7) Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Post -progression therapy \n\nThanyanan  Baisamut  (Reungwetwattana)  \n\n> Data cut -off 16 May 2022. PD, progressive disease; VEGF, vascular endothelial growth factor\n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nPatients with PD , n  68  48 \n\nAnti -cancer therapy after PD , n (%)  42 (61.8)  38 (79.2) \n\nALK inhibitor , n (%)  25 (36.8)  28 (58.3) \n\nAlectinib  5 (7.4)  14 (29.2) \n\nLorlatinib  8 (11.8)  6 (12.5) \n\nBrigatinib  6 (8.8)  7 (14.6) \n\nCrizotinib  7 (10.3)  2 (4.2) \n\nCeritinib  3 (4.4)  4 (8.3) \n\nEnsartinib  2 (2.9)  1 (2.1) \n\nInvestigational drug  1 (1.5)  0\n\nChemotherapy , n (%)  24 (35.3)  15 (31.3) \n\nAnti -VEGF therapies , n ( %Ôºâ 9 (13.2)  3 (6.3) \n\nImmunotherapy , n (%)  3 (4.4)  2 (4.2) \n\nOther therapies , n (%)  6 (8.8)  7 (14.6) \n\nMore crizotinib patients (79.2% vs 61.8% alectinib) received at least one anti -cancer therapy post -progression \n\nApproximately 30% of patients in the crizotinib arm received alectinib after their disease progressed Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## The safety profile of alectinib remained favourable with longer \n\n## follow -up; no new safety signals were observed \n\nThanyanan  Baisamut  (Reungwetwattana) \n\n> *Three additional fatal events occurred during the longer follow -up: one was due to COVID -19 pneumonia, and the other two were r eported as ‚Äòdeath‚Äô and not related to alectinib treatment\n> Data cut -off 16 May 2022. AE, adverse event; ALT, alanine aminotransferase; ECG, electrocardiogram\n\nEvent, n  (%) \n\nAlectinib \n\n(n=125) \n\nCrizotinib \n\n(n=62) \n\nPatients with ‚â•1 \n\nAll grade AEs  125 (100)  62 (100) \n\nSerious AEs  35 (28.0)  18 (29.0) \n\nGrade ‚â•3 AEs  60 (48.0)  34 (54.8) \n\nFatal AEs  5 (4.0)*  3 (4.8) \n\nAEs leading to treatment discontinuation  14 (11.2)  9 (14.5) \n\nAEs leading to dose reduction  33 (26.4)  17 (27.4) \n\nAEs leading to dose interruption  33 (26.4)  19 (30.6) \n\nGrade ‚â•3 AEs with ‚â•3% difference \n\nin frequency between treatment arms, n  (%) \n\nAlectinib \n\n(n=125) \n\nCrizotinib \n\n(n=62) \n\nWeight increased  11 (8.8)  1 (1.6) \n\nBlood creatine phosphokinase increased  8 (6.4)  2 (3.2) \n\nALT increased  3 (2.4)  4 (6.5) \n\nNausea  1 (0.8)  3 (4.8) \n\nNeutrophil count decreased  0 9 (14.5) \n\nECG QT prolonged  0 3 (4.8) \n\nWhite blood cell count decreased  0 3 (4.8) \n\nDecreased appetite  0 3 (4.8) \n\nHyponatraemia  0 3 (4.8) \n\nInterstitial lung disease  0 3 (4.8) \n\nVomiting  0 3 (4.8) \n\nBradycardia  0 2 (3.2) \n\nHepatic function abnormal  0 2 (3.2) \n\nMedian treatment duration was more than three -times greater for alectinib (42.3 months) \n\ncompared to crizotinib (12.6 months) Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Conclusions:  5-year update from the Phase 3 ALESIA study   \n\n> Thanyanan Baisamut (Reungwetwattana )\n\nWith  at least 5 years  of follow -up, 1L alectinib  600mg twice daily  continues \n\nto demonstrate clinical benefit to Asian patients with advanced  ALK+  NSCLC, \n\nconsistent with  that observed in the  global ALEX study \n\nTreatment with alectinib also delayed the time to CNS progression \n\nThis clinical benefit, coupled with a tolerable and manageable safety profile, \n\nconfirms alectinib as standard -of -care treatment \n\nfor patients with advanced  ALK+  NSCLC Acknowledgements \n\nWe thank the participating patients and their families, study investigators, and research nurses \n\nThe ALESIA study was funded by F. Hoffmann -La Roche Ltd \n\nMedical writing support for the development of this presentation, under the direction \n\nof the authors, was provided by Fiona Duthie, PhD, of Ashfield MedComms, \n\nan Inizio company, and was funded by F. Hoffmann -La Roche Ltd\n"}, {'type': 'image', 'image_url': 'https://www.umc.edu/Research/Centers-and-Institutes/External-Designation-Centers/Mississippi-Poison-Control-Center/images/Medication-Label-1-A-E.jpg', 'image_description': 'The document outlines the drug facts of a medication, including its active ingredient, purposes such as pain relief and fever reduction, specific uses, warnings about allergic reactions and stomach bleeding, and instructions for use.'}, {'type': 'image', 'image_url': 'https://images.ctfassets.net/gi8mrztylj0k/7uYtc358SoGmfbZJwSffV4/4a6b40b9f5e3f8e7fea16ea0a96f143a/pasted_image_0__10_.png', 'image_description': 'The contents list various classes of food ingredients along with their definitions and requirements for labeling, including edible oils, fats, fish, meat, cheese, spices, and gums.'}, {'type': 'image', 'image_url': 'https://images.ctfassets.net/gi8mrztylj0k/2SwoBWSwLlal4WhyRZp7mK/424ea61f0461de8a7b51935a15fc5019/pasted_image_0__11_.png', 'image_description': 'A table listing various food and ingredient classes along with their respective class titles.'}, {'type': 'image', 'image_url': 'https://i.etsystatic.com/16874044/r/il/a74daa/3750620251/il_fullxfull.3750620251_8kd8.jpg', 'image_description': 'A list of ingredients includes Cocoa Mass, Cocoa Butter, and Milk, among others.'}, {'type': 'image', 'image_url': 'https://7esl.com/wp-content/uploads/2021/03/Foods-starting-with-r-scaled.jpg', 'image_description': 'A poster of foods that start with the letter R.'}], {'query': '"For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter \'C\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name."', 'follow_up_questions': None, 'answer': None, 'images': [{'url': 'https://www.umc.edu/Research/Centers-and-Institutes/External-Designation-Centers/Mississippi-Poison-Control-Center/images/Medication-Label-1-A-E.jpg', 'description': 'The document outlines the drug facts of a medication, including its active ingredient, purposes such as pain relief and fever reduction, specific uses, warnings about allergic reactions and stomach bleeding, and instructions for use.'}, {'url': 'https://images.ctfassets.net/gi8mrztylj0k/7uYtc358SoGmfbZJwSffV4/4a6b40b9f5e3f8e7fea16ea0a96f143a/pasted_image_0__10_.png', 'description': 'The contents list various classes of food ingredients along with their definitions and requirements for labeling, including edible oils, fats, fish, meat, cheese, spices, and gums.'}, {'url': 'https://images.ctfassets.net/gi8mrztylj0k/2SwoBWSwLlal4WhyRZp7mK/424ea61f0461de8a7b51935a15fc5019/pasted_image_0__11_.png', 'description': 'A table listing various food and ingredient classes along with their respective class titles.'}, {'url': 'https://i.etsystatic.com/16874044/r/il/a74daa/3750620251/il_fullxfull.3750620251_8kd8.jpg', 'description': 'A list of ingredients includes Cocoa Mass, Cocoa Butter, and Milk, among others.'}, {'url': 'https://7esl.com/wp-content/uploads/2021/03/Foods-starting-with-r-scaled.jpg', 'description': 'A poster of foods that start with the letter R.'}], 'results': [{'url': 'https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp', 'title': 'AIM-Harvard/MedBrowseComp ¬∑ Datasets at Hugging Face', 'content': '| CRIZOTINIB | "For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter \'C\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient | [...] | PF PRISM CV | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name | [...] | May 12, 2027 | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |', 'score': 0.92684203, 'raw_content': 'AIM-Harvard/MedBrowseComp ¬∑ Datasets at Hugging Face\n\n===============\n\n[![Image 1: Hugging Face\'s logo](https://huggingface.co/front/assets/huggingface_logo-noborder.svg)Hugging Face](https://huggingface.co/)\n\n*   [Models](https://huggingface.co/models)\n*   [Datasets](https://huggingface.co/datasets)\n*   [Spaces](https://huggingface.co/spaces)\n*    Community  \n*   [Docs](https://huggingface.co/docs)\n*   [Enterprise](https://huggingface.co/enterprise)\n*   [Pricing](https://huggingface.co/pricing)\n*    \n*   \n* * *\n\n*   [Log In](https://huggingface.co/login)\n*   [Sign Up](https://huggingface.co/join)\n\n[Datasets:](https://huggingface.co/datasets)\n\n* * *\n\n[![Image 2](https://cdn-avatars.huggingface.co/v1/production/uploads/63600b93d9e4214b9a67807c/ZRnXCRmf600I8gTKJH-V0.png)](https://huggingface.co/AIM-Harvard)\n\n[AIM-Harvard](https://huggingface.co/AIM-Harvard)\n\n/\n\n[MedBrowseComp](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp)\n\nlike 1\n\nFollow\n\n![Image 3](https://cdn-avatars.huggingface.co/v1/production/uploads/63600b93d9e4214b9a67807c/ZRnXCRmf600I8gTKJH-V0.png)AIM-Harvard 23\n===================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================\n\nTasks: [Question Answering](https://huggingface.co/datasets?task_categories=task_categories%3Aquestion-answering)[Text Retrieval](https://huggingface.co/datasets?task_categories=task_categories%3Atext-retrieval)\n\nModalities: [Text](https://huggingface.co/datasets?modality=modality%3Atext)\n\nFormats: [csv](https://huggingface.co/datasets?format=format%3Acsv)\n\nLanguages: [English](https://huggingface.co/datasets?language=language%3Aen)\n\nSize: [1K - 10K](https://huggingface.co/datasets?size_categories=size_categories%3A1K%3Cn%3C10K)\n\nArXiv: \n\narxiv:2505.14963\n\nTags: [medical](https://huggingface.co/datasets?other=medical)[healthcare](https://huggingface.co/datasets?other=healthcare)[browsing](https://huggingface.co/datasets?other=browsing)[comparison](https://huggingface.co/datasets?other=comparison)\n\nLibraries: [Datasets](https://huggingface.co/datasets?library=library%3Adatasets)[pandas](https://huggingface.co/datasets?library=library%3Apandas)\n\nCroissant\n\n+ 1\n\nLicense: \n\napache-2.0\n\n[Dataset card](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp)[Data Studio](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/viewer/)[Files Files and versions](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/tree/main)[Community 1](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/discussions)\n\nDataset Viewer\n\n[Auto-converted to Parquet](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/tree/refs%2Fconvert%2Fparquet/default)API Embed Data Studio\n\nSubset (1)\n\ndefault¬∑1.14k rows\n\n \n\nSplit (3)\n\nMedBrowseComp_50¬∑50 rows\n\n \n\nSQL \n\n Console \n\n| gold string lengths 5 24 | prompt string lengths 227 657 | task_name string classes 5 values |\n| --- | --- | --- |\n| ENZALUTAMIDE | "For clinical trial NCT00974311. Among the more effective regimen ingredients, find which ingredient starts with the letter \'E\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| CRIZOTINIB | "For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter \'C\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| LENALIDOMIDE | "For clinical trial NCT01938001. Among the more effective regimen ingredients, find which ingredient starts with the letter \'L\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| AZACITIDINE | "For clinical trial NCT00071799. Among the more effective regimen ingredients, find which ingredient starts with the letter \'A\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| IRINOTECAN HYDROCHLORIDE | "For clinical trial NCT00720512. Among the more effective regimen ingredients, find which ingredient starts with the letter \'I\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| VENETOCLAX | "For clinical trial NCT02755597. Among the more effective regimen ingredients, find which ingredient starts with the letter \'V\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| DEXAMETHASONE | "For clinical trial NCT00833833. Among the more effective regimen ingredients, find which ingredient starts with the letter \'D\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| IBRUTINIB | "For clinical trial NCT01973387. Among the more effective regimen ingredients, find which ingredient starts with the letter \'I\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| LENALIDOMIDE | "For clinical trial NCT00843882. Among the more effective regimen ingredients, find which ingredient starts with the letter \'L\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| SIROLIMUS | "For clinical trial NCT01231412. Among the more effective regimen ingredients, find which ingredient starts with the letter \'S\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| ASTELLAS | "First, for clinical trial NCT00974311, among the more effective regimen ingredients, identify which ingredient starts with the letter \'E\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| PF PRISM CV | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| BRISTOL MYERS SQUIBB | "First, for clinical trial NCT01938001, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| BRISTOL | "First, for clinical trial NCT00071799, among the more effective regimen ingredients, identify which ingredient starts with the letter \'A\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| IPSEN | "First, for clinical trial NCT00720512, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| ABBVIE | "First, for clinical trial NCT02755597, among the more effective regimen ingredients, identify which ingredient starts with the letter \'V\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| DEXCEL | "First, for clinical trial NCT00833833, among the more effective regimen ingredients, identify which ingredient starts with the letter \'D\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| PHARMACYCLICS LLC | "First, for clinical trial NCT01973387, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| BRISTOL MYERS SQUIBB | "First, for clinical trial NCT00843882, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| AADI SUB | "First, for clinical trial NCT01231412, among the more effective regimen ingredients, identify which ingredient starts with the letter \'S\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| Aug 13, 2027 | "First, for clinical trial NCT00974311, among the more effective regimen ingredients, identify which ingredient starts with the letter \'E\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| May 12, 2027 | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Apr 27, 2027 | "First, for clinical trial NCT01938001, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| May 14, 2029 | "First, for clinical trial NCT00071799, among the more effective regimen ingredients, identify which ingredient starts with the letter \'A\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Jan 6, 2027 | "First, for clinical trial NCT00720512, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Jan 29, 2032 | "First, for clinical trial NCT02755597, among the more effective regimen ingredients, identify which ingredient starts with the letter \'V\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Dec 18, 2037 | "First, for clinical trial NCT00833833, among the more effective regimen ingredients, identify which ingredient starts with the letter \'D\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Dec 3, 2031 | "First, for clinical trial NCT01973387, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Apr 27, 2027 | "First, for clinical trial NCT00843882, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Mar 5, 2036 | "First, for clinical trial NCT01231412, among the more effective regimen ingredients, identify which ingredient starts with the letter \'S\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Nov 17, 2026 | "For clinical trial NCT00974311, among the more effective regimen ingredients, identify which ingredient starts with the letter \'E\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Jul 14, 2025 | "For clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| May 28, 2026 | "For clinical trial NCT01938001, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Sep 1, 2027 | "For clinical trial NCT00071799, among the more effective regimen ingredients, identify which ingredient starts with the letter \'A\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Feb 13, 2031 | "For clinical trial NCT00720512, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| May 15, 2026 | "For clinical trial NCT02755597, among the more effective regimen ingredients, identify which ingredient starts with the letter \'V\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Oct 3, 2026 | "For clinical trial NCT00833833, among the more effective regimen ingredients, identify which ingredient starts with the letter \'D\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Aug 24, 2029 | "For clinical trial NCT01973387, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| May 28, 2026 | "For clinical trial NCT00843882, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Nov 22, 2028 | "For clinical trial NCT01231412, among the more effective regimen ingredients, identify which ingredient starts with the letter \'S\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| 15.98999977 | "For clinical trial NCT00974311, review the more effective regimen ingredients and identify which ingredient starts with the letter \'E\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 34.47000122 | "For clinical trial NCT02838420, review the less effective regimen ingredients and identify which ingredient starts with the letter \'C\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 46.72999954 | "For clinical trial NCT01938001, review the more effective regimen ingredients and identify which ingredient starts with the letter \'L\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 62.20000076 | "For clinical trial NCT00071799, review the more effective regimen ingredients and identify which ingredient starts with the letter \'A\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 15.14000034 | "For clinical trial NCT00720512, review the more effective regimen ingredients and identify which ingredient starts with the letter \'I\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 58.59000015 | "For clinical trial NCT02755597, review the more effective regimen ingredients and identify which ingredient starts with the letter \'V\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| NOT LISTED | "For clinical trial NCT00833833, review the more effective regimen ingredients and identify which ingredient starts with the letter \'D\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| NOT LISTED | "For clinical trial NCT01973387, review the more effective regimen ingredients and identify which ingredient starts with the letter \'I\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 46.72999954 | "For clinical trial NCT00843882, review the more effective regimen ingredients and identify which ingredient starts with the letter \'L\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 39.84000015 | "For clinical trial NCT01231412, review the more effective regimen ingredients and identify which ingredient starts with the letter \'S\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n\n*   [Datasets](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#datasets "Datasets")\n\n*   [Usage](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#usage "Usage")\n\n*   [GitHub Repository](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#github-repository "GitHub Repository")\n\n*   [Citation](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#citation "Citation")\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#medbrowsecomp-dataset) MedBrowseComp Dataset\n=========================================================================================================\n\nThis repository contains datasets for medical information-seeking-oriented deep research and computer use tasks.\n\n[![Image 4: Overall](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/resolve/main/medcomp.png)](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/blob/main/medcomp.png)\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#datasets) Datasets\n-------------------------------------------------------------------------------\n\nThe repository contains three harmonized datasets:\n\n1.   **MedBrowseComp_50**: A collection of 50 medical entries for browsing and comparison.\n2.   **MedBrowseComp_605**: A comprehensive collection of 605 medical entries.\n3.   **MedBrowseComp_CUA**: A curated collection of medical data for comparison and analysis.\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#usage) Usage\n-------------------------------------------------------------------------\n\nThese datasets can be used for various medical text processing tasks, information retrieval, and comparative analysis.\n\nExample usage with the Hugging Face datasets library:\n\n```python\nfrom datasets import load_dataset\n\n# Load the dataset\ndataset = load_dataset("AIM-Harvard/MedBrowseComp")\n\n# Access specific splits\nmed50_data = dataset["MedBrowseComp_50"]\nmed605_data = dataset["MedBrowseComp_605"]\ncua_data = dataset["MedBrowseComp_CUA"]\n```\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#github-repository) GitHub Repository\n-------------------------------------------------------------------------------------------------\n\nFor more information and related tools, visit: [https://github.com/MedBrowseComp](https://github.com/MedBrowseComp)\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#citation) Citation\n-------------------------------------------------------------------------------\n\nIf you use this dataset in your research, please cite: [https://arxiv.org/abs/2505.14963](https://arxiv.org/abs/2505.14963)\n\n```\n@misc{chen2025medbrowsecompbenchmarkingmedicaldeep,\n      title={MedBrowseComp: Benchmarking Medical Deep Research and Computer Use}, \n      author={Shan Chen and Pedro Moreira and Yuxin Xiao and Sam Schmidgall and Jeremy Warner and Hugo Aerts and Thomas Hartvigsen and Jack Gallifant and Danielle S. Bitterman},\n      year={2025},\n      eprint={2505.14963},\n      archivePrefix={arXiv},\n      primaryClass={cs.CL},\n      url={https://arxiv.org/abs/2505.14963}, \n}\n```\n\nDownloads last month 179\n\n Use this dataset \n\nSize of downloaded dataset files: 448 kB[Size of the auto-converted Parquet files: 58 kB](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/tree/refs%2Fconvert%2Fparquet/)Number of rows: 1,139\n\nCollection including AIM-Harvard/MedBrowseComp\n----------------------------------------------\n\n[#### MedBrowseComp Collection MedBrowseComp: Benchmarking Medical Deep Research and Computer Use‚Ä¢ 3 items‚Ä¢ Updated 10 days ago](https://huggingface.co/collections/AIM-Harvard/medbrowsecomp-6822637df90521b5d8b8b23f)\n\n System theme \n\nCompany\n\n[TOS](https://huggingface.co/terms-of-service)[Privacy](https://huggingface.co/privacy)[About](https://huggingface.co/huggingface)[Jobs](https://apply.workable.com/huggingface/)[](https://huggingface.co/)\n\nWebsite\n\n[Models](https://huggingface.co/models)[Datasets](https://huggingface.co/datasets)[Spaces](https://huggingface.co/spaces)[Pricing](https://huggingface.co/pricing)[Docs](https://huggingface.co/docs)\n'}, {'title': 'Alectinib and Crizotinib in Anaplastic Lymphoma Kinase-positive Non ...', 'url': 'https://ichgcp.net/clinical-trials-registry/NCT02838420', 'content': 'USA (FDA)\n       UK (MHRA)\n       AUSTRALIA (NHMRC)\n       JAPAN (PMDA)\n       EU (EMA)\n\n   CRO List\n   Clinical Trials\n\n       US Clinical Trials Registry\n       EU Clinical Trials Registry\n       Pharmaceutical Companies\n       Clinical Research Labs\n       Service Companies\n       Clinical Research Events\n       Publications\n       Researchers\n\n   Jobs\n   Publications\n   News\n\n   \n   \n\n   ICH GCP\n   US Clinical Trials Registry\n   Clinical Trial NCT02838420', 'score': 0.54724693, 'raw_content': 'Published Time: 2022-12-12T02:32:10+00:00\n\nAlectinib and Crizotinib in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer - Clinical Trials Registry - ICH GCP\n\n===============\n\n[![Image 1: ICHGCP](https://ichgcp.net/img/ichgcp_logo.png)](https://ichgcp.net/)\n\n*   Regulations\n\n    *   [GLOBAL¬ª](https://ichgcp.net/clinical-trials-registry/NCT02838420#)\n\n        *   [ICH GCP (De)](https://ichgcp.net/de)\n        *   [ICH GCP (En)](https://ichgcp.net/)\n        *   [ICH GCP (Es)](https://ichgcp.net/es)\n        *   [ICH GCP (Fr)](https://ichgcp.net/fr)\n        *   [ICH GCP (It)](https://ichgcp.net/it)\n        *   [ICH GCP (Pt)](https://ichgcp.net/pt)\n        *   [ICH GCP (Ru)](https://ichgcp.net/ru)\n\n    *   [USA (FDA)](https://ichgcp.net/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects)\n    *   [UK (MHRA)](https://ichgcp.net/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol)\n    *   [AUSTRALIA (NHMRC)](https://ichgcp.net/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia)\n    *   [JAPAN (PMDA)](https://ichgcp.net/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan)\n    *   [EU (EMA)](https://ichgcp.net/ich-e-group-of-guidelines)\n\n*   [CRO List](https://ichgcp.net/cro-list)\n*   Clinical Trials\n\n    *   [US Clinical Trials Registry](https://ichgcp.net/clinical-trials-registry)\n    *   [EU Clinical Trials Registry](https://ichgcp.net/eu-clinical-trials-registry)\n    *   [Pharmaceutical Companies](https://ichgcp.net/pharma-list)\n    *   [Clinical Research Labs](https://ichgcp.net/labs)\n    *   [Service Companies](https://ichgcp.net/service-companies)\n    *   [Clinical Research Events](https://ichgcp.net/events)\n    *   [Publications](https://ichgcp.net/clinical-trials-registry/publications)\n    *   [Researchers](https://ichgcp.net/clinical-trials-registry/researchers)\n\n*   [Jobs](https://ichgcp.net/jobs)\n*   [Publications](https://ichgcp.net/publications)\n*   [News](https://ichgcp.net/news)\n\n*   [](https://telegram.me/share/url?url=https://ichgcp.net/clinical-trials-registry/NCT02838420&text= "Share on telegram")\n*   [](https://twitter.com/intent/tweet?url=https://ichgcp.net/clinical-trials-registry/NCT02838420 "Share on Twitter")\n\n*   [ICH GCP](https://ichgcp.net/)\n*   [US Clinical Trials Registry](https://ichgcp.net/clinical-trials-registry)\n*   Clinical Trial NCT02838420\n\nA Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)\n=========================================================================================================================================================================================================================================================================\n\nMarch 24, 2025 updated by: [Hoffmann-La Roche](https://ichgcp.net/clinical-trials-registry/research/list?spons=Hoffmann-La%20Roche "List all studies sponsored by Hoffmann-La Roche")\n\nRandomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Asian Patients With Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer\n--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\nThis randomized, multicenter, Phase III, open-label study will evaluate the efficacy and safety of alectinib versus crizotinib and to evaluate the pharmacokinetics of alectinib in asian participants with treatment-naive ALK-positive advanced NSCLC. Participants will be randomized 2:1 into one of the two treatment groups to receive either alectinib (600 milligrams [mg] twice daily [BID]) or crizotinib (250 mg BID) orally, respectively.\n\nStudy Overview\n--------------\n\n#### Status\n\nActive, not recruiting\n\n#### Conditions\n\n*   [Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%20Lymphoma%20Kinase-positive%20Non-small%20Cell%20Lung%20Cancer "List all studies focused on condition Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer")\n\n#### Intervention / Treatment\n\n*   [Drug: Alectinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Alectinib "List all studies with intervention Alectinib")\n*   [Drug: Crizotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Crizotinib "List all studies with intervention Crizotinib")\n\n#### Study Type\n\n Interventional \n\n#### Enrollment (Actual)\n\n 187 \n\n#### Phase\n\n*   Phase 3\n\nContacts and Locations\n----------------------\n\nThis section provides the contact details for those conducting the study, and information on where this study is being conducted.\n\n### Study Locations\n\n*   [China](https://ichgcp.net/clinical-trials-registry/research/list?locn=China "List all studies conducted in China") \n    *           *   Beijing, China, 100142 \n            *   Beijing Cancer Hospital\n\n        *   Beijing, China, 101149 \n            *   Beijing Chest Hospital\n\n        *   Changchun, China, 130021 \n            *   The First Hospital of Jilin University\n\n        *   Changchun, China, 132013 \n            *   Jilin cancer hospital\n\n        *   Chengdu, China, 610041 \n            *   West China Hospital, Sichuan University\n\n        *   Guangzhou, China, 510060 \n            *   Sun Yet-sen University Cancer Center\n\n        *   Guangzhou, China, 510080 \n            *   Guangdong General Hospital\n\n        *   Guangzhou, China, 510120 \n            *   The First Affiliated Hospital of Guangzhou Medical University\n\n        *   Hangzhou, China, 310003 \n            *   The First Affiliated Hospital of College of Medicine, Zhejiang University\n\n        *   Hangzhou, China, 310022 \n            *   Zhejiang Cancer Hospital\n\n        *   Harbin, China, 150081 \n            *   Harbin Medical University Cancer Hospital\n\n        *   Nanjing, China, 210009 \n            *   Jiangsu Cancer Hospital\n\n        *   Shanghai, China, 200030 \n            *   Shanghai Chest Hospital\n\n        *   Shanghai, China, 200032 \n            *   Fudan University Shanghai Cancer Center\n\n        *   Shanghai, China, 200433 \n            *   Shanghai Pulmonary Hospital\n\n*   [Korea, Republic of](https://ichgcp.net/clinical-trials-registry/research/list?locn=Korea%2C%20Republic%20of "List all studies conducted in Korea, Republic of") \n    *           *   Seoul, Korea, Republic of, 05505 \n            *   Asan Medical Center\n\n        *   Seoul, Korea, Republic of, 06351 \n            *   Samsung Medical Center\n\n        *   Seoul, Korea, Republic of, 03181 \n            *   Kangbuk Samsung Hospital\n\n*   [Thailand](https://ichgcp.net/clinical-trials-registry/research/list?locn=Thailand "List all studies conducted in Thailand") \n    *           *   Bangkok, Thailand, 10400 \n            *   Rajavithi Hospital\n\n        *   Bangkok, Thailand, 10400 \n            *   Ramathibodi Hospital\n\n        *   Songkhla, Thailand, 90110 \n            *   Songklanagarind hospital\n\nParticipation Criteria\n----------------------\n\nResearchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person\'s general health condition or prior treatments.\n\n### Eligibility Criteria\n\n#### Ages Eligible for Study\n\n 18 years and older (Adult, Older Adult) \n\n#### Accepts Healthy Volunteers\n\n No \n\n#### Description\n\nInclusion Criteria:\n\n*   Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive as assessed by the Ventana immunohistochemistry (IHC) test. Sufficient tumor tissue available to perform ALK IHC is required. Ventana IHC testing will be performed at the designated central laboratory\n*   Life expectancy of at least 12 weeks\n*   Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2\n*   No history of receiving systemic treatment for advanced, recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC\n*   Adequate hematologic function: Platelet count greater than equal to (>=) 100√ó10^9 per liter (/L); absolute neutrophil count (ANC) >=1500 cells per microliter (cells/mcL); hemoglobin>=9.0 grams per deciliter (g/dL)\n*   Adequate renal function: an estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease (MDRD) formula of >=45 milliliters per minute per 1.73 square meter\n*   Participants must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before receiving the first dose of study treatment\n*   Measurable disease (by Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v1.1]) before administration of study treatment\n*   Previous brain or leptomeningeal metastases are allowed if the participant is asymptomatic (e.g., diagnosed incidentally at study baseline). Asymptomatic central nervous system (CNS) lesions may be treated at the discretion of the investigator as per local clinical practice. If participant has neurological symptoms or signs because of CNS metastasis, the participant must complete whole-brain radiation or gamma knife irradiation treatment. In all cases, radiation treatment must be completed >=14 days before enrollment and disease must be clinically stable\n*   For all females of childbearing potential, a negative serum pregnancy test result must be obtained within 3 days prior to starting study treatment\n*   For women who are not postmenopausal (>=12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus), agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Examples of contraceptive methods with a failure rate of <1% per year include tubal ligation, male sterilization, hormonal implants, established, proper use of combined oral or injected hormonal contraceptives, and certain intrauterine devices. Alternatively, two methods (e.g., two barrier methods such as a condom and a cervical cap) may be combined to achieve a failure rate of <1% per year. Barrier methods must always be supplemented with the use of a spermicide\n*   For men, agreement to remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception\n\nExclusion Criteria:\n\n*   A malignancy within the previous 3 years (other than curatively treated basal cell carcinoma of the skin, early gastrointestinal (GI) cancer by endoscopic resection, in situ carcinoma of the cervix, or any cured cancer that is considered to have no impact in progression-free survival (PFS) or overall survival (OS) for the current NSCLC)\n*   Any GI disorder that may affect absorption of oral medications, such as malabsorption syndrome or status post-major bowel resection\n*   Liver disease characterized by:\n*   Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than (>) 3√ó the upper limit of normal (ULN; >=5√óULN for participants with concurrent liver metastases) confirmed on two consecutive measurements; or\n*   Impaired excretory function (e.g., hyperbilirubinemia), synthetic function, or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices; or\n*   Acute viral or active autoimmune, alcoholic, or other types of hepatitis\n*   National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 Grade 3 or higher toxicities because of any previous therapy (e.g., radiotherapy) (excluding alopecia), which have not shown improvement and are strictly considered to interfere with current study medication\n*   History of organ transplant\n*   Co-administration of anti-cancer therapies other than those administered in this study\n*   Baseline QTc >470 ms or symptomatic bradycardia\n*   Administration of strong/potent cytochrome P4503A inhibitors or inducers within 14 days prior to the receiving the first dose of study treatment and during treatment with alectinib or crizotinib\n*   Administration of agents with potential QT interval prolonging effects within 14 days prior to receiving the first dose of study drug\n*   History of hypersensitivity to any of the additives in the alectinib or crizotinib drug formulation\n*   Pregnant or lactating\n*   Known human immunodeficiency virus (HIV-positivity or acquired immunodeficiency syndrome (AIDS)-related illness\n*   Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or the absorption of oral medications or that would, in the opinion of the Principal Investigator, pose an unacceptable risk to the participant in this study\n*   Any psychological, familial, sociological, or geographical condition that potentially hampers compliance with the study protocol requirements or follow-up procedures; those conditions should be discussed with the participant before study entry\n\nStudy Plan\n----------\n\nThis section provides details of the study plan, including how the study is designed and what the study is measuring.\n\n### How is the study designed?\n\n#### Design Details\n\n*   **Primary Purpose**: Treatment\n*   **Allocation**: Randomized\n*   **Interventional Model**: Parallel Assignment\n*   **Masking**: None (Open Label)\n\n#### Number of Arms\n\n2\n\n#### Arms and Interventions\n\n| ##### Participant Group / Arm | ##### Intervention / Treatment |\n| --- | --- |\n| Experimental: Alectinib Participants will receive alectinib capsules orally at a dose of 600 mg BID with food until disease progression, unacceptable toxicity withdrawal of consent, or death. | [Drug: Alectinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Alectinib "List all studies with intervention Alectinib") Alectinib capsules will be administered orally at a dose of 600 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death. Other Names: * RO5424802 |\n| Active Comparator: Crizotinib Participants will receive crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity withdrawal of consent, or death. | [Drug: Crizotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Crizotinib "List all studies with intervention Crizotinib") Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death. |\n\n### What is the study measuring?\n\n#### Primary Outcome Measures\n\n| ##### Outcome Measure | ##### Measure Description | ##### Time Frame |\n| --- | --- | --- |\n| Progression-Free Survival (PFS) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 Time Frame: From the date of randomization to the date of the first documented disease progression or death, whichever occurred first (up to overall period of approximately 40 months) | PFS was defined as the time (in months) from randomization to the first documentation of disease progression, as determined by the investigators, or to death from any cause, whichever occurred first. | From the date of randomization to the date of the first documented disease progression or death, whichever occurred first (up to overall period of approximately 40 months) |\n\n#### Secondary Outcome Measures\n\n| ##### Outcome Measure | ##### Measure Description | ##### Time Frame |\n| --- | --- | --- |\n| PFS as Determined by Independent Review Committee (IRC) Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) | PFS was defined as the time (in months) from randomization to the first documentation of disease progression, as determined by an independent review committee, or to death from any cause, whichever occurred first. | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Percentage of Participants With Objective Response of Complete Response (CR) or Partial Response (PR) as Determined by Investigator Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Time to Progression of Disease in the CNS as Determined by IRC Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Time to Progression of Disease in the CNS as Determined by IRC Using Response Assessment in Neuro-Oncology (RANO) Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Duration of Response (DOR) Assessed by Investigator Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Overall Survival Time Time Frame: Baseline, until death (up to overall period of approximately 40 months) |  | Baseline, until death (up to overall period of approximately 40 months) |\n| Percentage of Participants With Non-serious Adverse Events and Serious Adverse Events Time Frame: Up to overall period of approximately 40 months | An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. | Up to overall period of approximately 40 months |\n| Time to Deterioration Assessed Using EORTC Quality of Life Questionnaire-Core (QLQ-C30) Score Time Frame: Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Time to Deterioration Assessed Using EORTC Quality of Life Questionnaire-Lung Cancer Module (QLQ-LC13) Score Time Frame: Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Area Under the Plasma Concentration-time Curve (AUC) of Alectinib and Its Metabolite Time Frame: Baseline and Week 4 predose (within 2 hours before administration of study drug) | AUC was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time. | Baseline and Week 4 predose (within 2 hours before administration of study drug) |\n| Maximum Plasma Concentration Observed (Cmax) of Alectinib and Its Metabolite Time Frame: Baseline and Week 4 predose (within 2 hours before administration of study drug) | Cmax was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time. | Baseline and Week 4 predose (within 2 hours before administration of study drug) |\n| Time to Cmax (Tmax) of Alectinib and Its Metabolite Time Frame: Baseline and Week 4 predose (within 2 hours before administration of study drug) | Tmax was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time. | Baseline and Week 4 predose (within 2 hours before administration of study drug) |\n\nCollaborators and Investigators\n-------------------------------\n\nThis is where you will find people and organizations involved with this study.\n\n#### Sponsor\n\n[Hoffmann-La Roche](https://ichgcp.net/clinical-trials-registry/research/list?spons=Hoffmann-La%20Roche "List all studies sponsored by Hoffmann-La Roche")\n\n#### Investigators\n\n*    Study Director: Clinical Trials, Hoffmann-La Roche \n\nPublications and helpful links\n------------------------------\n\nThe person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.\n\n#### General Publications\n\n*   [Zhou C, Kim SW, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang JJ, Cheng Y, Lee SH, Bu L, Xu T, Yang L, Wang C, Liu T, Morcos PN, Lu Y, Zhang L. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med. 2019 May;7(5):437-446. doi: 10.1016/S2213-2600(19)30053-0. Epub 2019 Apr 10.](https://pubmed.ncbi.nlm.nih.gov/30981696)\n\nStudy record dates\n------------------\n\nThese dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.\n\n### Study Major Dates\n\n#### Study Start (Actual)\n\n August 3, 2016 \n\n#### Primary Completion (Actual)\n\n May 31, 2018 \n\n#### Study Completion (Estimated)\n\n December 31, 2025 \n\n### Study Registration Dates\n\n#### First Submitted\n\nJuly 18, 2016\n\n#### First Submitted That Met QC Criteria\n\nJuly 18, 2016\n\n#### First Posted (Estimated)\n\nJuly 20, 2016\n\n### Study Record Updates\n\n#### Last Update Posted (Actual)\n\nMarch 25, 2025\n\n#### Last Update Submitted That Met QC Criteria\n\nMarch 24, 2025\n\n#### Last Verified\n\nMarch 1, 2025\n\nMore Information\n----------------\n\n### Terms related to this study\n\n#### Additional Relevant MeSH Terms\n\n*   [Neoplasms by Site](https://ichgcp.net/clinical-trials-registry/research/list?cond=Neoplasms%20by%20Site "List all studies by MeSH term: Neoplasms by Site")\n*   [Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Neoplasms "List all studies by MeSH term: Neoplasms")\n*   [Immune System Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Immune%20System%20Diseases "List all studies by MeSH term: Immune System Diseases")\n*   [Respiratory Tract Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Diseases "List all studies by MeSH term: Respiratory Tract Diseases")\n*   [Neoplasms by Histologic Type](https://ichgcp.net/clinical-trials-registry/research/list?cond=Neoplasms%20by%20Histologic%20Type "List all studies by MeSH term: Neoplasms by Histologic Type")\n*   [Lung Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%20Diseases "List all studies by MeSH term: Lung Diseases")\n*   [Respiratory Tract Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Neoplasms "List all studies by MeSH term: Respiratory Tract Neoplasms")\n*   [Thoracic Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Thoracic%20Neoplasms "List all studies by MeSH term: Thoracic Neoplasms")\n*   [Lymphatic Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphatic%20Diseases "List all studies by MeSH term: Lymphatic Diseases")\n*   [Lymphoproliferative Disorders](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoproliferative%20Disorders "List all studies by MeSH term: Lymphoproliferative Disorders")\n*   [Immunoproliferative Disorders](https://ichgcp.net/clinical-trials-registry/research/list?cond=Immunoproliferative%20Disorders "List all studies by MeSH term: Immunoproliferative Disorders")\n*   [Carcinoma, Bronchogenic](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%2C%20Bronchogenic "List all studies by MeSH term: Carcinoma, Bronchogenic")\n*   [Bronchial Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Bronchial%20Neoplasms "List all studies by MeSH term: Bronchial Neoplasms")\n*   [Lung Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%20Neoplasms "List all studies by MeSH term: Lung Neoplasms")\n*   [Lymphoma](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma "List all studies by MeSH term: Lymphoma")\n*   [Carcinoma, Non-Small-Cell Lung](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%2C%20Non-Small-Cell%20Lung "List all studies by MeSH term: Carcinoma, Non-Small-Cell Lung")\n*   [Tyrosine Kinase Inhibitors](https://ichgcp.net/clinical-trials-registry/research/list?intr=Tyrosine%20Kinase%20Inhibitors "List all studies by MeSH term: Tyrosine Kinase Inhibitors")\n*   [Antineoplastic Agents](https://ichgcp.net/clinical-trials-registry/research/list?intr=Antineoplastic%20Agents "List all studies by MeSH term: Antineoplastic Agents")\n*   [Molecular Mechanisms of Pharmacological Action](https://ichgcp.net/clinical-trials-registry/research/list?intr=Molecular%20Mechanisms%20of%20Pharmacological%20Action "List all studies by MeSH term: Molecular Mechanisms of Pharmacological Action")\n*   [Enzyme Inhibitors](https://ichgcp.net/clinical-trials-registry/research/list?intr=Enzyme%20Inhibitors "List all studies by MeSH term: Enzyme Inhibitors")\n*   [Protein Kinase Inhibitors](https://ichgcp.net/clinical-trials-registry/research/list?intr=Protein%20Kinase%20Inhibitors "List all studies by MeSH term: Protein Kinase Inhibitors")\n*   [Crizotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Crizotinib "List all studies by MeSH term: Crizotinib")\n*   [Alectinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Alectinib "List all studies by MeSH term: Alectinib")\n\n#### Other Study ID Numbers\n\n*    YO29449 \n\n### Drug and device information, study documents\n\n#### Studies a U.S. FDA-regulated drug product\n\n Yes \n\n#### Studies a U.S. FDA-regulated device product\n\n No \n\nThis information was retrieved directly from the website [clinicaltrials.gov](https://clinicaltrials.gov/) without any changes. If you have any requests to change, remove or update your study details, please contact [register@clinicaltrials.gov](mailto:register@clinicaltrials.gov). As soon as a change is implemented on [clinicaltrials.gov](https://clinicaltrials.gov/), this will be updated automatically on our website as well.\n\nClinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer\n---------------------------------------------------------------------------------\n\n*    Pfizer   Completed  [A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001)](https://ichgcp.net/clinical-trials-registry/NCT00585195)  Systemic Anaplastic Large-Cell Lymphoma | Non-Small Cell Lung Cancer ALK-positive | Non-Small Cell Lung Cancer c-Met Dependent | Non-Small Cell Lung Cancer ROS Marker Positive | Advanced Malignancies Except Leukemia   United States, Korea, Republic of, Australia, Japan    \n*    Novartis Pharmaceuticals   Available  [Managed Access Programs for LDK378, Ceritinib](https://ichgcp.net/clinical-trials-registry/NCT05100134)  Non-small Cell Lung Cancer (NSCLC) | Anaplastic Lymphoma Kinase (ALK)- Positive Tumors    \n*    Novartis Pharmaceuticals   Completed  [Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer](https://ichgcp.net/clinical-trials-registry/NCT01772797)  Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase (ALK)   Australia, Spain, Singapore, Italy, United States    \n*    Nuvalent Inc.   Recruiting  [Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC (ALKAZAR)](https://ichgcp.net/clinical-trials-registry/NCT06765109)  Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase-positive   United States    \n*    Intergroupe Francophone de Cancerologie Thoracique   Completed  [Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements (CLINALK)](https://ichgcp.net/clinical-trials-registry/NCT02727335)  Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase Gene Mutation   France    \n*    Takeda   Completed  [A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors](https://ichgcp.net/clinical-trials-registry/NCT03546894)  Carcinoma Non-small-cell Lung | Anaplastic Lymphoma Kinase-positive   United States    \n*    Astellas Pharma Inc   Completed  [Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)](https://ichgcp.net/clinical-trials-registry/NCT01284192)  Solid Tumor | B-Cell Lymphoma | Advanced Malignancies | Positive for Anaplastic Lymphoma Kinase | Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS   United States    \n*    University Medical Center Groningen  Radboud University Medical Center; Maastricht University Medical Center; Erasmus... and other collaborators    Recruiting  [Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels (ADAPT ALEC)](https://ichgcp.net/clinical-trials-registry/NCT05525338)  Carcinoma, Non-Small-Cell Lung | Lung Cancer | Drug Monitoring | Anaplastic Lymphoma Kinase Gene Mutation | Anaplastic Lymphoma Kinase Gene Translocation   Netherlands, France    \n*    Takeda   Withdrawn  [Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors](https://ichgcp.net/clinical-trials-registry/NCT04260009)  Solid Tumors | Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma | Inflammatory Myofibroblastic Tumors    \n*    Massachusetts General Hospital  LUNGevity Foundation; Addario Lung Cancer Medical Institute    Recruiting  [Immune and Genomic Markers in ALK+ NSCLC](https://ichgcp.net/clinical-trials-registry/NCT04881916)  Non-Small Cell Lung Cancer | Anaplastic Lymphoma Kinase Gene Translocation   United States    \n\nClinical Trials on Alectinib\n----------------------------\n\n*    Aarhus University Hospital  Roche Pharma AG    Enrolling by invitation  [Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients (MonAlec)](https://ichgcp.net/clinical-trials-registry/NCT04708639)  Lung Cancer | ALK Gene Mutation | Resistance, Disease | Mutation   Denmark    \n*    Hoffmann-La Roche   Completed  [A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (ATALK)](https://ichgcp.net/clinical-trials-registry/NCT03155009)  Carcinoma, Non-Small-Cell Lung   France    \n*    Hoffmann-La Roche   Completed  [Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea](https://ichgcp.net/clinical-trials-registry/NCT03271554)  Non-Small Cell Lung Cancer   Korea, Republic of    \n*    Dana-Farber Cancer Institute  Genentech, Inc.    Terminated  [A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer](https://ichgcp.net/clinical-trials-registry/NCT03131206)  ALK-positive Non-small Cell Lung Cancer (NSCLC) | RET-positive Non-small Cell Lung Cancer (NSCLC) | RET-positive Thyroid Cancer   United States    \n*    Hoffmann-La Roche   Completed  [Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib](https://ichgcp.net/clinical-trials-registry/NCT02621047)  Hepatic Impairment   Czechia, Slovakia    \n*    Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...  UnitedHealthcare    Not yet recruiting  [Pharmacogenomics IND EXEMPT SNP Clinical Study - Alectinib and Single Nucleotide Polymorphisms (Drugs-SNPs)](https://ichgcp.net/clinical-trials-registry/NCT05987956)  Non-small Cell Lung Cancer   United States    \n*    Hoffmann-La Roche   Terminated  [A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors (ALpha-T)](https://ichgcp.net/clinical-trials-registry/NCT04644315)  Digestive System Diseases | Gastrointestinal Diseases | Melanoma | Sarcoma | Neoplasms | Respiratory Tract Diseases | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasms | Head and Neck Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms and other conditions   United States    \n*    China Medical University Hospital   Active, not recruiting  [Alectinib in Combination with Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided with Serum RNase1 and Tumor Expression of PD-L1](https://ichgcp.net/clinical-trials-registry/NCT06354387)  Hepatocellular Carcinoma   Taiwan    \n*    Genentech, Inc.   No longer available  [Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy](https://ichgcp.net/clinical-trials-registry/NCT02271139)  Non-Small Cell Lung Cancer   United States    \n*    Hoffmann-La Roche   Completed  [A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)](https://ichgcp.net/clinical-trials-registry/NCT01871805)  Non-Small Cell Lung Cancer   United States, Canada    \n\nSearch Similar Trials\n---------------------\n\n*   [Clinical Trials on Lymphoma in Singapore](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=Singapore)\n*   [Clinical Trials on Lymphosarcoma in Australia](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=Australia)\n*   [Clinical Trials on Carcinoma, Non-Small-Cell Lung in Singapore](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BNon-Small-Cell%2BLung&locn=Singapore)\n*   [Clinical Trials on Lymphoma in New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=New%2BZealand)\n*   [Clinical Trials on Carcinoma, Non-Small-Cell Lung in United States](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BNon-Small-Cell%2BLung&locn=United%2BStates)\n*   [Clinical Trials on Lung Neoplasms in Ireland](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%2BNeoplasms&locn=Ireland)\n*   [Clinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%2BLymphoma%2BKinase-positive%2BNon-small%2BCell%2BLung%2BCancer&locn=South%2BAfrica)\n*   [Clinical Trials on Lymphosarcoma in India](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=India)\n*   [Clinical Trials on Lymphoma in United States](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=United%2BStates)\n*   [Clinical Trials on Lymphoma in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=South%2BAfrica)\n*   [Clinical Trials on Lymphoma in Hong Kong](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=Hong%2BKong)\n*   [Clinical Trials on Lymphosarcoma in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=South%2BAfrica)\n*   [Clinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer in Ireland](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%2BLymphoma%2BKinase-positive%2BNon-small%2BCell%2BLung%2BCancer&locn=Ireland)\n*   [Clinical Trials on Lung Neoplasms in New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%2BNeoplasms&locn=New%2BZealand)\n*   [Clinical Trials on Lung Neoplasms in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%2BNeoplasms&locn=South%2BAfrica)\n*   [Clinical Trials on Lymphoma in India](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=India)\n*   [Clinical Trials on Lymphosarcoma in Singapore](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=Singapore)\n*   [Clinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer in New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%2BLymphoma%2BKinase-positive%2BNon-small%2BCell%2BLung%2BCancer&locn=New%2BZealand)\n*   [Clinical Trials on Lymphosarcoma in United States](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=United%2BStates)\n*   [Clinical Trials on Carcinoma, Non-Small-Cell Lung in United Kingdom](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BNon-Small-Cell%2BLung&locn=United%2BKingdom)\n*   [Search All Trials](https://ichgcp.net/clinical-trials-registry/research/list)\n\nSponsors and Collaborators\n--------------------------\n\n*   [Eisai Korea Inc.](https://ichgcp.net/clinical-trials-registry/research/list?spons=Eisai%2BKorea%2BInc.)\n*   [Leukaemia & Blood Cancer New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?spons=Leukaemia%2B%2526%2BBlood%2BCancer%2BNew%2BZealand)\n*   [Udaan](https://ichgcp.net/clinical-trials-registry/research/list?spons=Udaan)\n*   [Makarenko Irina Romanovna](https://ichgcp.net/clinical-trials-registry/research/list?spons=Makarenko%2BIrina%2BRomanovna)\n*   [Adriane Aver Vanin](https://ichgcp.net/clinical-trials-registry/research/list?spons=Adriane%2BAver%2BVanin)\n*   [University of Memphis](https://ichgcp.net/clinical-trials-registry/research/list?spons=University%2Bof%2BMemphis)\n*   [Sleep Research Society Foundation](https://ichgcp.net/clinical-trials-registry/research/list?spons=Sleep%2BResearch%2BSociety%2BFoundation)\n*   [Immuron Ltd.](https://ichgcp.net/clinical-trials-registry/research/list?spons=Immuron%2BLtd.)\n*   [Arthro-Anda Tianjin Biologic Technology Co., Ltd.](https://ichgcp.net/clinical-trials-registry/research/list?spons=Arthro-Anda%2BTianjin%2BBiologic%2BTechnology%2BCo.%252C%2BLtd.)\n*   [CoheroHealth](https://ichgcp.net/clinical-trials-registry/research/list?spons=CoheroHealth)\n*   [Center for Military Mental Health, Berlin, Germany](https://ichgcp.net/clinical-trials-registry/research/list?spons=Center%2Bfor%2BMilitary%2BMental%2BHealth%252C%2BBerlin%252C%2BGermany)\n*   [Kevin Flanigan](https://ichgcp.net/clinical-trials-registry/research/list?spons=Kevin%2BFlanigan)\n*   [Periannan Kuppusamy](https://ichgcp.net/clinical-trials-registry/research/list?spons=Periannan%2BKuppusamy)\n*   [Chiang Mai University Hospital, THAILAND](https://ichgcp.net/clinical-trials-registry/research/list?spons=Chiang%2BMai%2BUniversity%2BHospital%252C%2BTHAILAND)\n*   [Centre for Emergency Health Sciences](https://ichgcp.net/clinical-trials-registry/research/list?spons=Centre%2Bfor%2BEmergency%2BHealth%2BSciences)\n*   [Therapex Co., Ltd](https://ichgcp.net/clinical-trials-registry/research/list?spons=Therapex%2BCo.%252C%2BLtd)\n*   [MIT William Asbjornsen Albert Memorial Fellowship](https://ichgcp.net/clinical-trials-registry/research/list?spons=MIT%2BWilliam%2BAsbjornsen%2BAlbert%2BMemorial%2BFellowship)\n*   [Fabiana Aceto](https://ichgcp.net/clinical-trials-registry/research/list?spons=Fabiana%2BAceto)\n*   [North American Spine Society](https://ichgcp.net/clinical-trials-registry/research/list?spons=North%2BAmerican%2BSpine%2BSociety)\n*   [SGS proderm GmbH](https://ichgcp.net/clinical-trials-registry/research/list?spons=SGS%2Bproderm%2BGmbH)\n*   [View Full List](https://ichgcp.net/clinical-trials-registry/research/browse/spns_alpha_all)\n\nMedical Conditions\n------------------\n\n*   [Infrarenal Abdominal Aortic Aneurysms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Infrarenal%2BAbdominal%2BAortic%2BAneurysms)\n*   [Myeloproliferative Disease, Not Classified](https://ichgcp.net/clinical-trials-registry/research/list?cond=Myeloproliferative%2BDisease%252C%2BNot%2BClassified)\n*   [Lifestyle-related Condition](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lifestyle-related%2BCondition)\n*   [Compliance](https://ichgcp.net/clinical-trials-registry/research/list?cond=Compliance)\n*   [Patients With Opioid Induced Constipation](https://ichgcp.net/clinical-trials-registry/research/list?cond=Patients%2BWith%2BOpioid%2BInduced%2BConstipation)\n*   [Femoral Vascular Anastomosis](https://ichgcp.net/clinical-trials-registry/research/list?cond=Femoral%2BVascular%2BAnastomosis)\n*   [Observation Safety](https://ichgcp.net/clinical-trials-registry/research/list?cond=Observation%2BSafety)\n*   [Improvement of Functionality](https://ichgcp.net/clinical-trials-registry/research/list?cond=Improvement%2Bof%2BFunctionality)\n*   [CD4 Deficiency](https://ichgcp.net/clinical-trials-registry/research/list?cond=CD4%2BDeficiency)\n*   [Malassezia Infection](https://ichgcp.net/clinical-trials-registry/research/list?cond=Malassezia%2BInfection)\n*   [Anti-cancer Cell Immunotherapy](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anti-cancer%2BCell%2BImmunotherapy)\n*   [Health Knowledge Attitudes and Practice](https://ichgcp.net/clinical-trials-registry/research/list?cond=Health%2BKnowledge%2BAttitudes%2Band%2BPractice)\n*   [School Adjustment](https://ichgcp.net/clinical-trials-registry/research/list?cond=School%2BAdjustment)\n*   [Difficult Mask Ventilation](https://ichgcp.net/clinical-trials-registry/research/list?cond=Difficult%2BMask%2BVentilation)\n*   [Intrapartum Mortality](https://ichgcp.net/clinical-trials-registry/research/list?cond=Intrapartum%2BMortality)\n*   [Diabetes Mellitus II](https://ichgcp.net/clinical-trials-registry/research/list?cond=Diabetes%2BMellitus%2BII)\n*   [Painless Myocardial Ischemia](https://ichgcp.net/clinical-trials-registry/research/list?cond=Painless%2BMyocardial%2BIschemia)\n*   [Corona Virus Disease 19 (COVID-19)](https://ichgcp.net/clinical-trials-registry/research/list?cond=Corona%2BVirus%2BDisease%2B19%2B%2528COVID-19%2529)\n*   [Pressure Injury Stage 2](https://ichgcp.net/clinical-trials-registry/research/list?cond=Pressure%2BInjury%2BStage%2B2)\n*   [Escape; Rhythm](https://ichgcp.net/clinical-trials-registry/research/list?cond=Escape%253B%2BRhythm)\n*   [View Full List](https://ichgcp.net/clinical-trials-registry/research/browse/cond_alpha_all)\n\nDrug Interventions\n------------------\n\n*   [Methylprednisolone](https://ichgcp.net/clinical-trials-registry/research/list?intr=Methylprednisolone)\n*   [Anetumab Ravtansine](https://ichgcp.net/clinical-trials-registry/research/list?intr=Anetumab%2BRavtansine)\n*   [ESES treated with clobazam](https://ichgcp.net/clinical-trials-registry/research/list?intr=ESES%2Btreated%2Bwith%2Bclobazam)\n*   [Droperidol Injectable Solution](https://ichgcp.net/clinical-trials-registry/research/list?intr=Droperidol%2BInjectable%2BSolution)\n*   [ATx201](https://ichgcp.net/clinical-trials-registry/research/list?intr=ATx201)\n*   [Cyclophosphamide](https://ichgcp.net/clinical-trials-registry/research/list?intr=Cyclophosphamide)\n*   [Pioglitazone](https://ichgcp.net/clinical-trials-registry/research/list?intr=Pioglitazone)\n*   [Botulinum Toxin A](https://ichgcp.net/clinical-trials-registry/research/list?intr=Botulinum%2BToxin%2BA)\n*   [Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Gefitinib%2B250mg%2Bpo%2Bqd%2Bor%2BTarceva%2B150mg%2Bpo%2Bqd%2Bor%2BIcotinib%2B125mg%2Bpo%2Btid%2BOther%2BName%253A%2BGefitinib%252FTarceva%252FIcotinib)\n*   [Ramosetron](https://ichgcp.net/clinical-trials-registry/research/list?intr=Ramosetron)\n*   [KN046](https://ichgcp.net/clinical-trials-registry/research/list?intr=KN046)\n*   [Doxorubicin](https://ichgcp.net/clinical-trials-registry/research/list?intr=Doxorubicin)\n*   [Corticosteroids (CS)](https://ichgcp.net/clinical-trials-registry/research/list?intr=Corticosteroids%2B%2528CS%2529)\n*   [Dimenhydrinate](https://ichgcp.net/clinical-trials-registry/research/list?intr=Dimenhydrinate)\n*   [Ropivacaine 150 mg](https://ichgcp.net/clinical-trials-registry/research/list?intr=Ropivacaine%2B150%2Bmg)\n*   [Iso-Fludelone](https://ichgcp.net/clinical-trials-registry/research/list?intr=Iso-Fludelone)\n*   [Clonidine](https://ichgcp.net/clinical-trials-registry/research/list?intr=Clonidine)\n*   [Lidocaine topical](https://ichgcp.net/clinical-trials-registry/research/list?intr=Lidocaine%2Btopical)\n*   [Nusinersen](https://ichgcp.net/clinical-trials-registry/research/list?intr=Nusinersen)\n*   [Cyclophosphamide and fludarabine](https://ichgcp.net/clinical-trials-registry/research/list?intr=Cyclophosphamide%2Band%2Bfludarabine)\n*   [View Full List](https://ichgcp.net/clinical-trials-registry/research/browse/intr_alpha_all)\n\n### CROs by country\n\n*   [Contract Research Organizations in Azerbaijan](https://ichgcp.net/cro-list/country/azerbaijan)\n*   [Contract Research Organizations in Bulgaria](https://ichgcp.net/cro-list/country/bulgaria)\n*   [Contract Research Organizations in Burundi](https://ichgcp.net/cro-list/country/burundi)\n*   [Contract Research Organizations in Dominican Republic](https://ichgcp.net/cro-list/country/dominican_republic)\n*   [Contract Research Organizations in Kosovo](https://ichgcp.net/cro-list/country/kosovo)\n*   [Contract Research Organizations in Mexico](https://ichgcp.net/cro-list/country/mexico)\n*   [Contract Research Organizations in Moldova](https://ichgcp.net/cro-list/country/moldova)\n*   [Contract Research Organizations in Poland](https://ichgcp.net/cro-list/country/poland)\n*   [Contract Research Organizations in Slovakia](https://ichgcp.net/cro-list/country/slovakia)\n*   [Contract Research Organizations in Sri Lanka](https://ichgcp.net/cro-list/country/sri_lanka)\n*   [Contract Research Organizations in Ukraine](https://ichgcp.net/cro-list/country/ukraine)\n*   [Contract Research Organizations in United Arab Emirates](https://ichgcp.net/cro-list/country/united_arab_emirates)\n*   [Contract Research Organizations in Uzbekistan](https://ichgcp.net/cro-list/country/uzbekistan)\n*   [CRO list by country](https://ichgcp.net/cro-list)\n\n### CROs in Ghana\n\n*   [54gene‚Äôs Clinical Programs Group (CPG)](https://ichgcp.net/cro-list/country/ghana/company/54gene_s_clinical_programs_group_cpg)\n*   [SGS](https://ichgcp.net/cro-list/country/ghana/company/sgs)\n*   [ACROSS Global](https://ichgcp.net/cro-list/country/ghana/company/across_global)\n*   [All CROs in Ghana](https://ichgcp.net/cro-list/country/ghana)\n\n### Conditions\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/cond_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/cond_cat)\n\n### Rare Diseases\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/ord_alpha_all)\n\n### Drug Interventions\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/intr_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/intr_cat)\n\n### Dietary Supplements\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/diet_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/diet_cat)\n\n### Sponsor/Collaborators\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/spns_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/spns_cat)\n\n### Locations\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/locn_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/locn_cat)\n\nRegulations\n\n*   [GLOBAL (ICH GCP)](https://ichgcp.net/)\n*   [USA (FDA)](https://ichgcp.net/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects)\n*   [UK (MHRA)](https://ichgcp.net/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol)\n*   [AUSTRALIA (NHMRC)](https://ichgcp.net/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia)\n*   [JAPAN (PMDA)](https://ichgcp.net/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan)\n*   [EU (EMA)](https://ichgcp.net/guideline-for-the-notification-of-serious-breaches-of-regulation-eu-no-536-2014)\n\nResources\n\n*   [CRO List](https://ichgcp.net/cro-list)\n*   [Pharmaceutical Companies](https://ichgcp.net/pharma-list)\n*   [Clinical Research Labs](https://ichgcp.net/labs)\n*   [Service Companies](https://ichgcp.net/service-companies)\n*   [Jobs](https://ichgcp.net/cra-jobs)\n*   [US Clinical Trials Registry](https://ichgcp.net/clinical-trials-registry)\n*   [EU Clinical Trials Registry](https://ichgcp.net/eu-clinical-trials-registry)\n\nArticles\n\n*   [Publications](https://ichgcp.net/publications)\n*   [News](https://ichgcp.net/news)\n*   [About us / Our mission](https://ichgcp.net/about-us-our-mission)\n\nSearch trials\n\nExample: Heart Attack\n\n¬© ICH GCP. All Rights Reserved.\n\n*   [Sitemap](https://ichgcp.net/sitemap)\n*   [Contact us](https://ichgcp.net/contact-us)\n*   [RSS feed](https://ichgcp.net/feed)\n*   [Privacy Policy](https://ichgcp.net/privacy)\n*   [Disclaimer](https://ichgcp.net/disclaimer)\n\n English \n\n[Dansk](https://ichgcp.net/da/clinical-trials-registry/NCT02838420)[Deutsch](https://ichgcp.net/de/clinical-trials-registry/NCT02838420)[English](https://ichgcp.net/clinical-trials-registry/NCT02838420)[Espa√±ol](https://ichgcp.net/es/clinical-trials-registry/NCT02838420)[Fran√ßais](https://ichgcp.net/fr/clinical-trials-registry/NCT02838420)[Italiano](https://ichgcp.net/it/clinical-trials-registry/NCT02838420)[Magyar](https://ichgcp.net/hu/clinical-trials-registry/NCT02838420)[Nederlands](https://ichgcp.net/nl/clinical-trials-registry/NCT02838420)[Norsk](https://ichgcp.net/no/clinical-trials-registry/NCT02838420)[Polski](https://ichgcp.net/pl/clinical-trials-registry/NCT02838420)[Portugu√™s](https://ichgcp.net/pt/clinical-trials-registry/NCT02838420)[Suomi](https://ichgcp.net/fi/clinical-trials-registry/NCT02838420)[Svenska](https://ichgcp.net/sv/clinical-trials-registry/NCT02838420)[ƒåe≈°tina](https://ichgcp.net/cs/clinical-trials-registry/NCT02838420)[–†—É—Å—Å–∫–∏–π](https://ichgcp.net/ru/clinical-trials-registry/NCT02838420)[Êó•Êú¨Ë™û](https://ichgcp.net/ja/clinical-trials-registry/NCT02838420)[ÁÆÄ‰Ωì‰∏≠Êñá](https://ichgcp.net/zh/clinical-trials-registry/NCT02838420)[ÌïúÍµ≠Ïñ¥](https://ichgcp.net/ko/clinical-trials-registry/NCT02838420)\n\nGOOD CLINICAL PRACTICE NETWORK\n\nSubscribe to receive notifications of new clinical trials you are interested in.\n\nSubscribe\n\n‚úï\n\nGOOD CLINICAL PRACTICE NETWORK\n\nSubscribe to receive notifications of new clinical trials you are interested in.\n\nSubscribe for upcoming trials that contain the following conditions: \n\n- [x] Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer \n\n[Choose more conditions](https://ichgcp.net/mailing-list/conditions)\n\nSubscribe for upcoming trials that contain the following interventions: \n\n- [x] Alectinib \n\n- [x] Crizotinib \n\n[Choose more interventions](https://ichgcp.net/mailing-list/interventions)\n\nSubscribe for upcoming trials sponsored by: \n\n- [x] Hoffmann-La Roche \n\n[Choose more organizations](https://ichgcp.net/mailing-list/organizations)\n\nSubscribe\n\nSubscribe\n\nSubscribe\n'}, {'title': 'Alectinib vs crizotinib in Asian patients with treatment-na√Øve ... - Roche', 'url': 'https://medically.roche.com/global/en/medical-material/ESMO-Asia-2022-presentation-zhou-alectinib-vs-crizotinib-in-asian-patients-with-treatment-naive-advanced-pdf.html', 'content': 'Data cut -off 16 May 2022. ClinicalTrials.gov: NCT02838420. CNS, central nervous system; DOR, duration of response;  ECOG PS, Eastern Cooperative Oncology Group performance status; IHC, immunohistochemistry; INV, investigator \n\nIRC, independent review committee; NSCLC, non -small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, p rogression -free survival \n\n2:1 \n\nN=187 \n\nR\n\nAlectinib \n\n600mg  twice daily \n\nCrizotinib \n\n250mg twice daily \n\nTreat until disease', 'score': 0.5393963, 'raw_content': "Alectinib vs crizotinib in Asian patients \n\n## with treatment -na√Øve advanced  ALK +\n\n## non -small cell lung cancer: 5 -year \n\n## update from the Phase 3 ALESIA study \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nFaculty of Medicine  Ramathibodi  Hospital, Mahidol University, \n\nBangkok, Thailand \n\nZhou C, 1 Lu Y, 2 Kim S -W, 3 Baisamut  (Reungwetwattana) T, 4 Zhou J, 5 Zhang Y, 6 He J, 7 Yang J -J, 8 Cheng Y, 9 Lee S -H, 10  Chang J, 11 \n\nFang J, 12  Liu Z, 13  Bu L, 14  Qian L, 14  Xu T, 14  Archer V, 15  Hilton M, 16  Zhou M, 14  Zhang L 17 \n\n1Shanghai Pulmonary Hospital, Tongji University, Shanghai, China;  2West China Hospital, Sichuan University, Chengdu, China;  3Asan Medical \n\nCenter , University of Ulsan College of Medicine, Seoul, South Korea;  4Faculty of Medicine  Ramathibodi  Hospital, Mahidol University, Bangkok, \n\nThailand;  5The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China;  6Zhejiang Cancer Hospital, Hangzhou, China; \n\n7The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;  8Guangdong Lung Cancer Institute, Guangdong General Hospital, \n\nGuangzhou, China;  9Jilin Cancer Hospital, Changchun, China;  10 Sungkyunkwan University School of Medicine, Seoul, South Korea;  11 Cancer \n\nHospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China;  12 Beijing Cancer \n\nHospital, Beijing, China;  13 Beijing Chest Hospital, Capital Medical University, Beijing, China;  14 Roche Pharma Development, Shanghai, China; \n\n15 Roche Products Ltd, Welwyn Garden City, UK;  16 F. Hoffmann -La Roche Ltd, Basel, Switzerland;  17 Sun  Yat -sen  University Cancer  Center ,\n\nState Key Laboratory of Oncology in South China, Collaborative Innovation  Center  for Cancer Medicine, Guangzhou, China Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## DECLARATION OF INTERESTS \n\nThanyanan  Baisamut  (Reungwetwattana) \n\n‚Ä¢ Received honorarium from AstraZeneca, Pfizer, MSD, Roche, BMS, Amgen, J&J, Novartis,  Yuhan  and  Zuellig \n\n‚Ä¢ Participated as Principal Investigator on clinical trials for AstraZeneca, MSD, Roche, Novartis and  Yuhan   \n\n> Thanyanan Baisamut (Reungwetwattana)\n\nContent of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## ALESIA: alectinib vs crizotinib in treatment -na√Øve Asian patients \n\n## with advanced  ALK+  NSCLC \n\n‚Ä¢ Stratification factors:  ECOG PS (0/1 vs 2) \n\nand CNS metastases at baseline (yes vs no) \n\n‚Ä¢ Primary endpoint:  PFS by INV \n\n‚Ä¢ Secondary endpoints:  Time to CNS \n\nprogression by IRC, ORR by INV, \n\nDOR by INV, OS and safety \n\n‚Ä¢ Median duration of survival follow -up: \n\n61 months  alectinib vs  51 months  crizotinib \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nPatients were enrolled from China, Thailand and South Korea. *Asymptomatic CNS metastases allowed. \n\nData cut -off 16 May 2022. ClinicalTrials.gov: NCT02838420. CNS, central nervous system; DOR, duration of response;  ECOG PS, Eastern Cooperative Oncology Group performance status; IHC, immunohistochemistry; INV, investigator \n\nIRC, independent review committee; NSCLC, non -small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, p rogression -free survival \n\n2:1 \n\nN=187 \n\nR\n\nAlectinib \n\n600mg  twice daily \n\nCrizotinib \n\n250mg twice daily \n\nTreat until disease \n\nprogression, toxicity, \n\nwithdrawal or death \n\nNo crossover permitted \n\nStage IIIB/IV  ALK + NSCLC* \n\n‚Ä¢ Asian patients \n\n‚Ä¢ Treatment na√Øve \n\n‚Ä¢ ECOG PS 0 ‚Äì2\n\n‚Ä¢ Central  ALK  testing (Ventana IHC) \n\nBaseline demographics \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nAge, years  Median (range)  51.0 (21‚àí78)  49.0 (28‚àí83) \n\nGender, %  Male / Female  51.2 / 48.8  54.8 / 45.2 \n\nECOG PS, %  0‚Äì1 / 2  96.8 / 3.2  98.4 / 1.6 \n\nSmoking status, %  Active smoker / Non -smoker / \n\nPast smoker  3.2 / 67.2 / 29.6  4.8 / 72.6 / 22.6 \n\nCNS metastases by IRC, %  Yes  35.2  37.1 \n\nCNS metastases by INV, %  Yes  33.6  32.3 \n\nPrior brain radiation, %  Yes  6.4  8.1 Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Updated analyses from ALESIA demonstrate durable PFS benefit for \n\n## alectinib versus crizotinib, irrespective of CNS involvement at baseline \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nData cut -off 16 May 2022. CI, confidence interval; CNS, central nervous system; HR, hazard ratio; ITT, intent -to -treat;  mets , metastases;  PFS, progression -free survival \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nMedian  PFS, months \n\n(95% CI) \n\n41.6 \n\n(33.1 ‚Äì58.9) \n\n11.1 \n\n(9.1 ‚Äì18.4) \n\nHR  (95% CI)  0.33  (0.23 ‚Äì0.49) \n\n0\n\n> PFS (%)\n\n6 36  66 60 54 48 42 30 24 18 12 \n\nTime (months) \n\n100 \n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\nCrizotinib (n=62) \n\nAlectinib (n=125) \n\nWith  CNS  mets  at baseline  Without  CNS  mets  at baseline \n\nAlectinib \n\nn=44 \n\nCrizotinib \n\nn=23 \n\nAlectinib \n\nn=81 \n\nCrizotinib \n\nn=39 \n\nMedian  PFS, months \n\n(95% CI) \n\n42.3 \n\n(27.8 ‚Äì60.7) \n\n9.2 \n\n(5.5 ‚Äì12.2) \n\n41.6 \n\n(29.5 ‚Äì64.9) \n\n12.7 \n\n(9.2 ‚Äì27.6) \n\nHR  (95% CI)  0.17  (0.09 ‚Äì0.33)  0.45  (0.29 ‚Äì0.71) \n\nCrizotinib (n=39) \n\nWithout  CNS  mets  at baseline \n\nAlectinib (n=81) \n\nUpdated PFS: ITT population \n\nTime (months) \n\n100 \n\n0\n\n> PFS (%)\n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\n36  66 54 18 6 60 42 30 24 12  48 \n\nCrizotinib (n=23) \n\nWith  CNS  mets  at baseline \n\nAlectinib (n=44) \n\nPFS according to CNS status at baseline Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## A clinically meaningful improvement in 5 -year OS rate was observed \n\n## for alectinib compared with crizotinib \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nData cut -off 16 May 2022. CI, confidence interval; CNS, central nervous system; HR, hazard ratio; ITT, intent -to -treat;  mets , metastases; NE, not evaluable; OS, overall survival; pts, patients \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nPts with event, n (%)  41 (32.8)  26 (41.9) \n\nMedian  OS, months \n\n(95% CI) \n\nNE \n\n(NE ‚ÄìNE) \n\nNE \n\n(45.5 ‚ÄìNE) \n\nHR  (95% CI)  0.60  (0.37 ‚Äì0.99) \n\n5-year OS rate , % \n\n(95% CI) \n\n66.4 \n\n(57.9 ‚Äì74.9) \n\n56.0 \n\n(43.0 ‚Äì69.1) \n\nPts remaining at risk, n  69  25 \n\n0\n\n> OS (%)\n\n6 36  66 60 54 48 42 30 24 18 12 \n\nTime (months) \n\n100 \n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\nCrizotinib (n=62) \n\nAlectinib (n=125) \n\nWith  CNS  mets  at baseline  Without  CNS  mets  at baseline \n\nAlectinib \n\nn=44 \n\nCrizotinib \n\nn=23 \n\nAlectinib \n\nn=81 \n\nCrizotinib \n\nn=39 \n\nPts with event, n (%)  16 (36.4)  12 (52.2)  25 (30.9)  14 (35.9) \n\nMedian  OS, months \n\n(95% CI) \n\nNE \n\n(51.4 ‚ÄìNE) \n\n46.2 \n\n(12.2 ‚ÄìNE) \n\nNE \n\n(NE ‚ÄìNE) \n\nNE \n\n(59.8 ‚ÄìNE) \n\nHR  (95% CI)  0.40  (0.19 ‚Äì0.85)  0.81  (0.42 ‚Äì1.55) \n\n5-year OS rate, % \n\n(95% CI) \n\n63.6 \n\n(48.9 ‚Äì78.3) \n\n39.3 \n\n(17.4 ‚Äì61.2) \n\n67.8 \n\n(57.4 ‚Äì78.2) \n\n64.9 \n\n(49.3 ‚Äì80.4) \n\nPts remaining at risk, n  25  6 44  19 \n\nCrizotinib (n=39) \n\nWithout  CNS  mets  at baseline \n\nAlectinib (n=81) \n\nUpdated OS: ITT population \n\nTime (months) \n\n100 \n\n0\n\n> OS (%)\n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\n36  66 54 18 6 60 42 30 24 12  48 \n\nCrizotinib (n=23) \n\nWith  CNS  mets  at baseline \n\nAlectinib (n=44) \n\nOS according to CNS status at baseline Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Treatment with alectinib delayed the time to CNS progression* \n\nThanyanan  Baisamut  (Reungwetwattana) \n\n*Derived from investigators' assessment. CNS PD = CNS Target Lesion PD per RECIST version 1.1, appearance of new CNS lesion(s ),  and/or unequivocal PD of Non -Target CNS lesion(s) \n\nData cut -off 16 May 2022. CI, confidence interval;  CIR, cumulative incidence rate;  CNS, central nervous system; HR, hazard ratio;  PD, progressive disease \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nCNS progression without prior systemic progression \n\nPatients with events, n (%)  18 (14.4)  22 (35.5) \n\nCause -specific HR  (95% CI)  0.16  (0.08 ‚Äì0.32) \n\nEstimated cumulative incidence, % (95% CI) \n\nAt 36 months  11.6 (6.7 ‚Äì18.1)  34.0 (22.1 ‚Äì46.2) \n\nAt 60 months  14.2 (8.6 ‚Äì21.1)  37.4 (25.0 ‚Äì49.7) \n\n40 \n\n0\n\n> Cumulative incidence (%)\n\n30 \n\n20 \n\n10 \n\n0 6 36  60 54 48 42 30 24 18 12 \n\nTime (months) \n\nCrizotinib (n=62) \n\nAlectinib (n=125) \n\nCIR: \n\n11.6% (95% CI 6.7 ‚Äì18.1) \n\nCIR: \n\n14.2% (95% CI 8.6 ‚Äì21.1) \n\nCIR: \n\n34.0% (95% CI 22.1 ‚Äì46.2) \n\nCIR: \n\n37.4% (95% CI 25.0 ‚Äì49.7) Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Post -progression therapy \n\nThanyanan  Baisamut  (Reungwetwattana)  \n\n> Data cut -off 16 May 2022. PD, progressive disease; VEGF, vascular endothelial growth factor\n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nPatients with PD , n  68  48 \n\nAnti -cancer therapy after PD , n (%)  42 (61.8)  38 (79.2) \n\nALK inhibitor , n (%)  25 (36.8)  28 (58.3) \n\nAlectinib  5 (7.4)  14 (29.2) \n\nLorlatinib  8 (11.8)  6 (12.5) \n\nBrigatinib  6 (8.8)  7 (14.6) \n\nCrizotinib  7 (10.3)  2 (4.2) \n\nCeritinib  3 (4.4)  4 (8.3) \n\nEnsartinib  2 (2.9)  1 (2.1) \n\nInvestigational drug  1 (1.5)  0\n\nChemotherapy , n (%)  24 (35.3)  15 (31.3) \n\nAnti -VEGF therapies , n ( %Ôºâ 9 (13.2)  3 (6.3) \n\nImmunotherapy , n (%)  3 (4.4)  2 (4.2) \n\nOther therapies , n (%)  6 (8.8)  7 (14.6) \n\nMore crizotinib patients (79.2% vs 61.8% alectinib) received at least one anti -cancer therapy post -progression \n\nApproximately 30% of patients in the crizotinib arm received alectinib after their disease progressed Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## The safety profile of alectinib remained favourable with longer \n\n## follow -up; no new safety signals were observed \n\nThanyanan  Baisamut  (Reungwetwattana) \n\n> *Three additional fatal events occurred during the longer follow -up: one was due to COVID -19 pneumonia, and the other two were r eported as ‚Äòdeath‚Äô and not related to alectinib treatment\n> Data cut -off 16 May 2022. AE, adverse event; ALT, alanine aminotransferase; ECG, electrocardiogram\n\nEvent, n  (%) \n\nAlectinib \n\n(n=125) \n\nCrizotinib \n\n(n=62) \n\nPatients with ‚â•1 \n\nAll grade AEs  125 (100)  62 (100) \n\nSerious AEs  35 (28.0)  18 (29.0) \n\nGrade ‚â•3 AEs  60 (48.0)  34 (54.8) \n\nFatal AEs  5 (4.0)*  3 (4.8) \n\nAEs leading to treatment discontinuation  14 (11.2)  9 (14.5) \n\nAEs leading to dose reduction  33 (26.4)  17 (27.4) \n\nAEs leading to dose interruption  33 (26.4)  19 (30.6) \n\nGrade ‚â•3 AEs with ‚â•3% difference \n\nin frequency between treatment arms, n  (%) \n\nAlectinib \n\n(n=125) \n\nCrizotinib \n\n(n=62) \n\nWeight increased  11 (8.8)  1 (1.6) \n\nBlood creatine phosphokinase increased  8 (6.4)  2 (3.2) \n\nALT increased  3 (2.4)  4 (6.5) \n\nNausea  1 (0.8)  3 (4.8) \n\nNeutrophil count decreased  0 9 (14.5) \n\nECG QT prolonged  0 3 (4.8) \n\nWhite blood cell count decreased  0 3 (4.8) \n\nDecreased appetite  0 3 (4.8) \n\nHyponatraemia  0 3 (4.8) \n\nInterstitial lung disease  0 3 (4.8) \n\nVomiting  0 3 (4.8) \n\nBradycardia  0 2 (3.2) \n\nHepatic function abnormal  0 2 (3.2) \n\nMedian treatment duration was more than three -times greater for alectinib (42.3 months) \n\ncompared to crizotinib (12.6 months) Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Conclusions:  5-year update from the Phase 3 ALESIA study   \n\n> Thanyanan Baisamut (Reungwetwattana )\n\nWith  at least 5 years  of follow -up, 1L alectinib  600mg twice daily  continues \n\nto demonstrate clinical benefit to Asian patients with advanced  ALK+  NSCLC, \n\nconsistent with  that observed in the  global ALEX study \n\nTreatment with alectinib also delayed the time to CNS progression \n\nThis clinical benefit, coupled with a tolerable and manageable safety profile, \n\nconfirms alectinib as standard -of -care treatment \n\nfor patients with advanced  ALK+  NSCLC Acknowledgements \n\nWe thank the participating patients and their families, study investigators, and research nurses \n\nThe ALESIA study was funded by F. Hoffmann -La Roche Ltd \n\nMedical writing support for the development of this presentation, under the direction \n\nof the authors, was provided by Fiona Duthie, PhD, of Ashfield MedComms, \n\nan Inizio company, and was funded by F. Hoffmann -La Roche Ltd\n"}], 'response_time': 0.7})
2025-06-18 19:19:09,937 - src.graph.nodes - INFO - Planner generating full plan
2025-06-18 19:19:20,926 - httpx - INFO - HTTP Request: POST https://2791-3-16-2-146.ngrok-free.app/v1/chat/completions "HTTP/1.1 200 OK"
2025-06-18 19:19:20,942 - process_medbrowse_questions - ERROR - Workflow execution failed: Failed to parse Plan from completion {"type": "image", "image_url": "https://www.roche.com/files/pres/presentation-alesia-phase-3-trial.pdf", "image_description": "This document provides the drug facts of a medication, including its active ingredient, purposes such as pain relief and fever reduction, specific uses, warnings about allergic reactions and stomach bleeding, and instructions for use."}. Got: 4 validation errors for Plan
locale
  Field required [type=missing, input_value={'type': 'image', 'image_... instructions for use.'}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
has_enough_context
  Field required [type=missing, input_value={'type': 'image', 'image_... instructions for use.'}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
thought
  Field required [type=missing, input_value={'type': 'image', 'image_... instructions for use.'}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
title
  Field required [type=missing, input_value={'type': 'image', 'image_... instructions for use.'}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
For troubleshooting, visit: https://python.langchain.com/docs/troubleshooting/errors/OUTPUT_PARSING_FAILURE 
2025-06-18 19:19:20,942 - process_medbrowse_questions - WARNING - Parser error (attempt 2/5) for question 2: Failed to parse Plan from completion {"type": "image", "image_url": "https://www.roche.com/files/pres/presentation-alesia-phase-3-trial.pdf", "image_description": "This document provides the drug fact...
2025-06-18 19:19:20,942 - process_medbrowse_questions - INFO - Will retry in 3s... (3/5)
2025-06-18 19:19:23,945 - process_medbrowse_questions - INFO - Retry attempt 3/5 for question 2
2025-06-18 19:19:23,945 - process_medbrowse_questions - INFO - Running workflow (attempt 3) with params: max_plan_iterations=1, max_step_num=3
2025-06-18 19:19:23,946 - src.workflow - INFO - Starting async workflow with user input: "For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter 'C'.\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name."
2025-06-18 19:19:23,951 - src.graph.nodes - INFO - Coordinator talking.
2025-06-18 19:19:23,951 - src.graph.nodes - INFO - Starting new research session - clearing previous sources
2025-06-18 19:19:23,951 - src.tools.tavily_extractor - DEBUG - Cleared 3 temp sources
2025-06-18 19:19:28,193 - httpx - INFO - HTTP Request: POST https://2791-3-16-2-146.ngrok-free.app/v1/chat/completions "HTTP/1.1 200 OK"
2025-06-18 19:19:28,197 - src.graph.nodes - DEBUG - Current state messages: [HumanMessage(content='"For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter \'C\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name."', additional_kwargs={}, response_metadata={}, id='40cefac0-88c4-474f-b55f-c9d49d68ac86')]
2025-06-18 19:19:28,199 - src.graph.nodes - INFO - background investigation node is running.
2025-06-18 19:19:28,199 - src.tools.decorators - DEBUG - Tool TavilySearchResultsWithImages._run called with parameters: "For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter 'C'.\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name."
2025-06-18 19:19:30,270 - src.tools.tavily_extractor - DEBUG - Stored Tavily source: AIM-Harvard/MedBrowseComp ¬∑ Datasets at Hugging Face
2025-06-18 19:19:30,270 - src.tools.tavily_extractor - DEBUG - Stored Tavily source: Alectinib and Crizotinib in Anaplastic Lymphoma Kinase-positive Non ...
2025-06-18 19:19:30,271 - src.tools.tavily_extractor - DEBUG - Stored Tavily source: Alectinib vs crizotinib in Asian patients with treatment-na√Øve ... - Roche
2025-06-18 19:19:30,274 - src.tools.decorators - DEBUG - Tool TavilySearchResultsWithImages returned: ([{'type': 'page', 'title': 'AIM-Harvard/MedBrowseComp ¬∑ Datasets at Hugging Face', 'url': 'https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp', 'content': '| CRIZOTINIB | "For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter \'C\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient | [...] | PF PRISM CV | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name | [...] | May 12, 2027 | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |', 'score': 0.92684203, 'raw_content': 'AIM-Harvard/MedBrowseComp ¬∑ Datasets at Hugging Face\n\n===============\n\n[![Image 1: Hugging Face\'s logo](https://huggingface.co/front/assets/huggingface_logo-noborder.svg)Hugging Face](https://huggingface.co/)\n\n*   [Models](https://huggingface.co/models)\n*   [Datasets](https://huggingface.co/datasets)\n*   [Spaces](https://huggingface.co/spaces)\n*    Community  \n*   [Docs](https://huggingface.co/docs)\n*   [Enterprise](https://huggingface.co/enterprise)\n*   [Pricing](https://huggingface.co/pricing)\n*    \n*   \n* * *\n\n*   [Log In](https://huggingface.co/login)\n*   [Sign Up](https://huggingface.co/join)\n\n[Datasets:](https://huggingface.co/datasets)\n\n* * *\n\n[![Image 2](https://cdn-avatars.huggingface.co/v1/production/uploads/63600b93d9e4214b9a67807c/ZRnXCRmf600I8gTKJH-V0.png)](https://huggingface.co/AIM-Harvard)\n\n[AIM-Harvard](https://huggingface.co/AIM-Harvard)\n\n/\n\n[MedBrowseComp](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp)\n\nlike 1\n\nFollow\n\n![Image 3](https://cdn-avatars.huggingface.co/v1/production/uploads/63600b93d9e4214b9a67807c/ZRnXCRmf600I8gTKJH-V0.png)AIM-Harvard 23\n===================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================\n\nTasks: [Question Answering](https://huggingface.co/datasets?task_categories=task_categories%3Aquestion-answering)[Text Retrieval](https://huggingface.co/datasets?task_categories=task_categories%3Atext-retrieval)\n\nModalities: [Text](https://huggingface.co/datasets?modality=modality%3Atext)\n\nFormats: [csv](https://huggingface.co/datasets?format=format%3Acsv)\n\nLanguages: [English](https://huggingface.co/datasets?language=language%3Aen)\n\nSize: [1K - 10K](https://huggingface.co/datasets?size_categories=size_categories%3A1K%3Cn%3C10K)\n\nArXiv: \n\narxiv:2505.14963\n\nTags: [medical](https://huggingface.co/datasets?other=medical)[healthcare](https://huggingface.co/datasets?other=healthcare)[browsing](https://huggingface.co/datasets?other=browsing)[comparison](https://huggingface.co/datasets?other=comparison)\n\nLibraries: [Datasets](https://huggingface.co/datasets?library=library%3Adatasets)[pandas](https://huggingface.co/datasets?library=library%3Apandas)\n\nCroissant\n\n+ 1\n\nLicense: \n\napache-2.0\n\n[Dataset card](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp)[Data Studio](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/viewer/)[Files Files and versions](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/tree/main)[Community 1](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/discussions)\n\nDataset Viewer\n\n[Auto-converted to Parquet](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/tree/refs%2Fconvert%2Fparquet/default)API Embed Data Studio\n\nSubset (1)\n\ndefault¬∑1.14k rows\n\n \n\nSplit (3)\n\nMedBrowseComp_50¬∑50 rows\n\n \n\nSQL \n\n Console \n\n| gold string lengths 5 24 | prompt string lengths 227 657 | task_name string classes 5 values |\n| --- | --- | --- |\n| ENZALUTAMIDE | "For clinical trial NCT00974311. Among the more effective regimen ingredients, find which ingredient starts with the letter \'E\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| CRIZOTINIB | "For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter \'C\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| LENALIDOMIDE | "For clinical trial NCT01938001. Among the more effective regimen ingredients, find which ingredient starts with the letter \'L\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| AZACITIDINE | "For clinical trial NCT00071799. Among the more effective regimen ingredients, find which ingredient starts with the letter \'A\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| IRINOTECAN HYDROCHLORIDE | "For clinical trial NCT00720512. Among the more effective regimen ingredients, find which ingredient starts with the letter \'I\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| VENETOCLAX | "For clinical trial NCT02755597. Among the more effective regimen ingredients, find which ingredient starts with the letter \'V\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| DEXAMETHASONE | "For clinical trial NCT00833833. Among the more effective regimen ingredients, find which ingredient starts with the letter \'D\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| IBRUTINIB | "For clinical trial NCT01973387. Among the more effective regimen ingredients, find which ingredient starts with the letter \'I\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| LENALIDOMIDE | "For clinical trial NCT00843882. Among the more effective regimen ingredients, find which ingredient starts with the letter \'L\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| SIROLIMUS | "For clinical trial NCT01231412. Among the more effective regimen ingredients, find which ingredient starts with the letter \'S\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| ASTELLAS | "First, for clinical trial NCT00974311, among the more effective regimen ingredients, identify which ingredient starts with the letter \'E\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| PF PRISM CV | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| BRISTOL MYERS SQUIBB | "First, for clinical trial NCT01938001, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| BRISTOL | "First, for clinical trial NCT00071799, among the more effective regimen ingredients, identify which ingredient starts with the letter \'A\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| IPSEN | "First, for clinical trial NCT00720512, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| ABBVIE | "First, for clinical trial NCT02755597, among the more effective regimen ingredients, identify which ingredient starts with the letter \'V\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| DEXCEL | "First, for clinical trial NCT00833833, among the more effective regimen ingredients, identify which ingredient starts with the letter \'D\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| PHARMACYCLICS LLC | "First, for clinical trial NCT01973387, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| BRISTOL MYERS SQUIBB | "First, for clinical trial NCT00843882, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| AADI SUB | "First, for clinical trial NCT01231412, among the more effective regimen ingredients, identify which ingredient starts with the letter \'S\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| Aug 13, 2027 | "First, for clinical trial NCT00974311, among the more effective regimen ingredients, identify which ingredient starts with the letter \'E\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| May 12, 2027 | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Apr 27, 2027 | "First, for clinical trial NCT01938001, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| May 14, 2029 | "First, for clinical trial NCT00071799, among the more effective regimen ingredients, identify which ingredient starts with the letter \'A\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Jan 6, 2027 | "First, for clinical trial NCT00720512, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Jan 29, 2032 | "First, for clinical trial NCT02755597, among the more effective regimen ingredients, identify which ingredient starts with the letter \'V\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Dec 18, 2037 | "First, for clinical trial NCT00833833, among the more effective regimen ingredients, identify which ingredient starts with the letter \'D\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Dec 3, 2031 | "First, for clinical trial NCT01973387, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Apr 27, 2027 | "First, for clinical trial NCT00843882, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Mar 5, 2036 | "First, for clinical trial NCT01231412, among the more effective regimen ingredients, identify which ingredient starts with the letter \'S\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Nov 17, 2026 | "For clinical trial NCT00974311, among the more effective regimen ingredients, identify which ingredient starts with the letter \'E\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Jul 14, 2025 | "For clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| May 28, 2026 | "For clinical trial NCT01938001, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Sep 1, 2027 | "For clinical trial NCT00071799, among the more effective regimen ingredients, identify which ingredient starts with the letter \'A\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Feb 13, 2031 | "For clinical trial NCT00720512, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| May 15, 2026 | "For clinical trial NCT02755597, among the more effective regimen ingredients, identify which ingredient starts with the letter \'V\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Oct 3, 2026 | "For clinical trial NCT00833833, among the more effective regimen ingredients, identify which ingredient starts with the letter \'D\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Aug 24, 2029 | "For clinical trial NCT01973387, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| May 28, 2026 | "For clinical trial NCT00843882, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Nov 22, 2028 | "For clinical trial NCT01231412, among the more effective regimen ingredients, identify which ingredient starts with the letter \'S\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| 15.98999977 | "For clinical trial NCT00974311, review the more effective regimen ingredients and identify which ingredient starts with the letter \'E\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 34.47000122 | "For clinical trial NCT02838420, review the less effective regimen ingredients and identify which ingredient starts with the letter \'C\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 46.72999954 | "For clinical trial NCT01938001, review the more effective regimen ingredients and identify which ingredient starts with the letter \'L\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 62.20000076 | "For clinical trial NCT00071799, review the more effective regimen ingredients and identify which ingredient starts with the letter \'A\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 15.14000034 | "For clinical trial NCT00720512, review the more effective regimen ingredients and identify which ingredient starts with the letter \'I\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 58.59000015 | "For clinical trial NCT02755597, review the more effective regimen ingredients and identify which ingredient starts with the letter \'V\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| NOT LISTED | "For clinical trial NCT00833833, review the more effective regimen ingredients and identify which ingredient starts with the letter \'D\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| NOT LISTED | "For clinical trial NCT01973387, review the more effective regimen ingredients and identify which ingredient starts with the letter \'I\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 46.72999954 | "For clinical trial NCT00843882, review the more effective regimen ingredients and identify which ingredient starts with the letter \'L\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 39.84000015 | "For clinical trial NCT01231412, review the more effective regimen ingredients and identify which ingredient starts with the letter \'S\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n\n*   [Datasets](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#datasets "Datasets")\n\n*   [Usage](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#usage "Usage")\n\n*   [GitHub Repository](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#github-repository "GitHub Repository")\n\n*   [Citation](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#citation "Citation")\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#medbrowsecomp-dataset) MedBrowseComp Dataset\n=========================================================================================================\n\nThis repository contains datasets for medical information-seeking-oriented deep research and computer use tasks.\n\n[![Image 4: Overall](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/resolve/main/medcomp.png)](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/blob/main/medcomp.png)\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#datasets) Datasets\n-------------------------------------------------------------------------------\n\nThe repository contains three harmonized datasets:\n\n1.   **MedBrowseComp_50**: A collection of 50 medical entries for browsing and comparison.\n2.   **MedBrowseComp_605**: A comprehensive collection of 605 medical entries.\n3.   **MedBrowseComp_CUA**: A curated collection of medical data for comparison and analysis.\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#usage) Usage\n-------------------------------------------------------------------------\n\nThese datasets can be used for various medical text processing tasks, information retrieval, and comparative analysis.\n\nExample usage with the Hugging Face datasets library:\n\n```python\nfrom datasets import load_dataset\n\n# Load the dataset\ndataset = load_dataset("AIM-Harvard/MedBrowseComp")\n\n# Access specific splits\nmed50_data = dataset["MedBrowseComp_50"]\nmed605_data = dataset["MedBrowseComp_605"]\ncua_data = dataset["MedBrowseComp_CUA"]\n```\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#github-repository) GitHub Repository\n-------------------------------------------------------------------------------------------------\n\nFor more information and related tools, visit: [https://github.com/MedBrowseComp](https://github.com/MedBrowseComp)\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#citation) Citation\n-------------------------------------------------------------------------------\n\nIf you use this dataset in your research, please cite: [https://arxiv.org/abs/2505.14963](https://arxiv.org/abs/2505.14963)\n\n```\n@misc{chen2025medbrowsecompbenchmarkingmedicaldeep,\n      title={MedBrowseComp: Benchmarking Medical Deep Research and Computer Use}, \n      author={Shan Chen and Pedro Moreira and Yuxin Xiao and Sam Schmidgall and Jeremy Warner and Hugo Aerts and Thomas Hartvigsen and Jack Gallifant and Danielle S. Bitterman},\n      year={2025},\n      eprint={2505.14963},\n      archivePrefix={arXiv},\n      primaryClass={cs.CL},\n      url={https://arxiv.org/abs/2505.14963}, \n}\n```\n\nDownloads last month 179\n\n Use this dataset \n\nSize of downloaded dataset files: 448 kB[Size of the auto-converted Parquet files: 58 kB](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/tree/refs%2Fconvert%2Fparquet/)Number of rows: 1,139\n\nCollection including AIM-Harvard/MedBrowseComp\n----------------------------------------------\n\n[#### MedBrowseComp Collection MedBrowseComp: Benchmarking Medical Deep Research and Computer Use‚Ä¢ 3 items‚Ä¢ Updated 10 days ago](https://huggingface.co/collections/AIM-Harvard/medbrowsecomp-6822637df90521b5d8b8b23f)\n\n System theme \n\nCompany\n\n[TOS](https://huggingface.co/terms-of-service)[Privacy](https://huggingface.co/privacy)[About](https://huggingface.co/huggingface)[Jobs](https://apply.workable.com/huggingface/)[](https://huggingface.co/)\n\nWebsite\n\n[Models](https://huggingface.co/models)[Datasets](https://huggingface.co/datasets)[Spaces](https://huggingface.co/spaces)[Pricing](https://huggingface.co/pricing)[Docs](https://huggingface.co/docs)\n'}, {'type': 'page', 'title': 'Alectinib and Crizotinib in Anaplastic Lymphoma Kinase-positive Non ...', 'url': 'https://ichgcp.net/clinical-trials-registry/NCT02838420', 'content': 'USA (FDA)\n       UK (MHRA)\n       AUSTRALIA (NHMRC)\n       JAPAN (PMDA)\n       EU (EMA)\n\n   CRO List\n   Clinical Trials\n\n       US Clinical Trials Registry\n       EU Clinical Trials Registry\n       Pharmaceutical Companies\n       Clinical Research Labs\n       Service Companies\n       Clinical Research Events\n       Publications\n       Researchers\n\n   Jobs\n   Publications\n   News\n\n   \n   \n\n   ICH GCP\n   US Clinical Trials Registry\n   Clinical Trial NCT02838420', 'score': 0.54724693, 'raw_content': 'Published Time: 2022-12-12T02:32:10+00:00\n\nAlectinib and Crizotinib in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer - Clinical Trials Registry - ICH GCP\n\n===============\n\n[![Image 1: ICHGCP](https://ichgcp.net/img/ichgcp_logo.png)](https://ichgcp.net/)\n\n*   Regulations\n\n    *   [GLOBAL¬ª](https://ichgcp.net/clinical-trials-registry/NCT02838420#)\n\n        *   [ICH GCP (De)](https://ichgcp.net/de)\n        *   [ICH GCP (En)](https://ichgcp.net/)\n        *   [ICH GCP (Es)](https://ichgcp.net/es)\n        *   [ICH GCP (Fr)](https://ichgcp.net/fr)\n        *   [ICH GCP (It)](https://ichgcp.net/it)\n        *   [ICH GCP (Pt)](https://ichgcp.net/pt)\n        *   [ICH GCP (Ru)](https://ichgcp.net/ru)\n\n    *   [USA (FDA)](https://ichgcp.net/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects)\n    *   [UK (MHRA)](https://ichgcp.net/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol)\n    *   [AUSTRALIA (NHMRC)](https://ichgcp.net/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia)\n    *   [JAPAN (PMDA)](https://ichgcp.net/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan)\n    *   [EU (EMA)](https://ichgcp.net/ich-e-group-of-guidelines)\n\n*   [CRO List](https://ichgcp.net/cro-list)\n*   Clinical Trials\n\n    *   [US Clinical Trials Registry](https://ichgcp.net/clinical-trials-registry)\n    *   [EU Clinical Trials Registry](https://ichgcp.net/eu-clinical-trials-registry)\n    *   [Pharmaceutical Companies](https://ichgcp.net/pharma-list)\n    *   [Clinical Research Labs](https://ichgcp.net/labs)\n    *   [Service Companies](https://ichgcp.net/service-companies)\n    *   [Clinical Research Events](https://ichgcp.net/events)\n    *   [Publications](https://ichgcp.net/clinical-trials-registry/publications)\n    *   [Researchers](https://ichgcp.net/clinical-trials-registry/researchers)\n\n*   [Jobs](https://ichgcp.net/jobs)\n*   [Publications](https://ichgcp.net/publications)\n*   [News](https://ichgcp.net/news)\n\n*   [](https://telegram.me/share/url?url=https://ichgcp.net/clinical-trials-registry/NCT02838420&text= "Share on telegram")\n*   [](https://twitter.com/intent/tweet?url=https://ichgcp.net/clinical-trials-registry/NCT02838420 "Share on Twitter")\n\n*   [ICH GCP](https://ichgcp.net/)\n*   [US Clinical Trials Registry](https://ichgcp.net/clinical-trials-registry)\n*   Clinical Trial NCT02838420\n\nA Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)\n=========================================================================================================================================================================================================================================================================\n\nMarch 24, 2025 updated by: [Hoffmann-La Roche](https://ichgcp.net/clinical-trials-registry/research/list?spons=Hoffmann-La%20Roche "List all studies sponsored by Hoffmann-La Roche")\n\nRandomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Asian Patients With Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer\n--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\nThis randomized, multicenter, Phase III, open-label study will evaluate the efficacy and safety of alectinib versus crizotinib and to evaluate the pharmacokinetics of alectinib in asian participants with treatment-naive ALK-positive advanced NSCLC. Participants will be randomized 2:1 into one of the two treatment groups to receive either alectinib (600 milligrams [mg] twice daily [BID]) or crizotinib (250 mg BID) orally, respectively.\n\nStudy Overview\n--------------\n\n#### Status\n\nActive, not recruiting\n\n#### Conditions\n\n*   [Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%20Lymphoma%20Kinase-positive%20Non-small%20Cell%20Lung%20Cancer "List all studies focused on condition Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer")\n\n#### Intervention / Treatment\n\n*   [Drug: Alectinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Alectinib "List all studies with intervention Alectinib")\n*   [Drug: Crizotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Crizotinib "List all studies with intervention Crizotinib")\n\n#### Study Type\n\n Interventional \n\n#### Enrollment (Actual)\n\n 187 \n\n#### Phase\n\n*   Phase 3\n\nContacts and Locations\n----------------------\n\nThis section provides the contact details for those conducting the study, and information on where this study is being conducted.\n\n### Study Locations\n\n*   [China](https://ichgcp.net/clinical-trials-registry/research/list?locn=China "List all studies conducted in China") \n    *           *   Beijing, China, 100142 \n            *   Beijing Cancer Hospital\n\n        *   Beijing, China, 101149 \n            *   Beijing Chest Hospital\n\n        *   Changchun, China, 130021 \n            *   The First Hospital of Jilin University\n\n        *   Changchun, China, 132013 \n            *   Jilin cancer hospital\n\n        *   Chengdu, China, 610041 \n            *   West China Hospital, Sichuan University\n\n        *   Guangzhou, China, 510060 \n            *   Sun Yet-sen University Cancer Center\n\n        *   Guangzhou, China, 510080 \n            *   Guangdong General Hospital\n\n        *   Guangzhou, China, 510120 \n            *   The First Affiliated Hospital of Guangzhou Medical University\n\n        *   Hangzhou, China, 310003 \n            *   The First Affiliated Hospital of College of Medicine, Zhejiang University\n\n        *   Hangzhou, China, 310022 \n            *   Zhejiang Cancer Hospital\n\n        *   Harbin, China, 150081 \n            *   Harbin Medical University Cancer Hospital\n\n        *   Nanjing, China, 210009 \n            *   Jiangsu Cancer Hospital\n\n        *   Shanghai, China, 200030 \n            *   Shanghai Chest Hospital\n\n        *   Shanghai, China, 200032 \n            *   Fudan University Shanghai Cancer Center\n\n        *   Shanghai, China, 200433 \n            *   Shanghai Pulmonary Hospital\n\n*   [Korea, Republic of](https://ichgcp.net/clinical-trials-registry/research/list?locn=Korea%2C%20Republic%20of "List all studies conducted in Korea, Republic of") \n    *           *   Seoul, Korea, Republic of, 05505 \n            *   Asan Medical Center\n\n        *   Seoul, Korea, Republic of, 06351 \n            *   Samsung Medical Center\n\n        *   Seoul, Korea, Republic of, 03181 \n            *   Kangbuk Samsung Hospital\n\n*   [Thailand](https://ichgcp.net/clinical-trials-registry/research/list?locn=Thailand "List all studies conducted in Thailand") \n    *           *   Bangkok, Thailand, 10400 \n            *   Rajavithi Hospital\n\n        *   Bangkok, Thailand, 10400 \n            *   Ramathibodi Hospital\n\n        *   Songkhla, Thailand, 90110 \n            *   Songklanagarind hospital\n\nParticipation Criteria\n----------------------\n\nResearchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person\'s general health condition or prior treatments.\n\n### Eligibility Criteria\n\n#### Ages Eligible for Study\n\n 18 years and older (Adult, Older Adult) \n\n#### Accepts Healthy Volunteers\n\n No \n\n#### Description\n\nInclusion Criteria:\n\n*   Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive as assessed by the Ventana immunohistochemistry (IHC) test. Sufficient tumor tissue available to perform ALK IHC is required. Ventana IHC testing will be performed at the designated central laboratory\n*   Life expectancy of at least 12 weeks\n*   Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2\n*   No history of receiving systemic treatment for advanced, recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC\n*   Adequate hematologic function: Platelet count greater than equal to (>=) 100√ó10^9 per liter (/L); absolute neutrophil count (ANC) >=1500 cells per microliter (cells/mcL); hemoglobin>=9.0 grams per deciliter (g/dL)\n*   Adequate renal function: an estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease (MDRD) formula of >=45 milliliters per minute per 1.73 square meter\n*   Participants must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before receiving the first dose of study treatment\n*   Measurable disease (by Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v1.1]) before administration of study treatment\n*   Previous brain or leptomeningeal metastases are allowed if the participant is asymptomatic (e.g., diagnosed incidentally at study baseline). Asymptomatic central nervous system (CNS) lesions may be treated at the discretion of the investigator as per local clinical practice. If participant has neurological symptoms or signs because of CNS metastasis, the participant must complete whole-brain radiation or gamma knife irradiation treatment. In all cases, radiation treatment must be completed >=14 days before enrollment and disease must be clinically stable\n*   For all females of childbearing potential, a negative serum pregnancy test result must be obtained within 3 days prior to starting study treatment\n*   For women who are not postmenopausal (>=12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus), agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Examples of contraceptive methods with a failure rate of <1% per year include tubal ligation, male sterilization, hormonal implants, established, proper use of combined oral or injected hormonal contraceptives, and certain intrauterine devices. Alternatively, two methods (e.g., two barrier methods such as a condom and a cervical cap) may be combined to achieve a failure rate of <1% per year. Barrier methods must always be supplemented with the use of a spermicide\n*   For men, agreement to remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception\n\nExclusion Criteria:\n\n*   A malignancy within the previous 3 years (other than curatively treated basal cell carcinoma of the skin, early gastrointestinal (GI) cancer by endoscopic resection, in situ carcinoma of the cervix, or any cured cancer that is considered to have no impact in progression-free survival (PFS) or overall survival (OS) for the current NSCLC)\n*   Any GI disorder that may affect absorption of oral medications, such as malabsorption syndrome or status post-major bowel resection\n*   Liver disease characterized by:\n*   Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than (>) 3√ó the upper limit of normal (ULN; >=5√óULN for participants with concurrent liver metastases) confirmed on two consecutive measurements; or\n*   Impaired excretory function (e.g., hyperbilirubinemia), synthetic function, or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices; or\n*   Acute viral or active autoimmune, alcoholic, or other types of hepatitis\n*   National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 Grade 3 or higher toxicities because of any previous therapy (e.g., radiotherapy) (excluding alopecia), which have not shown improvement and are strictly considered to interfere with current study medication\n*   History of organ transplant\n*   Co-administration of anti-cancer therapies other than those administered in this study\n*   Baseline QTc >470 ms or symptomatic bradycardia\n*   Administration of strong/potent cytochrome P4503A inhibitors or inducers within 14 days prior to the receiving the first dose of study treatment and during treatment with alectinib or crizotinib\n*   Administration of agents with potential QT interval prolonging effects within 14 days prior to receiving the first dose of study drug\n*   History of hypersensitivity to any of the additives in the alectinib or crizotinib drug formulation\n*   Pregnant or lactating\n*   Known human immunodeficiency virus (HIV-positivity or acquired immunodeficiency syndrome (AIDS)-related illness\n*   Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or the absorption of oral medications or that would, in the opinion of the Principal Investigator, pose an unacceptable risk to the participant in this study\n*   Any psychological, familial, sociological, or geographical condition that potentially hampers compliance with the study protocol requirements or follow-up procedures; those conditions should be discussed with the participant before study entry\n\nStudy Plan\n----------\n\nThis section provides details of the study plan, including how the study is designed and what the study is measuring.\n\n### How is the study designed?\n\n#### Design Details\n\n*   **Primary Purpose**: Treatment\n*   **Allocation**: Randomized\n*   **Interventional Model**: Parallel Assignment\n*   **Masking**: None (Open Label)\n\n#### Number of Arms\n\n2\n\n#### Arms and Interventions\n\n| ##### Participant Group / Arm | ##### Intervention / Treatment |\n| --- | --- |\n| Experimental: Alectinib Participants will receive alectinib capsules orally at a dose of 600 mg BID with food until disease progression, unacceptable toxicity withdrawal of consent, or death. | [Drug: Alectinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Alectinib "List all studies with intervention Alectinib") Alectinib capsules will be administered orally at a dose of 600 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death. Other Names: * RO5424802 |\n| Active Comparator: Crizotinib Participants will receive crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity withdrawal of consent, or death. | [Drug: Crizotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Crizotinib "List all studies with intervention Crizotinib") Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death. |\n\n### What is the study measuring?\n\n#### Primary Outcome Measures\n\n| ##### Outcome Measure | ##### Measure Description | ##### Time Frame |\n| --- | --- | --- |\n| Progression-Free Survival (PFS) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 Time Frame: From the date of randomization to the date of the first documented disease progression or death, whichever occurred first (up to overall period of approximately 40 months) | PFS was defined as the time (in months) from randomization to the first documentation of disease progression, as determined by the investigators, or to death from any cause, whichever occurred first. | From the date of randomization to the date of the first documented disease progression or death, whichever occurred first (up to overall period of approximately 40 months) |\n\n#### Secondary Outcome Measures\n\n| ##### Outcome Measure | ##### Measure Description | ##### Time Frame |\n| --- | --- | --- |\n| PFS as Determined by Independent Review Committee (IRC) Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) | PFS was defined as the time (in months) from randomization to the first documentation of disease progression, as determined by an independent review committee, or to death from any cause, whichever occurred first. | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Percentage of Participants With Objective Response of Complete Response (CR) or Partial Response (PR) as Determined by Investigator Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Time to Progression of Disease in the CNS as Determined by IRC Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Time to Progression of Disease in the CNS as Determined by IRC Using Response Assessment in Neuro-Oncology (RANO) Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Duration of Response (DOR) Assessed by Investigator Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Overall Survival Time Time Frame: Baseline, until death (up to overall period of approximately 40 months) |  | Baseline, until death (up to overall period of approximately 40 months) |\n| Percentage of Participants With Non-serious Adverse Events and Serious Adverse Events Time Frame: Up to overall period of approximately 40 months | An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. | Up to overall period of approximately 40 months |\n| Time to Deterioration Assessed Using EORTC Quality of Life Questionnaire-Core (QLQ-C30) Score Time Frame: Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Time to Deterioration Assessed Using EORTC Quality of Life Questionnaire-Lung Cancer Module (QLQ-LC13) Score Time Frame: Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Area Under the Plasma Concentration-time Curve (AUC) of Alectinib and Its Metabolite Time Frame: Baseline and Week 4 predose (within 2 hours before administration of study drug) | AUC was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time. | Baseline and Week 4 predose (within 2 hours before administration of study drug) |\n| Maximum Plasma Concentration Observed (Cmax) of Alectinib and Its Metabolite Time Frame: Baseline and Week 4 predose (within 2 hours before administration of study drug) | Cmax was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time. | Baseline and Week 4 predose (within 2 hours before administration of study drug) |\n| Time to Cmax (Tmax) of Alectinib and Its Metabolite Time Frame: Baseline and Week 4 predose (within 2 hours before administration of study drug) | Tmax was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time. | Baseline and Week 4 predose (within 2 hours before administration of study drug) |\n\nCollaborators and Investigators\n-------------------------------\n\nThis is where you will find people and organizations involved with this study.\n\n#### Sponsor\n\n[Hoffmann-La Roche](https://ichgcp.net/clinical-trials-registry/research/list?spons=Hoffmann-La%20Roche "List all studies sponsored by Hoffmann-La Roche")\n\n#### Investigators\n\n*    Study Director: Clinical Trials, Hoffmann-La Roche \n\nPublications and helpful links\n------------------------------\n\nThe person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.\n\n#### General Publications\n\n*   [Zhou C, Kim SW, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang JJ, Cheng Y, Lee SH, Bu L, Xu T, Yang L, Wang C, Liu T, Morcos PN, Lu Y, Zhang L. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med. 2019 May;7(5):437-446. doi: 10.1016/S2213-2600(19)30053-0. Epub 2019 Apr 10.](https://pubmed.ncbi.nlm.nih.gov/30981696)\n\nStudy record dates\n------------------\n\nThese dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.\n\n### Study Major Dates\n\n#### Study Start (Actual)\n\n August 3, 2016 \n\n#### Primary Completion (Actual)\n\n May 31, 2018 \n\n#### Study Completion (Estimated)\n\n December 31, 2025 \n\n### Study Registration Dates\n\n#### First Submitted\n\nJuly 18, 2016\n\n#### First Submitted That Met QC Criteria\n\nJuly 18, 2016\n\n#### First Posted (Estimated)\n\nJuly 20, 2016\n\n### Study Record Updates\n\n#### Last Update Posted (Actual)\n\nMarch 25, 2025\n\n#### Last Update Submitted That Met QC Criteria\n\nMarch 24, 2025\n\n#### Last Verified\n\nMarch 1, 2025\n\nMore Information\n----------------\n\n### Terms related to this study\n\n#### Additional Relevant MeSH Terms\n\n*   [Neoplasms by Site](https://ichgcp.net/clinical-trials-registry/research/list?cond=Neoplasms%20by%20Site "List all studies by MeSH term: Neoplasms by Site")\n*   [Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Neoplasms "List all studies by MeSH term: Neoplasms")\n*   [Immune System Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Immune%20System%20Diseases "List all studies by MeSH term: Immune System Diseases")\n*   [Respiratory Tract Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Diseases "List all studies by MeSH term: Respiratory Tract Diseases")\n*   [Neoplasms by Histologic Type](https://ichgcp.net/clinical-trials-registry/research/list?cond=Neoplasms%20by%20Histologic%20Type "List all studies by MeSH term: Neoplasms by Histologic Type")\n*   [Lung Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%20Diseases "List all studies by MeSH term: Lung Diseases")\n*   [Respiratory Tract Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Neoplasms "List all studies by MeSH term: Respiratory Tract Neoplasms")\n*   [Thoracic Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Thoracic%20Neoplasms "List all studies by MeSH term: Thoracic Neoplasms")\n*   [Lymphatic Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphatic%20Diseases "List all studies by MeSH term: Lymphatic Diseases")\n*   [Lymphoproliferative Disorders](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoproliferative%20Disorders "List all studies by MeSH term: Lymphoproliferative Disorders")\n*   [Immunoproliferative Disorders](https://ichgcp.net/clinical-trials-registry/research/list?cond=Immunoproliferative%20Disorders "List all studies by MeSH term: Immunoproliferative Disorders")\n*   [Carcinoma, Bronchogenic](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%2C%20Bronchogenic "List all studies by MeSH term: Carcinoma, Bronchogenic")\n*   [Bronchial Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Bronchial%20Neoplasms "List all studies by MeSH term: Bronchial Neoplasms")\n*   [Lung Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%20Neoplasms "List all studies by MeSH term: Lung Neoplasms")\n*   [Lymphoma](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma "List all studies by MeSH term: Lymphoma")\n*   [Carcinoma, Non-Small-Cell Lung](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%2C%20Non-Small-Cell%20Lung "List all studies by MeSH term: Carcinoma, Non-Small-Cell Lung")\n*   [Tyrosine Kinase Inhibitors](https://ichgcp.net/clinical-trials-registry/research/list?intr=Tyrosine%20Kinase%20Inhibitors "List all studies by MeSH term: Tyrosine Kinase Inhibitors")\n*   [Antineoplastic Agents](https://ichgcp.net/clinical-trials-registry/research/list?intr=Antineoplastic%20Agents "List all studies by MeSH term: Antineoplastic Agents")\n*   [Molecular Mechanisms of Pharmacological Action](https://ichgcp.net/clinical-trials-registry/research/list?intr=Molecular%20Mechanisms%20of%20Pharmacological%20Action "List all studies by MeSH term: Molecular Mechanisms of Pharmacological Action")\n*   [Enzyme Inhibitors](https://ichgcp.net/clinical-trials-registry/research/list?intr=Enzyme%20Inhibitors "List all studies by MeSH term: Enzyme Inhibitors")\n*   [Protein Kinase Inhibitors](https://ichgcp.net/clinical-trials-registry/research/list?intr=Protein%20Kinase%20Inhibitors "List all studies by MeSH term: Protein Kinase Inhibitors")\n*   [Crizotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Crizotinib "List all studies by MeSH term: Crizotinib")\n*   [Alectinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Alectinib "List all studies by MeSH term: Alectinib")\n\n#### Other Study ID Numbers\n\n*    YO29449 \n\n### Drug and device information, study documents\n\n#### Studies a U.S. FDA-regulated drug product\n\n Yes \n\n#### Studies a U.S. FDA-regulated device product\n\n No \n\nThis information was retrieved directly from the website [clinicaltrials.gov](https://clinicaltrials.gov/) without any changes. If you have any requests to change, remove or update your study details, please contact [register@clinicaltrials.gov](mailto:register@clinicaltrials.gov). As soon as a change is implemented on [clinicaltrials.gov](https://clinicaltrials.gov/), this will be updated automatically on our website as well.\n\nClinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer\n---------------------------------------------------------------------------------\n\n*    Pfizer   Completed  [A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001)](https://ichgcp.net/clinical-trials-registry/NCT00585195)  Systemic Anaplastic Large-Cell Lymphoma | Non-Small Cell Lung Cancer ALK-positive | Non-Small Cell Lung Cancer c-Met Dependent | Non-Small Cell Lung Cancer ROS Marker Positive | Advanced Malignancies Except Leukemia   United States, Korea, Republic of, Australia, Japan    \n*    Novartis Pharmaceuticals   Available  [Managed Access Programs for LDK378, Ceritinib](https://ichgcp.net/clinical-trials-registry/NCT05100134)  Non-small Cell Lung Cancer (NSCLC) | Anaplastic Lymphoma Kinase (ALK)- Positive Tumors    \n*    Novartis Pharmaceuticals   Completed  [Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer](https://ichgcp.net/clinical-trials-registry/NCT01772797)  Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase (ALK)   Australia, Spain, Singapore, Italy, United States    \n*    Nuvalent Inc.   Recruiting  [Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC (ALKAZAR)](https://ichgcp.net/clinical-trials-registry/NCT06765109)  Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase-positive   United States    \n*    Intergroupe Francophone de Cancerologie Thoracique   Completed  [Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements (CLINALK)](https://ichgcp.net/clinical-trials-registry/NCT02727335)  Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase Gene Mutation   France    \n*    Takeda   Completed  [A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors](https://ichgcp.net/clinical-trials-registry/NCT03546894)  Carcinoma Non-small-cell Lung | Anaplastic Lymphoma Kinase-positive   United States    \n*    Astellas Pharma Inc   Completed  [Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)](https://ichgcp.net/clinical-trials-registry/NCT01284192)  Solid Tumor | B-Cell Lymphoma | Advanced Malignancies | Positive for Anaplastic Lymphoma Kinase | Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS   United States    \n*    University Medical Center Groningen  Radboud University Medical Center; Maastricht University Medical Center; Erasmus... and other collaborators    Recruiting  [Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels (ADAPT ALEC)](https://ichgcp.net/clinical-trials-registry/NCT05525338)  Carcinoma, Non-Small-Cell Lung | Lung Cancer | Drug Monitoring | Anaplastic Lymphoma Kinase Gene Mutation | Anaplastic Lymphoma Kinase Gene Translocation   Netherlands, France    \n*    Takeda   Withdrawn  [Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors](https://ichgcp.net/clinical-trials-registry/NCT04260009)  Solid Tumors | Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma | Inflammatory Myofibroblastic Tumors    \n*    Massachusetts General Hospital  LUNGevity Foundation; Addario Lung Cancer Medical Institute    Recruiting  [Immune and Genomic Markers in ALK+ NSCLC](https://ichgcp.net/clinical-trials-registry/NCT04881916)  Non-Small Cell Lung Cancer | Anaplastic Lymphoma Kinase Gene Translocation   United States    \n\nClinical Trials on Alectinib\n----------------------------\n\n*    Aarhus University Hospital  Roche Pharma AG    Enrolling by invitation  [Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients (MonAlec)](https://ichgcp.net/clinical-trials-registry/NCT04708639)  Lung Cancer | ALK Gene Mutation | Resistance, Disease | Mutation   Denmark    \n*    Hoffmann-La Roche   Completed  [A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (ATALK)](https://ichgcp.net/clinical-trials-registry/NCT03155009)  Carcinoma, Non-Small-Cell Lung   France    \n*    Hoffmann-La Roche   Completed  [Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea](https://ichgcp.net/clinical-trials-registry/NCT03271554)  Non-Small Cell Lung Cancer   Korea, Republic of    \n*    Dana-Farber Cancer Institute  Genentech, Inc.    Terminated  [A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer](https://ichgcp.net/clinical-trials-registry/NCT03131206)  ALK-positive Non-small Cell Lung Cancer (NSCLC) | RET-positive Non-small Cell Lung Cancer (NSCLC) | RET-positive Thyroid Cancer   United States    \n*    Hoffmann-La Roche   Completed  [Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib](https://ichgcp.net/clinical-trials-registry/NCT02621047)  Hepatic Impairment   Czechia, Slovakia    \n*    Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...  UnitedHealthcare    Not yet recruiting  [Pharmacogenomics IND EXEMPT SNP Clinical Study - Alectinib and Single Nucleotide Polymorphisms (Drugs-SNPs)](https://ichgcp.net/clinical-trials-registry/NCT05987956)  Non-small Cell Lung Cancer   United States    \n*    Hoffmann-La Roche   Terminated  [A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors (ALpha-T)](https://ichgcp.net/clinical-trials-registry/NCT04644315)  Digestive System Diseases | Gastrointestinal Diseases | Melanoma | Sarcoma | Neoplasms | Respiratory Tract Diseases | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasms | Head and Neck Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms and other conditions   United States    \n*    China Medical University Hospital   Active, not recruiting  [Alectinib in Combination with Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided with Serum RNase1 and Tumor Expression of PD-L1](https://ichgcp.net/clinical-trials-registry/NCT06354387)  Hepatocellular Carcinoma   Taiwan    \n*    Genentech, Inc.   No longer available  [Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy](https://ichgcp.net/clinical-trials-registry/NCT02271139)  Non-Small Cell Lung Cancer   United States    \n*    Hoffmann-La Roche   Completed  [A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)](https://ichgcp.net/clinical-trials-registry/NCT01871805)  Non-Small Cell Lung Cancer   United States, Canada    \n\nSearch Similar Trials\n---------------------\n\n*   [Clinical Trials on Lymphoma in Singapore](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=Singapore)\n*   [Clinical Trials on Lymphosarcoma in Australia](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=Australia)\n*   [Clinical Trials on Carcinoma, Non-Small-Cell Lung in Singapore](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BNon-Small-Cell%2BLung&locn=Singapore)\n*   [Clinical Trials on Lymphoma in New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=New%2BZealand)\n*   [Clinical Trials on Carcinoma, Non-Small-Cell Lung in United States](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BNon-Small-Cell%2BLung&locn=United%2BStates)\n*   [Clinical Trials on Lung Neoplasms in Ireland](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%2BNeoplasms&locn=Ireland)\n*   [Clinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%2BLymphoma%2BKinase-positive%2BNon-small%2BCell%2BLung%2BCancer&locn=South%2BAfrica)\n*   [Clinical Trials on Lymphosarcoma in India](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=India)\n*   [Clinical Trials on Lymphoma in United States](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=United%2BStates)\n*   [Clinical Trials on Lymphoma in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=South%2BAfrica)\n*   [Clinical Trials on Lymphoma in Hong Kong](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=Hong%2BKong)\n*   [Clinical Trials on Lymphosarcoma in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=South%2BAfrica)\n*   [Clinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer in Ireland](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%2BLymphoma%2BKinase-positive%2BNon-small%2BCell%2BLung%2BCancer&locn=Ireland)\n*   [Clinical Trials on Lung Neoplasms in New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%2BNeoplasms&locn=New%2BZealand)\n*   [Clinical Trials on Lung Neoplasms in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%2BNeoplasms&locn=South%2BAfrica)\n*   [Clinical Trials on Lymphoma in India](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=India)\n*   [Clinical Trials on Lymphosarcoma in Singapore](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=Singapore)\n*   [Clinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer in New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%2BLymphoma%2BKinase-positive%2BNon-small%2BCell%2BLung%2BCancer&locn=New%2BZealand)\n*   [Clinical Trials on Lymphosarcoma in United States](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=United%2BStates)\n*   [Clinical Trials on Carcinoma, Non-Small-Cell Lung in United Kingdom](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BNon-Small-Cell%2BLung&locn=United%2BKingdom)\n*   [Search All Trials](https://ichgcp.net/clinical-trials-registry/research/list)\n\nSponsors and Collaborators\n--------------------------\n\n*   [Eisai Korea Inc.](https://ichgcp.net/clinical-trials-registry/research/list?spons=Eisai%2BKorea%2BInc.)\n*   [Leukaemia & Blood Cancer New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?spons=Leukaemia%2B%2526%2BBlood%2BCancer%2BNew%2BZealand)\n*   [Udaan](https://ichgcp.net/clinical-trials-registry/research/list?spons=Udaan)\n*   [Makarenko Irina Romanovna](https://ichgcp.net/clinical-trials-registry/research/list?spons=Makarenko%2BIrina%2BRomanovna)\n*   [Adriane Aver Vanin](https://ichgcp.net/clinical-trials-registry/research/list?spons=Adriane%2BAver%2BVanin)\n*   [University of Memphis](https://ichgcp.net/clinical-trials-registry/research/list?spons=University%2Bof%2BMemphis)\n*   [Sleep Research Society Foundation](https://ichgcp.net/clinical-trials-registry/research/list?spons=Sleep%2BResearch%2BSociety%2BFoundation)\n*   [Immuron Ltd.](https://ichgcp.net/clinical-trials-registry/research/list?spons=Immuron%2BLtd.)\n*   [Arthro-Anda Tianjin Biologic Technology Co., Ltd.](https://ichgcp.net/clinical-trials-registry/research/list?spons=Arthro-Anda%2BTianjin%2BBiologic%2BTechnology%2BCo.%252C%2BLtd.)\n*   [CoheroHealth](https://ichgcp.net/clinical-trials-registry/research/list?spons=CoheroHealth)\n*   [Center for Military Mental Health, Berlin, Germany](https://ichgcp.net/clinical-trials-registry/research/list?spons=Center%2Bfor%2BMilitary%2BMental%2BHealth%252C%2BBerlin%252C%2BGermany)\n*   [Kevin Flanigan](https://ichgcp.net/clinical-trials-registry/research/list?spons=Kevin%2BFlanigan)\n*   [Periannan Kuppusamy](https://ichgcp.net/clinical-trials-registry/research/list?spons=Periannan%2BKuppusamy)\n*   [Chiang Mai University Hospital, THAILAND](https://ichgcp.net/clinical-trials-registry/research/list?spons=Chiang%2BMai%2BUniversity%2BHospital%252C%2BTHAILAND)\n*   [Centre for Emergency Health Sciences](https://ichgcp.net/clinical-trials-registry/research/list?spons=Centre%2Bfor%2BEmergency%2BHealth%2BSciences)\n*   [Therapex Co., Ltd](https://ichgcp.net/clinical-trials-registry/research/list?spons=Therapex%2BCo.%252C%2BLtd)\n*   [MIT William Asbjornsen Albert Memorial Fellowship](https://ichgcp.net/clinical-trials-registry/research/list?spons=MIT%2BWilliam%2BAsbjornsen%2BAlbert%2BMemorial%2BFellowship)\n*   [Fabiana Aceto](https://ichgcp.net/clinical-trials-registry/research/list?spons=Fabiana%2BAceto)\n*   [North American Spine Society](https://ichgcp.net/clinical-trials-registry/research/list?spons=North%2BAmerican%2BSpine%2BSociety)\n*   [SGS proderm GmbH](https://ichgcp.net/clinical-trials-registry/research/list?spons=SGS%2Bproderm%2BGmbH)\n*   [View Full List](https://ichgcp.net/clinical-trials-registry/research/browse/spns_alpha_all)\n\nMedical Conditions\n------------------\n\n*   [Infrarenal Abdominal Aortic Aneurysms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Infrarenal%2BAbdominal%2BAortic%2BAneurysms)\n*   [Myeloproliferative Disease, Not Classified](https://ichgcp.net/clinical-trials-registry/research/list?cond=Myeloproliferative%2BDisease%252C%2BNot%2BClassified)\n*   [Lifestyle-related Condition](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lifestyle-related%2BCondition)\n*   [Compliance](https://ichgcp.net/clinical-trials-registry/research/list?cond=Compliance)\n*   [Patients With Opioid Induced Constipation](https://ichgcp.net/clinical-trials-registry/research/list?cond=Patients%2BWith%2BOpioid%2BInduced%2BConstipation)\n*   [Femoral Vascular Anastomosis](https://ichgcp.net/clinical-trials-registry/research/list?cond=Femoral%2BVascular%2BAnastomosis)\n*   [Observation Safety](https://ichgcp.net/clinical-trials-registry/research/list?cond=Observation%2BSafety)\n*   [Improvement of Functionality](https://ichgcp.net/clinical-trials-registry/research/list?cond=Improvement%2Bof%2BFunctionality)\n*   [CD4 Deficiency](https://ichgcp.net/clinical-trials-registry/research/list?cond=CD4%2BDeficiency)\n*   [Malassezia Infection](https://ichgcp.net/clinical-trials-registry/research/list?cond=Malassezia%2BInfection)\n*   [Anti-cancer Cell Immunotherapy](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anti-cancer%2BCell%2BImmunotherapy)\n*   [Health Knowledge Attitudes and Practice](https://ichgcp.net/clinical-trials-registry/research/list?cond=Health%2BKnowledge%2BAttitudes%2Band%2BPractice)\n*   [School Adjustment](https://ichgcp.net/clinical-trials-registry/research/list?cond=School%2BAdjustment)\n*   [Difficult Mask Ventilation](https://ichgcp.net/clinical-trials-registry/research/list?cond=Difficult%2BMask%2BVentilation)\n*   [Intrapartum Mortality](https://ichgcp.net/clinical-trials-registry/research/list?cond=Intrapartum%2BMortality)\n*   [Diabetes Mellitus II](https://ichgcp.net/clinical-trials-registry/research/list?cond=Diabetes%2BMellitus%2BII)\n*   [Painless Myocardial Ischemia](https://ichgcp.net/clinical-trials-registry/research/list?cond=Painless%2BMyocardial%2BIschemia)\n*   [Corona Virus Disease 19 (COVID-19)](https://ichgcp.net/clinical-trials-registry/research/list?cond=Corona%2BVirus%2BDisease%2B19%2B%2528COVID-19%2529)\n*   [Pressure Injury Stage 2](https://ichgcp.net/clinical-trials-registry/research/list?cond=Pressure%2BInjury%2BStage%2B2)\n*   [Escape; Rhythm](https://ichgcp.net/clinical-trials-registry/research/list?cond=Escape%253B%2BRhythm)\n*   [View Full List](https://ichgcp.net/clinical-trials-registry/research/browse/cond_alpha_all)\n\nDrug Interventions\n------------------\n\n*   [Methylprednisolone](https://ichgcp.net/clinical-trials-registry/research/list?intr=Methylprednisolone)\n*   [Anetumab Ravtansine](https://ichgcp.net/clinical-trials-registry/research/list?intr=Anetumab%2BRavtansine)\n*   [ESES treated with clobazam](https://ichgcp.net/clinical-trials-registry/research/list?intr=ESES%2Btreated%2Bwith%2Bclobazam)\n*   [Droperidol Injectable Solution](https://ichgcp.net/clinical-trials-registry/research/list?intr=Droperidol%2BInjectable%2BSolution)\n*   [ATx201](https://ichgcp.net/clinical-trials-registry/research/list?intr=ATx201)\n*   [Cyclophosphamide](https://ichgcp.net/clinical-trials-registry/research/list?intr=Cyclophosphamide)\n*   [Pioglitazone](https://ichgcp.net/clinical-trials-registry/research/list?intr=Pioglitazone)\n*   [Botulinum Toxin A](https://ichgcp.net/clinical-trials-registry/research/list?intr=Botulinum%2BToxin%2BA)\n*   [Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Gefitinib%2B250mg%2Bpo%2Bqd%2Bor%2BTarceva%2B150mg%2Bpo%2Bqd%2Bor%2BIcotinib%2B125mg%2Bpo%2Btid%2BOther%2BName%253A%2BGefitinib%252FTarceva%252FIcotinib)\n*   [Ramosetron](https://ichgcp.net/clinical-trials-registry/research/list?intr=Ramosetron)\n*   [KN046](https://ichgcp.net/clinical-trials-registry/research/list?intr=KN046)\n*   [Doxorubicin](https://ichgcp.net/clinical-trials-registry/research/list?intr=Doxorubicin)\n*   [Corticosteroids (CS)](https://ichgcp.net/clinical-trials-registry/research/list?intr=Corticosteroids%2B%2528CS%2529)\n*   [Dimenhydrinate](https://ichgcp.net/clinical-trials-registry/research/list?intr=Dimenhydrinate)\n*   [Ropivacaine 150 mg](https://ichgcp.net/clinical-trials-registry/research/list?intr=Ropivacaine%2B150%2Bmg)\n*   [Iso-Fludelone](https://ichgcp.net/clinical-trials-registry/research/list?intr=Iso-Fludelone)\n*   [Clonidine](https://ichgcp.net/clinical-trials-registry/research/list?intr=Clonidine)\n*   [Lidocaine topical](https://ichgcp.net/clinical-trials-registry/research/list?intr=Lidocaine%2Btopical)\n*   [Nusinersen](https://ichgcp.net/clinical-trials-registry/research/list?intr=Nusinersen)\n*   [Cyclophosphamide and fludarabine](https://ichgcp.net/clinical-trials-registry/research/list?intr=Cyclophosphamide%2Band%2Bfludarabine)\n*   [View Full List](https://ichgcp.net/clinical-trials-registry/research/browse/intr_alpha_all)\n\n### CROs by country\n\n*   [Contract Research Organizations in Azerbaijan](https://ichgcp.net/cro-list/country/azerbaijan)\n*   [Contract Research Organizations in Bulgaria](https://ichgcp.net/cro-list/country/bulgaria)\n*   [Contract Research Organizations in Burundi](https://ichgcp.net/cro-list/country/burundi)\n*   [Contract Research Organizations in Dominican Republic](https://ichgcp.net/cro-list/country/dominican_republic)\n*   [Contract Research Organizations in Kosovo](https://ichgcp.net/cro-list/country/kosovo)\n*   [Contract Research Organizations in Mexico](https://ichgcp.net/cro-list/country/mexico)\n*   [Contract Research Organizations in Moldova](https://ichgcp.net/cro-list/country/moldova)\n*   [Contract Research Organizations in Poland](https://ichgcp.net/cro-list/country/poland)\n*   [Contract Research Organizations in Slovakia](https://ichgcp.net/cro-list/country/slovakia)\n*   [Contract Research Organizations in Sri Lanka](https://ichgcp.net/cro-list/country/sri_lanka)\n*   [Contract Research Organizations in Ukraine](https://ichgcp.net/cro-list/country/ukraine)\n*   [Contract Research Organizations in United Arab Emirates](https://ichgcp.net/cro-list/country/united_arab_emirates)\n*   [Contract Research Organizations in Uzbekistan](https://ichgcp.net/cro-list/country/uzbekistan)\n*   [CRO list by country](https://ichgcp.net/cro-list)\n\n### CROs in Ghana\n\n*   [54gene‚Äôs Clinical Programs Group (CPG)](https://ichgcp.net/cro-list/country/ghana/company/54gene_s_clinical_programs_group_cpg)\n*   [SGS](https://ichgcp.net/cro-list/country/ghana/company/sgs)\n*   [ACROSS Global](https://ichgcp.net/cro-list/country/ghana/company/across_global)\n*   [All CROs in Ghana](https://ichgcp.net/cro-list/country/ghana)\n\n### Conditions\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/cond_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/cond_cat)\n\n### Rare Diseases\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/ord_alpha_all)\n\n### Drug Interventions\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/intr_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/intr_cat)\n\n### Dietary Supplements\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/diet_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/diet_cat)\n\n### Sponsor/Collaborators\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/spns_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/spns_cat)\n\n### Locations\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/locn_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/locn_cat)\n\nRegulations\n\n*   [GLOBAL (ICH GCP)](https://ichgcp.net/)\n*   [USA (FDA)](https://ichgcp.net/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects)\n*   [UK (MHRA)](https://ichgcp.net/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol)\n*   [AUSTRALIA (NHMRC)](https://ichgcp.net/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia)\n*   [JAPAN (PMDA)](https://ichgcp.net/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan)\n*   [EU (EMA)](https://ichgcp.net/guideline-for-the-notification-of-serious-breaches-of-regulation-eu-no-536-2014)\n\nResources\n\n*   [CRO List](https://ichgcp.net/cro-list)\n*   [Pharmaceutical Companies](https://ichgcp.net/pharma-list)\n*   [Clinical Research Labs](https://ichgcp.net/labs)\n*   [Service Companies](https://ichgcp.net/service-companies)\n*   [Jobs](https://ichgcp.net/cra-jobs)\n*   [US Clinical Trials Registry](https://ichgcp.net/clinical-trials-registry)\n*   [EU Clinical Trials Registry](https://ichgcp.net/eu-clinical-trials-registry)\n\nArticles\n\n*   [Publications](https://ichgcp.net/publications)\n*   [News](https://ichgcp.net/news)\n*   [About us / Our mission](https://ichgcp.net/about-us-our-mission)\n\nSearch trials\n\nExample: Heart Attack\n\n¬© ICH GCP. All Rights Reserved.\n\n*   [Sitemap](https://ichgcp.net/sitemap)\n*   [Contact us](https://ichgcp.net/contact-us)\n*   [RSS feed](https://ichgcp.net/feed)\n*   [Privacy Policy](https://ichgcp.net/privacy)\n*   [Disclaimer](https://ichgcp.net/disclaimer)\n\n English \n\n[Dansk](https://ichgcp.net/da/clinical-trials-registry/NCT02838420)[Deutsch](https://ichgcp.net/de/clinical-trials-registry/NCT02838420)[English](https://ichgcp.net/clinical-trials-registry/NCT02838420)[Espa√±ol](https://ichgcp.net/es/clinical-trials-registry/NCT02838420)[Fran√ßais](https://ichgcp.net/fr/clinical-trials-registry/NCT02838420)[Italiano](https://ichgcp.net/it/clinical-trials-registry/NCT02838420)[Magyar](https://ichgcp.net/hu/clinical-trials-registry/NCT02838420)[Nederlands](https://ichgcp.net/nl/clinical-trials-registry/NCT02838420)[Norsk](https://ichgcp.net/no/clinical-trials-registry/NCT02838420)[Polski](https://ichgcp.net/pl/clinical-trials-registry/NCT02838420)[Portugu√™s](https://ichgcp.net/pt/clinical-trials-registry/NCT02838420)[Suomi](https://ichgcp.net/fi/clinical-trials-registry/NCT02838420)[Svenska](https://ichgcp.net/sv/clinical-trials-registry/NCT02838420)[ƒåe≈°tina](https://ichgcp.net/cs/clinical-trials-registry/NCT02838420)[–†—É—Å—Å–∫–∏–π](https://ichgcp.net/ru/clinical-trials-registry/NCT02838420)[Êó•Êú¨Ë™û](https://ichgcp.net/ja/clinical-trials-registry/NCT02838420)[ÁÆÄ‰Ωì‰∏≠Êñá](https://ichgcp.net/zh/clinical-trials-registry/NCT02838420)[ÌïúÍµ≠Ïñ¥](https://ichgcp.net/ko/clinical-trials-registry/NCT02838420)\n\nGOOD CLINICAL PRACTICE NETWORK\n\nSubscribe to receive notifications of new clinical trials you are interested in.\n\nSubscribe\n\n‚úï\n\nGOOD CLINICAL PRACTICE NETWORK\n\nSubscribe to receive notifications of new clinical trials you are interested in.\n\nSubscribe for upcoming trials that contain the following conditions: \n\n- [x] Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer \n\n[Choose more conditions](https://ichgcp.net/mailing-list/conditions)\n\nSubscribe for upcoming trials that contain the following interventions: \n\n- [x] Alectinib \n\n- [x] Crizotinib \n\n[Choose more interventions](https://ichgcp.net/mailing-list/interventions)\n\nSubscribe for upcoming trials sponsored by: \n\n- [x] Hoffmann-La Roche \n\n[Choose more organizations](https://ichgcp.net/mailing-list/organizations)\n\nSubscribe\n\nSubscribe\n\nSubscribe\n'}, {'type': 'page', 'title': 'Alectinib vs crizotinib in Asian patients with treatment-na√Øve ... - Roche', 'url': 'https://medically.roche.com/global/en/medical-material/ESMO-Asia-2022-presentation-zhou-alectinib-vs-crizotinib-in-asian-patients-with-treatment-naive-advanced-pdf.html', 'content': 'Data cut -off 16 May 2022. ClinicalTrials.gov: NCT02838420. CNS, central nervous system; DOR, duration of response;  ECOG PS, Eastern Cooperative Oncology Group performance status; IHC, immunohistochemistry; INV, investigator \n\nIRC, independent review committee; NSCLC, non -small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, p rogression -free survival \n\n2:1 \n\nN=187 \n\nR\n\nAlectinib \n\n600mg  twice daily \n\nCrizotinib \n\n250mg twice daily \n\nTreat until disease', 'score': 0.5393963, 'raw_content': "Alectinib vs crizotinib in Asian patients \n\n## with treatment -na√Øve advanced  ALK +\n\n## non -small cell lung cancer: 5 -year \n\n## update from the Phase 3 ALESIA study \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nFaculty of Medicine  Ramathibodi  Hospital, Mahidol University, \n\nBangkok, Thailand \n\nZhou C, 1 Lu Y, 2 Kim S -W, 3 Baisamut  (Reungwetwattana) T, 4 Zhou J, 5 Zhang Y, 6 He J, 7 Yang J -J, 8 Cheng Y, 9 Lee S -H, 10  Chang J, 11 \n\nFang J, 12  Liu Z, 13  Bu L, 14  Qian L, 14  Xu T, 14  Archer V, 15  Hilton M, 16  Zhou M, 14  Zhang L 17 \n\n1Shanghai Pulmonary Hospital, Tongji University, Shanghai, China;  2West China Hospital, Sichuan University, Chengdu, China;  3Asan Medical \n\nCenter , University of Ulsan College of Medicine, Seoul, South Korea;  4Faculty of Medicine  Ramathibodi  Hospital, Mahidol University, Bangkok, \n\nThailand;  5The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China;  6Zhejiang Cancer Hospital, Hangzhou, China; \n\n7The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;  8Guangdong Lung Cancer Institute, Guangdong General Hospital, \n\nGuangzhou, China;  9Jilin Cancer Hospital, Changchun, China;  10 Sungkyunkwan University School of Medicine, Seoul, South Korea;  11 Cancer \n\nHospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China;  12 Beijing Cancer \n\nHospital, Beijing, China;  13 Beijing Chest Hospital, Capital Medical University, Beijing, China;  14 Roche Pharma Development, Shanghai, China; \n\n15 Roche Products Ltd, Welwyn Garden City, UK;  16 F. Hoffmann -La Roche Ltd, Basel, Switzerland;  17 Sun  Yat -sen  University Cancer  Center ,\n\nState Key Laboratory of Oncology in South China, Collaborative Innovation  Center  for Cancer Medicine, Guangzhou, China Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## DECLARATION OF INTERESTS \n\nThanyanan  Baisamut  (Reungwetwattana) \n\n‚Ä¢ Received honorarium from AstraZeneca, Pfizer, MSD, Roche, BMS, Amgen, J&J, Novartis,  Yuhan  and  Zuellig \n\n‚Ä¢ Participated as Principal Investigator on clinical trials for AstraZeneca, MSD, Roche, Novartis and  Yuhan   \n\n> Thanyanan Baisamut (Reungwetwattana)\n\nContent of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## ALESIA: alectinib vs crizotinib in treatment -na√Øve Asian patients \n\n## with advanced  ALK+  NSCLC \n\n‚Ä¢ Stratification factors:  ECOG PS (0/1 vs 2) \n\nand CNS metastases at baseline (yes vs no) \n\n‚Ä¢ Primary endpoint:  PFS by INV \n\n‚Ä¢ Secondary endpoints:  Time to CNS \n\nprogression by IRC, ORR by INV, \n\nDOR by INV, OS and safety \n\n‚Ä¢ Median duration of survival follow -up: \n\n61 months  alectinib vs  51 months  crizotinib \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nPatients were enrolled from China, Thailand and South Korea. *Asymptomatic CNS metastases allowed. \n\nData cut -off 16 May 2022. ClinicalTrials.gov: NCT02838420. CNS, central nervous system; DOR, duration of response;  ECOG PS, Eastern Cooperative Oncology Group performance status; IHC, immunohistochemistry; INV, investigator \n\nIRC, independent review committee; NSCLC, non -small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, p rogression -free survival \n\n2:1 \n\nN=187 \n\nR\n\nAlectinib \n\n600mg  twice daily \n\nCrizotinib \n\n250mg twice daily \n\nTreat until disease \n\nprogression, toxicity, \n\nwithdrawal or death \n\nNo crossover permitted \n\nStage IIIB/IV  ALK + NSCLC* \n\n‚Ä¢ Asian patients \n\n‚Ä¢ Treatment na√Øve \n\n‚Ä¢ ECOG PS 0 ‚Äì2\n\n‚Ä¢ Central  ALK  testing (Ventana IHC) \n\nBaseline demographics \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nAge, years  Median (range)  51.0 (21‚àí78)  49.0 (28‚àí83) \n\nGender, %  Male / Female  51.2 / 48.8  54.8 / 45.2 \n\nECOG PS, %  0‚Äì1 / 2  96.8 / 3.2  98.4 / 1.6 \n\nSmoking status, %  Active smoker / Non -smoker / \n\nPast smoker  3.2 / 67.2 / 29.6  4.8 / 72.6 / 22.6 \n\nCNS metastases by IRC, %  Yes  35.2  37.1 \n\nCNS metastases by INV, %  Yes  33.6  32.3 \n\nPrior brain radiation, %  Yes  6.4  8.1 Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Updated analyses from ALESIA demonstrate durable PFS benefit for \n\n## alectinib versus crizotinib, irrespective of CNS involvement at baseline \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nData cut -off 16 May 2022. CI, confidence interval; CNS, central nervous system; HR, hazard ratio; ITT, intent -to -treat;  mets , metastases;  PFS, progression -free survival \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nMedian  PFS, months \n\n(95% CI) \n\n41.6 \n\n(33.1 ‚Äì58.9) \n\n11.1 \n\n(9.1 ‚Äì18.4) \n\nHR  (95% CI)  0.33  (0.23 ‚Äì0.49) \n\n0\n\n> PFS (%)\n\n6 36  66 60 54 48 42 30 24 18 12 \n\nTime (months) \n\n100 \n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\nCrizotinib (n=62) \n\nAlectinib (n=125) \n\nWith  CNS  mets  at baseline  Without  CNS  mets  at baseline \n\nAlectinib \n\nn=44 \n\nCrizotinib \n\nn=23 \n\nAlectinib \n\nn=81 \n\nCrizotinib \n\nn=39 \n\nMedian  PFS, months \n\n(95% CI) \n\n42.3 \n\n(27.8 ‚Äì60.7) \n\n9.2 \n\n(5.5 ‚Äì12.2) \n\n41.6 \n\n(29.5 ‚Äì64.9) \n\n12.7 \n\n(9.2 ‚Äì27.6) \n\nHR  (95% CI)  0.17  (0.09 ‚Äì0.33)  0.45  (0.29 ‚Äì0.71) \n\nCrizotinib (n=39) \n\nWithout  CNS  mets  at baseline \n\nAlectinib (n=81) \n\nUpdated PFS: ITT population \n\nTime (months) \n\n100 \n\n0\n\n> PFS (%)\n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\n36  66 54 18 6 60 42 30 24 12  48 \n\nCrizotinib (n=23) \n\nWith  CNS  mets  at baseline \n\nAlectinib (n=44) \n\nPFS according to CNS status at baseline Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## A clinically meaningful improvement in 5 -year OS rate was observed \n\n## for alectinib compared with crizotinib \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nData cut -off 16 May 2022. CI, confidence interval; CNS, central nervous system; HR, hazard ratio; ITT, intent -to -treat;  mets , metastases; NE, not evaluable; OS, overall survival; pts, patients \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nPts with event, n (%)  41 (32.8)  26 (41.9) \n\nMedian  OS, months \n\n(95% CI) \n\nNE \n\n(NE ‚ÄìNE) \n\nNE \n\n(45.5 ‚ÄìNE) \n\nHR  (95% CI)  0.60  (0.37 ‚Äì0.99) \n\n5-year OS rate , % \n\n(95% CI) \n\n66.4 \n\n(57.9 ‚Äì74.9) \n\n56.0 \n\n(43.0 ‚Äì69.1) \n\nPts remaining at risk, n  69  25 \n\n0\n\n> OS (%)\n\n6 36  66 60 54 48 42 30 24 18 12 \n\nTime (months) \n\n100 \n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\nCrizotinib (n=62) \n\nAlectinib (n=125) \n\nWith  CNS  mets  at baseline  Without  CNS  mets  at baseline \n\nAlectinib \n\nn=44 \n\nCrizotinib \n\nn=23 \n\nAlectinib \n\nn=81 \n\nCrizotinib \n\nn=39 \n\nPts with event, n (%)  16 (36.4)  12 (52.2)  25 (30.9)  14 (35.9) \n\nMedian  OS, months \n\n(95% CI) \n\nNE \n\n(51.4 ‚ÄìNE) \n\n46.2 \n\n(12.2 ‚ÄìNE) \n\nNE \n\n(NE ‚ÄìNE) \n\nNE \n\n(59.8 ‚ÄìNE) \n\nHR  (95% CI)  0.40  (0.19 ‚Äì0.85)  0.81  (0.42 ‚Äì1.55) \n\n5-year OS rate, % \n\n(95% CI) \n\n63.6 \n\n(48.9 ‚Äì78.3) \n\n39.3 \n\n(17.4 ‚Äì61.2) \n\n67.8 \n\n(57.4 ‚Äì78.2) \n\n64.9 \n\n(49.3 ‚Äì80.4) \n\nPts remaining at risk, n  25  6 44  19 \n\nCrizotinib (n=39) \n\nWithout  CNS  mets  at baseline \n\nAlectinib (n=81) \n\nUpdated OS: ITT population \n\nTime (months) \n\n100 \n\n0\n\n> OS (%)\n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\n36  66 54 18 6 60 42 30 24 12  48 \n\nCrizotinib (n=23) \n\nWith  CNS  mets  at baseline \n\nAlectinib (n=44) \n\nOS according to CNS status at baseline Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Treatment with alectinib delayed the time to CNS progression* \n\nThanyanan  Baisamut  (Reungwetwattana) \n\n*Derived from investigators' assessment. CNS PD = CNS Target Lesion PD per RECIST version 1.1, appearance of new CNS lesion(s ),  and/or unequivocal PD of Non -Target CNS lesion(s) \n\nData cut -off 16 May 2022. CI, confidence interval;  CIR, cumulative incidence rate;  CNS, central nervous system; HR, hazard ratio;  PD, progressive disease \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nCNS progression without prior systemic progression \n\nPatients with events, n (%)  18 (14.4)  22 (35.5) \n\nCause -specific HR  (95% CI)  0.16  (0.08 ‚Äì0.32) \n\nEstimated cumulative incidence, % (95% CI) \n\nAt 36 months  11.6 (6.7 ‚Äì18.1)  34.0 (22.1 ‚Äì46.2) \n\nAt 60 months  14.2 (8.6 ‚Äì21.1)  37.4 (25.0 ‚Äì49.7) \n\n40 \n\n0\n\n> Cumulative incidence (%)\n\n30 \n\n20 \n\n10 \n\n0 6 36  60 54 48 42 30 24 18 12 \n\nTime (months) \n\nCrizotinib (n=62) \n\nAlectinib (n=125) \n\nCIR: \n\n11.6% (95% CI 6.7 ‚Äì18.1) \n\nCIR: \n\n14.2% (95% CI 8.6 ‚Äì21.1) \n\nCIR: \n\n34.0% (95% CI 22.1 ‚Äì46.2) \n\nCIR: \n\n37.4% (95% CI 25.0 ‚Äì49.7) Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Post -progression therapy \n\nThanyanan  Baisamut  (Reungwetwattana)  \n\n> Data cut -off 16 May 2022. PD, progressive disease; VEGF, vascular endothelial growth factor\n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nPatients with PD , n  68  48 \n\nAnti -cancer therapy after PD , n (%)  42 (61.8)  38 (79.2) \n\nALK inhibitor , n (%)  25 (36.8)  28 (58.3) \n\nAlectinib  5 (7.4)  14 (29.2) \n\nLorlatinib  8 (11.8)  6 (12.5) \n\nBrigatinib  6 (8.8)  7 (14.6) \n\nCrizotinib  7 (10.3)  2 (4.2) \n\nCeritinib  3 (4.4)  4 (8.3) \n\nEnsartinib  2 (2.9)  1 (2.1) \n\nInvestigational drug  1 (1.5)  0\n\nChemotherapy , n (%)  24 (35.3)  15 (31.3) \n\nAnti -VEGF therapies , n ( %Ôºâ 9 (13.2)  3 (6.3) \n\nImmunotherapy , n (%)  3 (4.4)  2 (4.2) \n\nOther therapies , n (%)  6 (8.8)  7 (14.6) \n\nMore crizotinib patients (79.2% vs 61.8% alectinib) received at least one anti -cancer therapy post -progression \n\nApproximately 30% of patients in the crizotinib arm received alectinib after their disease progressed Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## The safety profile of alectinib remained favourable with longer \n\n## follow -up; no new safety signals were observed \n\nThanyanan  Baisamut  (Reungwetwattana) \n\n> *Three additional fatal events occurred during the longer follow -up: one was due to COVID -19 pneumonia, and the other two were r eported as ‚Äòdeath‚Äô and not related to alectinib treatment\n> Data cut -off 16 May 2022. AE, adverse event; ALT, alanine aminotransferase; ECG, electrocardiogram\n\nEvent, n  (%) \n\nAlectinib \n\n(n=125) \n\nCrizotinib \n\n(n=62) \n\nPatients with ‚â•1 \n\nAll grade AEs  125 (100)  62 (100) \n\nSerious AEs  35 (28.0)  18 (29.0) \n\nGrade ‚â•3 AEs  60 (48.0)  34 (54.8) \n\nFatal AEs  5 (4.0)*  3 (4.8) \n\nAEs leading to treatment discontinuation  14 (11.2)  9 (14.5) \n\nAEs leading to dose reduction  33 (26.4)  17 (27.4) \n\nAEs leading to dose interruption  33 (26.4)  19 (30.6) \n\nGrade ‚â•3 AEs with ‚â•3% difference \n\nin frequency between treatment arms, n  (%) \n\nAlectinib \n\n(n=125) \n\nCrizotinib \n\n(n=62) \n\nWeight increased  11 (8.8)  1 (1.6) \n\nBlood creatine phosphokinase increased  8 (6.4)  2 (3.2) \n\nALT increased  3 (2.4)  4 (6.5) \n\nNausea  1 (0.8)  3 (4.8) \n\nNeutrophil count decreased  0 9 (14.5) \n\nECG QT prolonged  0 3 (4.8) \n\nWhite blood cell count decreased  0 3 (4.8) \n\nDecreased appetite  0 3 (4.8) \n\nHyponatraemia  0 3 (4.8) \n\nInterstitial lung disease  0 3 (4.8) \n\nVomiting  0 3 (4.8) \n\nBradycardia  0 2 (3.2) \n\nHepatic function abnormal  0 2 (3.2) \n\nMedian treatment duration was more than three -times greater for alectinib (42.3 months) \n\ncompared to crizotinib (12.6 months) Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Conclusions:  5-year update from the Phase 3 ALESIA study   \n\n> Thanyanan Baisamut (Reungwetwattana )\n\nWith  at least 5 years  of follow -up, 1L alectinib  600mg twice daily  continues \n\nto demonstrate clinical benefit to Asian patients with advanced  ALK+  NSCLC, \n\nconsistent with  that observed in the  global ALEX study \n\nTreatment with alectinib also delayed the time to CNS progression \n\nThis clinical benefit, coupled with a tolerable and manageable safety profile, \n\nconfirms alectinib as standard -of -care treatment \n\nfor patients with advanced  ALK+  NSCLC Acknowledgements \n\nWe thank the participating patients and their families, study investigators, and research nurses \n\nThe ALESIA study was funded by F. Hoffmann -La Roche Ltd \n\nMedical writing support for the development of this presentation, under the direction \n\nof the authors, was provided by Fiona Duthie, PhD, of Ashfield MedComms, \n\nan Inizio company, and was funded by F. Hoffmann -La Roche Ltd\n"}, {'type': 'image', 'image_url': 'https://www.umc.edu/Research/Centers-and-Institutes/External-Designation-Centers/Mississippi-Poison-Control-Center/images/Medication-Label-1-A-E.jpg', 'image_description': 'The document outlines the drug facts of a medication, including its active ingredient, purposes such as pain relief and fever reduction, specific uses, warnings about allergic reactions and stomach bleeding, and instructions for use.'}, {'type': 'image', 'image_url': 'https://images.ctfassets.net/gi8mrztylj0k/7uYtc358SoGmfbZJwSffV4/4a6b40b9f5e3f8e7fea16ea0a96f143a/pasted_image_0__10_.png', 'image_description': 'The contents list various classes of food ingredients along with their definitions and requirements for labeling, including edible oils, fats, fish, meat, cheese, spices, and gums.'}, {'type': 'image', 'image_url': 'https://images.ctfassets.net/gi8mrztylj0k/2SwoBWSwLlal4WhyRZp7mK/424ea61f0461de8a7b51935a15fc5019/pasted_image_0__11_.png', 'image_description': 'A table listing various food and ingredient classes along with their respective class titles.'}, {'type': 'image', 'image_url': 'https://i.etsystatic.com/16874044/r/il/a74daa/3750620251/il_fullxfull.3750620251_8kd8.jpg', 'image_description': 'A list of ingredients includes Cocoa Mass, Cocoa Butter, and Milk, among others.'}, {'type': 'image', 'image_url': 'https://7esl.com/wp-content/uploads/2021/03/Foods-starting-with-r-scaled.jpg', 'image_description': 'A poster of foods that start with the letter R.'}], {'query': '"For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter \'C\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name."', 'follow_up_questions': None, 'answer': None, 'images': [{'url': 'https://www.umc.edu/Research/Centers-and-Institutes/External-Designation-Centers/Mississippi-Poison-Control-Center/images/Medication-Label-1-A-E.jpg', 'description': 'The document outlines the drug facts of a medication, including its active ingredient, purposes such as pain relief and fever reduction, specific uses, warnings about allergic reactions and stomach bleeding, and instructions for use.'}, {'url': 'https://images.ctfassets.net/gi8mrztylj0k/7uYtc358SoGmfbZJwSffV4/4a6b40b9f5e3f8e7fea16ea0a96f143a/pasted_image_0__10_.png', 'description': 'The contents list various classes of food ingredients along with their definitions and requirements for labeling, including edible oils, fats, fish, meat, cheese, spices, and gums.'}, {'url': 'https://images.ctfassets.net/gi8mrztylj0k/2SwoBWSwLlal4WhyRZp7mK/424ea61f0461de8a7b51935a15fc5019/pasted_image_0__11_.png', 'description': 'A table listing various food and ingredient classes along with their respective class titles.'}, {'url': 'https://i.etsystatic.com/16874044/r/il/a74daa/3750620251/il_fullxfull.3750620251_8kd8.jpg', 'description': 'A list of ingredients includes Cocoa Mass, Cocoa Butter, and Milk, among others.'}, {'url': 'https://7esl.com/wp-content/uploads/2021/03/Foods-starting-with-r-scaled.jpg', 'description': 'A poster of foods that start with the letter R.'}], 'results': [{'url': 'https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp', 'title': 'AIM-Harvard/MedBrowseComp ¬∑ Datasets at Hugging Face', 'content': '| CRIZOTINIB | "For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter \'C\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient | [...] | PF PRISM CV | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name | [...] | May 12, 2027 | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |', 'score': 0.92684203, 'raw_content': 'AIM-Harvard/MedBrowseComp ¬∑ Datasets at Hugging Face\n\n===============\n\n[![Image 1: Hugging Face\'s logo](https://huggingface.co/front/assets/huggingface_logo-noborder.svg)Hugging Face](https://huggingface.co/)\n\n*   [Models](https://huggingface.co/models)\n*   [Datasets](https://huggingface.co/datasets)\n*   [Spaces](https://huggingface.co/spaces)\n*    Community  \n*   [Docs](https://huggingface.co/docs)\n*   [Enterprise](https://huggingface.co/enterprise)\n*   [Pricing](https://huggingface.co/pricing)\n*    \n*   \n* * *\n\n*   [Log In](https://huggingface.co/login)\n*   [Sign Up](https://huggingface.co/join)\n\n[Datasets:](https://huggingface.co/datasets)\n\n* * *\n\n[![Image 2](https://cdn-avatars.huggingface.co/v1/production/uploads/63600b93d9e4214b9a67807c/ZRnXCRmf600I8gTKJH-V0.png)](https://huggingface.co/AIM-Harvard)\n\n[AIM-Harvard](https://huggingface.co/AIM-Harvard)\n\n/\n\n[MedBrowseComp](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp)\n\nlike 1\n\nFollow\n\n![Image 3](https://cdn-avatars.huggingface.co/v1/production/uploads/63600b93d9e4214b9a67807c/ZRnXCRmf600I8gTKJH-V0.png)AIM-Harvard 23\n===================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================\n\nTasks: [Question Answering](https://huggingface.co/datasets?task_categories=task_categories%3Aquestion-answering)[Text Retrieval](https://huggingface.co/datasets?task_categories=task_categories%3Atext-retrieval)\n\nModalities: [Text](https://huggingface.co/datasets?modality=modality%3Atext)\n\nFormats: [csv](https://huggingface.co/datasets?format=format%3Acsv)\n\nLanguages: [English](https://huggingface.co/datasets?language=language%3Aen)\n\nSize: [1K - 10K](https://huggingface.co/datasets?size_categories=size_categories%3A1K%3Cn%3C10K)\n\nArXiv: \n\narxiv:2505.14963\n\nTags: [medical](https://huggingface.co/datasets?other=medical)[healthcare](https://huggingface.co/datasets?other=healthcare)[browsing](https://huggingface.co/datasets?other=browsing)[comparison](https://huggingface.co/datasets?other=comparison)\n\nLibraries: [Datasets](https://huggingface.co/datasets?library=library%3Adatasets)[pandas](https://huggingface.co/datasets?library=library%3Apandas)\n\nCroissant\n\n+ 1\n\nLicense: \n\napache-2.0\n\n[Dataset card](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp)[Data Studio](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/viewer/)[Files Files and versions](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/tree/main)[Community 1](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/discussions)\n\nDataset Viewer\n\n[Auto-converted to Parquet](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/tree/refs%2Fconvert%2Fparquet/default)API Embed Data Studio\n\nSubset (1)\n\ndefault¬∑1.14k rows\n\n \n\nSplit (3)\n\nMedBrowseComp_50¬∑50 rows\n\n \n\nSQL \n\n Console \n\n| gold string lengths 5 24 | prompt string lengths 227 657 | task_name string classes 5 values |\n| --- | --- | --- |\n| ENZALUTAMIDE | "For clinical trial NCT00974311. Among the more effective regimen ingredients, find which ingredient starts with the letter \'E\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| CRIZOTINIB | "For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter \'C\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| LENALIDOMIDE | "For clinical trial NCT01938001. Among the more effective regimen ingredients, find which ingredient starts with the letter \'L\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| AZACITIDINE | "For clinical trial NCT00071799. Among the more effective regimen ingredients, find which ingredient starts with the letter \'A\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| IRINOTECAN HYDROCHLORIDE | "For clinical trial NCT00720512. Among the more effective regimen ingredients, find which ingredient starts with the letter \'I\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| VENETOCLAX | "For clinical trial NCT02755597. Among the more effective regimen ingredients, find which ingredient starts with the letter \'V\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| DEXAMETHASONE | "For clinical trial NCT00833833. Among the more effective regimen ingredients, find which ingredient starts with the letter \'D\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| IBRUTINIB | "For clinical trial NCT01973387. Among the more effective regimen ingredients, find which ingredient starts with the letter \'I\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| LENALIDOMIDE | "For clinical trial NCT00843882. Among the more effective regimen ingredients, find which ingredient starts with the letter \'L\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| SIROLIMUS | "For clinical trial NCT01231412. Among the more effective regimen ingredients, find which ingredient starts with the letter \'S\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| ASTELLAS | "First, for clinical trial NCT00974311, among the more effective regimen ingredients, identify which ingredient starts with the letter \'E\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| PF PRISM CV | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| BRISTOL MYERS SQUIBB | "First, for clinical trial NCT01938001, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| BRISTOL | "First, for clinical trial NCT00071799, among the more effective regimen ingredients, identify which ingredient starts with the letter \'A\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| IPSEN | "First, for clinical trial NCT00720512, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| ABBVIE | "First, for clinical trial NCT02755597, among the more effective regimen ingredients, identify which ingredient starts with the letter \'V\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| DEXCEL | "First, for clinical trial NCT00833833, among the more effective regimen ingredients, identify which ingredient starts with the letter \'D\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| PHARMACYCLICS LLC | "First, for clinical trial NCT01973387, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| BRISTOL MYERS SQUIBB | "First, for clinical trial NCT00843882, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| AADI SUB | "First, for clinical trial NCT01231412, among the more effective regimen ingredients, identify which ingredient starts with the letter \'S\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| Aug 13, 2027 | "First, for clinical trial NCT00974311, among the more effective regimen ingredients, identify which ingredient starts with the letter \'E\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| May 12, 2027 | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Apr 27, 2027 | "First, for clinical trial NCT01938001, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| May 14, 2029 | "First, for clinical trial NCT00071799, among the more effective regimen ingredients, identify which ingredient starts with the letter \'A\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Jan 6, 2027 | "First, for clinical trial NCT00720512, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Jan 29, 2032 | "First, for clinical trial NCT02755597, among the more effective regimen ingredients, identify which ingredient starts with the letter \'V\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Dec 18, 2037 | "First, for clinical trial NCT00833833, among the more effective regimen ingredients, identify which ingredient starts with the letter \'D\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Dec 3, 2031 | "First, for clinical trial NCT01973387, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Apr 27, 2027 | "First, for clinical trial NCT00843882, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Mar 5, 2036 | "First, for clinical trial NCT01231412, among the more effective regimen ingredients, identify which ingredient starts with the letter \'S\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Nov 17, 2026 | "For clinical trial NCT00974311, among the more effective regimen ingredients, identify which ingredient starts with the letter \'E\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Jul 14, 2025 | "For clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| May 28, 2026 | "For clinical trial NCT01938001, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Sep 1, 2027 | "For clinical trial NCT00071799, among the more effective regimen ingredients, identify which ingredient starts with the letter \'A\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Feb 13, 2031 | "For clinical trial NCT00720512, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| May 15, 2026 | "For clinical trial NCT02755597, among the more effective regimen ingredients, identify which ingredient starts with the letter \'V\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Oct 3, 2026 | "For clinical trial NCT00833833, among the more effective regimen ingredients, identify which ingredient starts with the letter \'D\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Aug 24, 2029 | "For clinical trial NCT01973387, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| May 28, 2026 | "For clinical trial NCT00843882, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Nov 22, 2028 | "For clinical trial NCT01231412, among the more effective regimen ingredients, identify which ingredient starts with the letter \'S\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| 15.98999977 | "For clinical trial NCT00974311, review the more effective regimen ingredients and identify which ingredient starts with the letter \'E\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 34.47000122 | "For clinical trial NCT02838420, review the less effective regimen ingredients and identify which ingredient starts with the letter \'C\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 46.72999954 | "For clinical trial NCT01938001, review the more effective regimen ingredients and identify which ingredient starts with the letter \'L\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 62.20000076 | "For clinical trial NCT00071799, review the more effective regimen ingredients and identify which ingredient starts with the letter \'A\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 15.14000034 | "For clinical trial NCT00720512, review the more effective regimen ingredients and identify which ingredient starts with the letter \'I\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 58.59000015 | "For clinical trial NCT02755597, review the more effective regimen ingredients and identify which ingredient starts with the letter \'V\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| NOT LISTED | "For clinical trial NCT00833833, review the more effective regimen ingredients and identify which ingredient starts with the letter \'D\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| NOT LISTED | "For clinical trial NCT01973387, review the more effective regimen ingredients and identify which ingredient starts with the letter \'I\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 46.72999954 | "For clinical trial NCT00843882, review the more effective regimen ingredients and identify which ingredient starts with the letter \'L\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 39.84000015 | "For clinical trial NCT01231412, review the more effective regimen ingredients and identify which ingredient starts with the letter \'S\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n\n*   [Datasets](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#datasets "Datasets")\n\n*   [Usage](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#usage "Usage")\n\n*   [GitHub Repository](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#github-repository "GitHub Repository")\n\n*   [Citation](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#citation "Citation")\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#medbrowsecomp-dataset) MedBrowseComp Dataset\n=========================================================================================================\n\nThis repository contains datasets for medical information-seeking-oriented deep research and computer use tasks.\n\n[![Image 4: Overall](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/resolve/main/medcomp.png)](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/blob/main/medcomp.png)\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#datasets) Datasets\n-------------------------------------------------------------------------------\n\nThe repository contains three harmonized datasets:\n\n1.   **MedBrowseComp_50**: A collection of 50 medical entries for browsing and comparison.\n2.   **MedBrowseComp_605**: A comprehensive collection of 605 medical entries.\n3.   **MedBrowseComp_CUA**: A curated collection of medical data for comparison and analysis.\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#usage) Usage\n-------------------------------------------------------------------------\n\nThese datasets can be used for various medical text processing tasks, information retrieval, and comparative analysis.\n\nExample usage with the Hugging Face datasets library:\n\n```python\nfrom datasets import load_dataset\n\n# Load the dataset\ndataset = load_dataset("AIM-Harvard/MedBrowseComp")\n\n# Access specific splits\nmed50_data = dataset["MedBrowseComp_50"]\nmed605_data = dataset["MedBrowseComp_605"]\ncua_data = dataset["MedBrowseComp_CUA"]\n```\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#github-repository) GitHub Repository\n-------------------------------------------------------------------------------------------------\n\nFor more information and related tools, visit: [https://github.com/MedBrowseComp](https://github.com/MedBrowseComp)\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#citation) Citation\n-------------------------------------------------------------------------------\n\nIf you use this dataset in your research, please cite: [https://arxiv.org/abs/2505.14963](https://arxiv.org/abs/2505.14963)\n\n```\n@misc{chen2025medbrowsecompbenchmarkingmedicaldeep,\n      title={MedBrowseComp: Benchmarking Medical Deep Research and Computer Use}, \n      author={Shan Chen and Pedro Moreira and Yuxin Xiao and Sam Schmidgall and Jeremy Warner and Hugo Aerts and Thomas Hartvigsen and Jack Gallifant and Danielle S. Bitterman},\n      year={2025},\n      eprint={2505.14963},\n      archivePrefix={arXiv},\n      primaryClass={cs.CL},\n      url={https://arxiv.org/abs/2505.14963}, \n}\n```\n\nDownloads last month 179\n\n Use this dataset \n\nSize of downloaded dataset files: 448 kB[Size of the auto-converted Parquet files: 58 kB](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/tree/refs%2Fconvert%2Fparquet/)Number of rows: 1,139\n\nCollection including AIM-Harvard/MedBrowseComp\n----------------------------------------------\n\n[#### MedBrowseComp Collection MedBrowseComp: Benchmarking Medical Deep Research and Computer Use‚Ä¢ 3 items‚Ä¢ Updated 10 days ago](https://huggingface.co/collections/AIM-Harvard/medbrowsecomp-6822637df90521b5d8b8b23f)\n\n System theme \n\nCompany\n\n[TOS](https://huggingface.co/terms-of-service)[Privacy](https://huggingface.co/privacy)[About](https://huggingface.co/huggingface)[Jobs](https://apply.workable.com/huggingface/)[](https://huggingface.co/)\n\nWebsite\n\n[Models](https://huggingface.co/models)[Datasets](https://huggingface.co/datasets)[Spaces](https://huggingface.co/spaces)[Pricing](https://huggingface.co/pricing)[Docs](https://huggingface.co/docs)\n'}, {'title': 'Alectinib and Crizotinib in Anaplastic Lymphoma Kinase-positive Non ...', 'url': 'https://ichgcp.net/clinical-trials-registry/NCT02838420', 'content': 'USA (FDA)\n       UK (MHRA)\n       AUSTRALIA (NHMRC)\n       JAPAN (PMDA)\n       EU (EMA)\n\n   CRO List\n   Clinical Trials\n\n       US Clinical Trials Registry\n       EU Clinical Trials Registry\n       Pharmaceutical Companies\n       Clinical Research Labs\n       Service Companies\n       Clinical Research Events\n       Publications\n       Researchers\n\n   Jobs\n   Publications\n   News\n\n   \n   \n\n   ICH GCP\n   US Clinical Trials Registry\n   Clinical Trial NCT02838420', 'score': 0.54724693, 'raw_content': 'Published Time: 2022-12-12T02:32:10+00:00\n\nAlectinib and Crizotinib in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer - Clinical Trials Registry - ICH GCP\n\n===============\n\n[![Image 1: ICHGCP](https://ichgcp.net/img/ichgcp_logo.png)](https://ichgcp.net/)\n\n*   Regulations\n\n    *   [GLOBAL¬ª](https://ichgcp.net/clinical-trials-registry/NCT02838420#)\n\n        *   [ICH GCP (De)](https://ichgcp.net/de)\n        *   [ICH GCP (En)](https://ichgcp.net/)\n        *   [ICH GCP (Es)](https://ichgcp.net/es)\n        *   [ICH GCP (Fr)](https://ichgcp.net/fr)\n        *   [ICH GCP (It)](https://ichgcp.net/it)\n        *   [ICH GCP (Pt)](https://ichgcp.net/pt)\n        *   [ICH GCP (Ru)](https://ichgcp.net/ru)\n\n    *   [USA (FDA)](https://ichgcp.net/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects)\n    *   [UK (MHRA)](https://ichgcp.net/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol)\n    *   [AUSTRALIA (NHMRC)](https://ichgcp.net/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia)\n    *   [JAPAN (PMDA)](https://ichgcp.net/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan)\n    *   [EU (EMA)](https://ichgcp.net/ich-e-group-of-guidelines)\n\n*   [CRO List](https://ichgcp.net/cro-list)\n*   Clinical Trials\n\n    *   [US Clinical Trials Registry](https://ichgcp.net/clinical-trials-registry)\n    *   [EU Clinical Trials Registry](https://ichgcp.net/eu-clinical-trials-registry)\n    *   [Pharmaceutical Companies](https://ichgcp.net/pharma-list)\n    *   [Clinical Research Labs](https://ichgcp.net/labs)\n    *   [Service Companies](https://ichgcp.net/service-companies)\n    *   [Clinical Research Events](https://ichgcp.net/events)\n    *   [Publications](https://ichgcp.net/clinical-trials-registry/publications)\n    *   [Researchers](https://ichgcp.net/clinical-trials-registry/researchers)\n\n*   [Jobs](https://ichgcp.net/jobs)\n*   [Publications](https://ichgcp.net/publications)\n*   [News](https://ichgcp.net/news)\n\n*   [](https://telegram.me/share/url?url=https://ichgcp.net/clinical-trials-registry/NCT02838420&text= "Share on telegram")\n*   [](https://twitter.com/intent/tweet?url=https://ichgcp.net/clinical-trials-registry/NCT02838420 "Share on Twitter")\n\n*   [ICH GCP](https://ichgcp.net/)\n*   [US Clinical Trials Registry](https://ichgcp.net/clinical-trials-registry)\n*   Clinical Trial NCT02838420\n\nA Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)\n=========================================================================================================================================================================================================================================================================\n\nMarch 24, 2025 updated by: [Hoffmann-La Roche](https://ichgcp.net/clinical-trials-registry/research/list?spons=Hoffmann-La%20Roche "List all studies sponsored by Hoffmann-La Roche")\n\nRandomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Asian Patients With Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer\n--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\nThis randomized, multicenter, Phase III, open-label study will evaluate the efficacy and safety of alectinib versus crizotinib and to evaluate the pharmacokinetics of alectinib in asian participants with treatment-naive ALK-positive advanced NSCLC. Participants will be randomized 2:1 into one of the two treatment groups to receive either alectinib (600 milligrams [mg] twice daily [BID]) or crizotinib (250 mg BID) orally, respectively.\n\nStudy Overview\n--------------\n\n#### Status\n\nActive, not recruiting\n\n#### Conditions\n\n*   [Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%20Lymphoma%20Kinase-positive%20Non-small%20Cell%20Lung%20Cancer "List all studies focused on condition Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer")\n\n#### Intervention / Treatment\n\n*   [Drug: Alectinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Alectinib "List all studies with intervention Alectinib")\n*   [Drug: Crizotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Crizotinib "List all studies with intervention Crizotinib")\n\n#### Study Type\n\n Interventional \n\n#### Enrollment (Actual)\n\n 187 \n\n#### Phase\n\n*   Phase 3\n\nContacts and Locations\n----------------------\n\nThis section provides the contact details for those conducting the study, and information on where this study is being conducted.\n\n### Study Locations\n\n*   [China](https://ichgcp.net/clinical-trials-registry/research/list?locn=China "List all studies conducted in China") \n    *           *   Beijing, China, 100142 \n            *   Beijing Cancer Hospital\n\n        *   Beijing, China, 101149 \n            *   Beijing Chest Hospital\n\n        *   Changchun, China, 130021 \n            *   The First Hospital of Jilin University\n\n        *   Changchun, China, 132013 \n            *   Jilin cancer hospital\n\n        *   Chengdu, China, 610041 \n            *   West China Hospital, Sichuan University\n\n        *   Guangzhou, China, 510060 \n            *   Sun Yet-sen University Cancer Center\n\n        *   Guangzhou, China, 510080 \n            *   Guangdong General Hospital\n\n        *   Guangzhou, China, 510120 \n            *   The First Affiliated Hospital of Guangzhou Medical University\n\n        *   Hangzhou, China, 310003 \n            *   The First Affiliated Hospital of College of Medicine, Zhejiang University\n\n        *   Hangzhou, China, 310022 \n            *   Zhejiang Cancer Hospital\n\n        *   Harbin, China, 150081 \n            *   Harbin Medical University Cancer Hospital\n\n        *   Nanjing, China, 210009 \n            *   Jiangsu Cancer Hospital\n\n        *   Shanghai, China, 200030 \n            *   Shanghai Chest Hospital\n\n        *   Shanghai, China, 200032 \n            *   Fudan University Shanghai Cancer Center\n\n        *   Shanghai, China, 200433 \n            *   Shanghai Pulmonary Hospital\n\n*   [Korea, Republic of](https://ichgcp.net/clinical-trials-registry/research/list?locn=Korea%2C%20Republic%20of "List all studies conducted in Korea, Republic of") \n    *           *   Seoul, Korea, Republic of, 05505 \n            *   Asan Medical Center\n\n        *   Seoul, Korea, Republic of, 06351 \n            *   Samsung Medical Center\n\n        *   Seoul, Korea, Republic of, 03181 \n            *   Kangbuk Samsung Hospital\n\n*   [Thailand](https://ichgcp.net/clinical-trials-registry/research/list?locn=Thailand "List all studies conducted in Thailand") \n    *           *   Bangkok, Thailand, 10400 \n            *   Rajavithi Hospital\n\n        *   Bangkok, Thailand, 10400 \n            *   Ramathibodi Hospital\n\n        *   Songkhla, Thailand, 90110 \n            *   Songklanagarind hospital\n\nParticipation Criteria\n----------------------\n\nResearchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person\'s general health condition or prior treatments.\n\n### Eligibility Criteria\n\n#### Ages Eligible for Study\n\n 18 years and older (Adult, Older Adult) \n\n#### Accepts Healthy Volunteers\n\n No \n\n#### Description\n\nInclusion Criteria:\n\n*   Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive as assessed by the Ventana immunohistochemistry (IHC) test. Sufficient tumor tissue available to perform ALK IHC is required. Ventana IHC testing will be performed at the designated central laboratory\n*   Life expectancy of at least 12 weeks\n*   Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2\n*   No history of receiving systemic treatment for advanced, recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC\n*   Adequate hematologic function: Platelet count greater than equal to (>=) 100√ó10^9 per liter (/L); absolute neutrophil count (ANC) >=1500 cells per microliter (cells/mcL); hemoglobin>=9.0 grams per deciliter (g/dL)\n*   Adequate renal function: an estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease (MDRD) formula of >=45 milliliters per minute per 1.73 square meter\n*   Participants must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before receiving the first dose of study treatment\n*   Measurable disease (by Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v1.1]) before administration of study treatment\n*   Previous brain or leptomeningeal metastases are allowed if the participant is asymptomatic (e.g., diagnosed incidentally at study baseline). Asymptomatic central nervous system (CNS) lesions may be treated at the discretion of the investigator as per local clinical practice. If participant has neurological symptoms or signs because of CNS metastasis, the participant must complete whole-brain radiation or gamma knife irradiation treatment. In all cases, radiation treatment must be completed >=14 days before enrollment and disease must be clinically stable\n*   For all females of childbearing potential, a negative serum pregnancy test result must be obtained within 3 days prior to starting study treatment\n*   For women who are not postmenopausal (>=12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus), agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Examples of contraceptive methods with a failure rate of <1% per year include tubal ligation, male sterilization, hormonal implants, established, proper use of combined oral or injected hormonal contraceptives, and certain intrauterine devices. Alternatively, two methods (e.g., two barrier methods such as a condom and a cervical cap) may be combined to achieve a failure rate of <1% per year. Barrier methods must always be supplemented with the use of a spermicide\n*   For men, agreement to remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception\n\nExclusion Criteria:\n\n*   A malignancy within the previous 3 years (other than curatively treated basal cell carcinoma of the skin, early gastrointestinal (GI) cancer by endoscopic resection, in situ carcinoma of the cervix, or any cured cancer that is considered to have no impact in progression-free survival (PFS) or overall survival (OS) for the current NSCLC)\n*   Any GI disorder that may affect absorption of oral medications, such as malabsorption syndrome or status post-major bowel resection\n*   Liver disease characterized by:\n*   Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than (>) 3√ó the upper limit of normal (ULN; >=5√óULN for participants with concurrent liver metastases) confirmed on two consecutive measurements; or\n*   Impaired excretory function (e.g., hyperbilirubinemia), synthetic function, or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices; or\n*   Acute viral or active autoimmune, alcoholic, or other types of hepatitis\n*   National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 Grade 3 or higher toxicities because of any previous therapy (e.g., radiotherapy) (excluding alopecia), which have not shown improvement and are strictly considered to interfere with current study medication\n*   History of organ transplant\n*   Co-administration of anti-cancer therapies other than those administered in this study\n*   Baseline QTc >470 ms or symptomatic bradycardia\n*   Administration of strong/potent cytochrome P4503A inhibitors or inducers within 14 days prior to the receiving the first dose of study treatment and during treatment with alectinib or crizotinib\n*   Administration of agents with potential QT interval prolonging effects within 14 days prior to receiving the first dose of study drug\n*   History of hypersensitivity to any of the additives in the alectinib or crizotinib drug formulation\n*   Pregnant or lactating\n*   Known human immunodeficiency virus (HIV-positivity or acquired immunodeficiency syndrome (AIDS)-related illness\n*   Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or the absorption of oral medications or that would, in the opinion of the Principal Investigator, pose an unacceptable risk to the participant in this study\n*   Any psychological, familial, sociological, or geographical condition that potentially hampers compliance with the study protocol requirements or follow-up procedures; those conditions should be discussed with the participant before study entry\n\nStudy Plan\n----------\n\nThis section provides details of the study plan, including how the study is designed and what the study is measuring.\n\n### How is the study designed?\n\n#### Design Details\n\n*   **Primary Purpose**: Treatment\n*   **Allocation**: Randomized\n*   **Interventional Model**: Parallel Assignment\n*   **Masking**: None (Open Label)\n\n#### Number of Arms\n\n2\n\n#### Arms and Interventions\n\n| ##### Participant Group / Arm | ##### Intervention / Treatment |\n| --- | --- |\n| Experimental: Alectinib Participants will receive alectinib capsules orally at a dose of 600 mg BID with food until disease progression, unacceptable toxicity withdrawal of consent, or death. | [Drug: Alectinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Alectinib "List all studies with intervention Alectinib") Alectinib capsules will be administered orally at a dose of 600 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death. Other Names: * RO5424802 |\n| Active Comparator: Crizotinib Participants will receive crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity withdrawal of consent, or death. | [Drug: Crizotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Crizotinib "List all studies with intervention Crizotinib") Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death. |\n\n### What is the study measuring?\n\n#### Primary Outcome Measures\n\n| ##### Outcome Measure | ##### Measure Description | ##### Time Frame |\n| --- | --- | --- |\n| Progression-Free Survival (PFS) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 Time Frame: From the date of randomization to the date of the first documented disease progression or death, whichever occurred first (up to overall period of approximately 40 months) | PFS was defined as the time (in months) from randomization to the first documentation of disease progression, as determined by the investigators, or to death from any cause, whichever occurred first. | From the date of randomization to the date of the first documented disease progression or death, whichever occurred first (up to overall period of approximately 40 months) |\n\n#### Secondary Outcome Measures\n\n| ##### Outcome Measure | ##### Measure Description | ##### Time Frame |\n| --- | --- | --- |\n| PFS as Determined by Independent Review Committee (IRC) Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) | PFS was defined as the time (in months) from randomization to the first documentation of disease progression, as determined by an independent review committee, or to death from any cause, whichever occurred first. | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Percentage of Participants With Objective Response of Complete Response (CR) or Partial Response (PR) as Determined by Investigator Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Time to Progression of Disease in the CNS as Determined by IRC Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Time to Progression of Disease in the CNS as Determined by IRC Using Response Assessment in Neuro-Oncology (RANO) Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Duration of Response (DOR) Assessed by Investigator Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Overall Survival Time Time Frame: Baseline, until death (up to overall period of approximately 40 months) |  | Baseline, until death (up to overall period of approximately 40 months) |\n| Percentage of Participants With Non-serious Adverse Events and Serious Adverse Events Time Frame: Up to overall period of approximately 40 months | An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. | Up to overall period of approximately 40 months |\n| Time to Deterioration Assessed Using EORTC Quality of Life Questionnaire-Core (QLQ-C30) Score Time Frame: Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Time to Deterioration Assessed Using EORTC Quality of Life Questionnaire-Lung Cancer Module (QLQ-LC13) Score Time Frame: Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Area Under the Plasma Concentration-time Curve (AUC) of Alectinib and Its Metabolite Time Frame: Baseline and Week 4 predose (within 2 hours before administration of study drug) | AUC was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time. | Baseline and Week 4 predose (within 2 hours before administration of study drug) |\n| Maximum Plasma Concentration Observed (Cmax) of Alectinib and Its Metabolite Time Frame: Baseline and Week 4 predose (within 2 hours before administration of study drug) | Cmax was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time. | Baseline and Week 4 predose (within 2 hours before administration of study drug) |\n| Time to Cmax (Tmax) of Alectinib and Its Metabolite Time Frame: Baseline and Week 4 predose (within 2 hours before administration of study drug) | Tmax was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time. | Baseline and Week 4 predose (within 2 hours before administration of study drug) |\n\nCollaborators and Investigators\n-------------------------------\n\nThis is where you will find people and organizations involved with this study.\n\n#### Sponsor\n\n[Hoffmann-La Roche](https://ichgcp.net/clinical-trials-registry/research/list?spons=Hoffmann-La%20Roche "List all studies sponsored by Hoffmann-La Roche")\n\n#### Investigators\n\n*    Study Director: Clinical Trials, Hoffmann-La Roche \n\nPublications and helpful links\n------------------------------\n\nThe person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.\n\n#### General Publications\n\n*   [Zhou C, Kim SW, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang JJ, Cheng Y, Lee SH, Bu L, Xu T, Yang L, Wang C, Liu T, Morcos PN, Lu Y, Zhang L. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med. 2019 May;7(5):437-446. doi: 10.1016/S2213-2600(19)30053-0. Epub 2019 Apr 10.](https://pubmed.ncbi.nlm.nih.gov/30981696)\n\nStudy record dates\n------------------\n\nThese dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.\n\n### Study Major Dates\n\n#### Study Start (Actual)\n\n August 3, 2016 \n\n#### Primary Completion (Actual)\n\n May 31, 2018 \n\n#### Study Completion (Estimated)\n\n December 31, 2025 \n\n### Study Registration Dates\n\n#### First Submitted\n\nJuly 18, 2016\n\n#### First Submitted That Met QC Criteria\n\nJuly 18, 2016\n\n#### First Posted (Estimated)\n\nJuly 20, 2016\n\n### Study Record Updates\n\n#### Last Update Posted (Actual)\n\nMarch 25, 2025\n\n#### Last Update Submitted That Met QC Criteria\n\nMarch 24, 2025\n\n#### Last Verified\n\nMarch 1, 2025\n\nMore Information\n----------------\n\n### Terms related to this study\n\n#### Additional Relevant MeSH Terms\n\n*   [Neoplasms by Site](https://ichgcp.net/clinical-trials-registry/research/list?cond=Neoplasms%20by%20Site "List all studies by MeSH term: Neoplasms by Site")\n*   [Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Neoplasms "List all studies by MeSH term: Neoplasms")\n*   [Immune System Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Immune%20System%20Diseases "List all studies by MeSH term: Immune System Diseases")\n*   [Respiratory Tract Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Diseases "List all studies by MeSH term: Respiratory Tract Diseases")\n*   [Neoplasms by Histologic Type](https://ichgcp.net/clinical-trials-registry/research/list?cond=Neoplasms%20by%20Histologic%20Type "List all studies by MeSH term: Neoplasms by Histologic Type")\n*   [Lung Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%20Diseases "List all studies by MeSH term: Lung Diseases")\n*   [Respiratory Tract Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Neoplasms "List all studies by MeSH term: Respiratory Tract Neoplasms")\n*   [Thoracic Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Thoracic%20Neoplasms "List all studies by MeSH term: Thoracic Neoplasms")\n*   [Lymphatic Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphatic%20Diseases "List all studies by MeSH term: Lymphatic Diseases")\n*   [Lymphoproliferative Disorders](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoproliferative%20Disorders "List all studies by MeSH term: Lymphoproliferative Disorders")\n*   [Immunoproliferative Disorders](https://ichgcp.net/clinical-trials-registry/research/list?cond=Immunoproliferative%20Disorders "List all studies by MeSH term: Immunoproliferative Disorders")\n*   [Carcinoma, Bronchogenic](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%2C%20Bronchogenic "List all studies by MeSH term: Carcinoma, Bronchogenic")\n*   [Bronchial Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Bronchial%20Neoplasms "List all studies by MeSH term: Bronchial Neoplasms")\n*   [Lung Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%20Neoplasms "List all studies by MeSH term: Lung Neoplasms")\n*   [Lymphoma](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma "List all studies by MeSH term: Lymphoma")\n*   [Carcinoma, Non-Small-Cell Lung](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%2C%20Non-Small-Cell%20Lung "List all studies by MeSH term: Carcinoma, Non-Small-Cell Lung")\n*   [Tyrosine Kinase Inhibitors](https://ichgcp.net/clinical-trials-registry/research/list?intr=Tyrosine%20Kinase%20Inhibitors "List all studies by MeSH term: Tyrosine Kinase Inhibitors")\n*   [Antineoplastic Agents](https://ichgcp.net/clinical-trials-registry/research/list?intr=Antineoplastic%20Agents "List all studies by MeSH term: Antineoplastic Agents")\n*   [Molecular Mechanisms of Pharmacological Action](https://ichgcp.net/clinical-trials-registry/research/list?intr=Molecular%20Mechanisms%20of%20Pharmacological%20Action "List all studies by MeSH term: Molecular Mechanisms of Pharmacological Action")\n*   [Enzyme Inhibitors](https://ichgcp.net/clinical-trials-registry/research/list?intr=Enzyme%20Inhibitors "List all studies by MeSH term: Enzyme Inhibitors")\n*   [Protein Kinase Inhibitors](https://ichgcp.net/clinical-trials-registry/research/list?intr=Protein%20Kinase%20Inhibitors "List all studies by MeSH term: Protein Kinase Inhibitors")\n*   [Crizotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Crizotinib "List all studies by MeSH term: Crizotinib")\n*   [Alectinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Alectinib "List all studies by MeSH term: Alectinib")\n\n#### Other Study ID Numbers\n\n*    YO29449 \n\n### Drug and device information, study documents\n\n#### Studies a U.S. FDA-regulated drug product\n\n Yes \n\n#### Studies a U.S. FDA-regulated device product\n\n No \n\nThis information was retrieved directly from the website [clinicaltrials.gov](https://clinicaltrials.gov/) without any changes. If you have any requests to change, remove or update your study details, please contact [register@clinicaltrials.gov](mailto:register@clinicaltrials.gov). As soon as a change is implemented on [clinicaltrials.gov](https://clinicaltrials.gov/), this will be updated automatically on our website as well.\n\nClinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer\n---------------------------------------------------------------------------------\n\n*    Pfizer   Completed  [A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001)](https://ichgcp.net/clinical-trials-registry/NCT00585195)  Systemic Anaplastic Large-Cell Lymphoma | Non-Small Cell Lung Cancer ALK-positive | Non-Small Cell Lung Cancer c-Met Dependent | Non-Small Cell Lung Cancer ROS Marker Positive | Advanced Malignancies Except Leukemia   United States, Korea, Republic of, Australia, Japan    \n*    Novartis Pharmaceuticals   Available  [Managed Access Programs for LDK378, Ceritinib](https://ichgcp.net/clinical-trials-registry/NCT05100134)  Non-small Cell Lung Cancer (NSCLC) | Anaplastic Lymphoma Kinase (ALK)- Positive Tumors    \n*    Novartis Pharmaceuticals   Completed  [Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer](https://ichgcp.net/clinical-trials-registry/NCT01772797)  Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase (ALK)   Australia, Spain, Singapore, Italy, United States    \n*    Nuvalent Inc.   Recruiting  [Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC (ALKAZAR)](https://ichgcp.net/clinical-trials-registry/NCT06765109)  Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase-positive   United States    \n*    Intergroupe Francophone de Cancerologie Thoracique   Completed  [Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements (CLINALK)](https://ichgcp.net/clinical-trials-registry/NCT02727335)  Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase Gene Mutation   France    \n*    Takeda   Completed  [A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors](https://ichgcp.net/clinical-trials-registry/NCT03546894)  Carcinoma Non-small-cell Lung | Anaplastic Lymphoma Kinase-positive   United States    \n*    Astellas Pharma Inc   Completed  [Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)](https://ichgcp.net/clinical-trials-registry/NCT01284192)  Solid Tumor | B-Cell Lymphoma | Advanced Malignancies | Positive for Anaplastic Lymphoma Kinase | Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS   United States    \n*    University Medical Center Groningen  Radboud University Medical Center; Maastricht University Medical Center; Erasmus... and other collaborators    Recruiting  [Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels (ADAPT ALEC)](https://ichgcp.net/clinical-trials-registry/NCT05525338)  Carcinoma, Non-Small-Cell Lung | Lung Cancer | Drug Monitoring | Anaplastic Lymphoma Kinase Gene Mutation | Anaplastic Lymphoma Kinase Gene Translocation   Netherlands, France    \n*    Takeda   Withdrawn  [Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors](https://ichgcp.net/clinical-trials-registry/NCT04260009)  Solid Tumors | Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma | Inflammatory Myofibroblastic Tumors    \n*    Massachusetts General Hospital  LUNGevity Foundation; Addario Lung Cancer Medical Institute    Recruiting  [Immune and Genomic Markers in ALK+ NSCLC](https://ichgcp.net/clinical-trials-registry/NCT04881916)  Non-Small Cell Lung Cancer | Anaplastic Lymphoma Kinase Gene Translocation   United States    \n\nClinical Trials on Alectinib\n----------------------------\n\n*    Aarhus University Hospital  Roche Pharma AG    Enrolling by invitation  [Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients (MonAlec)](https://ichgcp.net/clinical-trials-registry/NCT04708639)  Lung Cancer | ALK Gene Mutation | Resistance, Disease | Mutation   Denmark    \n*    Hoffmann-La Roche   Completed  [A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (ATALK)](https://ichgcp.net/clinical-trials-registry/NCT03155009)  Carcinoma, Non-Small-Cell Lung   France    \n*    Hoffmann-La Roche   Completed  [Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea](https://ichgcp.net/clinical-trials-registry/NCT03271554)  Non-Small Cell Lung Cancer   Korea, Republic of    \n*    Dana-Farber Cancer Institute  Genentech, Inc.    Terminated  [A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer](https://ichgcp.net/clinical-trials-registry/NCT03131206)  ALK-positive Non-small Cell Lung Cancer (NSCLC) | RET-positive Non-small Cell Lung Cancer (NSCLC) | RET-positive Thyroid Cancer   United States    \n*    Hoffmann-La Roche   Completed  [Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib](https://ichgcp.net/clinical-trials-registry/NCT02621047)  Hepatic Impairment   Czechia, Slovakia    \n*    Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...  UnitedHealthcare    Not yet recruiting  [Pharmacogenomics IND EXEMPT SNP Clinical Study - Alectinib and Single Nucleotide Polymorphisms (Drugs-SNPs)](https://ichgcp.net/clinical-trials-registry/NCT05987956)  Non-small Cell Lung Cancer   United States    \n*    Hoffmann-La Roche   Terminated  [A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors (ALpha-T)](https://ichgcp.net/clinical-trials-registry/NCT04644315)  Digestive System Diseases | Gastrointestinal Diseases | Melanoma | Sarcoma | Neoplasms | Respiratory Tract Diseases | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasms | Head and Neck Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms and other conditions   United States    \n*    China Medical University Hospital   Active, not recruiting  [Alectinib in Combination with Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided with Serum RNase1 and Tumor Expression of PD-L1](https://ichgcp.net/clinical-trials-registry/NCT06354387)  Hepatocellular Carcinoma   Taiwan    \n*    Genentech, Inc.   No longer available  [Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy](https://ichgcp.net/clinical-trials-registry/NCT02271139)  Non-Small Cell Lung Cancer   United States    \n*    Hoffmann-La Roche   Completed  [A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)](https://ichgcp.net/clinical-trials-registry/NCT01871805)  Non-Small Cell Lung Cancer   United States, Canada    \n\nSearch Similar Trials\n---------------------\n\n*   [Clinical Trials on Lymphoma in Singapore](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=Singapore)\n*   [Clinical Trials on Lymphosarcoma in Australia](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=Australia)\n*   [Clinical Trials on Carcinoma, Non-Small-Cell Lung in Singapore](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BNon-Small-Cell%2BLung&locn=Singapore)\n*   [Clinical Trials on Lymphoma in New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=New%2BZealand)\n*   [Clinical Trials on Carcinoma, Non-Small-Cell Lung in United States](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BNon-Small-Cell%2BLung&locn=United%2BStates)\n*   [Clinical Trials on Lung Neoplasms in Ireland](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%2BNeoplasms&locn=Ireland)\n*   [Clinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%2BLymphoma%2BKinase-positive%2BNon-small%2BCell%2BLung%2BCancer&locn=South%2BAfrica)\n*   [Clinical Trials on Lymphosarcoma in India](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=India)\n*   [Clinical Trials on Lymphoma in United States](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=United%2BStates)\n*   [Clinical Trials on Lymphoma in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=South%2BAfrica)\n*   [Clinical Trials on Lymphoma in Hong Kong](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=Hong%2BKong)\n*   [Clinical Trials on Lymphosarcoma in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=South%2BAfrica)\n*   [Clinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer in Ireland](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%2BLymphoma%2BKinase-positive%2BNon-small%2BCell%2BLung%2BCancer&locn=Ireland)\n*   [Clinical Trials on Lung Neoplasms in New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%2BNeoplasms&locn=New%2BZealand)\n*   [Clinical Trials on Lung Neoplasms in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%2BNeoplasms&locn=South%2BAfrica)\n*   [Clinical Trials on Lymphoma in India](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=India)\n*   [Clinical Trials on Lymphosarcoma in Singapore](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=Singapore)\n*   [Clinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer in New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%2BLymphoma%2BKinase-positive%2BNon-small%2BCell%2BLung%2BCancer&locn=New%2BZealand)\n*   [Clinical Trials on Lymphosarcoma in United States](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=United%2BStates)\n*   [Clinical Trials on Carcinoma, Non-Small-Cell Lung in United Kingdom](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BNon-Small-Cell%2BLung&locn=United%2BKingdom)\n*   [Search All Trials](https://ichgcp.net/clinical-trials-registry/research/list)\n\nSponsors and Collaborators\n--------------------------\n\n*   [Eisai Korea Inc.](https://ichgcp.net/clinical-trials-registry/research/list?spons=Eisai%2BKorea%2BInc.)\n*   [Leukaemia & Blood Cancer New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?spons=Leukaemia%2B%2526%2BBlood%2BCancer%2BNew%2BZealand)\n*   [Udaan](https://ichgcp.net/clinical-trials-registry/research/list?spons=Udaan)\n*   [Makarenko Irina Romanovna](https://ichgcp.net/clinical-trials-registry/research/list?spons=Makarenko%2BIrina%2BRomanovna)\n*   [Adriane Aver Vanin](https://ichgcp.net/clinical-trials-registry/research/list?spons=Adriane%2BAver%2BVanin)\n*   [University of Memphis](https://ichgcp.net/clinical-trials-registry/research/list?spons=University%2Bof%2BMemphis)\n*   [Sleep Research Society Foundation](https://ichgcp.net/clinical-trials-registry/research/list?spons=Sleep%2BResearch%2BSociety%2BFoundation)\n*   [Immuron Ltd.](https://ichgcp.net/clinical-trials-registry/research/list?spons=Immuron%2BLtd.)\n*   [Arthro-Anda Tianjin Biologic Technology Co., Ltd.](https://ichgcp.net/clinical-trials-registry/research/list?spons=Arthro-Anda%2BTianjin%2BBiologic%2BTechnology%2BCo.%252C%2BLtd.)\n*   [CoheroHealth](https://ichgcp.net/clinical-trials-registry/research/list?spons=CoheroHealth)\n*   [Center for Military Mental Health, Berlin, Germany](https://ichgcp.net/clinical-trials-registry/research/list?spons=Center%2Bfor%2BMilitary%2BMental%2BHealth%252C%2BBerlin%252C%2BGermany)\n*   [Kevin Flanigan](https://ichgcp.net/clinical-trials-registry/research/list?spons=Kevin%2BFlanigan)\n*   [Periannan Kuppusamy](https://ichgcp.net/clinical-trials-registry/research/list?spons=Periannan%2BKuppusamy)\n*   [Chiang Mai University Hospital, THAILAND](https://ichgcp.net/clinical-trials-registry/research/list?spons=Chiang%2BMai%2BUniversity%2BHospital%252C%2BTHAILAND)\n*   [Centre for Emergency Health Sciences](https://ichgcp.net/clinical-trials-registry/research/list?spons=Centre%2Bfor%2BEmergency%2BHealth%2BSciences)\n*   [Therapex Co., Ltd](https://ichgcp.net/clinical-trials-registry/research/list?spons=Therapex%2BCo.%252C%2BLtd)\n*   [MIT William Asbjornsen Albert Memorial Fellowship](https://ichgcp.net/clinical-trials-registry/research/list?spons=MIT%2BWilliam%2BAsbjornsen%2BAlbert%2BMemorial%2BFellowship)\n*   [Fabiana Aceto](https://ichgcp.net/clinical-trials-registry/research/list?spons=Fabiana%2BAceto)\n*   [North American Spine Society](https://ichgcp.net/clinical-trials-registry/research/list?spons=North%2BAmerican%2BSpine%2BSociety)\n*   [SGS proderm GmbH](https://ichgcp.net/clinical-trials-registry/research/list?spons=SGS%2Bproderm%2BGmbH)\n*   [View Full List](https://ichgcp.net/clinical-trials-registry/research/browse/spns_alpha_all)\n\nMedical Conditions\n------------------\n\n*   [Infrarenal Abdominal Aortic Aneurysms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Infrarenal%2BAbdominal%2BAortic%2BAneurysms)\n*   [Myeloproliferative Disease, Not Classified](https://ichgcp.net/clinical-trials-registry/research/list?cond=Myeloproliferative%2BDisease%252C%2BNot%2BClassified)\n*   [Lifestyle-related Condition](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lifestyle-related%2BCondition)\n*   [Compliance](https://ichgcp.net/clinical-trials-registry/research/list?cond=Compliance)\n*   [Patients With Opioid Induced Constipation](https://ichgcp.net/clinical-trials-registry/research/list?cond=Patients%2BWith%2BOpioid%2BInduced%2BConstipation)\n*   [Femoral Vascular Anastomosis](https://ichgcp.net/clinical-trials-registry/research/list?cond=Femoral%2BVascular%2BAnastomosis)\n*   [Observation Safety](https://ichgcp.net/clinical-trials-registry/research/list?cond=Observation%2BSafety)\n*   [Improvement of Functionality](https://ichgcp.net/clinical-trials-registry/research/list?cond=Improvement%2Bof%2BFunctionality)\n*   [CD4 Deficiency](https://ichgcp.net/clinical-trials-registry/research/list?cond=CD4%2BDeficiency)\n*   [Malassezia Infection](https://ichgcp.net/clinical-trials-registry/research/list?cond=Malassezia%2BInfection)\n*   [Anti-cancer Cell Immunotherapy](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anti-cancer%2BCell%2BImmunotherapy)\n*   [Health Knowledge Attitudes and Practice](https://ichgcp.net/clinical-trials-registry/research/list?cond=Health%2BKnowledge%2BAttitudes%2Band%2BPractice)\n*   [School Adjustment](https://ichgcp.net/clinical-trials-registry/research/list?cond=School%2BAdjustment)\n*   [Difficult Mask Ventilation](https://ichgcp.net/clinical-trials-registry/research/list?cond=Difficult%2BMask%2BVentilation)\n*   [Intrapartum Mortality](https://ichgcp.net/clinical-trials-registry/research/list?cond=Intrapartum%2BMortality)\n*   [Diabetes Mellitus II](https://ichgcp.net/clinical-trials-registry/research/list?cond=Diabetes%2BMellitus%2BII)\n*   [Painless Myocardial Ischemia](https://ichgcp.net/clinical-trials-registry/research/list?cond=Painless%2BMyocardial%2BIschemia)\n*   [Corona Virus Disease 19 (COVID-19)](https://ichgcp.net/clinical-trials-registry/research/list?cond=Corona%2BVirus%2BDisease%2B19%2B%2528COVID-19%2529)\n*   [Pressure Injury Stage 2](https://ichgcp.net/clinical-trials-registry/research/list?cond=Pressure%2BInjury%2BStage%2B2)\n*   [Escape; Rhythm](https://ichgcp.net/clinical-trials-registry/research/list?cond=Escape%253B%2BRhythm)\n*   [View Full List](https://ichgcp.net/clinical-trials-registry/research/browse/cond_alpha_all)\n\nDrug Interventions\n------------------\n\n*   [Methylprednisolone](https://ichgcp.net/clinical-trials-registry/research/list?intr=Methylprednisolone)\n*   [Anetumab Ravtansine](https://ichgcp.net/clinical-trials-registry/research/list?intr=Anetumab%2BRavtansine)\n*   [ESES treated with clobazam](https://ichgcp.net/clinical-trials-registry/research/list?intr=ESES%2Btreated%2Bwith%2Bclobazam)\n*   [Droperidol Injectable Solution](https://ichgcp.net/clinical-trials-registry/research/list?intr=Droperidol%2BInjectable%2BSolution)\n*   [ATx201](https://ichgcp.net/clinical-trials-registry/research/list?intr=ATx201)\n*   [Cyclophosphamide](https://ichgcp.net/clinical-trials-registry/research/list?intr=Cyclophosphamide)\n*   [Pioglitazone](https://ichgcp.net/clinical-trials-registry/research/list?intr=Pioglitazone)\n*   [Botulinum Toxin A](https://ichgcp.net/clinical-trials-registry/research/list?intr=Botulinum%2BToxin%2BA)\n*   [Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Gefitinib%2B250mg%2Bpo%2Bqd%2Bor%2BTarceva%2B150mg%2Bpo%2Bqd%2Bor%2BIcotinib%2B125mg%2Bpo%2Btid%2BOther%2BName%253A%2BGefitinib%252FTarceva%252FIcotinib)\n*   [Ramosetron](https://ichgcp.net/clinical-trials-registry/research/list?intr=Ramosetron)\n*   [KN046](https://ichgcp.net/clinical-trials-registry/research/list?intr=KN046)\n*   [Doxorubicin](https://ichgcp.net/clinical-trials-registry/research/list?intr=Doxorubicin)\n*   [Corticosteroids (CS)](https://ichgcp.net/clinical-trials-registry/research/list?intr=Corticosteroids%2B%2528CS%2529)\n*   [Dimenhydrinate](https://ichgcp.net/clinical-trials-registry/research/list?intr=Dimenhydrinate)\n*   [Ropivacaine 150 mg](https://ichgcp.net/clinical-trials-registry/research/list?intr=Ropivacaine%2B150%2Bmg)\n*   [Iso-Fludelone](https://ichgcp.net/clinical-trials-registry/research/list?intr=Iso-Fludelone)\n*   [Clonidine](https://ichgcp.net/clinical-trials-registry/research/list?intr=Clonidine)\n*   [Lidocaine topical](https://ichgcp.net/clinical-trials-registry/research/list?intr=Lidocaine%2Btopical)\n*   [Nusinersen](https://ichgcp.net/clinical-trials-registry/research/list?intr=Nusinersen)\n*   [Cyclophosphamide and fludarabine](https://ichgcp.net/clinical-trials-registry/research/list?intr=Cyclophosphamide%2Band%2Bfludarabine)\n*   [View Full List](https://ichgcp.net/clinical-trials-registry/research/browse/intr_alpha_all)\n\n### CROs by country\n\n*   [Contract Research Organizations in Azerbaijan](https://ichgcp.net/cro-list/country/azerbaijan)\n*   [Contract Research Organizations in Bulgaria](https://ichgcp.net/cro-list/country/bulgaria)\n*   [Contract Research Organizations in Burundi](https://ichgcp.net/cro-list/country/burundi)\n*   [Contract Research Organizations in Dominican Republic](https://ichgcp.net/cro-list/country/dominican_republic)\n*   [Contract Research Organizations in Kosovo](https://ichgcp.net/cro-list/country/kosovo)\n*   [Contract Research Organizations in Mexico](https://ichgcp.net/cro-list/country/mexico)\n*   [Contract Research Organizations in Moldova](https://ichgcp.net/cro-list/country/moldova)\n*   [Contract Research Organizations in Poland](https://ichgcp.net/cro-list/country/poland)\n*   [Contract Research Organizations in Slovakia](https://ichgcp.net/cro-list/country/slovakia)\n*   [Contract Research Organizations in Sri Lanka](https://ichgcp.net/cro-list/country/sri_lanka)\n*   [Contract Research Organizations in Ukraine](https://ichgcp.net/cro-list/country/ukraine)\n*   [Contract Research Organizations in United Arab Emirates](https://ichgcp.net/cro-list/country/united_arab_emirates)\n*   [Contract Research Organizations in Uzbekistan](https://ichgcp.net/cro-list/country/uzbekistan)\n*   [CRO list by country](https://ichgcp.net/cro-list)\n\n### CROs in Ghana\n\n*   [54gene‚Äôs Clinical Programs Group (CPG)](https://ichgcp.net/cro-list/country/ghana/company/54gene_s_clinical_programs_group_cpg)\n*   [SGS](https://ichgcp.net/cro-list/country/ghana/company/sgs)\n*   [ACROSS Global](https://ichgcp.net/cro-list/country/ghana/company/across_global)\n*   [All CROs in Ghana](https://ichgcp.net/cro-list/country/ghana)\n\n### Conditions\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/cond_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/cond_cat)\n\n### Rare Diseases\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/ord_alpha_all)\n\n### Drug Interventions\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/intr_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/intr_cat)\n\n### Dietary Supplements\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/diet_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/diet_cat)\n\n### Sponsor/Collaborators\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/spns_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/spns_cat)\n\n### Locations\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/locn_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/locn_cat)\n\nRegulations\n\n*   [GLOBAL (ICH GCP)](https://ichgcp.net/)\n*   [USA (FDA)](https://ichgcp.net/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects)\n*   [UK (MHRA)](https://ichgcp.net/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol)\n*   [AUSTRALIA (NHMRC)](https://ichgcp.net/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia)\n*   [JAPAN (PMDA)](https://ichgcp.net/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan)\n*   [EU (EMA)](https://ichgcp.net/guideline-for-the-notification-of-serious-breaches-of-regulation-eu-no-536-2014)\n\nResources\n\n*   [CRO List](https://ichgcp.net/cro-list)\n*   [Pharmaceutical Companies](https://ichgcp.net/pharma-list)\n*   [Clinical Research Labs](https://ichgcp.net/labs)\n*   [Service Companies](https://ichgcp.net/service-companies)\n*   [Jobs](https://ichgcp.net/cra-jobs)\n*   [US Clinical Trials Registry](https://ichgcp.net/clinical-trials-registry)\n*   [EU Clinical Trials Registry](https://ichgcp.net/eu-clinical-trials-registry)\n\nArticles\n\n*   [Publications](https://ichgcp.net/publications)\n*   [News](https://ichgcp.net/news)\n*   [About us / Our mission](https://ichgcp.net/about-us-our-mission)\n\nSearch trials\n\nExample: Heart Attack\n\n¬© ICH GCP. All Rights Reserved.\n\n*   [Sitemap](https://ichgcp.net/sitemap)\n*   [Contact us](https://ichgcp.net/contact-us)\n*   [RSS feed](https://ichgcp.net/feed)\n*   [Privacy Policy](https://ichgcp.net/privacy)\n*   [Disclaimer](https://ichgcp.net/disclaimer)\n\n English \n\n[Dansk](https://ichgcp.net/da/clinical-trials-registry/NCT02838420)[Deutsch](https://ichgcp.net/de/clinical-trials-registry/NCT02838420)[English](https://ichgcp.net/clinical-trials-registry/NCT02838420)[Espa√±ol](https://ichgcp.net/es/clinical-trials-registry/NCT02838420)[Fran√ßais](https://ichgcp.net/fr/clinical-trials-registry/NCT02838420)[Italiano](https://ichgcp.net/it/clinical-trials-registry/NCT02838420)[Magyar](https://ichgcp.net/hu/clinical-trials-registry/NCT02838420)[Nederlands](https://ichgcp.net/nl/clinical-trials-registry/NCT02838420)[Norsk](https://ichgcp.net/no/clinical-trials-registry/NCT02838420)[Polski](https://ichgcp.net/pl/clinical-trials-registry/NCT02838420)[Portugu√™s](https://ichgcp.net/pt/clinical-trials-registry/NCT02838420)[Suomi](https://ichgcp.net/fi/clinical-trials-registry/NCT02838420)[Svenska](https://ichgcp.net/sv/clinical-trials-registry/NCT02838420)[ƒåe≈°tina](https://ichgcp.net/cs/clinical-trials-registry/NCT02838420)[–†—É—Å—Å–∫–∏–π](https://ichgcp.net/ru/clinical-trials-registry/NCT02838420)[Êó•Êú¨Ë™û](https://ichgcp.net/ja/clinical-trials-registry/NCT02838420)[ÁÆÄ‰Ωì‰∏≠Êñá](https://ichgcp.net/zh/clinical-trials-registry/NCT02838420)[ÌïúÍµ≠Ïñ¥](https://ichgcp.net/ko/clinical-trials-registry/NCT02838420)\n\nGOOD CLINICAL PRACTICE NETWORK\n\nSubscribe to receive notifications of new clinical trials you are interested in.\n\nSubscribe\n\n‚úï\n\nGOOD CLINICAL PRACTICE NETWORK\n\nSubscribe to receive notifications of new clinical trials you are interested in.\n\nSubscribe for upcoming trials that contain the following conditions: \n\n- [x] Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer \n\n[Choose more conditions](https://ichgcp.net/mailing-list/conditions)\n\nSubscribe for upcoming trials that contain the following interventions: \n\n- [x] Alectinib \n\n- [x] Crizotinib \n\n[Choose more interventions](https://ichgcp.net/mailing-list/interventions)\n\nSubscribe for upcoming trials sponsored by: \n\n- [x] Hoffmann-La Roche \n\n[Choose more organizations](https://ichgcp.net/mailing-list/organizations)\n\nSubscribe\n\nSubscribe\n\nSubscribe\n'}, {'title': 'Alectinib vs crizotinib in Asian patients with treatment-na√Øve ... - Roche', 'url': 'https://medically.roche.com/global/en/medical-material/ESMO-Asia-2022-presentation-zhou-alectinib-vs-crizotinib-in-asian-patients-with-treatment-naive-advanced-pdf.html', 'content': 'Data cut -off 16 May 2022. ClinicalTrials.gov: NCT02838420. CNS, central nervous system; DOR, duration of response;  ECOG PS, Eastern Cooperative Oncology Group performance status; IHC, immunohistochemistry; INV, investigator \n\nIRC, independent review committee; NSCLC, non -small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, p rogression -free survival \n\n2:1 \n\nN=187 \n\nR\n\nAlectinib \n\n600mg  twice daily \n\nCrizotinib \n\n250mg twice daily \n\nTreat until disease', 'score': 0.5393963, 'raw_content': "Alectinib vs crizotinib in Asian patients \n\n## with treatment -na√Øve advanced  ALK +\n\n## non -small cell lung cancer: 5 -year \n\n## update from the Phase 3 ALESIA study \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nFaculty of Medicine  Ramathibodi  Hospital, Mahidol University, \n\nBangkok, Thailand \n\nZhou C, 1 Lu Y, 2 Kim S -W, 3 Baisamut  (Reungwetwattana) T, 4 Zhou J, 5 Zhang Y, 6 He J, 7 Yang J -J, 8 Cheng Y, 9 Lee S -H, 10  Chang J, 11 \n\nFang J, 12  Liu Z, 13  Bu L, 14  Qian L, 14  Xu T, 14  Archer V, 15  Hilton M, 16  Zhou M, 14  Zhang L 17 \n\n1Shanghai Pulmonary Hospital, Tongji University, Shanghai, China;  2West China Hospital, Sichuan University, Chengdu, China;  3Asan Medical \n\nCenter , University of Ulsan College of Medicine, Seoul, South Korea;  4Faculty of Medicine  Ramathibodi  Hospital, Mahidol University, Bangkok, \n\nThailand;  5The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China;  6Zhejiang Cancer Hospital, Hangzhou, China; \n\n7The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;  8Guangdong Lung Cancer Institute, Guangdong General Hospital, \n\nGuangzhou, China;  9Jilin Cancer Hospital, Changchun, China;  10 Sungkyunkwan University School of Medicine, Seoul, South Korea;  11 Cancer \n\nHospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China;  12 Beijing Cancer \n\nHospital, Beijing, China;  13 Beijing Chest Hospital, Capital Medical University, Beijing, China;  14 Roche Pharma Development, Shanghai, China; \n\n15 Roche Products Ltd, Welwyn Garden City, UK;  16 F. Hoffmann -La Roche Ltd, Basel, Switzerland;  17 Sun  Yat -sen  University Cancer  Center ,\n\nState Key Laboratory of Oncology in South China, Collaborative Innovation  Center  for Cancer Medicine, Guangzhou, China Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## DECLARATION OF INTERESTS \n\nThanyanan  Baisamut  (Reungwetwattana) \n\n‚Ä¢ Received honorarium from AstraZeneca, Pfizer, MSD, Roche, BMS, Amgen, J&J, Novartis,  Yuhan  and  Zuellig \n\n‚Ä¢ Participated as Principal Investigator on clinical trials for AstraZeneca, MSD, Roche, Novartis and  Yuhan   \n\n> Thanyanan Baisamut (Reungwetwattana)\n\nContent of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## ALESIA: alectinib vs crizotinib in treatment -na√Øve Asian patients \n\n## with advanced  ALK+  NSCLC \n\n‚Ä¢ Stratification factors:  ECOG PS (0/1 vs 2) \n\nand CNS metastases at baseline (yes vs no) \n\n‚Ä¢ Primary endpoint:  PFS by INV \n\n‚Ä¢ Secondary endpoints:  Time to CNS \n\nprogression by IRC, ORR by INV, \n\nDOR by INV, OS and safety \n\n‚Ä¢ Median duration of survival follow -up: \n\n61 months  alectinib vs  51 months  crizotinib \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nPatients were enrolled from China, Thailand and South Korea. *Asymptomatic CNS metastases allowed. \n\nData cut -off 16 May 2022. ClinicalTrials.gov: NCT02838420. CNS, central nervous system; DOR, duration of response;  ECOG PS, Eastern Cooperative Oncology Group performance status; IHC, immunohistochemistry; INV, investigator \n\nIRC, independent review committee; NSCLC, non -small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, p rogression -free survival \n\n2:1 \n\nN=187 \n\nR\n\nAlectinib \n\n600mg  twice daily \n\nCrizotinib \n\n250mg twice daily \n\nTreat until disease \n\nprogression, toxicity, \n\nwithdrawal or death \n\nNo crossover permitted \n\nStage IIIB/IV  ALK + NSCLC* \n\n‚Ä¢ Asian patients \n\n‚Ä¢ Treatment na√Øve \n\n‚Ä¢ ECOG PS 0 ‚Äì2\n\n‚Ä¢ Central  ALK  testing (Ventana IHC) \n\nBaseline demographics \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nAge, years  Median (range)  51.0 (21‚àí78)  49.0 (28‚àí83) \n\nGender, %  Male / Female  51.2 / 48.8  54.8 / 45.2 \n\nECOG PS, %  0‚Äì1 / 2  96.8 / 3.2  98.4 / 1.6 \n\nSmoking status, %  Active smoker / Non -smoker / \n\nPast smoker  3.2 / 67.2 / 29.6  4.8 / 72.6 / 22.6 \n\nCNS metastases by IRC, %  Yes  35.2  37.1 \n\nCNS metastases by INV, %  Yes  33.6  32.3 \n\nPrior brain radiation, %  Yes  6.4  8.1 Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Updated analyses from ALESIA demonstrate durable PFS benefit for \n\n## alectinib versus crizotinib, irrespective of CNS involvement at baseline \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nData cut -off 16 May 2022. CI, confidence interval; CNS, central nervous system; HR, hazard ratio; ITT, intent -to -treat;  mets , metastases;  PFS, progression -free survival \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nMedian  PFS, months \n\n(95% CI) \n\n41.6 \n\n(33.1 ‚Äì58.9) \n\n11.1 \n\n(9.1 ‚Äì18.4) \n\nHR  (95% CI)  0.33  (0.23 ‚Äì0.49) \n\n0\n\n> PFS (%)\n\n6 36  66 60 54 48 42 30 24 18 12 \n\nTime (months) \n\n100 \n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\nCrizotinib (n=62) \n\nAlectinib (n=125) \n\nWith  CNS  mets  at baseline  Without  CNS  mets  at baseline \n\nAlectinib \n\nn=44 \n\nCrizotinib \n\nn=23 \n\nAlectinib \n\nn=81 \n\nCrizotinib \n\nn=39 \n\nMedian  PFS, months \n\n(95% CI) \n\n42.3 \n\n(27.8 ‚Äì60.7) \n\n9.2 \n\n(5.5 ‚Äì12.2) \n\n41.6 \n\n(29.5 ‚Äì64.9) \n\n12.7 \n\n(9.2 ‚Äì27.6) \n\nHR  (95% CI)  0.17  (0.09 ‚Äì0.33)  0.45  (0.29 ‚Äì0.71) \n\nCrizotinib (n=39) \n\nWithout  CNS  mets  at baseline \n\nAlectinib (n=81) \n\nUpdated PFS: ITT population \n\nTime (months) \n\n100 \n\n0\n\n> PFS (%)\n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\n36  66 54 18 6 60 42 30 24 12  48 \n\nCrizotinib (n=23) \n\nWith  CNS  mets  at baseline \n\nAlectinib (n=44) \n\nPFS according to CNS status at baseline Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## A clinically meaningful improvement in 5 -year OS rate was observed \n\n## for alectinib compared with crizotinib \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nData cut -off 16 May 2022. CI, confidence interval; CNS, central nervous system; HR, hazard ratio; ITT, intent -to -treat;  mets , metastases; NE, not evaluable; OS, overall survival; pts, patients \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nPts with event, n (%)  41 (32.8)  26 (41.9) \n\nMedian  OS, months \n\n(95% CI) \n\nNE \n\n(NE ‚ÄìNE) \n\nNE \n\n(45.5 ‚ÄìNE) \n\nHR  (95% CI)  0.60  (0.37 ‚Äì0.99) \n\n5-year OS rate , % \n\n(95% CI) \n\n66.4 \n\n(57.9 ‚Äì74.9) \n\n56.0 \n\n(43.0 ‚Äì69.1) \n\nPts remaining at risk, n  69  25 \n\n0\n\n> OS (%)\n\n6 36  66 60 54 48 42 30 24 18 12 \n\nTime (months) \n\n100 \n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\nCrizotinib (n=62) \n\nAlectinib (n=125) \n\nWith  CNS  mets  at baseline  Without  CNS  mets  at baseline \n\nAlectinib \n\nn=44 \n\nCrizotinib \n\nn=23 \n\nAlectinib \n\nn=81 \n\nCrizotinib \n\nn=39 \n\nPts with event, n (%)  16 (36.4)  12 (52.2)  25 (30.9)  14 (35.9) \n\nMedian  OS, months \n\n(95% CI) \n\nNE \n\n(51.4 ‚ÄìNE) \n\n46.2 \n\n(12.2 ‚ÄìNE) \n\nNE \n\n(NE ‚ÄìNE) \n\nNE \n\n(59.8 ‚ÄìNE) \n\nHR  (95% CI)  0.40  (0.19 ‚Äì0.85)  0.81  (0.42 ‚Äì1.55) \n\n5-year OS rate, % \n\n(95% CI) \n\n63.6 \n\n(48.9 ‚Äì78.3) \n\n39.3 \n\n(17.4 ‚Äì61.2) \n\n67.8 \n\n(57.4 ‚Äì78.2) \n\n64.9 \n\n(49.3 ‚Äì80.4) \n\nPts remaining at risk, n  25  6 44  19 \n\nCrizotinib (n=39) \n\nWithout  CNS  mets  at baseline \n\nAlectinib (n=81) \n\nUpdated OS: ITT population \n\nTime (months) \n\n100 \n\n0\n\n> OS (%)\n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\n36  66 54 18 6 60 42 30 24 12  48 \n\nCrizotinib (n=23) \n\nWith  CNS  mets  at baseline \n\nAlectinib (n=44) \n\nOS according to CNS status at baseline Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Treatment with alectinib delayed the time to CNS progression* \n\nThanyanan  Baisamut  (Reungwetwattana) \n\n*Derived from investigators' assessment. CNS PD = CNS Target Lesion PD per RECIST version 1.1, appearance of new CNS lesion(s ),  and/or unequivocal PD of Non -Target CNS lesion(s) \n\nData cut -off 16 May 2022. CI, confidence interval;  CIR, cumulative incidence rate;  CNS, central nervous system; HR, hazard ratio;  PD, progressive disease \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nCNS progression without prior systemic progression \n\nPatients with events, n (%)  18 (14.4)  22 (35.5) \n\nCause -specific HR  (95% CI)  0.16  (0.08 ‚Äì0.32) \n\nEstimated cumulative incidence, % (95% CI) \n\nAt 36 months  11.6 (6.7 ‚Äì18.1)  34.0 (22.1 ‚Äì46.2) \n\nAt 60 months  14.2 (8.6 ‚Äì21.1)  37.4 (25.0 ‚Äì49.7) \n\n40 \n\n0\n\n> Cumulative incidence (%)\n\n30 \n\n20 \n\n10 \n\n0 6 36  60 54 48 42 30 24 18 12 \n\nTime (months) \n\nCrizotinib (n=62) \n\nAlectinib (n=125) \n\nCIR: \n\n11.6% (95% CI 6.7 ‚Äì18.1) \n\nCIR: \n\n14.2% (95% CI 8.6 ‚Äì21.1) \n\nCIR: \n\n34.0% (95% CI 22.1 ‚Äì46.2) \n\nCIR: \n\n37.4% (95% CI 25.0 ‚Äì49.7) Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Post -progression therapy \n\nThanyanan  Baisamut  (Reungwetwattana)  \n\n> Data cut -off 16 May 2022. PD, progressive disease; VEGF, vascular endothelial growth factor\n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nPatients with PD , n  68  48 \n\nAnti -cancer therapy after PD , n (%)  42 (61.8)  38 (79.2) \n\nALK inhibitor , n (%)  25 (36.8)  28 (58.3) \n\nAlectinib  5 (7.4)  14 (29.2) \n\nLorlatinib  8 (11.8)  6 (12.5) \n\nBrigatinib  6 (8.8)  7 (14.6) \n\nCrizotinib  7 (10.3)  2 (4.2) \n\nCeritinib  3 (4.4)  4 (8.3) \n\nEnsartinib  2 (2.9)  1 (2.1) \n\nInvestigational drug  1 (1.5)  0\n\nChemotherapy , n (%)  24 (35.3)  15 (31.3) \n\nAnti -VEGF therapies , n ( %Ôºâ 9 (13.2)  3 (6.3) \n\nImmunotherapy , n (%)  3 (4.4)  2 (4.2) \n\nOther therapies , n (%)  6 (8.8)  7 (14.6) \n\nMore crizotinib patients (79.2% vs 61.8% alectinib) received at least one anti -cancer therapy post -progression \n\nApproximately 30% of patients in the crizotinib arm received alectinib after their disease progressed Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## The safety profile of alectinib remained favourable with longer \n\n## follow -up; no new safety signals were observed \n\nThanyanan  Baisamut  (Reungwetwattana) \n\n> *Three additional fatal events occurred during the longer follow -up: one was due to COVID -19 pneumonia, and the other two were r eported as ‚Äòdeath‚Äô and not related to alectinib treatment\n> Data cut -off 16 May 2022. AE, adverse event; ALT, alanine aminotransferase; ECG, electrocardiogram\n\nEvent, n  (%) \n\nAlectinib \n\n(n=125) \n\nCrizotinib \n\n(n=62) \n\nPatients with ‚â•1 \n\nAll grade AEs  125 (100)  62 (100) \n\nSerious AEs  35 (28.0)  18 (29.0) \n\nGrade ‚â•3 AEs  60 (48.0)  34 (54.8) \n\nFatal AEs  5 (4.0)*  3 (4.8) \n\nAEs leading to treatment discontinuation  14 (11.2)  9 (14.5) \n\nAEs leading to dose reduction  33 (26.4)  17 (27.4) \n\nAEs leading to dose interruption  33 (26.4)  19 (30.6) \n\nGrade ‚â•3 AEs with ‚â•3% difference \n\nin frequency between treatment arms, n  (%) \n\nAlectinib \n\n(n=125) \n\nCrizotinib \n\n(n=62) \n\nWeight increased  11 (8.8)  1 (1.6) \n\nBlood creatine phosphokinase increased  8 (6.4)  2 (3.2) \n\nALT increased  3 (2.4)  4 (6.5) \n\nNausea  1 (0.8)  3 (4.8) \n\nNeutrophil count decreased  0 9 (14.5) \n\nECG QT prolonged  0 3 (4.8) \n\nWhite blood cell count decreased  0 3 (4.8) \n\nDecreased appetite  0 3 (4.8) \n\nHyponatraemia  0 3 (4.8) \n\nInterstitial lung disease  0 3 (4.8) \n\nVomiting  0 3 (4.8) \n\nBradycardia  0 2 (3.2) \n\nHepatic function abnormal  0 2 (3.2) \n\nMedian treatment duration was more than three -times greater for alectinib (42.3 months) \n\ncompared to crizotinib (12.6 months) Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Conclusions:  5-year update from the Phase 3 ALESIA study   \n\n> Thanyanan Baisamut (Reungwetwattana )\n\nWith  at least 5 years  of follow -up, 1L alectinib  600mg twice daily  continues \n\nto demonstrate clinical benefit to Asian patients with advanced  ALK+  NSCLC, \n\nconsistent with  that observed in the  global ALEX study \n\nTreatment with alectinib also delayed the time to CNS progression \n\nThis clinical benefit, coupled with a tolerable and manageable safety profile, \n\nconfirms alectinib as standard -of -care treatment \n\nfor patients with advanced  ALK+  NSCLC Acknowledgements \n\nWe thank the participating patients and their families, study investigators, and research nurses \n\nThe ALESIA study was funded by F. Hoffmann -La Roche Ltd \n\nMedical writing support for the development of this presentation, under the direction \n\nof the authors, was provided by Fiona Duthie, PhD, of Ashfield MedComms, \n\nan Inizio company, and was funded by F. Hoffmann -La Roche Ltd\n"}], 'response_time': 1.64})
2025-06-18 19:19:30,277 - src.graph.nodes - INFO - Planner generating full plan
2025-06-18 19:20:09,368 - httpx - INFO - HTTP Request: POST https://2791-3-16-2-146.ngrok-free.app/v1/chat/completions "HTTP/1.1 200 OK"
2025-06-18 19:20:09,376 - process_medbrowse_questions - ERROR - Workflow execution failed: Failed to parse Plan from completion {"title": "Clinical Trial Update on Alectinib for ALK+ NSCLC Patients 5 Years Post-Treatment, Medication Label, and Various Food Ingredients Listings", "bullet_points": ["**ALESIA Trial Update after 5 Years of Follow-up:**\n  - Alectinib at 600 mg twice daily continues to offer clinical benefits to Asian patients diagnosed with advanced ALK+ NSCLC, with these benefits consistent with the global ALEX study findings.\n  - The drug's favorable safety profile persists, with no new safety signals over the extended follow-up period.\n  - Alectinib notably delayed the onset of CNS progression in these patients.\n  - Clinical advantages, combined with its manageable safety profile, support its use as a standard-of-care treatment for ALK+ NSCLC patients.\n\n**Safety Profile of Alectinib:\n  - Among adverse events (AEs), all grade AEs occurred in all patients, with serious AEs noted in 28% of alectinib patients compared to 29% in the crizotinib group.\n  - Grade \u22653 AEs affected 48% of alectinib versus 54.8% of crizotinib-treated patients.\n  - Alectinib had a median treatment duration significantly longer compared to crizotinib, which may relate to its reduced toxicity profile.\n\n**Post-Progression Therapies:\n  - Approximately 30% of crizotinib patients switched to alectinib after disease progression.\n  - Other therapies included ALK inhibitors such as lorlatinib, brigatinib, and ceritinib among other drug types.\n\nDrug Facts Documentation:\n  - Active Ingredient: Provides pain relief and reduces fever.\n  - Contains warnings about allergic reactions and potential stomach bleeding.\n  - Directions for usage are included on the medication label.\n\n**Food Ingredients Information:\n  - Classification and labeling requirements for ingredients such as edible oils, fats, fish, meat, cheese, spices, and gums are detailed.\n  - A table lists various food ingredient classes.\n\nOther Food Lists Mentioned:\n  - One list includes specific ingredients like Cocoa Mass, Cocoa Butter, and Milk.\n\n**Educational Content on Foods:\n  - A poster lists foods that start with the letter R for educational or informational purposes."], "conclusion": "The ALESIA study confirms alectinib as a preferred treatment for ALK+ NSCLC with long-term efficacy and manageable safety. Medication labeling for drugs and detailed food ingredient listings highlight the varied documentation needs across healthcare and food industries. The educational poster aids in recognizing different categories of foods, particularly those beginning with the letter 'R'. Further studies and monitoring of long-term adverse effects are necessary to maintain optimal patient management strategies."}. Got: 3 validation errors for Plan
locale
  Field required [type=missing, input_value={'title': 'Clinical Trial...management strategies."}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
has_enough_context
  Field required [type=missing, input_value={'title': 'Clinical Trial...management strategies."}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
thought
  Field required [type=missing, input_value={'title': 'Clinical Trial...management strategies."}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
For troubleshooting, visit: https://python.langchain.com/docs/troubleshooting/errors/OUTPUT_PARSING_FAILURE 
2025-06-18 19:20:09,376 - process_medbrowse_questions - WARNING - Parser error (attempt 3/5) for question 2: Failed to parse Plan from completion {"title": "Clinical Trial Update on Alectinib for ALK+ NSCLC Patients 5 Years Post-Treatment, Medication Label, and Various Food Ingredients Listings", "bullet_poi...
2025-06-18 19:20:09,376 - process_medbrowse_questions - INFO - Will retry in 5s... (4/5)
2025-06-18 19:20:14,378 - process_medbrowse_questions - INFO - Retry attempt 4/5 for question 2
2025-06-18 19:20:14,382 - process_medbrowse_questions - INFO - Running workflow (attempt 4) with params: max_plan_iterations=1, max_step_num=3
2025-06-18 19:20:14,384 - src.workflow - INFO - Starting async workflow with user input: "For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter 'C'.\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name."
2025-06-18 19:20:14,407 - src.graph.nodes - INFO - Coordinator talking.
2025-06-18 19:20:14,407 - src.graph.nodes - INFO - Starting new research session - clearing previous sources
2025-06-18 19:20:14,407 - src.tools.tavily_extractor - DEBUG - Cleared 3 temp sources
2025-06-18 19:20:18,892 - httpx - INFO - HTTP Request: POST https://2791-3-16-2-146.ngrok-free.app/v1/chat/completions "HTTP/1.1 200 OK"
2025-06-18 19:20:18,898 - src.graph.nodes - DEBUG - Current state messages: [HumanMessage(content='"For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter \'C\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name."', additional_kwargs={}, response_metadata={}, id='2f345a35-6d95-49b5-91ca-bdc60ac30081')]
2025-06-18 19:20:18,900 - src.graph.nodes - INFO - background investigation node is running.
2025-06-18 19:20:18,901 - src.tools.decorators - DEBUG - Tool TavilySearchResultsWithImages._run called with parameters: "For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter 'C'.\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name."
2025-06-18 19:20:20,937 - src.tools.tavily_extractor - DEBUG - Stored Tavily source: AIM-Harvard/MedBrowseComp ¬∑ Datasets at Hugging Face
2025-06-18 19:20:20,937 - src.tools.tavily_extractor - DEBUG - Stored Tavily source: Alectinib and Crizotinib in Anaplastic Lymphoma Kinase-positive Non ...
2025-06-18 19:20:20,937 - src.tools.tavily_extractor - DEBUG - Stored Tavily source: Alectinib vs crizotinib in Asian patients with treatment-na√Øve ... - Roche
2025-06-18 19:20:20,940 - src.tools.decorators - DEBUG - Tool TavilySearchResultsWithImages returned: ([{'type': 'page', 'title': 'AIM-Harvard/MedBrowseComp ¬∑ Datasets at Hugging Face', 'url': 'https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp', 'content': '| CRIZOTINIB | "For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter \'C\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient | [...] | PF PRISM CV | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name | [...] | May 12, 2027 | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |', 'score': 0.92684203, 'raw_content': 'AIM-Harvard/MedBrowseComp ¬∑ Datasets at Hugging Face\n\n===============\n\n[![Image 1: Hugging Face\'s logo](https://huggingface.co/front/assets/huggingface_logo-noborder.svg)Hugging Face](https://huggingface.co/)\n\n*   [Models](https://huggingface.co/models)\n*   [Datasets](https://huggingface.co/datasets)\n*   [Spaces](https://huggingface.co/spaces)\n*    Community  \n*   [Docs](https://huggingface.co/docs)\n*   [Enterprise](https://huggingface.co/enterprise)\n*   [Pricing](https://huggingface.co/pricing)\n*    \n*   \n* * *\n\n*   [Log In](https://huggingface.co/login)\n*   [Sign Up](https://huggingface.co/join)\n\n[Datasets:](https://huggingface.co/datasets)\n\n* * *\n\n[![Image 2](https://cdn-avatars.huggingface.co/v1/production/uploads/63600b93d9e4214b9a67807c/ZRnXCRmf600I8gTKJH-V0.png)](https://huggingface.co/AIM-Harvard)\n\n[AIM-Harvard](https://huggingface.co/AIM-Harvard)\n\n/\n\n[MedBrowseComp](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp)\n\nlike 1\n\nFollow\n\n![Image 3](https://cdn-avatars.huggingface.co/v1/production/uploads/63600b93d9e4214b9a67807c/ZRnXCRmf600I8gTKJH-V0.png)AIM-Harvard 23\n===================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================\n\nTasks: [Question Answering](https://huggingface.co/datasets?task_categories=task_categories%3Aquestion-answering)[Text Retrieval](https://huggingface.co/datasets?task_categories=task_categories%3Atext-retrieval)\n\nModalities: [Text](https://huggingface.co/datasets?modality=modality%3Atext)\n\nFormats: [csv](https://huggingface.co/datasets?format=format%3Acsv)\n\nLanguages: [English](https://huggingface.co/datasets?language=language%3Aen)\n\nSize: [1K - 10K](https://huggingface.co/datasets?size_categories=size_categories%3A1K%3Cn%3C10K)\n\nArXiv: \n\narxiv:2505.14963\n\nTags: [medical](https://huggingface.co/datasets?other=medical)[healthcare](https://huggingface.co/datasets?other=healthcare)[browsing](https://huggingface.co/datasets?other=browsing)[comparison](https://huggingface.co/datasets?other=comparison)\n\nLibraries: [Datasets](https://huggingface.co/datasets?library=library%3Adatasets)[pandas](https://huggingface.co/datasets?library=library%3Apandas)\n\nCroissant\n\n+ 1\n\nLicense: \n\napache-2.0\n\n[Dataset card](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp)[Data Studio](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/viewer/)[Files Files and versions](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/tree/main)[Community 1](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/discussions)\n\nDataset Viewer\n\n[Auto-converted to Parquet](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/tree/refs%2Fconvert%2Fparquet/default)API Embed Data Studio\n\nSubset (1)\n\ndefault¬∑1.14k rows\n\n \n\nSplit (3)\n\nMedBrowseComp_50¬∑50 rows\n\n \n\nSQL \n\n Console \n\n| gold string lengths 5 24 | prompt string lengths 227 657 | task_name string classes 5 values |\n| --- | --- | --- |\n| ENZALUTAMIDE | "For clinical trial NCT00974311. Among the more effective regimen ingredients, find which ingredient starts with the letter \'E\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| CRIZOTINIB | "For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter \'C\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| LENALIDOMIDE | "For clinical trial NCT01938001. Among the more effective regimen ingredients, find which ingredient starts with the letter \'L\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| AZACITIDINE | "For clinical trial NCT00071799. Among the more effective regimen ingredients, find which ingredient starts with the letter \'A\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| IRINOTECAN HYDROCHLORIDE | "For clinical trial NCT00720512. Among the more effective regimen ingredients, find which ingredient starts with the letter \'I\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| VENETOCLAX | "For clinical trial NCT02755597. Among the more effective regimen ingredients, find which ingredient starts with the letter \'V\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| DEXAMETHASONE | "For clinical trial NCT00833833. Among the more effective regimen ingredients, find which ingredient starts with the letter \'D\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| IBRUTINIB | "For clinical trial NCT01973387. Among the more effective regimen ingredients, find which ingredient starts with the letter \'I\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| LENALIDOMIDE | "For clinical trial NCT00843882. Among the more effective regimen ingredients, find which ingredient starts with the letter \'L\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| SIROLIMUS | "For clinical trial NCT01231412. Among the more effective regimen ingredients, find which ingredient starts with the letter \'S\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| ASTELLAS | "First, for clinical trial NCT00974311, among the more effective regimen ingredients, identify which ingredient starts with the letter \'E\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| PF PRISM CV | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| BRISTOL MYERS SQUIBB | "First, for clinical trial NCT01938001, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| BRISTOL | "First, for clinical trial NCT00071799, among the more effective regimen ingredients, identify which ingredient starts with the letter \'A\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| IPSEN | "First, for clinical trial NCT00720512, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| ABBVIE | "First, for clinical trial NCT02755597, among the more effective regimen ingredients, identify which ingredient starts with the letter \'V\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| DEXCEL | "First, for clinical trial NCT00833833, among the more effective regimen ingredients, identify which ingredient starts with the letter \'D\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| PHARMACYCLICS LLC | "First, for clinical trial NCT01973387, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| BRISTOL MYERS SQUIBB | "First, for clinical trial NCT00843882, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| AADI SUB | "First, for clinical trial NCT01231412, among the more effective regimen ingredients, identify which ingredient starts with the letter \'S\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| Aug 13, 2027 | "First, for clinical trial NCT00974311, among the more effective regimen ingredients, identify which ingredient starts with the letter \'E\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| May 12, 2027 | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Apr 27, 2027 | "First, for clinical trial NCT01938001, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| May 14, 2029 | "First, for clinical trial NCT00071799, among the more effective regimen ingredients, identify which ingredient starts with the letter \'A\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Jan 6, 2027 | "First, for clinical trial NCT00720512, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Jan 29, 2032 | "First, for clinical trial NCT02755597, among the more effective regimen ingredients, identify which ingredient starts with the letter \'V\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Dec 18, 2037 | "First, for clinical trial NCT00833833, among the more effective regimen ingredients, identify which ingredient starts with the letter \'D\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Dec 3, 2031 | "First, for clinical trial NCT01973387, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Apr 27, 2027 | "First, for clinical trial NCT00843882, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Mar 5, 2036 | "First, for clinical trial NCT01231412, among the more effective regimen ingredients, identify which ingredient starts with the letter \'S\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Nov 17, 2026 | "For clinical trial NCT00974311, among the more effective regimen ingredients, identify which ingredient starts with the letter \'E\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Jul 14, 2025 | "For clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| May 28, 2026 | "For clinical trial NCT01938001, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Sep 1, 2027 | "For clinical trial NCT00071799, among the more effective regimen ingredients, identify which ingredient starts with the letter \'A\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Feb 13, 2031 | "For clinical trial NCT00720512, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| May 15, 2026 | "For clinical trial NCT02755597, among the more effective regimen ingredients, identify which ingredient starts with the letter \'V\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Oct 3, 2026 | "For clinical trial NCT00833833, among the more effective regimen ingredients, identify which ingredient starts with the letter \'D\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Aug 24, 2029 | "For clinical trial NCT01973387, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| May 28, 2026 | "For clinical trial NCT00843882, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Nov 22, 2028 | "For clinical trial NCT01231412, among the more effective regimen ingredients, identify which ingredient starts with the letter \'S\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| 15.98999977 | "For clinical trial NCT00974311, review the more effective regimen ingredients and identify which ingredient starts with the letter \'E\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 34.47000122 | "For clinical trial NCT02838420, review the less effective regimen ingredients and identify which ingredient starts with the letter \'C\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 46.72999954 | "For clinical trial NCT01938001, review the more effective regimen ingredients and identify which ingredient starts with the letter \'L\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 62.20000076 | "For clinical trial NCT00071799, review the more effective regimen ingredients and identify which ingredient starts with the letter \'A\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 15.14000034 | "For clinical trial NCT00720512, review the more effective regimen ingredients and identify which ingredient starts with the letter \'I\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 58.59000015 | "For clinical trial NCT02755597, review the more effective regimen ingredients and identify which ingredient starts with the letter \'V\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| NOT LISTED | "For clinical trial NCT00833833, review the more effective regimen ingredients and identify which ingredient starts with the letter \'D\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| NOT LISTED | "For clinical trial NCT01973387, review the more effective regimen ingredients and identify which ingredient starts with the letter \'I\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 46.72999954 | "For clinical trial NCT00843882, review the more effective regimen ingredients and identify which ingredient starts with the letter \'L\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 39.84000015 | "For clinical trial NCT01231412, review the more effective regimen ingredients and identify which ingredient starts with the letter \'S\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n\n*   [Datasets](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#datasets "Datasets")\n\n*   [Usage](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#usage "Usage")\n\n*   [GitHub Repository](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#github-repository "GitHub Repository")\n\n*   [Citation](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#citation "Citation")\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#medbrowsecomp-dataset) MedBrowseComp Dataset\n=========================================================================================================\n\nThis repository contains datasets for medical information-seeking-oriented deep research and computer use tasks.\n\n[![Image 4: Overall](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/resolve/main/medcomp.png)](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/blob/main/medcomp.png)\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#datasets) Datasets\n-------------------------------------------------------------------------------\n\nThe repository contains three harmonized datasets:\n\n1.   **MedBrowseComp_50**: A collection of 50 medical entries for browsing and comparison.\n2.   **MedBrowseComp_605**: A comprehensive collection of 605 medical entries.\n3.   **MedBrowseComp_CUA**: A curated collection of medical data for comparison and analysis.\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#usage) Usage\n-------------------------------------------------------------------------\n\nThese datasets can be used for various medical text processing tasks, information retrieval, and comparative analysis.\n\nExample usage with the Hugging Face datasets library:\n\n```python\nfrom datasets import load_dataset\n\n# Load the dataset\ndataset = load_dataset("AIM-Harvard/MedBrowseComp")\n\n# Access specific splits\nmed50_data = dataset["MedBrowseComp_50"]\nmed605_data = dataset["MedBrowseComp_605"]\ncua_data = dataset["MedBrowseComp_CUA"]\n```\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#github-repository) GitHub Repository\n-------------------------------------------------------------------------------------------------\n\nFor more information and related tools, visit: [https://github.com/MedBrowseComp](https://github.com/MedBrowseComp)\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#citation) Citation\n-------------------------------------------------------------------------------\n\nIf you use this dataset in your research, please cite: [https://arxiv.org/abs/2505.14963](https://arxiv.org/abs/2505.14963)\n\n```\n@misc{chen2025medbrowsecompbenchmarkingmedicaldeep,\n      title={MedBrowseComp: Benchmarking Medical Deep Research and Computer Use}, \n      author={Shan Chen and Pedro Moreira and Yuxin Xiao and Sam Schmidgall and Jeremy Warner and Hugo Aerts and Thomas Hartvigsen and Jack Gallifant and Danielle S. Bitterman},\n      year={2025},\n      eprint={2505.14963},\n      archivePrefix={arXiv},\n      primaryClass={cs.CL},\n      url={https://arxiv.org/abs/2505.14963}, \n}\n```\n\nDownloads last month 179\n\n Use this dataset \n\nSize of downloaded dataset files: 448 kB[Size of the auto-converted Parquet files: 58 kB](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/tree/refs%2Fconvert%2Fparquet/)Number of rows: 1,139\n\nCollection including AIM-Harvard/MedBrowseComp\n----------------------------------------------\n\n[#### MedBrowseComp Collection MedBrowseComp: Benchmarking Medical Deep Research and Computer Use‚Ä¢ 3 items‚Ä¢ Updated 10 days ago](https://huggingface.co/collections/AIM-Harvard/medbrowsecomp-6822637df90521b5d8b8b23f)\n\n System theme \n\nCompany\n\n[TOS](https://huggingface.co/terms-of-service)[Privacy](https://huggingface.co/privacy)[About](https://huggingface.co/huggingface)[Jobs](https://apply.workable.com/huggingface/)[](https://huggingface.co/)\n\nWebsite\n\n[Models](https://huggingface.co/models)[Datasets](https://huggingface.co/datasets)[Spaces](https://huggingface.co/spaces)[Pricing](https://huggingface.co/pricing)[Docs](https://huggingface.co/docs)\n'}, {'type': 'page', 'title': 'Alectinib and Crizotinib in Anaplastic Lymphoma Kinase-positive Non ...', 'url': 'https://ichgcp.net/clinical-trials-registry/NCT02838420', 'content': 'USA (FDA)\n       UK (MHRA)\n       AUSTRALIA (NHMRC)\n       JAPAN (PMDA)\n       EU (EMA)\n\n   CRO List\n   Clinical Trials\n\n       US Clinical Trials Registry\n       EU Clinical Trials Registry\n       Pharmaceutical Companies\n       Clinical Research Labs\n       Service Companies\n       Clinical Research Events\n       Publications\n       Researchers\n\n   Jobs\n   Publications\n   News\n\n   \n   \n\n   ICH GCP\n   US Clinical Trials Registry\n   Clinical Trial NCT02838420', 'score': 0.54724693, 'raw_content': 'Published Time: 2022-12-12T02:32:10+00:00\n\nAlectinib and Crizotinib in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer - Clinical Trials Registry - ICH GCP\n\n===============\n\n[![Image 1: ICHGCP](https://ichgcp.net/img/ichgcp_logo.png)](https://ichgcp.net/)\n\n*   Regulations\n\n    *   [GLOBAL¬ª](https://ichgcp.net/clinical-trials-registry/NCT02838420#)\n\n        *   [ICH GCP (De)](https://ichgcp.net/de)\n        *   [ICH GCP (En)](https://ichgcp.net/)\n        *   [ICH GCP (Es)](https://ichgcp.net/es)\n        *   [ICH GCP (Fr)](https://ichgcp.net/fr)\n        *   [ICH GCP (It)](https://ichgcp.net/it)\n        *   [ICH GCP (Pt)](https://ichgcp.net/pt)\n        *   [ICH GCP (Ru)](https://ichgcp.net/ru)\n\n    *   [USA (FDA)](https://ichgcp.net/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects)\n    *   [UK (MHRA)](https://ichgcp.net/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol)\n    *   [AUSTRALIA (NHMRC)](https://ichgcp.net/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia)\n    *   [JAPAN (PMDA)](https://ichgcp.net/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan)\n    *   [EU (EMA)](https://ichgcp.net/ich-e-group-of-guidelines)\n\n*   [CRO List](https://ichgcp.net/cro-list)\n*   Clinical Trials\n\n    *   [US Clinical Trials Registry](https://ichgcp.net/clinical-trials-registry)\n    *   [EU Clinical Trials Registry](https://ichgcp.net/eu-clinical-trials-registry)\n    *   [Pharmaceutical Companies](https://ichgcp.net/pharma-list)\n    *   [Clinical Research Labs](https://ichgcp.net/labs)\n    *   [Service Companies](https://ichgcp.net/service-companies)\n    *   [Clinical Research Events](https://ichgcp.net/events)\n    *   [Publications](https://ichgcp.net/clinical-trials-registry/publications)\n    *   [Researchers](https://ichgcp.net/clinical-trials-registry/researchers)\n\n*   [Jobs](https://ichgcp.net/jobs)\n*   [Publications](https://ichgcp.net/publications)\n*   [News](https://ichgcp.net/news)\n\n*   [](https://telegram.me/share/url?url=https://ichgcp.net/clinical-trials-registry/NCT02838420&text= "Share on telegram")\n*   [](https://twitter.com/intent/tweet?url=https://ichgcp.net/clinical-trials-registry/NCT02838420 "Share on Twitter")\n\n*   [ICH GCP](https://ichgcp.net/)\n*   [US Clinical Trials Registry](https://ichgcp.net/clinical-trials-registry)\n*   Clinical Trial NCT02838420\n\nA Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)\n=========================================================================================================================================================================================================================================================================\n\nMarch 24, 2025 updated by: [Hoffmann-La Roche](https://ichgcp.net/clinical-trials-registry/research/list?spons=Hoffmann-La%20Roche "List all studies sponsored by Hoffmann-La Roche")\n\nRandomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Asian Patients With Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer\n--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\nThis randomized, multicenter, Phase III, open-label study will evaluate the efficacy and safety of alectinib versus crizotinib and to evaluate the pharmacokinetics of alectinib in asian participants with treatment-naive ALK-positive advanced NSCLC. Participants will be randomized 2:1 into one of the two treatment groups to receive either alectinib (600 milligrams [mg] twice daily [BID]) or crizotinib (250 mg BID) orally, respectively.\n\nStudy Overview\n--------------\n\n#### Status\n\nActive, not recruiting\n\n#### Conditions\n\n*   [Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%20Lymphoma%20Kinase-positive%20Non-small%20Cell%20Lung%20Cancer "List all studies focused on condition Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer")\n\n#### Intervention / Treatment\n\n*   [Drug: Alectinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Alectinib "List all studies with intervention Alectinib")\n*   [Drug: Crizotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Crizotinib "List all studies with intervention Crizotinib")\n\n#### Study Type\n\n Interventional \n\n#### Enrollment (Actual)\n\n 187 \n\n#### Phase\n\n*   Phase 3\n\nContacts and Locations\n----------------------\n\nThis section provides the contact details for those conducting the study, and information on where this study is being conducted.\n\n### Study Locations\n\n*   [China](https://ichgcp.net/clinical-trials-registry/research/list?locn=China "List all studies conducted in China") \n    *           *   Beijing, China, 100142 \n            *   Beijing Cancer Hospital\n\n        *   Beijing, China, 101149 \n            *   Beijing Chest Hospital\n\n        *   Changchun, China, 130021 \n            *   The First Hospital of Jilin University\n\n        *   Changchun, China, 132013 \n            *   Jilin cancer hospital\n\n        *   Chengdu, China, 610041 \n            *   West China Hospital, Sichuan University\n\n        *   Guangzhou, China, 510060 \n            *   Sun Yet-sen University Cancer Center\n\n        *   Guangzhou, China, 510080 \n            *   Guangdong General Hospital\n\n        *   Guangzhou, China, 510120 \n            *   The First Affiliated Hospital of Guangzhou Medical University\n\n        *   Hangzhou, China, 310003 \n            *   The First Affiliated Hospital of College of Medicine, Zhejiang University\n\n        *   Hangzhou, China, 310022 \n            *   Zhejiang Cancer Hospital\n\n        *   Harbin, China, 150081 \n            *   Harbin Medical University Cancer Hospital\n\n        *   Nanjing, China, 210009 \n            *   Jiangsu Cancer Hospital\n\n        *   Shanghai, China, 200030 \n            *   Shanghai Chest Hospital\n\n        *   Shanghai, China, 200032 \n            *   Fudan University Shanghai Cancer Center\n\n        *   Shanghai, China, 200433 \n            *   Shanghai Pulmonary Hospital\n\n*   [Korea, Republic of](https://ichgcp.net/clinical-trials-registry/research/list?locn=Korea%2C%20Republic%20of "List all studies conducted in Korea, Republic of") \n    *           *   Seoul, Korea, Republic of, 05505 \n            *   Asan Medical Center\n\n        *   Seoul, Korea, Republic of, 06351 \n            *   Samsung Medical Center\n\n        *   Seoul, Korea, Republic of, 03181 \n            *   Kangbuk Samsung Hospital\n\n*   [Thailand](https://ichgcp.net/clinical-trials-registry/research/list?locn=Thailand "List all studies conducted in Thailand") \n    *           *   Bangkok, Thailand, 10400 \n            *   Rajavithi Hospital\n\n        *   Bangkok, Thailand, 10400 \n            *   Ramathibodi Hospital\n\n        *   Songkhla, Thailand, 90110 \n            *   Songklanagarind hospital\n\nParticipation Criteria\n----------------------\n\nResearchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person\'s general health condition or prior treatments.\n\n### Eligibility Criteria\n\n#### Ages Eligible for Study\n\n 18 years and older (Adult, Older Adult) \n\n#### Accepts Healthy Volunteers\n\n No \n\n#### Description\n\nInclusion Criteria:\n\n*   Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive as assessed by the Ventana immunohistochemistry (IHC) test. Sufficient tumor tissue available to perform ALK IHC is required. Ventana IHC testing will be performed at the designated central laboratory\n*   Life expectancy of at least 12 weeks\n*   Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2\n*   No history of receiving systemic treatment for advanced, recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC\n*   Adequate hematologic function: Platelet count greater than equal to (>=) 100√ó10^9 per liter (/L); absolute neutrophil count (ANC) >=1500 cells per microliter (cells/mcL); hemoglobin>=9.0 grams per deciliter (g/dL)\n*   Adequate renal function: an estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease (MDRD) formula of >=45 milliliters per minute per 1.73 square meter\n*   Participants must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before receiving the first dose of study treatment\n*   Measurable disease (by Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v1.1]) before administration of study treatment\n*   Previous brain or leptomeningeal metastases are allowed if the participant is asymptomatic (e.g., diagnosed incidentally at study baseline). Asymptomatic central nervous system (CNS) lesions may be treated at the discretion of the investigator as per local clinical practice. If participant has neurological symptoms or signs because of CNS metastasis, the participant must complete whole-brain radiation or gamma knife irradiation treatment. In all cases, radiation treatment must be completed >=14 days before enrollment and disease must be clinically stable\n*   For all females of childbearing potential, a negative serum pregnancy test result must be obtained within 3 days prior to starting study treatment\n*   For women who are not postmenopausal (>=12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus), agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Examples of contraceptive methods with a failure rate of <1% per year include tubal ligation, male sterilization, hormonal implants, established, proper use of combined oral or injected hormonal contraceptives, and certain intrauterine devices. Alternatively, two methods (e.g., two barrier methods such as a condom and a cervical cap) may be combined to achieve a failure rate of <1% per year. Barrier methods must always be supplemented with the use of a spermicide\n*   For men, agreement to remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception\n\nExclusion Criteria:\n\n*   A malignancy within the previous 3 years (other than curatively treated basal cell carcinoma of the skin, early gastrointestinal (GI) cancer by endoscopic resection, in situ carcinoma of the cervix, or any cured cancer that is considered to have no impact in progression-free survival (PFS) or overall survival (OS) for the current NSCLC)\n*   Any GI disorder that may affect absorption of oral medications, such as malabsorption syndrome or status post-major bowel resection\n*   Liver disease characterized by:\n*   Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than (>) 3√ó the upper limit of normal (ULN; >=5√óULN for participants with concurrent liver metastases) confirmed on two consecutive measurements; or\n*   Impaired excretory function (e.g., hyperbilirubinemia), synthetic function, or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices; or\n*   Acute viral or active autoimmune, alcoholic, or other types of hepatitis\n*   National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 Grade 3 or higher toxicities because of any previous therapy (e.g., radiotherapy) (excluding alopecia), which have not shown improvement and are strictly considered to interfere with current study medication\n*   History of organ transplant\n*   Co-administration of anti-cancer therapies other than those administered in this study\n*   Baseline QTc >470 ms or symptomatic bradycardia\n*   Administration of strong/potent cytochrome P4503A inhibitors or inducers within 14 days prior to the receiving the first dose of study treatment and during treatment with alectinib or crizotinib\n*   Administration of agents with potential QT interval prolonging effects within 14 days prior to receiving the first dose of study drug\n*   History of hypersensitivity to any of the additives in the alectinib or crizotinib drug formulation\n*   Pregnant or lactating\n*   Known human immunodeficiency virus (HIV-positivity or acquired immunodeficiency syndrome (AIDS)-related illness\n*   Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or the absorption of oral medications or that would, in the opinion of the Principal Investigator, pose an unacceptable risk to the participant in this study\n*   Any psychological, familial, sociological, or geographical condition that potentially hampers compliance with the study protocol requirements or follow-up procedures; those conditions should be discussed with the participant before study entry\n\nStudy Plan\n----------\n\nThis section provides details of the study plan, including how the study is designed and what the study is measuring.\n\n### How is the study designed?\n\n#### Design Details\n\n*   **Primary Purpose**: Treatment\n*   **Allocation**: Randomized\n*   **Interventional Model**: Parallel Assignment\n*   **Masking**: None (Open Label)\n\n#### Number of Arms\n\n2\n\n#### Arms and Interventions\n\n| ##### Participant Group / Arm | ##### Intervention / Treatment |\n| --- | --- |\n| Experimental: Alectinib Participants will receive alectinib capsules orally at a dose of 600 mg BID with food until disease progression, unacceptable toxicity withdrawal of consent, or death. | [Drug: Alectinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Alectinib "List all studies with intervention Alectinib") Alectinib capsules will be administered orally at a dose of 600 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death. Other Names: * RO5424802 |\n| Active Comparator: Crizotinib Participants will receive crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity withdrawal of consent, or death. | [Drug: Crizotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Crizotinib "List all studies with intervention Crizotinib") Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death. |\n\n### What is the study measuring?\n\n#### Primary Outcome Measures\n\n| ##### Outcome Measure | ##### Measure Description | ##### Time Frame |\n| --- | --- | --- |\n| Progression-Free Survival (PFS) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 Time Frame: From the date of randomization to the date of the first documented disease progression or death, whichever occurred first (up to overall period of approximately 40 months) | PFS was defined as the time (in months) from randomization to the first documentation of disease progression, as determined by the investigators, or to death from any cause, whichever occurred first. | From the date of randomization to the date of the first documented disease progression or death, whichever occurred first (up to overall period of approximately 40 months) |\n\n#### Secondary Outcome Measures\n\n| ##### Outcome Measure | ##### Measure Description | ##### Time Frame |\n| --- | --- | --- |\n| PFS as Determined by Independent Review Committee (IRC) Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) | PFS was defined as the time (in months) from randomization to the first documentation of disease progression, as determined by an independent review committee, or to death from any cause, whichever occurred first. | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Percentage of Participants With Objective Response of Complete Response (CR) or Partial Response (PR) as Determined by Investigator Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Time to Progression of Disease in the CNS as Determined by IRC Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Time to Progression of Disease in the CNS as Determined by IRC Using Response Assessment in Neuro-Oncology (RANO) Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Duration of Response (DOR) Assessed by Investigator Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Overall Survival Time Time Frame: Baseline, until death (up to overall period of approximately 40 months) |  | Baseline, until death (up to overall period of approximately 40 months) |\n| Percentage of Participants With Non-serious Adverse Events and Serious Adverse Events Time Frame: Up to overall period of approximately 40 months | An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. | Up to overall period of approximately 40 months |\n| Time to Deterioration Assessed Using EORTC Quality of Life Questionnaire-Core (QLQ-C30) Score Time Frame: Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Time to Deterioration Assessed Using EORTC Quality of Life Questionnaire-Lung Cancer Module (QLQ-LC13) Score Time Frame: Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Area Under the Plasma Concentration-time Curve (AUC) of Alectinib and Its Metabolite Time Frame: Baseline and Week 4 predose (within 2 hours before administration of study drug) | AUC was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time. | Baseline and Week 4 predose (within 2 hours before administration of study drug) |\n| Maximum Plasma Concentration Observed (Cmax) of Alectinib and Its Metabolite Time Frame: Baseline and Week 4 predose (within 2 hours before administration of study drug) | Cmax was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time. | Baseline and Week 4 predose (within 2 hours before administration of study drug) |\n| Time to Cmax (Tmax) of Alectinib and Its Metabolite Time Frame: Baseline and Week 4 predose (within 2 hours before administration of study drug) | Tmax was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time. | Baseline and Week 4 predose (within 2 hours before administration of study drug) |\n\nCollaborators and Investigators\n-------------------------------\n\nThis is where you will find people and organizations involved with this study.\n\n#### Sponsor\n\n[Hoffmann-La Roche](https://ichgcp.net/clinical-trials-registry/research/list?spons=Hoffmann-La%20Roche "List all studies sponsored by Hoffmann-La Roche")\n\n#### Investigators\n\n*    Study Director: Clinical Trials, Hoffmann-La Roche \n\nPublications and helpful links\n------------------------------\n\nThe person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.\n\n#### General Publications\n\n*   [Zhou C, Kim SW, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang JJ, Cheng Y, Lee SH, Bu L, Xu T, Yang L, Wang C, Liu T, Morcos PN, Lu Y, Zhang L. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med. 2019 May;7(5):437-446. doi: 10.1016/S2213-2600(19)30053-0. Epub 2019 Apr 10.](https://pubmed.ncbi.nlm.nih.gov/30981696)\n\nStudy record dates\n------------------\n\nThese dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.\n\n### Study Major Dates\n\n#### Study Start (Actual)\n\n August 3, 2016 \n\n#### Primary Completion (Actual)\n\n May 31, 2018 \n\n#### Study Completion (Estimated)\n\n December 31, 2025 \n\n### Study Registration Dates\n\n#### First Submitted\n\nJuly 18, 2016\n\n#### First Submitted That Met QC Criteria\n\nJuly 18, 2016\n\n#### First Posted (Estimated)\n\nJuly 20, 2016\n\n### Study Record Updates\n\n#### Last Update Posted (Actual)\n\nMarch 25, 2025\n\n#### Last Update Submitted That Met QC Criteria\n\nMarch 24, 2025\n\n#### Last Verified\n\nMarch 1, 2025\n\nMore Information\n----------------\n\n### Terms related to this study\n\n#### Additional Relevant MeSH Terms\n\n*   [Neoplasms by Site](https://ichgcp.net/clinical-trials-registry/research/list?cond=Neoplasms%20by%20Site "List all studies by MeSH term: Neoplasms by Site")\n*   [Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Neoplasms "List all studies by MeSH term: Neoplasms")\n*   [Immune System Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Immune%20System%20Diseases "List all studies by MeSH term: Immune System Diseases")\n*   [Respiratory Tract Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Diseases "List all studies by MeSH term: Respiratory Tract Diseases")\n*   [Neoplasms by Histologic Type](https://ichgcp.net/clinical-trials-registry/research/list?cond=Neoplasms%20by%20Histologic%20Type "List all studies by MeSH term: Neoplasms by Histologic Type")\n*   [Lung Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%20Diseases "List all studies by MeSH term: Lung Diseases")\n*   [Respiratory Tract Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Neoplasms "List all studies by MeSH term: Respiratory Tract Neoplasms")\n*   [Thoracic Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Thoracic%20Neoplasms "List all studies by MeSH term: Thoracic Neoplasms")\n*   [Lymphatic Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphatic%20Diseases "List all studies by MeSH term: Lymphatic Diseases")\n*   [Lymphoproliferative Disorders](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoproliferative%20Disorders "List all studies by MeSH term: Lymphoproliferative Disorders")\n*   [Immunoproliferative Disorders](https://ichgcp.net/clinical-trials-registry/research/list?cond=Immunoproliferative%20Disorders "List all studies by MeSH term: Immunoproliferative Disorders")\n*   [Carcinoma, Bronchogenic](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%2C%20Bronchogenic "List all studies by MeSH term: Carcinoma, Bronchogenic")\n*   [Bronchial Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Bronchial%20Neoplasms "List all studies by MeSH term: Bronchial Neoplasms")\n*   [Lung Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%20Neoplasms "List all studies by MeSH term: Lung Neoplasms")\n*   [Lymphoma](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma "List all studies by MeSH term: Lymphoma")\n*   [Carcinoma, Non-Small-Cell Lung](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%2C%20Non-Small-Cell%20Lung "List all studies by MeSH term: Carcinoma, Non-Small-Cell Lung")\n*   [Tyrosine Kinase Inhibitors](https://ichgcp.net/clinical-trials-registry/research/list?intr=Tyrosine%20Kinase%20Inhibitors "List all studies by MeSH term: Tyrosine Kinase Inhibitors")\n*   [Antineoplastic Agents](https://ichgcp.net/clinical-trials-registry/research/list?intr=Antineoplastic%20Agents "List all studies by MeSH term: Antineoplastic Agents")\n*   [Molecular Mechanisms of Pharmacological Action](https://ichgcp.net/clinical-trials-registry/research/list?intr=Molecular%20Mechanisms%20of%20Pharmacological%20Action "List all studies by MeSH term: Molecular Mechanisms of Pharmacological Action")\n*   [Enzyme Inhibitors](https://ichgcp.net/clinical-trials-registry/research/list?intr=Enzyme%20Inhibitors "List all studies by MeSH term: Enzyme Inhibitors")\n*   [Protein Kinase Inhibitors](https://ichgcp.net/clinical-trials-registry/research/list?intr=Protein%20Kinase%20Inhibitors "List all studies by MeSH term: Protein Kinase Inhibitors")\n*   [Crizotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Crizotinib "List all studies by MeSH term: Crizotinib")\n*   [Alectinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Alectinib "List all studies by MeSH term: Alectinib")\n\n#### Other Study ID Numbers\n\n*    YO29449 \n\n### Drug and device information, study documents\n\n#### Studies a U.S. FDA-regulated drug product\n\n Yes \n\n#### Studies a U.S. FDA-regulated device product\n\n No \n\nThis information was retrieved directly from the website [clinicaltrials.gov](https://clinicaltrials.gov/) without any changes. If you have any requests to change, remove or update your study details, please contact [register@clinicaltrials.gov](mailto:register@clinicaltrials.gov). As soon as a change is implemented on [clinicaltrials.gov](https://clinicaltrials.gov/), this will be updated automatically on our website as well.\n\nClinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer\n---------------------------------------------------------------------------------\n\n*    Pfizer   Completed  [A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001)](https://ichgcp.net/clinical-trials-registry/NCT00585195)  Systemic Anaplastic Large-Cell Lymphoma | Non-Small Cell Lung Cancer ALK-positive | Non-Small Cell Lung Cancer c-Met Dependent | Non-Small Cell Lung Cancer ROS Marker Positive | Advanced Malignancies Except Leukemia   United States, Korea, Republic of, Australia, Japan    \n*    Novartis Pharmaceuticals   Available  [Managed Access Programs for LDK378, Ceritinib](https://ichgcp.net/clinical-trials-registry/NCT05100134)  Non-small Cell Lung Cancer (NSCLC) | Anaplastic Lymphoma Kinase (ALK)- Positive Tumors    \n*    Novartis Pharmaceuticals   Completed  [Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer](https://ichgcp.net/clinical-trials-registry/NCT01772797)  Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase (ALK)   Australia, Spain, Singapore, Italy, United States    \n*    Nuvalent Inc.   Recruiting  [Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC (ALKAZAR)](https://ichgcp.net/clinical-trials-registry/NCT06765109)  Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase-positive   United States    \n*    Intergroupe Francophone de Cancerologie Thoracique   Completed  [Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements (CLINALK)](https://ichgcp.net/clinical-trials-registry/NCT02727335)  Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase Gene Mutation   France    \n*    Takeda   Completed  [A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors](https://ichgcp.net/clinical-trials-registry/NCT03546894)  Carcinoma Non-small-cell Lung | Anaplastic Lymphoma Kinase-positive   United States    \n*    Astellas Pharma Inc   Completed  [Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)](https://ichgcp.net/clinical-trials-registry/NCT01284192)  Solid Tumor | B-Cell Lymphoma | Advanced Malignancies | Positive for Anaplastic Lymphoma Kinase | Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS   United States    \n*    University Medical Center Groningen  Radboud University Medical Center; Maastricht University Medical Center; Erasmus... and other collaborators    Recruiting  [Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels (ADAPT ALEC)](https://ichgcp.net/clinical-trials-registry/NCT05525338)  Carcinoma, Non-Small-Cell Lung | Lung Cancer | Drug Monitoring | Anaplastic Lymphoma Kinase Gene Mutation | Anaplastic Lymphoma Kinase Gene Translocation   Netherlands, France    \n*    Takeda   Withdrawn  [Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors](https://ichgcp.net/clinical-trials-registry/NCT04260009)  Solid Tumors | Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma | Inflammatory Myofibroblastic Tumors    \n*    Massachusetts General Hospital  LUNGevity Foundation; Addario Lung Cancer Medical Institute    Recruiting  [Immune and Genomic Markers in ALK+ NSCLC](https://ichgcp.net/clinical-trials-registry/NCT04881916)  Non-Small Cell Lung Cancer | Anaplastic Lymphoma Kinase Gene Translocation   United States    \n\nClinical Trials on Alectinib\n----------------------------\n\n*    Aarhus University Hospital  Roche Pharma AG    Enrolling by invitation  [Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients (MonAlec)](https://ichgcp.net/clinical-trials-registry/NCT04708639)  Lung Cancer | ALK Gene Mutation | Resistance, Disease | Mutation   Denmark    \n*    Hoffmann-La Roche   Completed  [A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (ATALK)](https://ichgcp.net/clinical-trials-registry/NCT03155009)  Carcinoma, Non-Small-Cell Lung   France    \n*    Hoffmann-La Roche   Completed  [Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea](https://ichgcp.net/clinical-trials-registry/NCT03271554)  Non-Small Cell Lung Cancer   Korea, Republic of    \n*    Dana-Farber Cancer Institute  Genentech, Inc.    Terminated  [A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer](https://ichgcp.net/clinical-trials-registry/NCT03131206)  ALK-positive Non-small Cell Lung Cancer (NSCLC) | RET-positive Non-small Cell Lung Cancer (NSCLC) | RET-positive Thyroid Cancer   United States    \n*    Hoffmann-La Roche   Completed  [Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib](https://ichgcp.net/clinical-trials-registry/NCT02621047)  Hepatic Impairment   Czechia, Slovakia    \n*    Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...  UnitedHealthcare    Not yet recruiting  [Pharmacogenomics IND EXEMPT SNP Clinical Study - Alectinib and Single Nucleotide Polymorphisms (Drugs-SNPs)](https://ichgcp.net/clinical-trials-registry/NCT05987956)  Non-small Cell Lung Cancer   United States    \n*    Hoffmann-La Roche   Terminated  [A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors (ALpha-T)](https://ichgcp.net/clinical-trials-registry/NCT04644315)  Digestive System Diseases | Gastrointestinal Diseases | Melanoma | Sarcoma | Neoplasms | Respiratory Tract Diseases | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasms | Head and Neck Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms and other conditions   United States    \n*    China Medical University Hospital   Active, not recruiting  [Alectinib in Combination with Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided with Serum RNase1 and Tumor Expression of PD-L1](https://ichgcp.net/clinical-trials-registry/NCT06354387)  Hepatocellular Carcinoma   Taiwan    \n*    Genentech, Inc.   No longer available  [Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy](https://ichgcp.net/clinical-trials-registry/NCT02271139)  Non-Small Cell Lung Cancer   United States    \n*    Hoffmann-La Roche   Completed  [A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)](https://ichgcp.net/clinical-trials-registry/NCT01871805)  Non-Small Cell Lung Cancer   United States, Canada    \n\nSearch Similar Trials\n---------------------\n\n*   [Clinical Trials on Lymphoma in Singapore](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=Singapore)\n*   [Clinical Trials on Lymphosarcoma in Australia](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=Australia)\n*   [Clinical Trials on Carcinoma, Non-Small-Cell Lung in Singapore](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BNon-Small-Cell%2BLung&locn=Singapore)\n*   [Clinical Trials on Lymphoma in New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=New%2BZealand)\n*   [Clinical Trials on Carcinoma, Non-Small-Cell Lung in United States](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BNon-Small-Cell%2BLung&locn=United%2BStates)\n*   [Clinical Trials on Lung Neoplasms in Ireland](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%2BNeoplasms&locn=Ireland)\n*   [Clinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%2BLymphoma%2BKinase-positive%2BNon-small%2BCell%2BLung%2BCancer&locn=South%2BAfrica)\n*   [Clinical Trials on Lymphosarcoma in India](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=India)\n*   [Clinical Trials on Lymphoma in United States](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=United%2BStates)\n*   [Clinical Trials on Lymphoma in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=South%2BAfrica)\n*   [Clinical Trials on Lymphoma in Hong Kong](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=Hong%2BKong)\n*   [Clinical Trials on Lymphosarcoma in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=South%2BAfrica)\n*   [Clinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer in Ireland](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%2BLymphoma%2BKinase-positive%2BNon-small%2BCell%2BLung%2BCancer&locn=Ireland)\n*   [Clinical Trials on Lung Neoplasms in New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%2BNeoplasms&locn=New%2BZealand)\n*   [Clinical Trials on Lung Neoplasms in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%2BNeoplasms&locn=South%2BAfrica)\n*   [Clinical Trials on Lymphoma in India](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=India)\n*   [Clinical Trials on Lymphosarcoma in Singapore](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=Singapore)\n*   [Clinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer in New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%2BLymphoma%2BKinase-positive%2BNon-small%2BCell%2BLung%2BCancer&locn=New%2BZealand)\n*   [Clinical Trials on Lymphosarcoma in United States](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=United%2BStates)\n*   [Clinical Trials on Carcinoma, Non-Small-Cell Lung in United Kingdom](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BNon-Small-Cell%2BLung&locn=United%2BKingdom)\n*   [Search All Trials](https://ichgcp.net/clinical-trials-registry/research/list)\n\nSponsors and Collaborators\n--------------------------\n\n*   [Eisai Korea Inc.](https://ichgcp.net/clinical-trials-registry/research/list?spons=Eisai%2BKorea%2BInc.)\n*   [Leukaemia & Blood Cancer New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?spons=Leukaemia%2B%2526%2BBlood%2BCancer%2BNew%2BZealand)\n*   [Udaan](https://ichgcp.net/clinical-trials-registry/research/list?spons=Udaan)\n*   [Makarenko Irina Romanovna](https://ichgcp.net/clinical-trials-registry/research/list?spons=Makarenko%2BIrina%2BRomanovna)\n*   [Adriane Aver Vanin](https://ichgcp.net/clinical-trials-registry/research/list?spons=Adriane%2BAver%2BVanin)\n*   [University of Memphis](https://ichgcp.net/clinical-trials-registry/research/list?spons=University%2Bof%2BMemphis)\n*   [Sleep Research Society Foundation](https://ichgcp.net/clinical-trials-registry/research/list?spons=Sleep%2BResearch%2BSociety%2BFoundation)\n*   [Immuron Ltd.](https://ichgcp.net/clinical-trials-registry/research/list?spons=Immuron%2BLtd.)\n*   [Arthro-Anda Tianjin Biologic Technology Co., Ltd.](https://ichgcp.net/clinical-trials-registry/research/list?spons=Arthro-Anda%2BTianjin%2BBiologic%2BTechnology%2BCo.%252C%2BLtd.)\n*   [CoheroHealth](https://ichgcp.net/clinical-trials-registry/research/list?spons=CoheroHealth)\n*   [Center for Military Mental Health, Berlin, Germany](https://ichgcp.net/clinical-trials-registry/research/list?spons=Center%2Bfor%2BMilitary%2BMental%2BHealth%252C%2BBerlin%252C%2BGermany)\n*   [Kevin Flanigan](https://ichgcp.net/clinical-trials-registry/research/list?spons=Kevin%2BFlanigan)\n*   [Periannan Kuppusamy](https://ichgcp.net/clinical-trials-registry/research/list?spons=Periannan%2BKuppusamy)\n*   [Chiang Mai University Hospital, THAILAND](https://ichgcp.net/clinical-trials-registry/research/list?spons=Chiang%2BMai%2BUniversity%2BHospital%252C%2BTHAILAND)\n*   [Centre for Emergency Health Sciences](https://ichgcp.net/clinical-trials-registry/research/list?spons=Centre%2Bfor%2BEmergency%2BHealth%2BSciences)\n*   [Therapex Co., Ltd](https://ichgcp.net/clinical-trials-registry/research/list?spons=Therapex%2BCo.%252C%2BLtd)\n*   [MIT William Asbjornsen Albert Memorial Fellowship](https://ichgcp.net/clinical-trials-registry/research/list?spons=MIT%2BWilliam%2BAsbjornsen%2BAlbert%2BMemorial%2BFellowship)\n*   [Fabiana Aceto](https://ichgcp.net/clinical-trials-registry/research/list?spons=Fabiana%2BAceto)\n*   [North American Spine Society](https://ichgcp.net/clinical-trials-registry/research/list?spons=North%2BAmerican%2BSpine%2BSociety)\n*   [SGS proderm GmbH](https://ichgcp.net/clinical-trials-registry/research/list?spons=SGS%2Bproderm%2BGmbH)\n*   [View Full List](https://ichgcp.net/clinical-trials-registry/research/browse/spns_alpha_all)\n\nMedical Conditions\n------------------\n\n*   [Infrarenal Abdominal Aortic Aneurysms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Infrarenal%2BAbdominal%2BAortic%2BAneurysms)\n*   [Myeloproliferative Disease, Not Classified](https://ichgcp.net/clinical-trials-registry/research/list?cond=Myeloproliferative%2BDisease%252C%2BNot%2BClassified)\n*   [Lifestyle-related Condition](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lifestyle-related%2BCondition)\n*   [Compliance](https://ichgcp.net/clinical-trials-registry/research/list?cond=Compliance)\n*   [Patients With Opioid Induced Constipation](https://ichgcp.net/clinical-trials-registry/research/list?cond=Patients%2BWith%2BOpioid%2BInduced%2BConstipation)\n*   [Femoral Vascular Anastomosis](https://ichgcp.net/clinical-trials-registry/research/list?cond=Femoral%2BVascular%2BAnastomosis)\n*   [Observation Safety](https://ichgcp.net/clinical-trials-registry/research/list?cond=Observation%2BSafety)\n*   [Improvement of Functionality](https://ichgcp.net/clinical-trials-registry/research/list?cond=Improvement%2Bof%2BFunctionality)\n*   [CD4 Deficiency](https://ichgcp.net/clinical-trials-registry/research/list?cond=CD4%2BDeficiency)\n*   [Malassezia Infection](https://ichgcp.net/clinical-trials-registry/research/list?cond=Malassezia%2BInfection)\n*   [Anti-cancer Cell Immunotherapy](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anti-cancer%2BCell%2BImmunotherapy)\n*   [Health Knowledge Attitudes and Practice](https://ichgcp.net/clinical-trials-registry/research/list?cond=Health%2BKnowledge%2BAttitudes%2Band%2BPractice)\n*   [School Adjustment](https://ichgcp.net/clinical-trials-registry/research/list?cond=School%2BAdjustment)\n*   [Difficult Mask Ventilation](https://ichgcp.net/clinical-trials-registry/research/list?cond=Difficult%2BMask%2BVentilation)\n*   [Intrapartum Mortality](https://ichgcp.net/clinical-trials-registry/research/list?cond=Intrapartum%2BMortality)\n*   [Diabetes Mellitus II](https://ichgcp.net/clinical-trials-registry/research/list?cond=Diabetes%2BMellitus%2BII)\n*   [Painless Myocardial Ischemia](https://ichgcp.net/clinical-trials-registry/research/list?cond=Painless%2BMyocardial%2BIschemia)\n*   [Corona Virus Disease 19 (COVID-19)](https://ichgcp.net/clinical-trials-registry/research/list?cond=Corona%2BVirus%2BDisease%2B19%2B%2528COVID-19%2529)\n*   [Pressure Injury Stage 2](https://ichgcp.net/clinical-trials-registry/research/list?cond=Pressure%2BInjury%2BStage%2B2)\n*   [Escape; Rhythm](https://ichgcp.net/clinical-trials-registry/research/list?cond=Escape%253B%2BRhythm)\n*   [View Full List](https://ichgcp.net/clinical-trials-registry/research/browse/cond_alpha_all)\n\nDrug Interventions\n------------------\n\n*   [Methylprednisolone](https://ichgcp.net/clinical-trials-registry/research/list?intr=Methylprednisolone)\n*   [Anetumab Ravtansine](https://ichgcp.net/clinical-trials-registry/research/list?intr=Anetumab%2BRavtansine)\n*   [ESES treated with clobazam](https://ichgcp.net/clinical-trials-registry/research/list?intr=ESES%2Btreated%2Bwith%2Bclobazam)\n*   [Droperidol Injectable Solution](https://ichgcp.net/clinical-trials-registry/research/list?intr=Droperidol%2BInjectable%2BSolution)\n*   [ATx201](https://ichgcp.net/clinical-trials-registry/research/list?intr=ATx201)\n*   [Cyclophosphamide](https://ichgcp.net/clinical-trials-registry/research/list?intr=Cyclophosphamide)\n*   [Pioglitazone](https://ichgcp.net/clinical-trials-registry/research/list?intr=Pioglitazone)\n*   [Botulinum Toxin A](https://ichgcp.net/clinical-trials-registry/research/list?intr=Botulinum%2BToxin%2BA)\n*   [Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Gefitinib%2B250mg%2Bpo%2Bqd%2Bor%2BTarceva%2B150mg%2Bpo%2Bqd%2Bor%2BIcotinib%2B125mg%2Bpo%2Btid%2BOther%2BName%253A%2BGefitinib%252FTarceva%252FIcotinib)\n*   [Ramosetron](https://ichgcp.net/clinical-trials-registry/research/list?intr=Ramosetron)\n*   [KN046](https://ichgcp.net/clinical-trials-registry/research/list?intr=KN046)\n*   [Doxorubicin](https://ichgcp.net/clinical-trials-registry/research/list?intr=Doxorubicin)\n*   [Corticosteroids (CS)](https://ichgcp.net/clinical-trials-registry/research/list?intr=Corticosteroids%2B%2528CS%2529)\n*   [Dimenhydrinate](https://ichgcp.net/clinical-trials-registry/research/list?intr=Dimenhydrinate)\n*   [Ropivacaine 150 mg](https://ichgcp.net/clinical-trials-registry/research/list?intr=Ropivacaine%2B150%2Bmg)\n*   [Iso-Fludelone](https://ichgcp.net/clinical-trials-registry/research/list?intr=Iso-Fludelone)\n*   [Clonidine](https://ichgcp.net/clinical-trials-registry/research/list?intr=Clonidine)\n*   [Lidocaine topical](https://ichgcp.net/clinical-trials-registry/research/list?intr=Lidocaine%2Btopical)\n*   [Nusinersen](https://ichgcp.net/clinical-trials-registry/research/list?intr=Nusinersen)\n*   [Cyclophosphamide and fludarabine](https://ichgcp.net/clinical-trials-registry/research/list?intr=Cyclophosphamide%2Band%2Bfludarabine)\n*   [View Full List](https://ichgcp.net/clinical-trials-registry/research/browse/intr_alpha_all)\n\n### CROs by country\n\n*   [Contract Research Organizations in Azerbaijan](https://ichgcp.net/cro-list/country/azerbaijan)\n*   [Contract Research Organizations in Bulgaria](https://ichgcp.net/cro-list/country/bulgaria)\n*   [Contract Research Organizations in Burundi](https://ichgcp.net/cro-list/country/burundi)\n*   [Contract Research Organizations in Dominican Republic](https://ichgcp.net/cro-list/country/dominican_republic)\n*   [Contract Research Organizations in Kosovo](https://ichgcp.net/cro-list/country/kosovo)\n*   [Contract Research Organizations in Mexico](https://ichgcp.net/cro-list/country/mexico)\n*   [Contract Research Organizations in Moldova](https://ichgcp.net/cro-list/country/moldova)\n*   [Contract Research Organizations in Poland](https://ichgcp.net/cro-list/country/poland)\n*   [Contract Research Organizations in Slovakia](https://ichgcp.net/cro-list/country/slovakia)\n*   [Contract Research Organizations in Sri Lanka](https://ichgcp.net/cro-list/country/sri_lanka)\n*   [Contract Research Organizations in Ukraine](https://ichgcp.net/cro-list/country/ukraine)\n*   [Contract Research Organizations in United Arab Emirates](https://ichgcp.net/cro-list/country/united_arab_emirates)\n*   [Contract Research Organizations in Uzbekistan](https://ichgcp.net/cro-list/country/uzbekistan)\n*   [CRO list by country](https://ichgcp.net/cro-list)\n\n### CROs in Ghana\n\n*   [54gene‚Äôs Clinical Programs Group (CPG)](https://ichgcp.net/cro-list/country/ghana/company/54gene_s_clinical_programs_group_cpg)\n*   [SGS](https://ichgcp.net/cro-list/country/ghana/company/sgs)\n*   [ACROSS Global](https://ichgcp.net/cro-list/country/ghana/company/across_global)\n*   [All CROs in Ghana](https://ichgcp.net/cro-list/country/ghana)\n\n### Conditions\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/cond_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/cond_cat)\n\n### Rare Diseases\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/ord_alpha_all)\n\n### Drug Interventions\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/intr_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/intr_cat)\n\n### Dietary Supplements\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/diet_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/diet_cat)\n\n### Sponsor/Collaborators\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/spns_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/spns_cat)\n\n### Locations\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/locn_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/locn_cat)\n\nRegulations\n\n*   [GLOBAL (ICH GCP)](https://ichgcp.net/)\n*   [USA (FDA)](https://ichgcp.net/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects)\n*   [UK (MHRA)](https://ichgcp.net/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol)\n*   [AUSTRALIA (NHMRC)](https://ichgcp.net/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia)\n*   [JAPAN (PMDA)](https://ichgcp.net/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan)\n*   [EU (EMA)](https://ichgcp.net/guideline-for-the-notification-of-serious-breaches-of-regulation-eu-no-536-2014)\n\nResources\n\n*   [CRO List](https://ichgcp.net/cro-list)\n*   [Pharmaceutical Companies](https://ichgcp.net/pharma-list)\n*   [Clinical Research Labs](https://ichgcp.net/labs)\n*   [Service Companies](https://ichgcp.net/service-companies)\n*   [Jobs](https://ichgcp.net/cra-jobs)\n*   [US Clinical Trials Registry](https://ichgcp.net/clinical-trials-registry)\n*   [EU Clinical Trials Registry](https://ichgcp.net/eu-clinical-trials-registry)\n\nArticles\n\n*   [Publications](https://ichgcp.net/publications)\n*   [News](https://ichgcp.net/news)\n*   [About us / Our mission](https://ichgcp.net/about-us-our-mission)\n\nSearch trials\n\nExample: Heart Attack\n\n¬© ICH GCP. All Rights Reserved.\n\n*   [Sitemap](https://ichgcp.net/sitemap)\n*   [Contact us](https://ichgcp.net/contact-us)\n*   [RSS feed](https://ichgcp.net/feed)\n*   [Privacy Policy](https://ichgcp.net/privacy)\n*   [Disclaimer](https://ichgcp.net/disclaimer)\n\n English \n\n[Dansk](https://ichgcp.net/da/clinical-trials-registry/NCT02838420)[Deutsch](https://ichgcp.net/de/clinical-trials-registry/NCT02838420)[English](https://ichgcp.net/clinical-trials-registry/NCT02838420)[Espa√±ol](https://ichgcp.net/es/clinical-trials-registry/NCT02838420)[Fran√ßais](https://ichgcp.net/fr/clinical-trials-registry/NCT02838420)[Italiano](https://ichgcp.net/it/clinical-trials-registry/NCT02838420)[Magyar](https://ichgcp.net/hu/clinical-trials-registry/NCT02838420)[Nederlands](https://ichgcp.net/nl/clinical-trials-registry/NCT02838420)[Norsk](https://ichgcp.net/no/clinical-trials-registry/NCT02838420)[Polski](https://ichgcp.net/pl/clinical-trials-registry/NCT02838420)[Portugu√™s](https://ichgcp.net/pt/clinical-trials-registry/NCT02838420)[Suomi](https://ichgcp.net/fi/clinical-trials-registry/NCT02838420)[Svenska](https://ichgcp.net/sv/clinical-trials-registry/NCT02838420)[ƒåe≈°tina](https://ichgcp.net/cs/clinical-trials-registry/NCT02838420)[–†—É—Å—Å–∫–∏–π](https://ichgcp.net/ru/clinical-trials-registry/NCT02838420)[Êó•Êú¨Ë™û](https://ichgcp.net/ja/clinical-trials-registry/NCT02838420)[ÁÆÄ‰Ωì‰∏≠Êñá](https://ichgcp.net/zh/clinical-trials-registry/NCT02838420)[ÌïúÍµ≠Ïñ¥](https://ichgcp.net/ko/clinical-trials-registry/NCT02838420)\n\nGOOD CLINICAL PRACTICE NETWORK\n\nSubscribe to receive notifications of new clinical trials you are interested in.\n\nSubscribe\n\n‚úï\n\nGOOD CLINICAL PRACTICE NETWORK\n\nSubscribe to receive notifications of new clinical trials you are interested in.\n\nSubscribe for upcoming trials that contain the following conditions: \n\n- [x] Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer \n\n[Choose more conditions](https://ichgcp.net/mailing-list/conditions)\n\nSubscribe for upcoming trials that contain the following interventions: \n\n- [x] Alectinib \n\n- [x] Crizotinib \n\n[Choose more interventions](https://ichgcp.net/mailing-list/interventions)\n\nSubscribe for upcoming trials sponsored by: \n\n- [x] Hoffmann-La Roche \n\n[Choose more organizations](https://ichgcp.net/mailing-list/organizations)\n\nSubscribe\n\nSubscribe\n\nSubscribe\n'}, {'type': 'page', 'title': 'Alectinib vs crizotinib in Asian patients with treatment-na√Øve ... - Roche', 'url': 'https://medically.roche.com/global/en/medical-material/ESMO-Asia-2022-presentation-zhou-alectinib-vs-crizotinib-in-asian-patients-with-treatment-naive-advanced-pdf.html', 'content': 'Data cut -off 16 May 2022. ClinicalTrials.gov: NCT02838420. CNS, central nervous system; DOR, duration of response;  ECOG PS, Eastern Cooperative Oncology Group performance status; IHC, immunohistochemistry; INV, investigator \n\nIRC, independent review committee; NSCLC, non -small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, p rogression -free survival \n\n2:1 \n\nN=187 \n\nR\n\nAlectinib \n\n600mg  twice daily \n\nCrizotinib \n\n250mg twice daily \n\nTreat until disease', 'score': 0.5393963, 'raw_content': "Alectinib vs crizotinib in Asian patients \n\n## with treatment -na√Øve advanced  ALK +\n\n## non -small cell lung cancer: 5 -year \n\n## update from the Phase 3 ALESIA study \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nFaculty of Medicine  Ramathibodi  Hospital, Mahidol University, \n\nBangkok, Thailand \n\nZhou C, 1 Lu Y, 2 Kim S -W, 3 Baisamut  (Reungwetwattana) T, 4 Zhou J, 5 Zhang Y, 6 He J, 7 Yang J -J, 8 Cheng Y, 9 Lee S -H, 10  Chang J, 11 \n\nFang J, 12  Liu Z, 13  Bu L, 14  Qian L, 14  Xu T, 14  Archer V, 15  Hilton M, 16  Zhou M, 14  Zhang L 17 \n\n1Shanghai Pulmonary Hospital, Tongji University, Shanghai, China;  2West China Hospital, Sichuan University, Chengdu, China;  3Asan Medical \n\nCenter , University of Ulsan College of Medicine, Seoul, South Korea;  4Faculty of Medicine  Ramathibodi  Hospital, Mahidol University, Bangkok, \n\nThailand;  5The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China;  6Zhejiang Cancer Hospital, Hangzhou, China; \n\n7The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;  8Guangdong Lung Cancer Institute, Guangdong General Hospital, \n\nGuangzhou, China;  9Jilin Cancer Hospital, Changchun, China;  10 Sungkyunkwan University School of Medicine, Seoul, South Korea;  11 Cancer \n\nHospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China;  12 Beijing Cancer \n\nHospital, Beijing, China;  13 Beijing Chest Hospital, Capital Medical University, Beijing, China;  14 Roche Pharma Development, Shanghai, China; \n\n15 Roche Products Ltd, Welwyn Garden City, UK;  16 F. Hoffmann -La Roche Ltd, Basel, Switzerland;  17 Sun  Yat -sen  University Cancer  Center ,\n\nState Key Laboratory of Oncology in South China, Collaborative Innovation  Center  for Cancer Medicine, Guangzhou, China Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## DECLARATION OF INTERESTS \n\nThanyanan  Baisamut  (Reungwetwattana) \n\n‚Ä¢ Received honorarium from AstraZeneca, Pfizer, MSD, Roche, BMS, Amgen, J&J, Novartis,  Yuhan  and  Zuellig \n\n‚Ä¢ Participated as Principal Investigator on clinical trials for AstraZeneca, MSD, Roche, Novartis and  Yuhan   \n\n> Thanyanan Baisamut (Reungwetwattana)\n\nContent of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## ALESIA: alectinib vs crizotinib in treatment -na√Øve Asian patients \n\n## with advanced  ALK+  NSCLC \n\n‚Ä¢ Stratification factors:  ECOG PS (0/1 vs 2) \n\nand CNS metastases at baseline (yes vs no) \n\n‚Ä¢ Primary endpoint:  PFS by INV \n\n‚Ä¢ Secondary endpoints:  Time to CNS \n\nprogression by IRC, ORR by INV, \n\nDOR by INV, OS and safety \n\n‚Ä¢ Median duration of survival follow -up: \n\n61 months  alectinib vs  51 months  crizotinib \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nPatients were enrolled from China, Thailand and South Korea. *Asymptomatic CNS metastases allowed. \n\nData cut -off 16 May 2022. ClinicalTrials.gov: NCT02838420. CNS, central nervous system; DOR, duration of response;  ECOG PS, Eastern Cooperative Oncology Group performance status; IHC, immunohistochemistry; INV, investigator \n\nIRC, independent review committee; NSCLC, non -small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, p rogression -free survival \n\n2:1 \n\nN=187 \n\nR\n\nAlectinib \n\n600mg  twice daily \n\nCrizotinib \n\n250mg twice daily \n\nTreat until disease \n\nprogression, toxicity, \n\nwithdrawal or death \n\nNo crossover permitted \n\nStage IIIB/IV  ALK + NSCLC* \n\n‚Ä¢ Asian patients \n\n‚Ä¢ Treatment na√Øve \n\n‚Ä¢ ECOG PS 0 ‚Äì2\n\n‚Ä¢ Central  ALK  testing (Ventana IHC) \n\nBaseline demographics \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nAge, years  Median (range)  51.0 (21‚àí78)  49.0 (28‚àí83) \n\nGender, %  Male / Female  51.2 / 48.8  54.8 / 45.2 \n\nECOG PS, %  0‚Äì1 / 2  96.8 / 3.2  98.4 / 1.6 \n\nSmoking status, %  Active smoker / Non -smoker / \n\nPast smoker  3.2 / 67.2 / 29.6  4.8 / 72.6 / 22.6 \n\nCNS metastases by IRC, %  Yes  35.2  37.1 \n\nCNS metastases by INV, %  Yes  33.6  32.3 \n\nPrior brain radiation, %  Yes  6.4  8.1 Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Updated analyses from ALESIA demonstrate durable PFS benefit for \n\n## alectinib versus crizotinib, irrespective of CNS involvement at baseline \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nData cut -off 16 May 2022. CI, confidence interval; CNS, central nervous system; HR, hazard ratio; ITT, intent -to -treat;  mets , metastases;  PFS, progression -free survival \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nMedian  PFS, months \n\n(95% CI) \n\n41.6 \n\n(33.1 ‚Äì58.9) \n\n11.1 \n\n(9.1 ‚Äì18.4) \n\nHR  (95% CI)  0.33  (0.23 ‚Äì0.49) \n\n0\n\n> PFS (%)\n\n6 36  66 60 54 48 42 30 24 18 12 \n\nTime (months) \n\n100 \n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\nCrizotinib (n=62) \n\nAlectinib (n=125) \n\nWith  CNS  mets  at baseline  Without  CNS  mets  at baseline \n\nAlectinib \n\nn=44 \n\nCrizotinib \n\nn=23 \n\nAlectinib \n\nn=81 \n\nCrizotinib \n\nn=39 \n\nMedian  PFS, months \n\n(95% CI) \n\n42.3 \n\n(27.8 ‚Äì60.7) \n\n9.2 \n\n(5.5 ‚Äì12.2) \n\n41.6 \n\n(29.5 ‚Äì64.9) \n\n12.7 \n\n(9.2 ‚Äì27.6) \n\nHR  (95% CI)  0.17  (0.09 ‚Äì0.33)  0.45  (0.29 ‚Äì0.71) \n\nCrizotinib (n=39) \n\nWithout  CNS  mets  at baseline \n\nAlectinib (n=81) \n\nUpdated PFS: ITT population \n\nTime (months) \n\n100 \n\n0\n\n> PFS (%)\n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\n36  66 54 18 6 60 42 30 24 12  48 \n\nCrizotinib (n=23) \n\nWith  CNS  mets  at baseline \n\nAlectinib (n=44) \n\nPFS according to CNS status at baseline Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## A clinically meaningful improvement in 5 -year OS rate was observed \n\n## for alectinib compared with crizotinib \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nData cut -off 16 May 2022. CI, confidence interval; CNS, central nervous system; HR, hazard ratio; ITT, intent -to -treat;  mets , metastases; NE, not evaluable; OS, overall survival; pts, patients \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nPts with event, n (%)  41 (32.8)  26 (41.9) \n\nMedian  OS, months \n\n(95% CI) \n\nNE \n\n(NE ‚ÄìNE) \n\nNE \n\n(45.5 ‚ÄìNE) \n\nHR  (95% CI)  0.60  (0.37 ‚Äì0.99) \n\n5-year OS rate , % \n\n(95% CI) \n\n66.4 \n\n(57.9 ‚Äì74.9) \n\n56.0 \n\n(43.0 ‚Äì69.1) \n\nPts remaining at risk, n  69  25 \n\n0\n\n> OS (%)\n\n6 36  66 60 54 48 42 30 24 18 12 \n\nTime (months) \n\n100 \n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\nCrizotinib (n=62) \n\nAlectinib (n=125) \n\nWith  CNS  mets  at baseline  Without  CNS  mets  at baseline \n\nAlectinib \n\nn=44 \n\nCrizotinib \n\nn=23 \n\nAlectinib \n\nn=81 \n\nCrizotinib \n\nn=39 \n\nPts with event, n (%)  16 (36.4)  12 (52.2)  25 (30.9)  14 (35.9) \n\nMedian  OS, months \n\n(95% CI) \n\nNE \n\n(51.4 ‚ÄìNE) \n\n46.2 \n\n(12.2 ‚ÄìNE) \n\nNE \n\n(NE ‚ÄìNE) \n\nNE \n\n(59.8 ‚ÄìNE) \n\nHR  (95% CI)  0.40  (0.19 ‚Äì0.85)  0.81  (0.42 ‚Äì1.55) \n\n5-year OS rate, % \n\n(95% CI) \n\n63.6 \n\n(48.9 ‚Äì78.3) \n\n39.3 \n\n(17.4 ‚Äì61.2) \n\n67.8 \n\n(57.4 ‚Äì78.2) \n\n64.9 \n\n(49.3 ‚Äì80.4) \n\nPts remaining at risk, n  25  6 44  19 \n\nCrizotinib (n=39) \n\nWithout  CNS  mets  at baseline \n\nAlectinib (n=81) \n\nUpdated OS: ITT population \n\nTime (months) \n\n100 \n\n0\n\n> OS (%)\n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\n36  66 54 18 6 60 42 30 24 12  48 \n\nCrizotinib (n=23) \n\nWith  CNS  mets  at baseline \n\nAlectinib (n=44) \n\nOS according to CNS status at baseline Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Treatment with alectinib delayed the time to CNS progression* \n\nThanyanan  Baisamut  (Reungwetwattana) \n\n*Derived from investigators' assessment. CNS PD = CNS Target Lesion PD per RECIST version 1.1, appearance of new CNS lesion(s ),  and/or unequivocal PD of Non -Target CNS lesion(s) \n\nData cut -off 16 May 2022. CI, confidence interval;  CIR, cumulative incidence rate;  CNS, central nervous system; HR, hazard ratio;  PD, progressive disease \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nCNS progression without prior systemic progression \n\nPatients with events, n (%)  18 (14.4)  22 (35.5) \n\nCause -specific HR  (95% CI)  0.16  (0.08 ‚Äì0.32) \n\nEstimated cumulative incidence, % (95% CI) \n\nAt 36 months  11.6 (6.7 ‚Äì18.1)  34.0 (22.1 ‚Äì46.2) \n\nAt 60 months  14.2 (8.6 ‚Äì21.1)  37.4 (25.0 ‚Äì49.7) \n\n40 \n\n0\n\n> Cumulative incidence (%)\n\n30 \n\n20 \n\n10 \n\n0 6 36  60 54 48 42 30 24 18 12 \n\nTime (months) \n\nCrizotinib (n=62) \n\nAlectinib (n=125) \n\nCIR: \n\n11.6% (95% CI 6.7 ‚Äì18.1) \n\nCIR: \n\n14.2% (95% CI 8.6 ‚Äì21.1) \n\nCIR: \n\n34.0% (95% CI 22.1 ‚Äì46.2) \n\nCIR: \n\n37.4% (95% CI 25.0 ‚Äì49.7) Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Post -progression therapy \n\nThanyanan  Baisamut  (Reungwetwattana)  \n\n> Data cut -off 16 May 2022. PD, progressive disease; VEGF, vascular endothelial growth factor\n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nPatients with PD , n  68  48 \n\nAnti -cancer therapy after PD , n (%)  42 (61.8)  38 (79.2) \n\nALK inhibitor , n (%)  25 (36.8)  28 (58.3) \n\nAlectinib  5 (7.4)  14 (29.2) \n\nLorlatinib  8 (11.8)  6 (12.5) \n\nBrigatinib  6 (8.8)  7 (14.6) \n\nCrizotinib  7 (10.3)  2 (4.2) \n\nCeritinib  3 (4.4)  4 (8.3) \n\nEnsartinib  2 (2.9)  1 (2.1) \n\nInvestigational drug  1 (1.5)  0\n\nChemotherapy , n (%)  24 (35.3)  15 (31.3) \n\nAnti -VEGF therapies , n ( %Ôºâ 9 (13.2)  3 (6.3) \n\nImmunotherapy , n (%)  3 (4.4)  2 (4.2) \n\nOther therapies , n (%)  6 (8.8)  7 (14.6) \n\nMore crizotinib patients (79.2% vs 61.8% alectinib) received at least one anti -cancer therapy post -progression \n\nApproximately 30% of patients in the crizotinib arm received alectinib after their disease progressed Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## The safety profile of alectinib remained favourable with longer \n\n## follow -up; no new safety signals were observed \n\nThanyanan  Baisamut  (Reungwetwattana) \n\n> *Three additional fatal events occurred during the longer follow -up: one was due to COVID -19 pneumonia, and the other two were r eported as ‚Äòdeath‚Äô and not related to alectinib treatment\n> Data cut -off 16 May 2022. AE, adverse event; ALT, alanine aminotransferase; ECG, electrocardiogram\n\nEvent, n  (%) \n\nAlectinib \n\n(n=125) \n\nCrizotinib \n\n(n=62) \n\nPatients with ‚â•1 \n\nAll grade AEs  125 (100)  62 (100) \n\nSerious AEs  35 (28.0)  18 (29.0) \n\nGrade ‚â•3 AEs  60 (48.0)  34 (54.8) \n\nFatal AEs  5 (4.0)*  3 (4.8) \n\nAEs leading to treatment discontinuation  14 (11.2)  9 (14.5) \n\nAEs leading to dose reduction  33 (26.4)  17 (27.4) \n\nAEs leading to dose interruption  33 (26.4)  19 (30.6) \n\nGrade ‚â•3 AEs with ‚â•3% difference \n\nin frequency between treatment arms, n  (%) \n\nAlectinib \n\n(n=125) \n\nCrizotinib \n\n(n=62) \n\nWeight increased  11 (8.8)  1 (1.6) \n\nBlood creatine phosphokinase increased  8 (6.4)  2 (3.2) \n\nALT increased  3 (2.4)  4 (6.5) \n\nNausea  1 (0.8)  3 (4.8) \n\nNeutrophil count decreased  0 9 (14.5) \n\nECG QT prolonged  0 3 (4.8) \n\nWhite blood cell count decreased  0 3 (4.8) \n\nDecreased appetite  0 3 (4.8) \n\nHyponatraemia  0 3 (4.8) \n\nInterstitial lung disease  0 3 (4.8) \n\nVomiting  0 3 (4.8) \n\nBradycardia  0 2 (3.2) \n\nHepatic function abnormal  0 2 (3.2) \n\nMedian treatment duration was more than three -times greater for alectinib (42.3 months) \n\ncompared to crizotinib (12.6 months) Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Conclusions:  5-year update from the Phase 3 ALESIA study   \n\n> Thanyanan Baisamut (Reungwetwattana )\n\nWith  at least 5 years  of follow -up, 1L alectinib  600mg twice daily  continues \n\nto demonstrate clinical benefit to Asian patients with advanced  ALK+  NSCLC, \n\nconsistent with  that observed in the  global ALEX study \n\nTreatment with alectinib also delayed the time to CNS progression \n\nThis clinical benefit, coupled with a tolerable and manageable safety profile, \n\nconfirms alectinib as standard -of -care treatment \n\nfor patients with advanced  ALK+  NSCLC Acknowledgements \n\nWe thank the participating patients and their families, study investigators, and research nurses \n\nThe ALESIA study was funded by F. Hoffmann -La Roche Ltd \n\nMedical writing support for the development of this presentation, under the direction \n\nof the authors, was provided by Fiona Duthie, PhD, of Ashfield MedComms, \n\nan Inizio company, and was funded by F. Hoffmann -La Roche Ltd\n"}, {'type': 'image', 'image_url': 'https://www.umc.edu/Research/Centers-and-Institutes/External-Designation-Centers/Mississippi-Poison-Control-Center/images/Medication-Label-1-A-E.jpg', 'image_description': 'The document outlines the drug facts of a medication, including its active ingredient, purposes such as pain relief and fever reduction, specific uses, warnings about allergic reactions and stomach bleeding, and instructions for use.'}, {'type': 'image', 'image_url': 'https://images.ctfassets.net/gi8mrztylj0k/7uYtc358SoGmfbZJwSffV4/4a6b40b9f5e3f8e7fea16ea0a96f143a/pasted_image_0__10_.png', 'image_description': 'The contents list various classes of food ingredients along with their definitions and requirements for labeling, including edible oils, fats, fish, meat, cheese, spices, and gums.'}, {'type': 'image', 'image_url': 'https://images.ctfassets.net/gi8mrztylj0k/2SwoBWSwLlal4WhyRZp7mK/424ea61f0461de8a7b51935a15fc5019/pasted_image_0__11_.png', 'image_description': 'A table listing various food and ingredient classes along with their respective class titles.'}, {'type': 'image', 'image_url': 'https://i.etsystatic.com/16874044/r/il/a74daa/3750620251/il_fullxfull.3750620251_8kd8.jpg', 'image_description': 'A list of ingredients includes Cocoa Mass, Cocoa Butter, and Milk, among others.'}, {'type': 'image', 'image_url': 'https://7esl.com/wp-content/uploads/2021/03/Foods-starting-with-r-scaled.jpg', 'image_description': 'A poster of foods that start with the letter R.'}], {'query': '"For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter \'C\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name."', 'follow_up_questions': None, 'answer': None, 'images': [{'url': 'https://www.umc.edu/Research/Centers-and-Institutes/External-Designation-Centers/Mississippi-Poison-Control-Center/images/Medication-Label-1-A-E.jpg', 'description': 'The document outlines the drug facts of a medication, including its active ingredient, purposes such as pain relief and fever reduction, specific uses, warnings about allergic reactions and stomach bleeding, and instructions for use.'}, {'url': 'https://images.ctfassets.net/gi8mrztylj0k/7uYtc358SoGmfbZJwSffV4/4a6b40b9f5e3f8e7fea16ea0a96f143a/pasted_image_0__10_.png', 'description': 'The contents list various classes of food ingredients along with their definitions and requirements for labeling, including edible oils, fats, fish, meat, cheese, spices, and gums.'}, {'url': 'https://images.ctfassets.net/gi8mrztylj0k/2SwoBWSwLlal4WhyRZp7mK/424ea61f0461de8a7b51935a15fc5019/pasted_image_0__11_.png', 'description': 'A table listing various food and ingredient classes along with their respective class titles.'}, {'url': 'https://i.etsystatic.com/16874044/r/il/a74daa/3750620251/il_fullxfull.3750620251_8kd8.jpg', 'description': 'A list of ingredients includes Cocoa Mass, Cocoa Butter, and Milk, among others.'}, {'url': 'https://7esl.com/wp-content/uploads/2021/03/Foods-starting-with-r-scaled.jpg', 'description': 'A poster of foods that start with the letter R.'}], 'results': [{'url': 'https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp', 'title': 'AIM-Harvard/MedBrowseComp ¬∑ Datasets at Hugging Face', 'content': '| CRIZOTINIB | "For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter \'C\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient | [...] | PF PRISM CV | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name | [...] | May 12, 2027 | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |', 'score': 0.92684203, 'raw_content': 'AIM-Harvard/MedBrowseComp ¬∑ Datasets at Hugging Face\n\n===============\n\n[![Image 1: Hugging Face\'s logo](https://huggingface.co/front/assets/huggingface_logo-noborder.svg)Hugging Face](https://huggingface.co/)\n\n*   [Models](https://huggingface.co/models)\n*   [Datasets](https://huggingface.co/datasets)\n*   [Spaces](https://huggingface.co/spaces)\n*    Community  \n*   [Docs](https://huggingface.co/docs)\n*   [Enterprise](https://huggingface.co/enterprise)\n*   [Pricing](https://huggingface.co/pricing)\n*    \n*   \n* * *\n\n*   [Log In](https://huggingface.co/login)\n*   [Sign Up](https://huggingface.co/join)\n\n[Datasets:](https://huggingface.co/datasets)\n\n* * *\n\n[![Image 2](https://cdn-avatars.huggingface.co/v1/production/uploads/63600b93d9e4214b9a67807c/ZRnXCRmf600I8gTKJH-V0.png)](https://huggingface.co/AIM-Harvard)\n\n[AIM-Harvard](https://huggingface.co/AIM-Harvard)\n\n/\n\n[MedBrowseComp](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp)\n\nlike 1\n\nFollow\n\n![Image 3](https://cdn-avatars.huggingface.co/v1/production/uploads/63600b93d9e4214b9a67807c/ZRnXCRmf600I8gTKJH-V0.png)AIM-Harvard 23\n===================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================\n\nTasks: [Question Answering](https://huggingface.co/datasets?task_categories=task_categories%3Aquestion-answering)[Text Retrieval](https://huggingface.co/datasets?task_categories=task_categories%3Atext-retrieval)\n\nModalities: [Text](https://huggingface.co/datasets?modality=modality%3Atext)\n\nFormats: [csv](https://huggingface.co/datasets?format=format%3Acsv)\n\nLanguages: [English](https://huggingface.co/datasets?language=language%3Aen)\n\nSize: [1K - 10K](https://huggingface.co/datasets?size_categories=size_categories%3A1K%3Cn%3C10K)\n\nArXiv: \n\narxiv:2505.14963\n\nTags: [medical](https://huggingface.co/datasets?other=medical)[healthcare](https://huggingface.co/datasets?other=healthcare)[browsing](https://huggingface.co/datasets?other=browsing)[comparison](https://huggingface.co/datasets?other=comparison)\n\nLibraries: [Datasets](https://huggingface.co/datasets?library=library%3Adatasets)[pandas](https://huggingface.co/datasets?library=library%3Apandas)\n\nCroissant\n\n+ 1\n\nLicense: \n\napache-2.0\n\n[Dataset card](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp)[Data Studio](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/viewer/)[Files Files and versions](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/tree/main)[Community 1](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/discussions)\n\nDataset Viewer\n\n[Auto-converted to Parquet](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/tree/refs%2Fconvert%2Fparquet/default)API Embed Data Studio\n\nSubset (1)\n\ndefault¬∑1.14k rows\n\n \n\nSplit (3)\n\nMedBrowseComp_50¬∑50 rows\n\n \n\nSQL \n\n Console \n\n| gold string lengths 5 24 | prompt string lengths 227 657 | task_name string classes 5 values |\n| --- | --- | --- |\n| ENZALUTAMIDE | "For clinical trial NCT00974311. Among the more effective regimen ingredients, find which ingredient starts with the letter \'E\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| CRIZOTINIB | "For clinical trial NCT02838420. Among the less effective regimen ingredients, find which ingredient starts with the letter \'C\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| LENALIDOMIDE | "For clinical trial NCT01938001. Among the more effective regimen ingredients, find which ingredient starts with the letter \'L\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| AZACITIDINE | "For clinical trial NCT00071799. Among the more effective regimen ingredients, find which ingredient starts with the letter \'A\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| IRINOTECAN HYDROCHLORIDE | "For clinical trial NCT00720512. Among the more effective regimen ingredients, find which ingredient starts with the letter \'I\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| VENETOCLAX | "For clinical trial NCT02755597. Among the more effective regimen ingredients, find which ingredient starts with the letter \'V\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| DEXAMETHASONE | "For clinical trial NCT00833833. Among the more effective regimen ingredients, find which ingredient starts with the letter \'D\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| IBRUTINIB | "For clinical trial NCT01973387. Among the more effective regimen ingredients, find which ingredient starts with the letter \'I\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| LENALIDOMIDE | "For clinical trial NCT00843882. Among the more effective regimen ingredients, find which ingredient starts with the letter \'L\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| SIROLIMUS | "For clinical trial NCT01231412. Among the more effective regimen ingredients, find which ingredient starts with the letter \'S\'.\\nReturn only the name of the ingredient or UNKNOWN in all CAPS in the format of INGREDIENT: name." | Ingredient |\n| ASTELLAS | "First, for clinical trial NCT00974311, among the more effective regimen ingredients, identify which ingredient starts with the letter \'E\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| PF PRISM CV | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| BRISTOL MYERS SQUIBB | "First, for clinical trial NCT01938001, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| BRISTOL | "First, for clinical trial NCT00071799, among the more effective regimen ingredients, identify which ingredient starts with the letter \'A\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| IPSEN | "First, for clinical trial NCT00720512, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| ABBVIE | "First, for clinical trial NCT02755597, among the more effective regimen ingredients, identify which ingredient starts with the letter \'V\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| DEXCEL | "First, for clinical trial NCT00833833, among the more effective regimen ingredients, identify which ingredient starts with the letter \'D\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| PHARMACYCLICS LLC | "First, for clinical trial NCT01973387, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| BRISTOL MYERS SQUIBB | "First, for clinical trial NCT00843882, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| AADI SUB | "First, for clinical trial NCT01231412, among the more effective regimen ingredients, identify which ingredient starts with the letter \'S\'.\\n\\nThen, find which company has the latest FDA approval date up till Dec, 2024 for this identified ingredient. Note that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the company name in format of COMPANY: name." | Applicant_Full_Name |\n| Aug 13, 2027 | "First, for clinical trial NCT00974311, among the more effective regimen ingredients, identify which ingredient starts with the letter \'E\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| May 12, 2027 | "First, for clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Apr 27, 2027 | "First, for clinical trial NCT01938001, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| May 14, 2029 | "First, for clinical trial NCT00071799, among the more effective regimen ingredients, identify which ingredient starts with the letter \'A\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Jan 6, 2027 | "First, for clinical trial NCT00720512, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Jan 29, 2032 | "First, for clinical trial NCT02755597, among the more effective regimen ingredients, identify which ingredient starts with the letter \'V\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Dec 18, 2037 | "First, for clinical trial NCT00833833, among the more effective regimen ingredients, identify which ingredient starts with the letter \'D\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Dec 3, 2031 | "First, for clinical trial NCT01973387, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Apr 27, 2027 | "First, for clinical trial NCT00843882, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Mar 5, 2036 | "First, for clinical trial NCT01231412, among the more effective regimen ingredients, identify which ingredient starts with the letter \'S\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its patent expiration date?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in YYYY format: date: YYYY." | Patent_Expire_Date_Text_prompt |\n| Nov 17, 2026 | "For clinical trial NCT00974311, among the more effective regimen ingredients, identify which ingredient starts with the letter \'E\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Jul 14, 2025 | "For clinical trial NCT02838420, among the less effective regimen ingredients, identify which ingredient starts with the letter \'C\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| May 28, 2026 | "For clinical trial NCT01938001, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Sep 1, 2027 | "For clinical trial NCT00071799, among the more effective regimen ingredients, identify which ingredient starts with the letter \'A\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Feb 13, 2031 | "For clinical trial NCT00720512, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| May 15, 2026 | "For clinical trial NCT02755597, among the more effective regimen ingredients, identify which ingredient starts with the letter \'V\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Oct 3, 2026 | "For clinical trial NCT00833833, among the more effective regimen ingredients, identify which ingredient starts with the letter \'D\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Aug 24, 2029 | "For clinical trial NCT01973387, among the more effective regimen ingredients, identify which ingredient starts with the letter \'I\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| May 28, 2026 | "For clinical trial NCT00843882, among the more effective regimen ingredients, identify which ingredient starts with the letter \'L\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| Nov 22, 2028 | "For clinical trial NCT01231412, among the more effective regimen ingredients, identify which ingredient starts with the letter \'S\'.\\n\\nThen, for this identified ingredient that was last approved up till Dec, 2024, when is its exclusivity date according to the FDA?\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\nReturn only the date in MM-DD-YYYY format: date: MM-DD-YYYY." | Exclusivity_Date |\n| 15.98999977 | "For clinical trial NCT00974311, review the more effective regimen ingredients and identify which ingredient starts with the letter \'E\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 34.47000122 | "For clinical trial NCT02838420, review the less effective regimen ingredients and identify which ingredient starts with the letter \'C\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 46.72999954 | "For clinical trial NCT01938001, review the more effective regimen ingredients and identify which ingredient starts with the letter \'L\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 62.20000076 | "For clinical trial NCT00071799, review the more effective regimen ingredients and identify which ingredient starts with the letter \'A\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 15.14000034 | "For clinical trial NCT00720512, review the more effective regimen ingredients and identify which ingredient starts with the letter \'I\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 58.59000015 | "For clinical trial NCT02755597, review the more effective regimen ingredients and identify which ingredient starts with the letter \'V\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| NOT LISTED | "For clinical trial NCT00833833, review the more effective regimen ingredients and identify which ingredient starts with the letter \'D\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| NOT LISTED | "For clinical trial NCT01973387, review the more effective regimen ingredients and identify which ingredient starts with the letter \'I\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 46.72999954 | "For clinical trial NCT00843882, review the more effective regimen ingredients and identify which ingredient starts with the letter \'L\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n| 39.84000015 | "For clinical trial NCT01231412, review the more effective regimen ingredients and identify which ingredient starts with the letter \'S\'.\\n\\nThen, determine which pharmaceutical company received the most recent FDA approval (up until December 2024) for this identified ingredient.\\nNote that we are only looking for overall FDA drug approval, not new indications or supplemental approvals.\\n\\nIf this company is listed on any US stock market (including over-the-counter markets), provide:\\n1. The stock ticker symbol\\n2. The opening stock price on the FDA approval date\\n\\nIf the company is not listed on any US stock market, please indicate \\"NOT LISTED\\"." | Open_on_Approval |\n\n*   [Datasets](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#datasets "Datasets")\n\n*   [Usage](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#usage "Usage")\n\n*   [GitHub Repository](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#github-repository "GitHub Repository")\n\n*   [Citation](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#citation "Citation")\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#medbrowsecomp-dataset) MedBrowseComp Dataset\n=========================================================================================================\n\nThis repository contains datasets for medical information-seeking-oriented deep research and computer use tasks.\n\n[![Image 4: Overall](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/resolve/main/medcomp.png)](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/blob/main/medcomp.png)\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#datasets) Datasets\n-------------------------------------------------------------------------------\n\nThe repository contains three harmonized datasets:\n\n1.   **MedBrowseComp_50**: A collection of 50 medical entries for browsing and comparison.\n2.   **MedBrowseComp_605**: A comprehensive collection of 605 medical entries.\n3.   **MedBrowseComp_CUA**: A curated collection of medical data for comparison and analysis.\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#usage) Usage\n-------------------------------------------------------------------------\n\nThese datasets can be used for various medical text processing tasks, information retrieval, and comparative analysis.\n\nExample usage with the Hugging Face datasets library:\n\n```python\nfrom datasets import load_dataset\n\n# Load the dataset\ndataset = load_dataset("AIM-Harvard/MedBrowseComp")\n\n# Access specific splits\nmed50_data = dataset["MedBrowseComp_50"]\nmed605_data = dataset["MedBrowseComp_605"]\ncua_data = dataset["MedBrowseComp_CUA"]\n```\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#github-repository) GitHub Repository\n-------------------------------------------------------------------------------------------------\n\nFor more information and related tools, visit: [https://github.com/MedBrowseComp](https://github.com/MedBrowseComp)\n\n[](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp#citation) Citation\n-------------------------------------------------------------------------------\n\nIf you use this dataset in your research, please cite: [https://arxiv.org/abs/2505.14963](https://arxiv.org/abs/2505.14963)\n\n```\n@misc{chen2025medbrowsecompbenchmarkingmedicaldeep,\n      title={MedBrowseComp: Benchmarking Medical Deep Research and Computer Use}, \n      author={Shan Chen and Pedro Moreira and Yuxin Xiao and Sam Schmidgall and Jeremy Warner and Hugo Aerts and Thomas Hartvigsen and Jack Gallifant and Danielle S. Bitterman},\n      year={2025},\n      eprint={2505.14963},\n      archivePrefix={arXiv},\n      primaryClass={cs.CL},\n      url={https://arxiv.org/abs/2505.14963}, \n}\n```\n\nDownloads last month 179\n\n Use this dataset \n\nSize of downloaded dataset files: 448 kB[Size of the auto-converted Parquet files: 58 kB](https://huggingface.co/datasets/AIM-Harvard/MedBrowseComp/tree/refs%2Fconvert%2Fparquet/)Number of rows: 1,139\n\nCollection including AIM-Harvard/MedBrowseComp\n----------------------------------------------\n\n[#### MedBrowseComp Collection MedBrowseComp: Benchmarking Medical Deep Research and Computer Use‚Ä¢ 3 items‚Ä¢ Updated 10 days ago](https://huggingface.co/collections/AIM-Harvard/medbrowsecomp-6822637df90521b5d8b8b23f)\n\n System theme \n\nCompany\n\n[TOS](https://huggingface.co/terms-of-service)[Privacy](https://huggingface.co/privacy)[About](https://huggingface.co/huggingface)[Jobs](https://apply.workable.com/huggingface/)[](https://huggingface.co/)\n\nWebsite\n\n[Models](https://huggingface.co/models)[Datasets](https://huggingface.co/datasets)[Spaces](https://huggingface.co/spaces)[Pricing](https://huggingface.co/pricing)[Docs](https://huggingface.co/docs)\n'}, {'title': 'Alectinib and Crizotinib in Anaplastic Lymphoma Kinase-positive Non ...', 'url': 'https://ichgcp.net/clinical-trials-registry/NCT02838420', 'content': 'USA (FDA)\n       UK (MHRA)\n       AUSTRALIA (NHMRC)\n       JAPAN (PMDA)\n       EU (EMA)\n\n   CRO List\n   Clinical Trials\n\n       US Clinical Trials Registry\n       EU Clinical Trials Registry\n       Pharmaceutical Companies\n       Clinical Research Labs\n       Service Companies\n       Clinical Research Events\n       Publications\n       Researchers\n\n   Jobs\n   Publications\n   News\n\n   \n   \n\n   ICH GCP\n   US Clinical Trials Registry\n   Clinical Trial NCT02838420', 'score': 0.54724693, 'raw_content': 'Published Time: 2022-12-12T02:32:10+00:00\n\nAlectinib and Crizotinib in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer - Clinical Trials Registry - ICH GCP\n\n===============\n\n[![Image 1: ICHGCP](https://ichgcp.net/img/ichgcp_logo.png)](https://ichgcp.net/)\n\n*   Regulations\n\n    *   [GLOBAL¬ª](https://ichgcp.net/clinical-trials-registry/NCT02838420#)\n\n        *   [ICH GCP (De)](https://ichgcp.net/de)\n        *   [ICH GCP (En)](https://ichgcp.net/)\n        *   [ICH GCP (Es)](https://ichgcp.net/es)\n        *   [ICH GCP (Fr)](https://ichgcp.net/fr)\n        *   [ICH GCP (It)](https://ichgcp.net/it)\n        *   [ICH GCP (Pt)](https://ichgcp.net/pt)\n        *   [ICH GCP (Ru)](https://ichgcp.net/ru)\n\n    *   [USA (FDA)](https://ichgcp.net/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects)\n    *   [UK (MHRA)](https://ichgcp.net/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol)\n    *   [AUSTRALIA (NHMRC)](https://ichgcp.net/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia)\n    *   [JAPAN (PMDA)](https://ichgcp.net/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan)\n    *   [EU (EMA)](https://ichgcp.net/ich-e-group-of-guidelines)\n\n*   [CRO List](https://ichgcp.net/cro-list)\n*   Clinical Trials\n\n    *   [US Clinical Trials Registry](https://ichgcp.net/clinical-trials-registry)\n    *   [EU Clinical Trials Registry](https://ichgcp.net/eu-clinical-trials-registry)\n    *   [Pharmaceutical Companies](https://ichgcp.net/pharma-list)\n    *   [Clinical Research Labs](https://ichgcp.net/labs)\n    *   [Service Companies](https://ichgcp.net/service-companies)\n    *   [Clinical Research Events](https://ichgcp.net/events)\n    *   [Publications](https://ichgcp.net/clinical-trials-registry/publications)\n    *   [Researchers](https://ichgcp.net/clinical-trials-registry/researchers)\n\n*   [Jobs](https://ichgcp.net/jobs)\n*   [Publications](https://ichgcp.net/publications)\n*   [News](https://ichgcp.net/news)\n\n*   [](https://telegram.me/share/url?url=https://ichgcp.net/clinical-trials-registry/NCT02838420&text= "Share on telegram")\n*   [](https://twitter.com/intent/tweet?url=https://ichgcp.net/clinical-trials-registry/NCT02838420 "Share on Twitter")\n\n*   [ICH GCP](https://ichgcp.net/)\n*   [US Clinical Trials Registry](https://ichgcp.net/clinical-trials-registry)\n*   Clinical Trial NCT02838420\n\nA Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)\n=========================================================================================================================================================================================================================================================================\n\nMarch 24, 2025 updated by: [Hoffmann-La Roche](https://ichgcp.net/clinical-trials-registry/research/list?spons=Hoffmann-La%20Roche "List all studies sponsored by Hoffmann-La Roche")\n\nRandomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Asian Patients With Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer\n--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\nThis randomized, multicenter, Phase III, open-label study will evaluate the efficacy and safety of alectinib versus crizotinib and to evaluate the pharmacokinetics of alectinib in asian participants with treatment-naive ALK-positive advanced NSCLC. Participants will be randomized 2:1 into one of the two treatment groups to receive either alectinib (600 milligrams [mg] twice daily [BID]) or crizotinib (250 mg BID) orally, respectively.\n\nStudy Overview\n--------------\n\n#### Status\n\nActive, not recruiting\n\n#### Conditions\n\n*   [Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%20Lymphoma%20Kinase-positive%20Non-small%20Cell%20Lung%20Cancer "List all studies focused on condition Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer")\n\n#### Intervention / Treatment\n\n*   [Drug: Alectinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Alectinib "List all studies with intervention Alectinib")\n*   [Drug: Crizotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Crizotinib "List all studies with intervention Crizotinib")\n\n#### Study Type\n\n Interventional \n\n#### Enrollment (Actual)\n\n 187 \n\n#### Phase\n\n*   Phase 3\n\nContacts and Locations\n----------------------\n\nThis section provides the contact details for those conducting the study, and information on where this study is being conducted.\n\n### Study Locations\n\n*   [China](https://ichgcp.net/clinical-trials-registry/research/list?locn=China "List all studies conducted in China") \n    *           *   Beijing, China, 100142 \n            *   Beijing Cancer Hospital\n\n        *   Beijing, China, 101149 \n            *   Beijing Chest Hospital\n\n        *   Changchun, China, 130021 \n            *   The First Hospital of Jilin University\n\n        *   Changchun, China, 132013 \n            *   Jilin cancer hospital\n\n        *   Chengdu, China, 610041 \n            *   West China Hospital, Sichuan University\n\n        *   Guangzhou, China, 510060 \n            *   Sun Yet-sen University Cancer Center\n\n        *   Guangzhou, China, 510080 \n            *   Guangdong General Hospital\n\n        *   Guangzhou, China, 510120 \n            *   The First Affiliated Hospital of Guangzhou Medical University\n\n        *   Hangzhou, China, 310003 \n            *   The First Affiliated Hospital of College of Medicine, Zhejiang University\n\n        *   Hangzhou, China, 310022 \n            *   Zhejiang Cancer Hospital\n\n        *   Harbin, China, 150081 \n            *   Harbin Medical University Cancer Hospital\n\n        *   Nanjing, China, 210009 \n            *   Jiangsu Cancer Hospital\n\n        *   Shanghai, China, 200030 \n            *   Shanghai Chest Hospital\n\n        *   Shanghai, China, 200032 \n            *   Fudan University Shanghai Cancer Center\n\n        *   Shanghai, China, 200433 \n            *   Shanghai Pulmonary Hospital\n\n*   [Korea, Republic of](https://ichgcp.net/clinical-trials-registry/research/list?locn=Korea%2C%20Republic%20of "List all studies conducted in Korea, Republic of") \n    *           *   Seoul, Korea, Republic of, 05505 \n            *   Asan Medical Center\n\n        *   Seoul, Korea, Republic of, 06351 \n            *   Samsung Medical Center\n\n        *   Seoul, Korea, Republic of, 03181 \n            *   Kangbuk Samsung Hospital\n\n*   [Thailand](https://ichgcp.net/clinical-trials-registry/research/list?locn=Thailand "List all studies conducted in Thailand") \n    *           *   Bangkok, Thailand, 10400 \n            *   Rajavithi Hospital\n\n        *   Bangkok, Thailand, 10400 \n            *   Ramathibodi Hospital\n\n        *   Songkhla, Thailand, 90110 \n            *   Songklanagarind hospital\n\nParticipation Criteria\n----------------------\n\nResearchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person\'s general health condition or prior treatments.\n\n### Eligibility Criteria\n\n#### Ages Eligible for Study\n\n 18 years and older (Adult, Older Adult) \n\n#### Accepts Healthy Volunteers\n\n No \n\n#### Description\n\nInclusion Criteria:\n\n*   Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive as assessed by the Ventana immunohistochemistry (IHC) test. Sufficient tumor tissue available to perform ALK IHC is required. Ventana IHC testing will be performed at the designated central laboratory\n*   Life expectancy of at least 12 weeks\n*   Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2\n*   No history of receiving systemic treatment for advanced, recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC\n*   Adequate hematologic function: Platelet count greater than equal to (>=) 100√ó10^9 per liter (/L); absolute neutrophil count (ANC) >=1500 cells per microliter (cells/mcL); hemoglobin>=9.0 grams per deciliter (g/dL)\n*   Adequate renal function: an estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease (MDRD) formula of >=45 milliliters per minute per 1.73 square meter\n*   Participants must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before receiving the first dose of study treatment\n*   Measurable disease (by Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v1.1]) before administration of study treatment\n*   Previous brain or leptomeningeal metastases are allowed if the participant is asymptomatic (e.g., diagnosed incidentally at study baseline). Asymptomatic central nervous system (CNS) lesions may be treated at the discretion of the investigator as per local clinical practice. If participant has neurological symptoms or signs because of CNS metastasis, the participant must complete whole-brain radiation or gamma knife irradiation treatment. In all cases, radiation treatment must be completed >=14 days before enrollment and disease must be clinically stable\n*   For all females of childbearing potential, a negative serum pregnancy test result must be obtained within 3 days prior to starting study treatment\n*   For women who are not postmenopausal (>=12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus), agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Examples of contraceptive methods with a failure rate of <1% per year include tubal ligation, male sterilization, hormonal implants, established, proper use of combined oral or injected hormonal contraceptives, and certain intrauterine devices. Alternatively, two methods (e.g., two barrier methods such as a condom and a cervical cap) may be combined to achieve a failure rate of <1% per year. Barrier methods must always be supplemented with the use of a spermicide\n*   For men, agreement to remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of <1% per year during the treatment period and for at least 3 months after the last dose of study drug. Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception\n\nExclusion Criteria:\n\n*   A malignancy within the previous 3 years (other than curatively treated basal cell carcinoma of the skin, early gastrointestinal (GI) cancer by endoscopic resection, in situ carcinoma of the cervix, or any cured cancer that is considered to have no impact in progression-free survival (PFS) or overall survival (OS) for the current NSCLC)\n*   Any GI disorder that may affect absorption of oral medications, such as malabsorption syndrome or status post-major bowel resection\n*   Liver disease characterized by:\n*   Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than (>) 3√ó the upper limit of normal (ULN; >=5√óULN for participants with concurrent liver metastases) confirmed on two consecutive measurements; or\n*   Impaired excretory function (e.g., hyperbilirubinemia), synthetic function, or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices; or\n*   Acute viral or active autoimmune, alcoholic, or other types of hepatitis\n*   National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 Grade 3 or higher toxicities because of any previous therapy (e.g., radiotherapy) (excluding alopecia), which have not shown improvement and are strictly considered to interfere with current study medication\n*   History of organ transplant\n*   Co-administration of anti-cancer therapies other than those administered in this study\n*   Baseline QTc >470 ms or symptomatic bradycardia\n*   Administration of strong/potent cytochrome P4503A inhibitors or inducers within 14 days prior to the receiving the first dose of study treatment and during treatment with alectinib or crizotinib\n*   Administration of agents with potential QT interval prolonging effects within 14 days prior to receiving the first dose of study drug\n*   History of hypersensitivity to any of the additives in the alectinib or crizotinib drug formulation\n*   Pregnant or lactating\n*   Known human immunodeficiency virus (HIV-positivity or acquired immunodeficiency syndrome (AIDS)-related illness\n*   Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or the absorption of oral medications or that would, in the opinion of the Principal Investigator, pose an unacceptable risk to the participant in this study\n*   Any psychological, familial, sociological, or geographical condition that potentially hampers compliance with the study protocol requirements or follow-up procedures; those conditions should be discussed with the participant before study entry\n\nStudy Plan\n----------\n\nThis section provides details of the study plan, including how the study is designed and what the study is measuring.\n\n### How is the study designed?\n\n#### Design Details\n\n*   **Primary Purpose**: Treatment\n*   **Allocation**: Randomized\n*   **Interventional Model**: Parallel Assignment\n*   **Masking**: None (Open Label)\n\n#### Number of Arms\n\n2\n\n#### Arms and Interventions\n\n| ##### Participant Group / Arm | ##### Intervention / Treatment |\n| --- | --- |\n| Experimental: Alectinib Participants will receive alectinib capsules orally at a dose of 600 mg BID with food until disease progression, unacceptable toxicity withdrawal of consent, or death. | [Drug: Alectinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Alectinib "List all studies with intervention Alectinib") Alectinib capsules will be administered orally at a dose of 600 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death. Other Names: * RO5424802 |\n| Active Comparator: Crizotinib Participants will receive crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity withdrawal of consent, or death. | [Drug: Crizotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Crizotinib "List all studies with intervention Crizotinib") Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death. |\n\n### What is the study measuring?\n\n#### Primary Outcome Measures\n\n| ##### Outcome Measure | ##### Measure Description | ##### Time Frame |\n| --- | --- | --- |\n| Progression-Free Survival (PFS) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 Time Frame: From the date of randomization to the date of the first documented disease progression or death, whichever occurred first (up to overall period of approximately 40 months) | PFS was defined as the time (in months) from randomization to the first documentation of disease progression, as determined by the investigators, or to death from any cause, whichever occurred first. | From the date of randomization to the date of the first documented disease progression or death, whichever occurred first (up to overall period of approximately 40 months) |\n\n#### Secondary Outcome Measures\n\n| ##### Outcome Measure | ##### Measure Description | ##### Time Frame |\n| --- | --- | --- |\n| PFS as Determined by Independent Review Committee (IRC) Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) | PFS was defined as the time (in months) from randomization to the first documentation of disease progression, as determined by an independent review committee, or to death from any cause, whichever occurred first. | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Percentage of Participants With Objective Response of Complete Response (CR) or Partial Response (PR) as Determined by Investigator Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Time to Progression of Disease in the CNS as Determined by IRC Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Time to Progression of Disease in the CNS as Determined by IRC Using Response Assessment in Neuro-Oncology (RANO) Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Duration of Response (DOR) Assessed by Investigator Using RECIST v1.1 Time Frame: Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 8, thereafter every 8 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Overall Survival Time Time Frame: Baseline, until death (up to overall period of approximately 40 months) |  | Baseline, until death (up to overall period of approximately 40 months) |\n| Percentage of Participants With Non-serious Adverse Events and Serious Adverse Events Time Frame: Up to overall period of approximately 40 months | An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. | Up to overall period of approximately 40 months |\n| Time to Deterioration Assessed Using EORTC Quality of Life Questionnaire-Core (QLQ-C30) Score Time Frame: Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Time to Deterioration Assessed Using EORTC Quality of Life Questionnaire-Lung Cancer Module (QLQ-LC13) Score Time Frame: Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |  | Baseline, Week 4, thereafter every 4 weeks until disease progression, death or withdrawal from the study and 4 weeks after permanent discontinuation (up to overall period of approximately 40 months) |\n| Area Under the Plasma Concentration-time Curve (AUC) of Alectinib and Its Metabolite Time Frame: Baseline and Week 4 predose (within 2 hours before administration of study drug) | AUC was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time. | Baseline and Week 4 predose (within 2 hours before administration of study drug) |\n| Maximum Plasma Concentration Observed (Cmax) of Alectinib and Its Metabolite Time Frame: Baseline and Week 4 predose (within 2 hours before administration of study drug) | Cmax was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time. | Baseline and Week 4 predose (within 2 hours before administration of study drug) |\n| Time to Cmax (Tmax) of Alectinib and Its Metabolite Time Frame: Baseline and Week 4 predose (within 2 hours before administration of study drug) | Tmax was collected for both alectinib and its major metabolite, M4, and was based on their concentrations in plasma over time. | Baseline and Week 4 predose (within 2 hours before administration of study drug) |\n\nCollaborators and Investigators\n-------------------------------\n\nThis is where you will find people and organizations involved with this study.\n\n#### Sponsor\n\n[Hoffmann-La Roche](https://ichgcp.net/clinical-trials-registry/research/list?spons=Hoffmann-La%20Roche "List all studies sponsored by Hoffmann-La Roche")\n\n#### Investigators\n\n*    Study Director: Clinical Trials, Hoffmann-La Roche \n\nPublications and helpful links\n------------------------------\n\nThe person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.\n\n#### General Publications\n\n*   [Zhou C, Kim SW, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang JJ, Cheng Y, Lee SH, Bu L, Xu T, Yang L, Wang C, Liu T, Morcos PN, Lu Y, Zhang L. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med. 2019 May;7(5):437-446. doi: 10.1016/S2213-2600(19)30053-0. Epub 2019 Apr 10.](https://pubmed.ncbi.nlm.nih.gov/30981696)\n\nStudy record dates\n------------------\n\nThese dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.\n\n### Study Major Dates\n\n#### Study Start (Actual)\n\n August 3, 2016 \n\n#### Primary Completion (Actual)\n\n May 31, 2018 \n\n#### Study Completion (Estimated)\n\n December 31, 2025 \n\n### Study Registration Dates\n\n#### First Submitted\n\nJuly 18, 2016\n\n#### First Submitted That Met QC Criteria\n\nJuly 18, 2016\n\n#### First Posted (Estimated)\n\nJuly 20, 2016\n\n### Study Record Updates\n\n#### Last Update Posted (Actual)\n\nMarch 25, 2025\n\n#### Last Update Submitted That Met QC Criteria\n\nMarch 24, 2025\n\n#### Last Verified\n\nMarch 1, 2025\n\nMore Information\n----------------\n\n### Terms related to this study\n\n#### Additional Relevant MeSH Terms\n\n*   [Neoplasms by Site](https://ichgcp.net/clinical-trials-registry/research/list?cond=Neoplasms%20by%20Site "List all studies by MeSH term: Neoplasms by Site")\n*   [Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Neoplasms "List all studies by MeSH term: Neoplasms")\n*   [Immune System Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Immune%20System%20Diseases "List all studies by MeSH term: Immune System Diseases")\n*   [Respiratory Tract Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Diseases "List all studies by MeSH term: Respiratory Tract Diseases")\n*   [Neoplasms by Histologic Type](https://ichgcp.net/clinical-trials-registry/research/list?cond=Neoplasms%20by%20Histologic%20Type "List all studies by MeSH term: Neoplasms by Histologic Type")\n*   [Lung Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%20Diseases "List all studies by MeSH term: Lung Diseases")\n*   [Respiratory Tract Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Neoplasms "List all studies by MeSH term: Respiratory Tract Neoplasms")\n*   [Thoracic Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Thoracic%20Neoplasms "List all studies by MeSH term: Thoracic Neoplasms")\n*   [Lymphatic Diseases](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphatic%20Diseases "List all studies by MeSH term: Lymphatic Diseases")\n*   [Lymphoproliferative Disorders](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoproliferative%20Disorders "List all studies by MeSH term: Lymphoproliferative Disorders")\n*   [Immunoproliferative Disorders](https://ichgcp.net/clinical-trials-registry/research/list?cond=Immunoproliferative%20Disorders "List all studies by MeSH term: Immunoproliferative Disorders")\n*   [Carcinoma, Bronchogenic](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%2C%20Bronchogenic "List all studies by MeSH term: Carcinoma, Bronchogenic")\n*   [Bronchial Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Bronchial%20Neoplasms "List all studies by MeSH term: Bronchial Neoplasms")\n*   [Lung Neoplasms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%20Neoplasms "List all studies by MeSH term: Lung Neoplasms")\n*   [Lymphoma](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma "List all studies by MeSH term: Lymphoma")\n*   [Carcinoma, Non-Small-Cell Lung](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%2C%20Non-Small-Cell%20Lung "List all studies by MeSH term: Carcinoma, Non-Small-Cell Lung")\n*   [Tyrosine Kinase Inhibitors](https://ichgcp.net/clinical-trials-registry/research/list?intr=Tyrosine%20Kinase%20Inhibitors "List all studies by MeSH term: Tyrosine Kinase Inhibitors")\n*   [Antineoplastic Agents](https://ichgcp.net/clinical-trials-registry/research/list?intr=Antineoplastic%20Agents "List all studies by MeSH term: Antineoplastic Agents")\n*   [Molecular Mechanisms of Pharmacological Action](https://ichgcp.net/clinical-trials-registry/research/list?intr=Molecular%20Mechanisms%20of%20Pharmacological%20Action "List all studies by MeSH term: Molecular Mechanisms of Pharmacological Action")\n*   [Enzyme Inhibitors](https://ichgcp.net/clinical-trials-registry/research/list?intr=Enzyme%20Inhibitors "List all studies by MeSH term: Enzyme Inhibitors")\n*   [Protein Kinase Inhibitors](https://ichgcp.net/clinical-trials-registry/research/list?intr=Protein%20Kinase%20Inhibitors "List all studies by MeSH term: Protein Kinase Inhibitors")\n*   [Crizotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Crizotinib "List all studies by MeSH term: Crizotinib")\n*   [Alectinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Alectinib "List all studies by MeSH term: Alectinib")\n\n#### Other Study ID Numbers\n\n*    YO29449 \n\n### Drug and device information, study documents\n\n#### Studies a U.S. FDA-regulated drug product\n\n Yes \n\n#### Studies a U.S. FDA-regulated device product\n\n No \n\nThis information was retrieved directly from the website [clinicaltrials.gov](https://clinicaltrials.gov/) without any changes. If you have any requests to change, remove or update your study details, please contact [register@clinicaltrials.gov](mailto:register@clinicaltrials.gov). As soon as a change is implemented on [clinicaltrials.gov](https://clinicaltrials.gov/), this will be updated automatically on our website as well.\n\nClinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer\n---------------------------------------------------------------------------------\n\n*    Pfizer   Completed  [A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001)](https://ichgcp.net/clinical-trials-registry/NCT00585195)  Systemic Anaplastic Large-Cell Lymphoma | Non-Small Cell Lung Cancer ALK-positive | Non-Small Cell Lung Cancer c-Met Dependent | Non-Small Cell Lung Cancer ROS Marker Positive | Advanced Malignancies Except Leukemia   United States, Korea, Republic of, Australia, Japan    \n*    Novartis Pharmaceuticals   Available  [Managed Access Programs for LDK378, Ceritinib](https://ichgcp.net/clinical-trials-registry/NCT05100134)  Non-small Cell Lung Cancer (NSCLC) | Anaplastic Lymphoma Kinase (ALK)- Positive Tumors    \n*    Novartis Pharmaceuticals   Completed  [Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer](https://ichgcp.net/clinical-trials-registry/NCT01772797)  Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase (ALK)   Australia, Spain, Singapore, Italy, United States    \n*    Nuvalent Inc.   Recruiting  [Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC (ALKAZAR)](https://ichgcp.net/clinical-trials-registry/NCT06765109)  Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase-positive   United States    \n*    Intergroupe Francophone de Cancerologie Thoracique   Completed  [Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements (CLINALK)](https://ichgcp.net/clinical-trials-registry/NCT02727335)  Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase Gene Mutation   France    \n*    Takeda   Completed  [A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors](https://ichgcp.net/clinical-trials-registry/NCT03546894)  Carcinoma Non-small-cell Lung | Anaplastic Lymphoma Kinase-positive   United States    \n*    Astellas Pharma Inc   Completed  [Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)](https://ichgcp.net/clinical-trials-registry/NCT01284192)  Solid Tumor | B-Cell Lymphoma | Advanced Malignancies | Positive for Anaplastic Lymphoma Kinase | Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS   United States    \n*    University Medical Center Groningen  Radboud University Medical Center; Maastricht University Medical Center; Erasmus... and other collaborators    Recruiting  [Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels (ADAPT ALEC)](https://ichgcp.net/clinical-trials-registry/NCT05525338)  Carcinoma, Non-Small-Cell Lung | Lung Cancer | Drug Monitoring | Anaplastic Lymphoma Kinase Gene Mutation | Anaplastic Lymphoma Kinase Gene Translocation   Netherlands, France    \n*    Takeda   Withdrawn  [Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors](https://ichgcp.net/clinical-trials-registry/NCT04260009)  Solid Tumors | Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma | Inflammatory Myofibroblastic Tumors    \n*    Massachusetts General Hospital  LUNGevity Foundation; Addario Lung Cancer Medical Institute    Recruiting  [Immune and Genomic Markers in ALK+ NSCLC](https://ichgcp.net/clinical-trials-registry/NCT04881916)  Non-Small Cell Lung Cancer | Anaplastic Lymphoma Kinase Gene Translocation   United States    \n\nClinical Trials on Alectinib\n----------------------------\n\n*    Aarhus University Hospital  Roche Pharma AG    Enrolling by invitation  [Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients (MonAlec)](https://ichgcp.net/clinical-trials-registry/NCT04708639)  Lung Cancer | ALK Gene Mutation | Resistance, Disease | Mutation   Denmark    \n*    Hoffmann-La Roche   Completed  [A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (ATALK)](https://ichgcp.net/clinical-trials-registry/NCT03155009)  Carcinoma, Non-Small-Cell Lung   France    \n*    Hoffmann-La Roche   Completed  [Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea](https://ichgcp.net/clinical-trials-registry/NCT03271554)  Non-Small Cell Lung Cancer   Korea, Republic of    \n*    Dana-Farber Cancer Institute  Genentech, Inc.    Terminated  [A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer](https://ichgcp.net/clinical-trials-registry/NCT03131206)  ALK-positive Non-small Cell Lung Cancer (NSCLC) | RET-positive Non-small Cell Lung Cancer (NSCLC) | RET-positive Thyroid Cancer   United States    \n*    Hoffmann-La Roche   Completed  [Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib](https://ichgcp.net/clinical-trials-registry/NCT02621047)  Hepatic Impairment   Czechia, Slovakia    \n*    Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...  UnitedHealthcare    Not yet recruiting  [Pharmacogenomics IND EXEMPT SNP Clinical Study - Alectinib and Single Nucleotide Polymorphisms (Drugs-SNPs)](https://ichgcp.net/clinical-trials-registry/NCT05987956)  Non-small Cell Lung Cancer   United States    \n*    Hoffmann-La Roche   Terminated  [A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors (ALpha-T)](https://ichgcp.net/clinical-trials-registry/NCT04644315)  Digestive System Diseases | Gastrointestinal Diseases | Melanoma | Sarcoma | Neoplasms | Respiratory Tract Diseases | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasms | Head and Neck Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms and other conditions   United States    \n*    China Medical University Hospital   Active, not recruiting  [Alectinib in Combination with Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided with Serum RNase1 and Tumor Expression of PD-L1](https://ichgcp.net/clinical-trials-registry/NCT06354387)  Hepatocellular Carcinoma   Taiwan    \n*    Genentech, Inc.   No longer available  [Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy](https://ichgcp.net/clinical-trials-registry/NCT02271139)  Non-Small Cell Lung Cancer   United States    \n*    Hoffmann-La Roche   Completed  [A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)](https://ichgcp.net/clinical-trials-registry/NCT01871805)  Non-Small Cell Lung Cancer   United States, Canada    \n\nSearch Similar Trials\n---------------------\n\n*   [Clinical Trials on Lymphoma in Singapore](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=Singapore)\n*   [Clinical Trials on Lymphosarcoma in Australia](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=Australia)\n*   [Clinical Trials on Carcinoma, Non-Small-Cell Lung in Singapore](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BNon-Small-Cell%2BLung&locn=Singapore)\n*   [Clinical Trials on Lymphoma in New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=New%2BZealand)\n*   [Clinical Trials on Carcinoma, Non-Small-Cell Lung in United States](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BNon-Small-Cell%2BLung&locn=United%2BStates)\n*   [Clinical Trials on Lung Neoplasms in Ireland](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%2BNeoplasms&locn=Ireland)\n*   [Clinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%2BLymphoma%2BKinase-positive%2BNon-small%2BCell%2BLung%2BCancer&locn=South%2BAfrica)\n*   [Clinical Trials on Lymphosarcoma in India](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=India)\n*   [Clinical Trials on Lymphoma in United States](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=United%2BStates)\n*   [Clinical Trials on Lymphoma in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=South%2BAfrica)\n*   [Clinical Trials on Lymphoma in Hong Kong](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=Hong%2BKong)\n*   [Clinical Trials on Lymphosarcoma in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=South%2BAfrica)\n*   [Clinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer in Ireland](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%2BLymphoma%2BKinase-positive%2BNon-small%2BCell%2BLung%2BCancer&locn=Ireland)\n*   [Clinical Trials on Lung Neoplasms in New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%2BNeoplasms&locn=New%2BZealand)\n*   [Clinical Trials on Lung Neoplasms in South Africa](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lung%2BNeoplasms&locn=South%2BAfrica)\n*   [Clinical Trials on Lymphoma in India](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphoma&locn=India)\n*   [Clinical Trials on Lymphosarcoma in Singapore](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=Singapore)\n*   [Clinical Trials on Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer in New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anaplastic%2BLymphoma%2BKinase-positive%2BNon-small%2BCell%2BLung%2BCancer&locn=New%2BZealand)\n*   [Clinical Trials on Lymphosarcoma in United States](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lymphosarcoma&locn=United%2BStates)\n*   [Clinical Trials on Carcinoma, Non-Small-Cell Lung in United Kingdom](https://ichgcp.net/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BNon-Small-Cell%2BLung&locn=United%2BKingdom)\n*   [Search All Trials](https://ichgcp.net/clinical-trials-registry/research/list)\n\nSponsors and Collaborators\n--------------------------\n\n*   [Eisai Korea Inc.](https://ichgcp.net/clinical-trials-registry/research/list?spons=Eisai%2BKorea%2BInc.)\n*   [Leukaemia & Blood Cancer New Zealand](https://ichgcp.net/clinical-trials-registry/research/list?spons=Leukaemia%2B%2526%2BBlood%2BCancer%2BNew%2BZealand)\n*   [Udaan](https://ichgcp.net/clinical-trials-registry/research/list?spons=Udaan)\n*   [Makarenko Irina Romanovna](https://ichgcp.net/clinical-trials-registry/research/list?spons=Makarenko%2BIrina%2BRomanovna)\n*   [Adriane Aver Vanin](https://ichgcp.net/clinical-trials-registry/research/list?spons=Adriane%2BAver%2BVanin)\n*   [University of Memphis](https://ichgcp.net/clinical-trials-registry/research/list?spons=University%2Bof%2BMemphis)\n*   [Sleep Research Society Foundation](https://ichgcp.net/clinical-trials-registry/research/list?spons=Sleep%2BResearch%2BSociety%2BFoundation)\n*   [Immuron Ltd.](https://ichgcp.net/clinical-trials-registry/research/list?spons=Immuron%2BLtd.)\n*   [Arthro-Anda Tianjin Biologic Technology Co., Ltd.](https://ichgcp.net/clinical-trials-registry/research/list?spons=Arthro-Anda%2BTianjin%2BBiologic%2BTechnology%2BCo.%252C%2BLtd.)\n*   [CoheroHealth](https://ichgcp.net/clinical-trials-registry/research/list?spons=CoheroHealth)\n*   [Center for Military Mental Health, Berlin, Germany](https://ichgcp.net/clinical-trials-registry/research/list?spons=Center%2Bfor%2BMilitary%2BMental%2BHealth%252C%2BBerlin%252C%2BGermany)\n*   [Kevin Flanigan](https://ichgcp.net/clinical-trials-registry/research/list?spons=Kevin%2BFlanigan)\n*   [Periannan Kuppusamy](https://ichgcp.net/clinical-trials-registry/research/list?spons=Periannan%2BKuppusamy)\n*   [Chiang Mai University Hospital, THAILAND](https://ichgcp.net/clinical-trials-registry/research/list?spons=Chiang%2BMai%2BUniversity%2BHospital%252C%2BTHAILAND)\n*   [Centre for Emergency Health Sciences](https://ichgcp.net/clinical-trials-registry/research/list?spons=Centre%2Bfor%2BEmergency%2BHealth%2BSciences)\n*   [Therapex Co., Ltd](https://ichgcp.net/clinical-trials-registry/research/list?spons=Therapex%2BCo.%252C%2BLtd)\n*   [MIT William Asbjornsen Albert Memorial Fellowship](https://ichgcp.net/clinical-trials-registry/research/list?spons=MIT%2BWilliam%2BAsbjornsen%2BAlbert%2BMemorial%2BFellowship)\n*   [Fabiana Aceto](https://ichgcp.net/clinical-trials-registry/research/list?spons=Fabiana%2BAceto)\n*   [North American Spine Society](https://ichgcp.net/clinical-trials-registry/research/list?spons=North%2BAmerican%2BSpine%2BSociety)\n*   [SGS proderm GmbH](https://ichgcp.net/clinical-trials-registry/research/list?spons=SGS%2Bproderm%2BGmbH)\n*   [View Full List](https://ichgcp.net/clinical-trials-registry/research/browse/spns_alpha_all)\n\nMedical Conditions\n------------------\n\n*   [Infrarenal Abdominal Aortic Aneurysms](https://ichgcp.net/clinical-trials-registry/research/list?cond=Infrarenal%2BAbdominal%2BAortic%2BAneurysms)\n*   [Myeloproliferative Disease, Not Classified](https://ichgcp.net/clinical-trials-registry/research/list?cond=Myeloproliferative%2BDisease%252C%2BNot%2BClassified)\n*   [Lifestyle-related Condition](https://ichgcp.net/clinical-trials-registry/research/list?cond=Lifestyle-related%2BCondition)\n*   [Compliance](https://ichgcp.net/clinical-trials-registry/research/list?cond=Compliance)\n*   [Patients With Opioid Induced Constipation](https://ichgcp.net/clinical-trials-registry/research/list?cond=Patients%2BWith%2BOpioid%2BInduced%2BConstipation)\n*   [Femoral Vascular Anastomosis](https://ichgcp.net/clinical-trials-registry/research/list?cond=Femoral%2BVascular%2BAnastomosis)\n*   [Observation Safety](https://ichgcp.net/clinical-trials-registry/research/list?cond=Observation%2BSafety)\n*   [Improvement of Functionality](https://ichgcp.net/clinical-trials-registry/research/list?cond=Improvement%2Bof%2BFunctionality)\n*   [CD4 Deficiency](https://ichgcp.net/clinical-trials-registry/research/list?cond=CD4%2BDeficiency)\n*   [Malassezia Infection](https://ichgcp.net/clinical-trials-registry/research/list?cond=Malassezia%2BInfection)\n*   [Anti-cancer Cell Immunotherapy](https://ichgcp.net/clinical-trials-registry/research/list?cond=Anti-cancer%2BCell%2BImmunotherapy)\n*   [Health Knowledge Attitudes and Practice](https://ichgcp.net/clinical-trials-registry/research/list?cond=Health%2BKnowledge%2BAttitudes%2Band%2BPractice)\n*   [School Adjustment](https://ichgcp.net/clinical-trials-registry/research/list?cond=School%2BAdjustment)\n*   [Difficult Mask Ventilation](https://ichgcp.net/clinical-trials-registry/research/list?cond=Difficult%2BMask%2BVentilation)\n*   [Intrapartum Mortality](https://ichgcp.net/clinical-trials-registry/research/list?cond=Intrapartum%2BMortality)\n*   [Diabetes Mellitus II](https://ichgcp.net/clinical-trials-registry/research/list?cond=Diabetes%2BMellitus%2BII)\n*   [Painless Myocardial Ischemia](https://ichgcp.net/clinical-trials-registry/research/list?cond=Painless%2BMyocardial%2BIschemia)\n*   [Corona Virus Disease 19 (COVID-19)](https://ichgcp.net/clinical-trials-registry/research/list?cond=Corona%2BVirus%2BDisease%2B19%2B%2528COVID-19%2529)\n*   [Pressure Injury Stage 2](https://ichgcp.net/clinical-trials-registry/research/list?cond=Pressure%2BInjury%2BStage%2B2)\n*   [Escape; Rhythm](https://ichgcp.net/clinical-trials-registry/research/list?cond=Escape%253B%2BRhythm)\n*   [View Full List](https://ichgcp.net/clinical-trials-registry/research/browse/cond_alpha_all)\n\nDrug Interventions\n------------------\n\n*   [Methylprednisolone](https://ichgcp.net/clinical-trials-registry/research/list?intr=Methylprednisolone)\n*   [Anetumab Ravtansine](https://ichgcp.net/clinical-trials-registry/research/list?intr=Anetumab%2BRavtansine)\n*   [ESES treated with clobazam](https://ichgcp.net/clinical-trials-registry/research/list?intr=ESES%2Btreated%2Bwith%2Bclobazam)\n*   [Droperidol Injectable Solution](https://ichgcp.net/clinical-trials-registry/research/list?intr=Droperidol%2BInjectable%2BSolution)\n*   [ATx201](https://ichgcp.net/clinical-trials-registry/research/list?intr=ATx201)\n*   [Cyclophosphamide](https://ichgcp.net/clinical-trials-registry/research/list?intr=Cyclophosphamide)\n*   [Pioglitazone](https://ichgcp.net/clinical-trials-registry/research/list?intr=Pioglitazone)\n*   [Botulinum Toxin A](https://ichgcp.net/clinical-trials-registry/research/list?intr=Botulinum%2BToxin%2BA)\n*   [Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib](https://ichgcp.net/clinical-trials-registry/research/list?intr=Gefitinib%2B250mg%2Bpo%2Bqd%2Bor%2BTarceva%2B150mg%2Bpo%2Bqd%2Bor%2BIcotinib%2B125mg%2Bpo%2Btid%2BOther%2BName%253A%2BGefitinib%252FTarceva%252FIcotinib)\n*   [Ramosetron](https://ichgcp.net/clinical-trials-registry/research/list?intr=Ramosetron)\n*   [KN046](https://ichgcp.net/clinical-trials-registry/research/list?intr=KN046)\n*   [Doxorubicin](https://ichgcp.net/clinical-trials-registry/research/list?intr=Doxorubicin)\n*   [Corticosteroids (CS)](https://ichgcp.net/clinical-trials-registry/research/list?intr=Corticosteroids%2B%2528CS%2529)\n*   [Dimenhydrinate](https://ichgcp.net/clinical-trials-registry/research/list?intr=Dimenhydrinate)\n*   [Ropivacaine 150 mg](https://ichgcp.net/clinical-trials-registry/research/list?intr=Ropivacaine%2B150%2Bmg)\n*   [Iso-Fludelone](https://ichgcp.net/clinical-trials-registry/research/list?intr=Iso-Fludelone)\n*   [Clonidine](https://ichgcp.net/clinical-trials-registry/research/list?intr=Clonidine)\n*   [Lidocaine topical](https://ichgcp.net/clinical-trials-registry/research/list?intr=Lidocaine%2Btopical)\n*   [Nusinersen](https://ichgcp.net/clinical-trials-registry/research/list?intr=Nusinersen)\n*   [Cyclophosphamide and fludarabine](https://ichgcp.net/clinical-trials-registry/research/list?intr=Cyclophosphamide%2Band%2Bfludarabine)\n*   [View Full List](https://ichgcp.net/clinical-trials-registry/research/browse/intr_alpha_all)\n\n### CROs by country\n\n*   [Contract Research Organizations in Azerbaijan](https://ichgcp.net/cro-list/country/azerbaijan)\n*   [Contract Research Organizations in Bulgaria](https://ichgcp.net/cro-list/country/bulgaria)\n*   [Contract Research Organizations in Burundi](https://ichgcp.net/cro-list/country/burundi)\n*   [Contract Research Organizations in Dominican Republic](https://ichgcp.net/cro-list/country/dominican_republic)\n*   [Contract Research Organizations in Kosovo](https://ichgcp.net/cro-list/country/kosovo)\n*   [Contract Research Organizations in Mexico](https://ichgcp.net/cro-list/country/mexico)\n*   [Contract Research Organizations in Moldova](https://ichgcp.net/cro-list/country/moldova)\n*   [Contract Research Organizations in Poland](https://ichgcp.net/cro-list/country/poland)\n*   [Contract Research Organizations in Slovakia](https://ichgcp.net/cro-list/country/slovakia)\n*   [Contract Research Organizations in Sri Lanka](https://ichgcp.net/cro-list/country/sri_lanka)\n*   [Contract Research Organizations in Ukraine](https://ichgcp.net/cro-list/country/ukraine)\n*   [Contract Research Organizations in United Arab Emirates](https://ichgcp.net/cro-list/country/united_arab_emirates)\n*   [Contract Research Organizations in Uzbekistan](https://ichgcp.net/cro-list/country/uzbekistan)\n*   [CRO list by country](https://ichgcp.net/cro-list)\n\n### CROs in Ghana\n\n*   [54gene‚Äôs Clinical Programs Group (CPG)](https://ichgcp.net/cro-list/country/ghana/company/54gene_s_clinical_programs_group_cpg)\n*   [SGS](https://ichgcp.net/cro-list/country/ghana/company/sgs)\n*   [ACROSS Global](https://ichgcp.net/cro-list/country/ghana/company/across_global)\n*   [All CROs in Ghana](https://ichgcp.net/cro-list/country/ghana)\n\n### Conditions\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/cond_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/cond_cat)\n\n### Rare Diseases\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/ord_alpha_all)\n\n### Drug Interventions\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/intr_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/intr_cat)\n\n### Dietary Supplements\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/diet_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/diet_cat)\n\n### Sponsor/Collaborators\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/spns_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/spns_cat)\n\n### Locations\n\n*   [Alphabetic (A-Z)](https://ichgcp.net/clinical-trials-registry/research/browse/locn_alpha_all)\n*   [By Category](https://ichgcp.net/clinical-trials-registry/research/browse/locn_cat)\n\nRegulations\n\n*   [GLOBAL (ICH GCP)](https://ichgcp.net/)\n*   [USA (FDA)](https://ichgcp.net/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects)\n*   [UK (MHRA)](https://ichgcp.net/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol)\n*   [AUSTRALIA (NHMRC)](https://ichgcp.net/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia)\n*   [JAPAN (PMDA)](https://ichgcp.net/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan)\n*   [EU (EMA)](https://ichgcp.net/guideline-for-the-notification-of-serious-breaches-of-regulation-eu-no-536-2014)\n\nResources\n\n*   [CRO List](https://ichgcp.net/cro-list)\n*   [Pharmaceutical Companies](https://ichgcp.net/pharma-list)\n*   [Clinical Research Labs](https://ichgcp.net/labs)\n*   [Service Companies](https://ichgcp.net/service-companies)\n*   [Jobs](https://ichgcp.net/cra-jobs)\n*   [US Clinical Trials Registry](https://ichgcp.net/clinical-trials-registry)\n*   [EU Clinical Trials Registry](https://ichgcp.net/eu-clinical-trials-registry)\n\nArticles\n\n*   [Publications](https://ichgcp.net/publications)\n*   [News](https://ichgcp.net/news)\n*   [About us / Our mission](https://ichgcp.net/about-us-our-mission)\n\nSearch trials\n\nExample: Heart Attack\n\n¬© ICH GCP. All Rights Reserved.\n\n*   [Sitemap](https://ichgcp.net/sitemap)\n*   [Contact us](https://ichgcp.net/contact-us)\n*   [RSS feed](https://ichgcp.net/feed)\n*   [Privacy Policy](https://ichgcp.net/privacy)\n*   [Disclaimer](https://ichgcp.net/disclaimer)\n\n English \n\n[Dansk](https://ichgcp.net/da/clinical-trials-registry/NCT02838420)[Deutsch](https://ichgcp.net/de/clinical-trials-registry/NCT02838420)[English](https://ichgcp.net/clinical-trials-registry/NCT02838420)[Espa√±ol](https://ichgcp.net/es/clinical-trials-registry/NCT02838420)[Fran√ßais](https://ichgcp.net/fr/clinical-trials-registry/NCT02838420)[Italiano](https://ichgcp.net/it/clinical-trials-registry/NCT02838420)[Magyar](https://ichgcp.net/hu/clinical-trials-registry/NCT02838420)[Nederlands](https://ichgcp.net/nl/clinical-trials-registry/NCT02838420)[Norsk](https://ichgcp.net/no/clinical-trials-registry/NCT02838420)[Polski](https://ichgcp.net/pl/clinical-trials-registry/NCT02838420)[Portugu√™s](https://ichgcp.net/pt/clinical-trials-registry/NCT02838420)[Suomi](https://ichgcp.net/fi/clinical-trials-registry/NCT02838420)[Svenska](https://ichgcp.net/sv/clinical-trials-registry/NCT02838420)[ƒåe≈°tina](https://ichgcp.net/cs/clinical-trials-registry/NCT02838420)[–†—É—Å—Å–∫–∏–π](https://ichgcp.net/ru/clinical-trials-registry/NCT02838420)[Êó•Êú¨Ë™û](https://ichgcp.net/ja/clinical-trials-registry/NCT02838420)[ÁÆÄ‰Ωì‰∏≠Êñá](https://ichgcp.net/zh/clinical-trials-registry/NCT02838420)[ÌïúÍµ≠Ïñ¥](https://ichgcp.net/ko/clinical-trials-registry/NCT02838420)\n\nGOOD CLINICAL PRACTICE NETWORK\n\nSubscribe to receive notifications of new clinical trials you are interested in.\n\nSubscribe\n\n‚úï\n\nGOOD CLINICAL PRACTICE NETWORK\n\nSubscribe to receive notifications of new clinical trials you are interested in.\n\nSubscribe for upcoming trials that contain the following conditions: \n\n- [x] Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer \n\n[Choose more conditions](https://ichgcp.net/mailing-list/conditions)\n\nSubscribe for upcoming trials that contain the following interventions: \n\n- [x] Alectinib \n\n- [x] Crizotinib \n\n[Choose more interventions](https://ichgcp.net/mailing-list/interventions)\n\nSubscribe for upcoming trials sponsored by: \n\n- [x] Hoffmann-La Roche \n\n[Choose more organizations](https://ichgcp.net/mailing-list/organizations)\n\nSubscribe\n\nSubscribe\n\nSubscribe\n'}, {'title': 'Alectinib vs crizotinib in Asian patients with treatment-na√Øve ... - Roche', 'url': 'https://medically.roche.com/global/en/medical-material/ESMO-Asia-2022-presentation-zhou-alectinib-vs-crizotinib-in-asian-patients-with-treatment-naive-advanced-pdf.html', 'content': 'Data cut -off 16 May 2022. ClinicalTrials.gov: NCT02838420. CNS, central nervous system; DOR, duration of response;  ECOG PS, Eastern Cooperative Oncology Group performance status; IHC, immunohistochemistry; INV, investigator \n\nIRC, independent review committee; NSCLC, non -small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, p rogression -free survival \n\n2:1 \n\nN=187 \n\nR\n\nAlectinib \n\n600mg  twice daily \n\nCrizotinib \n\n250mg twice daily \n\nTreat until disease', 'score': 0.5393963, 'raw_content': "Alectinib vs crizotinib in Asian patients \n\n## with treatment -na√Øve advanced  ALK +\n\n## non -small cell lung cancer: 5 -year \n\n## update from the Phase 3 ALESIA study \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nFaculty of Medicine  Ramathibodi  Hospital, Mahidol University, \n\nBangkok, Thailand \n\nZhou C, 1 Lu Y, 2 Kim S -W, 3 Baisamut  (Reungwetwattana) T, 4 Zhou J, 5 Zhang Y, 6 He J, 7 Yang J -J, 8 Cheng Y, 9 Lee S -H, 10  Chang J, 11 \n\nFang J, 12  Liu Z, 13  Bu L, 14  Qian L, 14  Xu T, 14  Archer V, 15  Hilton M, 16  Zhou M, 14  Zhang L 17 \n\n1Shanghai Pulmonary Hospital, Tongji University, Shanghai, China;  2West China Hospital, Sichuan University, Chengdu, China;  3Asan Medical \n\nCenter , University of Ulsan College of Medicine, Seoul, South Korea;  4Faculty of Medicine  Ramathibodi  Hospital, Mahidol University, Bangkok, \n\nThailand;  5The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China;  6Zhejiang Cancer Hospital, Hangzhou, China; \n\n7The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;  8Guangdong Lung Cancer Institute, Guangdong General Hospital, \n\nGuangzhou, China;  9Jilin Cancer Hospital, Changchun, China;  10 Sungkyunkwan University School of Medicine, Seoul, South Korea;  11 Cancer \n\nHospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China;  12 Beijing Cancer \n\nHospital, Beijing, China;  13 Beijing Chest Hospital, Capital Medical University, Beijing, China;  14 Roche Pharma Development, Shanghai, China; \n\n15 Roche Products Ltd, Welwyn Garden City, UK;  16 F. Hoffmann -La Roche Ltd, Basel, Switzerland;  17 Sun  Yat -sen  University Cancer  Center ,\n\nState Key Laboratory of Oncology in South China, Collaborative Innovation  Center  for Cancer Medicine, Guangzhou, China Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## DECLARATION OF INTERESTS \n\nThanyanan  Baisamut  (Reungwetwattana) \n\n‚Ä¢ Received honorarium from AstraZeneca, Pfizer, MSD, Roche, BMS, Amgen, J&J, Novartis,  Yuhan  and  Zuellig \n\n‚Ä¢ Participated as Principal Investigator on clinical trials for AstraZeneca, MSD, Roche, Novartis and  Yuhan   \n\n> Thanyanan Baisamut (Reungwetwattana)\n\nContent of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## ALESIA: alectinib vs crizotinib in treatment -na√Øve Asian patients \n\n## with advanced  ALK+  NSCLC \n\n‚Ä¢ Stratification factors:  ECOG PS (0/1 vs 2) \n\nand CNS metastases at baseline (yes vs no) \n\n‚Ä¢ Primary endpoint:  PFS by INV \n\n‚Ä¢ Secondary endpoints:  Time to CNS \n\nprogression by IRC, ORR by INV, \n\nDOR by INV, OS and safety \n\n‚Ä¢ Median duration of survival follow -up: \n\n61 months  alectinib vs  51 months  crizotinib \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nPatients were enrolled from China, Thailand and South Korea. *Asymptomatic CNS metastases allowed. \n\nData cut -off 16 May 2022. ClinicalTrials.gov: NCT02838420. CNS, central nervous system; DOR, duration of response;  ECOG PS, Eastern Cooperative Oncology Group performance status; IHC, immunohistochemistry; INV, investigator \n\nIRC, independent review committee; NSCLC, non -small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, p rogression -free survival \n\n2:1 \n\nN=187 \n\nR\n\nAlectinib \n\n600mg  twice daily \n\nCrizotinib \n\n250mg twice daily \n\nTreat until disease \n\nprogression, toxicity, \n\nwithdrawal or death \n\nNo crossover permitted \n\nStage IIIB/IV  ALK + NSCLC* \n\n‚Ä¢ Asian patients \n\n‚Ä¢ Treatment na√Øve \n\n‚Ä¢ ECOG PS 0 ‚Äì2\n\n‚Ä¢ Central  ALK  testing (Ventana IHC) \n\nBaseline demographics \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nAge, years  Median (range)  51.0 (21‚àí78)  49.0 (28‚àí83) \n\nGender, %  Male / Female  51.2 / 48.8  54.8 / 45.2 \n\nECOG PS, %  0‚Äì1 / 2  96.8 / 3.2  98.4 / 1.6 \n\nSmoking status, %  Active smoker / Non -smoker / \n\nPast smoker  3.2 / 67.2 / 29.6  4.8 / 72.6 / 22.6 \n\nCNS metastases by IRC, %  Yes  35.2  37.1 \n\nCNS metastases by INV, %  Yes  33.6  32.3 \n\nPrior brain radiation, %  Yes  6.4  8.1 Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Updated analyses from ALESIA demonstrate durable PFS benefit for \n\n## alectinib versus crizotinib, irrespective of CNS involvement at baseline \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nData cut -off 16 May 2022. CI, confidence interval; CNS, central nervous system; HR, hazard ratio; ITT, intent -to -treat;  mets , metastases;  PFS, progression -free survival \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nMedian  PFS, months \n\n(95% CI) \n\n41.6 \n\n(33.1 ‚Äì58.9) \n\n11.1 \n\n(9.1 ‚Äì18.4) \n\nHR  (95% CI)  0.33  (0.23 ‚Äì0.49) \n\n0\n\n> PFS (%)\n\n6 36  66 60 54 48 42 30 24 18 12 \n\nTime (months) \n\n100 \n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\nCrizotinib (n=62) \n\nAlectinib (n=125) \n\nWith  CNS  mets  at baseline  Without  CNS  mets  at baseline \n\nAlectinib \n\nn=44 \n\nCrizotinib \n\nn=23 \n\nAlectinib \n\nn=81 \n\nCrizotinib \n\nn=39 \n\nMedian  PFS, months \n\n(95% CI) \n\n42.3 \n\n(27.8 ‚Äì60.7) \n\n9.2 \n\n(5.5 ‚Äì12.2) \n\n41.6 \n\n(29.5 ‚Äì64.9) \n\n12.7 \n\n(9.2 ‚Äì27.6) \n\nHR  (95% CI)  0.17  (0.09 ‚Äì0.33)  0.45  (0.29 ‚Äì0.71) \n\nCrizotinib (n=39) \n\nWithout  CNS  mets  at baseline \n\nAlectinib (n=81) \n\nUpdated PFS: ITT population \n\nTime (months) \n\n100 \n\n0\n\n> PFS (%)\n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\n36  66 54 18 6 60 42 30 24 12  48 \n\nCrizotinib (n=23) \n\nWith  CNS  mets  at baseline \n\nAlectinib (n=44) \n\nPFS according to CNS status at baseline Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## A clinically meaningful improvement in 5 -year OS rate was observed \n\n## for alectinib compared with crizotinib \n\nThanyanan  Baisamut  (Reungwetwattana) \n\nData cut -off 16 May 2022. CI, confidence interval; CNS, central nervous system; HR, hazard ratio; ITT, intent -to -treat;  mets , metastases; NE, not evaluable; OS, overall survival; pts, patients \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nPts with event, n (%)  41 (32.8)  26 (41.9) \n\nMedian  OS, months \n\n(95% CI) \n\nNE \n\n(NE ‚ÄìNE) \n\nNE \n\n(45.5 ‚ÄìNE) \n\nHR  (95% CI)  0.60  (0.37 ‚Äì0.99) \n\n5-year OS rate , % \n\n(95% CI) \n\n66.4 \n\n(57.9 ‚Äì74.9) \n\n56.0 \n\n(43.0 ‚Äì69.1) \n\nPts remaining at risk, n  69  25 \n\n0\n\n> OS (%)\n\n6 36  66 60 54 48 42 30 24 18 12 \n\nTime (months) \n\n100 \n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\nCrizotinib (n=62) \n\nAlectinib (n=125) \n\nWith  CNS  mets  at baseline  Without  CNS  mets  at baseline \n\nAlectinib \n\nn=44 \n\nCrizotinib \n\nn=23 \n\nAlectinib \n\nn=81 \n\nCrizotinib \n\nn=39 \n\nPts with event, n (%)  16 (36.4)  12 (52.2)  25 (30.9)  14 (35.9) \n\nMedian  OS, months \n\n(95% CI) \n\nNE \n\n(51.4 ‚ÄìNE) \n\n46.2 \n\n(12.2 ‚ÄìNE) \n\nNE \n\n(NE ‚ÄìNE) \n\nNE \n\n(59.8 ‚ÄìNE) \n\nHR  (95% CI)  0.40  (0.19 ‚Äì0.85)  0.81  (0.42 ‚Äì1.55) \n\n5-year OS rate, % \n\n(95% CI) \n\n63.6 \n\n(48.9 ‚Äì78.3) \n\n39.3 \n\n(17.4 ‚Äì61.2) \n\n67.8 \n\n(57.4 ‚Äì78.2) \n\n64.9 \n\n(49.3 ‚Äì80.4) \n\nPts remaining at risk, n  25  6 44  19 \n\nCrizotinib (n=39) \n\nWithout  CNS  mets  at baseline \n\nAlectinib (n=81) \n\nUpdated OS: ITT population \n\nTime (months) \n\n100 \n\n0\n\n> OS (%)\n\n80 \n\n60 \n\n40 \n\n20 \n\n0\n\n36  66 54 18 6 60 42 30 24 12  48 \n\nCrizotinib (n=23) \n\nWith  CNS  mets  at baseline \n\nAlectinib (n=44) \n\nOS according to CNS status at baseline Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Treatment with alectinib delayed the time to CNS progression* \n\nThanyanan  Baisamut  (Reungwetwattana) \n\n*Derived from investigators' assessment. CNS PD = CNS Target Lesion PD per RECIST version 1.1, appearance of new CNS lesion(s ),  and/or unequivocal PD of Non -Target CNS lesion(s) \n\nData cut -off 16 May 2022. CI, confidence interval;  CIR, cumulative incidence rate;  CNS, central nervous system; HR, hazard ratio;  PD, progressive disease \n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nCNS progression without prior systemic progression \n\nPatients with events, n (%)  18 (14.4)  22 (35.5) \n\nCause -specific HR  (95% CI)  0.16  (0.08 ‚Äì0.32) \n\nEstimated cumulative incidence, % (95% CI) \n\nAt 36 months  11.6 (6.7 ‚Äì18.1)  34.0 (22.1 ‚Äì46.2) \n\nAt 60 months  14.2 (8.6 ‚Äì21.1)  37.4 (25.0 ‚Äì49.7) \n\n40 \n\n0\n\n> Cumulative incidence (%)\n\n30 \n\n20 \n\n10 \n\n0 6 36  60 54 48 42 30 24 18 12 \n\nTime (months) \n\nCrizotinib (n=62) \n\nAlectinib (n=125) \n\nCIR: \n\n11.6% (95% CI 6.7 ‚Äì18.1) \n\nCIR: \n\n14.2% (95% CI 8.6 ‚Äì21.1) \n\nCIR: \n\n34.0% (95% CI 22.1 ‚Äì46.2) \n\nCIR: \n\n37.4% (95% CI 25.0 ‚Äì49.7) Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Post -progression therapy \n\nThanyanan  Baisamut  (Reungwetwattana)  \n\n> Data cut -off 16 May 2022. PD, progressive disease; VEGF, vascular endothelial growth factor\n\nAlectinib \n\nn=125 \n\nCrizotinib \n\nn=62 \n\nPatients with PD , n  68  48 \n\nAnti -cancer therapy after PD , n (%)  42 (61.8)  38 (79.2) \n\nALK inhibitor , n (%)  25 (36.8)  28 (58.3) \n\nAlectinib  5 (7.4)  14 (29.2) \n\nLorlatinib  8 (11.8)  6 (12.5) \n\nBrigatinib  6 (8.8)  7 (14.6) \n\nCrizotinib  7 (10.3)  2 (4.2) \n\nCeritinib  3 (4.4)  4 (8.3) \n\nEnsartinib  2 (2.9)  1 (2.1) \n\nInvestigational drug  1 (1.5)  0\n\nChemotherapy , n (%)  24 (35.3)  15 (31.3) \n\nAnti -VEGF therapies , n ( %Ôºâ 9 (13.2)  3 (6.3) \n\nImmunotherapy , n (%)  3 (4.4)  2 (4.2) \n\nOther therapies , n (%)  6 (8.8)  7 (14.6) \n\nMore crizotinib patients (79.2% vs 61.8% alectinib) received at least one anti -cancer therapy post -progression \n\nApproximately 30% of patients in the crizotinib arm received alectinib after their disease progressed Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## The safety profile of alectinib remained favourable with longer \n\n## follow -up; no new safety signals were observed \n\nThanyanan  Baisamut  (Reungwetwattana) \n\n> *Three additional fatal events occurred during the longer follow -up: one was due to COVID -19 pneumonia, and the other two were r eported as ‚Äòdeath‚Äô and not related to alectinib treatment\n> Data cut -off 16 May 2022. AE, adverse event; ALT, alanine aminotransferase; ECG, electrocardiogram\n\nEvent, n  (%) \n\nAlectinib \n\n(n=125) \n\nCrizotinib \n\n(n=62) \n\nPatients with ‚â•1 \n\nAll grade AEs  125 (100)  62 (100) \n\nSerious AEs  35 (28.0)  18 (29.0) \n\nGrade ‚â•3 AEs  60 (48.0)  34 (54.8) \n\nFatal AEs  5 (4.0)*  3 (4.8) \n\nAEs leading to treatment discontinuation  14 (11.2)  9 (14.5) \n\nAEs leading to dose reduction  33 (26.4)  17 (27.4) \n\nAEs leading to dose interruption  33 (26.4)  19 (30.6) \n\nGrade ‚â•3 AEs with ‚â•3% difference \n\nin frequency between treatment arms, n  (%) \n\nAlectinib \n\n(n=125) \n\nCrizotinib \n\n(n=62) \n\nWeight increased  11 (8.8)  1 (1.6) \n\nBlood creatine phosphokinase increased  8 (6.4)  2 (3.2) \n\nALT increased  3 (2.4)  4 (6.5) \n\nNausea  1 (0.8)  3 (4.8) \n\nNeutrophil count decreased  0 9 (14.5) \n\nECG QT prolonged  0 3 (4.8) \n\nWhite blood cell count decreased  0 3 (4.8) \n\nDecreased appetite  0 3 (4.8) \n\nHyponatraemia  0 3 (4.8) \n\nInterstitial lung disease  0 3 (4.8) \n\nVomiting  0 3 (4.8) \n\nBradycardia  0 2 (3.2) \n\nHepatic function abnormal  0 2 (3.2) \n\nMedian treatment duration was more than three -times greater for alectinib (42.3 months) \n\ncompared to crizotinib (12.6 months) Content of this presentation is copyright  and responsibility of the author. Permission is required for re -use .\n\n## Conclusions:  5-year update from the Phase 3 ALESIA study   \n\n> Thanyanan Baisamut (Reungwetwattana )\n\nWith  at least 5 years  of follow -up, 1L alectinib  600mg twice daily  continues \n\nto demonstrate clinical benefit to Asian patients with advanced  ALK+  NSCLC, \n\nconsistent with  that observed in the  global ALEX study \n\nTreatment with alectinib also delayed the time to CNS progression \n\nThis clinical benefit, coupled with a tolerable and manageable safety profile, \n\nconfirms alectinib as standard -of -care treatment \n\nfor patients with advanced  ALK+  NSCLC Acknowledgements \n\nWe thank the participating patients and their families, study investigators, and research nurses \n\nThe ALESIA study was funded by F. Hoffmann -La Roche Ltd \n\nMedical writing support for the development of this presentation, under the direction \n\nof the authors, was provided by Fiona Duthie, PhD, of Ashfield MedComms, \n\nan Inizio company, and was funded by F. Hoffmann -La Roche Ltd\n"}], 'response_time': 1.54})
2025-06-18 19:20:20,943 - src.graph.nodes - INFO - Planner generating full plan
2025-06-18 19:20:30,668 - httpx - INFO - HTTP Request: POST https://2791-3-16-2-146.ngrok-free.app/v1/chat/completions "HTTP/1.1 200 OK"
2025-06-18 19:20:30,675 - process_medbrowse_questions - ERROR - Workflow execution failed: Failed to parse Plan from completion {"type": "image", "image_url": "https://7esl.com/wp-content/uploads/2021/03/Foods-starting-with-r-scaled.jpg", "image_description": "A poster of foods that start with the letter R."}. Got: 4 validation errors for Plan
locale
  Field required [type=missing, input_value={'type': 'image', 'image_...art with the letter R.'}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
has_enough_context
  Field required [type=missing, input_value={'type': 'image', 'image_...art with the letter R.'}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
thought
  Field required [type=missing, input_value={'type': 'image', 'image_...art with the letter R.'}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
title
  Field required [type=missing, input_value={'type': 'image', 'image_...art with the letter R.'}, input_type=dict]
    For further information visit https://errors.pydantic.dev/2.10/v/missing
For troubleshooting, visit: https://python.langchain.com/docs/troubleshooting/errors/OUTPUT_PARSING_FAILURE 
2025-06-18 19:20:30,677 - process_medbrowse_questions - WARNING - Parser error (attempt 4/5) for question 2: Failed to parse Plan from completion {"type": "image", "image_url": "https://7esl.com/wp-content/uploads/2021/03/Foods-starting-with-r-scaled.jpg", "image_description": "A poster of foods that start w...
2025-06-18 19:20:30,677 - process_medbrowse_questions - INFO - Will retry in 9s... (5/5)
/opt/anaconda3/lib/python3.12/multiprocessing/resource_tracker.py:254: UserWarning: resource_tracker: There appear to be 1 leaked semaphore objects to clean up at shutdown
  warnings.warn('resource_tracker: There appear to be %d '
